p16 |
low grade dysplasia |
In addition, p16 was not identified in non-dysplastic tissue and low grade dysplasia. |
15328914 |
Human |
p16 |
low grade dysplasia |
CDC6 may be a biomarker of high grade and invasive lesions of the cervix, with limited use in low grade dysplasia. p16(INK4A) was the most reliable marker of cervical dysplasia. |
15858126 |
Human |
p16 |
serrated adenomas |
In this study, 46 serrated adenomas from 39 patients, 32 conventional (nonserrated) adenomas from 31 patients, and 18 hyperplastic polyps from 16 patients were evaluated for loss of heterozygosity (LOH) of APC, p53, p16, and 3p and for K-ras mutations of |
11823977 |
Human |
p16 |
hyperplastic polyps |
In this study, 46 serrated adenomas from 39 patients, 32 conventional (nonserrated) adenomas from 31 patients, and 18 hyperplastic polyps from 16 patients were evaluated for loss of heterozygosity (LOH) of APC, p53, p16, and 3p and for K-ras mutations of |
11823977 |
Human |
cdkn2 |
tumor |
Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de |
15161057 |
Human |
mts1 |
tumor |
Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de |
15161057 |
Human |
ink4a |
tumor |
Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de |
15161057 |
Human |
p16 |
tumor |
Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de |
15161057 |
Human |
cdkn2a |
skin cancer |
Both of these genes have been identified as risk factors in skin cancer, MC1R variants are associated with increased risk to both melanoma and nonmelanoma skin cancers, and p16/CDKN2A with increased risk of melanoma. |
11830546 |
Human |
p16 |
skin cancer |
Both of these genes have been identified as risk factors in skin cancer, MC1R variants are associated with increased risk to both melanoma and nonmelanoma skin cancers, and p16/CDKN2A with increased risk of melanoma. |
11830546 |
Human |
p16 |
skin cancer |
This link between p16 and MC1R may provide a molecular basis for the increased skin cancer risk associated with MC1R polymorphisms. |
11830546 |
Human |
p16 |
polyposis |
Methylation of p16, MINT1, MINT2, MINT31, and hMLH1 was analyzed by methylation-specific polymerase chain reaction in 102 HPs, 8 serrated adenomas, 19 tubular adenomas, and 9 adenocarcinomas from 17 patients, with multiple/large HPs or hyperplastic polypo |
11839573 |
Human |
p16 |
serrated adenomas |
Methylation of p16, MINT1, MINT2, MINT31, and hMLH1 was analyzed by methylation-specific polymerase chain reaction in 102 HPs, 8 serrated adenomas, 19 tubular adenomas, and 9 adenocarcinomas from 17 patients, with multiple/large HPs or hyperplastic polypo |
11839573 |
Human |
p16 |
tubular adenomas |
Methylation of p16, MINT1, MINT2, MINT31, and hMLH1 was analyzed by methylation-specific polymerase chain reaction in 102 HPs, 8 serrated adenomas, 19 tubular adenomas, and 9 adenocarcinomas from 17 patients, with multiple/large HPs or hyperplastic polypo |
11839573 |
Human |
p16 |
idiopathic myelofibrosis |
Hypermethylation of p15 and p16 genes was determined in 32 patients with agnogenic myeloid metaplasia(AMM), also known as idiopathic myelofibrosis (MF). |
11849214 |
Human |
p16 |
mycosis fungoides and sezary syndrome |
Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome. |
11874489 |
Human |
p16 |
mycosis fungoides and sezary syndrome |
This study suggests that abnormalities of the P15 and P16 genes are common in both early and advanced stages of mycosis fungoides and Sezary syndrome and that these genes may be inactivated by allelic loss and aberrant promoter methylation. |
11874489 |
Human |
p14arf |
benign melanocytic nevi |
P14ARF expression was investigated by immunohistochemical staining of 32 tissue samples of benign melanocytic nevi (n=14), melanomas (n=12) and melanoma metastases (n=6). |
11876522 |
Human |
p14arf |
benign melanocytic nevi |
In summary, we demonstrated a significant inverse correlation between p14ARF protein expression and progression of melanocytic tumors since the amount of p14ARF protein staining decreased from benign melanocytic nevi to metastatic melanoma in situ. |
11876522 |
Human |
arf |
tumor angiogenesis |
The latter finding raises the possibility that Arf may function as a tumor suppressor at least in part by regulating tumor angiogenesis. |
11891301 |
Mouse |
p16 |
colorectal adenocarcinomas |
In this study, seven components of cell-cycle control [cyclin D1, retinoblastoma (pRb), p21, p27, p16, p53, and proliferating cell nuclear antigen (PCNA)] were examined in a large series of well-characterized colorectal adenocarcinomas using immunohistoch |
11920733 |
Human |
p16 |
differentiated carcinomas |
The P16 positive rate was negatively correlated with the degree of tumor histological differentiation, and the rate difference between the high differentiated carcinomas was significant (P < 0.05). |
11930651 |
Human |
p16 |
epithelial-myoepithelial carcinoma |
Samples of NSG, pleomorphic adenoma (PA), adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), epithelial-myoepithelial carcinoma (EMC), malignant myoepithelioma (MEM), carcinoma ex pleomorphic adenoma (CEPA), and polymorphous, low-grade adenoc |
14747065 |
Human |
p16 |
carcinoma ex-pleomorphic adenoma (cepa) |
Samples of NSG, pleomorphic adenoma (PA), adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), epithelial-myoepithelial carcinoma (EMC), malignant myoepithelioma (MEM), carcinoma ex pleomorphic adenoma (CEPA), and polymorphous, low-grade adenoc |
14747065 |
Human |
p16 |
adenoid-cystic carcinoma (acc) |
Samples of NSG, pleomorphic adenoma (PA), adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), epithelial-myoepithelial carcinoma (EMC), malignant myoepithelioma (MEM), carcinoma ex pleomorphic adenoma (CEPA), and polymorphous, low-grade adenoc |
14747065 |
Human |
p16 |
malignant myoepithelioma |
Samples of NSG, pleomorphic adenoma (PA), adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), epithelial-myoepithelial carcinoma (EMC), malignant myoepithelioma (MEM), carcinoma ex pleomorphic adenoma (CEPA), and polymorphous, low-grade adenoc |
14747065 |
Human |
p16 |
pancreatic intraepithelial neoplasia |
Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. |
12000709 |
Human |
p16 |
hyperplastic polyps |
METHODS: Thirty-nine hyperplastic polyps from 26 CUC patients, 39 sporadic hyperplastic polyps from 29 age- and sex-matched patients without CUC, and 26 colonic mucosal biopsies from 22 patients with CUC but without hyperplastic polyps were analyzed by po |
12014733 |
Human |
p16 |
hyperplastic polyps |
Loss of heterozygosity of APC, 3p, p53, p16, and K-ras mutations were present in 21%, 40%, 27%, 20%, and 19% of CUC patients with hyperplastic polyps, respectively, and in 0%, 11%, 20%, 13%, and 13% of non-CUC patients with sporadic polyps, respectively. |
12014733 |
Human |
p16 |
b-cell acute lymphoblastic leukaemia |
We examined deletion and methylation of the p15INK4B (p15) and p16INK4A (p16) genes, using Southern blotting and methylation-specific polymerase chain reaction (PCR), in 70 untreated adult patients with precursor B-cell acute lymphoblastic leukaemia (PBC- |
12028019 |
Human |
ink4 |
relapsed childhood all |
These findings argue against an independent prognostic role of INK4 deletions in relapsed childhood ALL. |
12036898 |
Human |
p16 |
primary cutaneous b-cell lymphomas |
We analyzed DNA from 36 cases of primary cutaneous B cell lymphomas, four systemic B cell lymphomas, and six benign B cell lymphoproliferative infiltrates for abnormalities of p15 and p16 using microsatellite markers for 9p21, methylation specific polymer |
12060387 |
Human |
p16 |
primary cutaneous b-cell lymphomas |
In primary cutaneous B cell lymphomas with allelic loss or promotor hypermethylation of either p15 or p16, loss of expression in tumor cells was identified in 5 of 8 and 9 of 10 cases, respectively. |
12060387 |
Human |
cdkn2a |
yolk-sac tumor |
Twenty-five primary intracranial germ cell tumors (11 germinomas, 5 teratomas, 5 mixed teratomas-germinomas. 1 mixed choriocarcinoma-teratoma, 1 yolk sac tumor, 1 mixed yolk sac tumor-teratoma, and 1embryonal carcinoma; from 24 males and 1 female) were st |
12071636 |
Human |
p16 |
yolk-sac tumor |
Twenty-five primary intracranial germ cell tumors (11 germinomas, 5 teratomas, 5 mixed teratomas-germinomas. 1 mixed choriocarcinoma-teratoma, 1 yolk sac tumor, 1 mixed yolk sac tumor-teratoma, and 1embryonal carcinoma; from 24 males and 1 female) were st |
12071636 |
Human |
arf |
colon tumors |
A PCR-based analysis of ARF and p53 cDNAs in normal colon tissues and AOM-induced colon tumors failed to detect mutations in either of these two critical tumor suppressor genes. |
12097273 |
Human |
arf |
colon tumors |
A marked increase in ARF mRNA and protein levels was observed in colon tumors, indicating activation of the ARF-p53 pathway in these tumors. |
12097273 |
Human |
p16 |
differentiated cancer |
We report the establishment of a novel AVC cell line (AVC1) derived from a moderately differentiated cancer, having a mutated K- ras, wild-type p53, and methylated p16. |
14677066 |
Human |
p16 |
serous carcinoma |
In serous carcinoma, p53 mutation is the most frequent genetic alteration, followed by inactivation of p16 and e-cadherin and amplification of her2/neu. p53 mutation occurs in endometrial intraepithelial carcinoma, the putative precursor of serous carcino |
14747944 |
Human |
p16 |
pancreatoblastoma |
Although the cytomorphologic features alone were not specific, the presence of a markedly elevated serum lipase level, cutaneous lesions of fat necrosis, and loss of heterozygosity at 1p, 5q25 at the APC locus, 9p21 at the p16 locus, and 17p13 at the p53 |
12112815 |
Human |
p16 |
endometrial polyps |
Cytological atypia in endometrial polyps and immunostaining for p16, p53 and Ki67. |
12121245 |
Human |
p16 |
superficial bladder cancers |
To study whether specific or bulk hypermethylation predicts intrabladder recurrence, we determined the frequency of aberrant promoter hypermethylation of seven genes, hMLH1, O(6)-methylguanine-DNA-methyltransferase (MGMT), p16, Von Hippel-Lindau (VHL), de |
12124340 |
Human |
p16 |
acute lymphoblastic leukemia |
Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia. |
12127556 |
Human |
p16 |
spindle cell neoplasms |
Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. |
12152785 |
Human |
p16 |
metastatic human prostate cancer |
Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. |
12169393 |
Human |
p16 |
multiple myeloma |
These findings showed methylation of the p16 gene was a frequent event inMM patients at diagnosis, and was associated with an increased proliferative rate of plasma cells and a poor prognosis, indicating an important role for p16 gene in the cell cycle re |
12199782 |
Human |
p16 |
tumour |
These findings showed methylation of the p16 gene was a frequent event inMM patients at diagnosis, and was associated with an increased proliferative rate of plasma cells and a poor prognosis, indicating an important role for p16 gene in the cell cycle re |
12199782 |
Human |
p16 |
eccrine porocarcinoma |
Aberrant expression of p16 and RB protein in eccrine porocarcinoma. |
12207741 |
Human |
p16 |
eccrine porocarcinoma |
Furthermore, one case of eccrine porocarcinoma was analyzed for p16 gene mutation. |
12207741 |
Human |
p16 |
eccrine porocarcinoma |
Conversely, one case of eccrine porocarcinoma did not show immunoreactivity for p16 protein, whereas RB protein was positive in the scattered nuclei. |
12207741 |
Human |
p16 |
eccrine porocarcinoma |
No p16 gene mutation was detected in the investigated eccrine porocarcinoma case. |
12207741 |
Human |
p16 |
eccrine porocarcinoma |
CONCLUSIONS: These results indicate that detectable p16 protein and loss of RB protein are common occurrences in eccrine porocarcinoma lesions. |
12207741 |
Human |
p16 |
eccrine porocarcinoma |
Moreover, overexpression of p16 protein may be an additional, simple and useful diagnostic marker for eccrine porocarcinoma on routine laboratory screening. |
12207741 |
Human |
arf |
oral cancer |
These data support that INK4a/ARF locus alterations are frequent events preceding the development of oral cancer and that p16(INK4a) inactivation occurs to a greater extent in oral dysplasia than does p14(ARF) inactivation. |
12234999 |
Human |
ink4a |
oral cancer |
These data support that INK4a/ARF locus alterations are frequent events preceding the development of oral cancer and that p16(INK4a) inactivation occurs to a greater extent in oral dysplasia than does p14(ARF) inactivation. |
12234999 |
Human |
p16 |
cervical squamous cell carcinomas |
The cyclin-dependent kinase inhibitor p16(ink4) is expressed in cervical squamous cell carcinomas, their precursors, and cervical ACs, and there is a strong relationship between p16 expression and the presence of human papillomavirus (HPV)-encoded E6/E7 t |
12378514 |
Human |
p16 |
glandular neoplasms |
The diffuse distribution of p16 immunostaining in HPV16/18-positive glandular neoplasms supports a strong association with HPV infection and indicates that this biomarker may discriminate ACIS from its benign mimics. |
12378514 |
Human |
ink4a |
childhood cancer |
The marked synergism in mice between aberrant c-Met signaling and Ink4a/Arf inactivation, lesions individually implicated in human RMS, suggests a therapeutic combination to combat this devastating childhood cancer. |
12368906 |
Human |
arf |
childhood cancer |
The marked synergism in mice between aberrant c-Met signaling and Ink4a/Arf inactivation, lesions individually implicated in human RMS, suggests a therapeutic combination to combat this devastating childhood cancer. |
12368906 |
Human |
p16 |
squamous cell carcinoma in situ |
We hypothesized that there may be an appreciable difference in expression of p16 between normal skin, actinic keratoses, squamous cell carcinoma in situ, and invasive squamous cell carcinoma. |
12429789 |
Human |
p16 |
lymphoid leukemia |
To understand molecular pathways underlying 9p21 deletions, which lead to inactivation of the p16/CDKN2A, p14/ARF, and/or p15/CDKN2B genes, in lymphoid leukemia, 30 breakpoints were cloned from 15 lymphoid leukemia cell lines. |
12228235 |
Human |
cdkn2a |
lymphoid leukemia |
To understand molecular pathways underlying 9p21 deletions, which lead to inactivation of the p16/CDKN2A, p14/ARF, and/or p15/CDKN2B genes, in lymphoid leukemia, 30 breakpoints were cloned from 15 lymphoid leukemia cell lines. |
12228235 |
Human |
p16 |
head and neck squamous cell carcinoma |
Neither p16 promoter hypermethylation nor apparent loss of p16 protein expression appears to be an independent prognostic factor, although loss of p16 protein may be used to predict overall patient survival in early-stage head and neck squamous cell carci |
13679459 |
Human |
p16 |
nodular melanomas |
Overall, 52 (48%) tumours expressed p16; nodular melanomas had significantly lower levels of p16 immunoreactivity than superficial spreading melanomas (P = 0.015). |
12459643 |
Human |
arf |
pituitary tumor |
ARF mutation accelerates pituitary tumor development in Rb+/- mice. |
12486224 |
Mouse |
p14arf |
intestinal-type cancers |
Whereas p14ARF methylation was found more frequently in intestinal type cancers in an early stage and in diffuse type cancers in an advanced stage, MSI tended to be related especially to p14ARF methylation in cancers of the intestinal type. |
12608655 |
Human |
cdkn2a |
plasma cell tumors |
Concomitantly, resistant C57BL/6 mice, from which both gene products of the Cdkn2a gene have been eliminated, developed pristane-induced plasma cell tumors over a shorter latency period than the traditionally susceptible BALB/cAn strain. |
11113205 |
Mouse |
p14arf |
plexiform neurofibroma |
We have determined the methylation status of the CpG island of 11 tumour-related genes (RB1, p14ARF, p16INK4a, p73, TIMP-3, MGMT, DAPK, THBS1, caspase 8, TP53 and GSTP1) in 18 neurofibromas (including one plexiform neurofibroma) and three neurofibrosarcom |
12883734 |
Human |
ink4a |
marginal-zone lymphomas (mzl) |
Chronic antigenic stimulation at these sites or in response to infection with Hepatitis C provides the milieu for mutations at FAS, API2/ML, TP53 and INK4a/p19ARF and the development of marginal zone lymphomas (MZL) in node, spleen and MALT. |
11166833 |
Human |
p16 |
bladder carcinomas |
Prognostic implications of aberrations in p16/pRb pathway in urothelial bladder carcinomas: a multivariate analysis including p53 expression and proliferation markers. |
11223676 |
Human |
p16 |
acute promyelocytic leukemia |
Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. |
11283136 |
Human |
p16 |
therapy-related myelodysplastic syndrome |
During follow-up, p16 methylation was acquired in two patients, one during the third hematologic relapse, and the other during transformation into therapy-related myelodysplastic syndrome. |
11283136 |
Human |
ink4a |
mouse lymphomas |
The BMI-1 gene is a putative oncogene belonging to the Polycomb group family that cooperates with c-myc in the generation of mouse lymphomas and seems to participate in cell cycle regulation and senescence by acting as a transcriptional repressor of the I |
11289106 |
Human |
arf |
mouse lymphomas |
The BMI-1 gene is a putative oncogene belonging to the Polycomb group family that cooperates with c-myc in the generation of mouse lymphomas and seems to participate in cell cycle regulation and senescence by acting as a transcriptional repressor of the I |
11289106 |
Human |
p14arf |
endometrial neoplasms |
We also studied the profile of p14ARF promoter hypermethylation in an extensive collection of 559 human primary tumors of different cell types, observing that in colorectal, gastric, renal, esophageal, and endometrial neoplasms and gliomas, aberrant methy |
11306450 |
Human |
p16 |
metaplasia |
DAP-kinase was methylated at a similar frequency in all four stages, whereas hMLH1 and p16 were methylated in cancer samples (20.3% and 42.2%, respectively) more frequently than in intestinal metaplasia (6.3% and 2.1%, respectively) or adenomas (9.8% and |
11306456 |
Human |
p16 |
metaplasia |
The hMLH1, THBS1, and TIMP-3 hypermethylation frequencies were similar in both intestinal metaplasia and adenomas, but the p16 hypermethylation frequency tended to be higher in adenomas (11.5%) than in intestinal metaplasia (2.1%; P = 0.073). |
11306456 |
Human |
p14arf |
anaplasia |
In one tumor containing distinct areas with and without anaplasia, p14ARF hypermethylation was detected in the WHO grade II area, while homozygous co-deletion of p14ARF and p16INK4a was found in the region with anaplastic features (grade III). |
11307615 |
Human |
p14arf |
peritumoral vessel invasion |
The analysis of concomitant P14ARF and TP73 overexpression and clinicopathologic parameters of the tumors showed a statistically significant difference with respect to peritumoral vessel invasion (P = 0.01), lymph node metastasis (P = 0.03), negative ERBB |
11319797 |
Human |
cdkn2a |
melanoma in situ |
Among many gene alterations detected in human melanoma, defect of CDKN2A located at chromosome 9p21 seems to be most important in the earlier developmental phase, though significance of this gene in the evolution of melanoma in situ has not been confirmed |
11323215 |
Human |
ink4a |
enchondroma |
The correlation between INK4A/p16 protein expression and tumour grade, and the retention of expression in enchondromas, indicates that loss of INK4A/p16 protein expression may be an important event during tumour progression from enchondroma to conventiona |
14991902 |
Human |
p16 |
enchondroma |
The correlation between INK4A/p16 protein expression and tumour grade, and the retention of expression in enchondromas, indicates that loss of INK4A/p16 protein expression may be an important event during tumour progression from enchondroma to conventiona |
14991902 |
Human |
ink4a |
b16 melanoma |
In the spontaneous B16 melanoma cell lines, expression of p16Ink4a and p19Arf tumor suppressor proteins was lost as a consequence of a large deletion spanning Ink4a/Arf exons 1alpha, 1beta, and 2. |
14743208 |
Human |
arf |
b16 melanoma |
In the spontaneous B16 melanoma cell lines, expression of p16Ink4a and p19Arf tumor suppressor proteins was lost as a consequence of a large deletion spanning Ink4a/Arf exons 1alpha, 1beta, and 2. |
14743208 |
Human |
cdkn2 |
mesenchymal tumors |
We previously demonstrated that approximately one-half of soft-tissue sarcomas were devoid of either pRB, the product of the retinoblastoma gene, or 16, the product of the MTS1/CDKN2 gene, while a smaller subset of aggressive mesenchymal tumors without me |
11341347 |
Human |
mts1 |
mesenchymal tumors |
We previously demonstrated that approximately one-half of soft-tissue sarcomas were devoid of either pRB, the product of the retinoblastoma gene, or 16, the product of the MTS1/CDKN2 gene, while a smaller subset of aggressive mesenchymal tumors without me |
11341347 |
Human |
p14arf |
burkitt lymphoma |
p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. |
11360201 |
Human |
ink4a |
polycythemia vera |
Increased expression of the INK4a/ARF locus in polycythemia vera. |
11369633 |
Human |
arf |
polycythemia vera |
Increased expression of the INK4a/ARF locus in polycythemia vera. |
11369633 |
Human |
ink4a |
primary carcinomas |
Molecular analysis of the INK4A and INK4B gene loci in human breast cancer cell lines and primary carcinomas. |
11369056 |
Human |
ink4a |
neurofibromatosis |
SUMMARY: Karyotypic complexities associated with frequent loss or rearrangement of a number of chromosome arms, deletions, and mutations affecting the TP53 region, and molecular alterations of the INK4A gene have been reported in sporadic and/or neurofibr |
11406645 |
Human |
p16 |
condylomas |
Limitations in specificity included minimal or no suprabasal staining for Ki-67 in immature condylomas and occasional suprabasal staining of reactive epithelial changes (10%), diffuse weak nuclear cyclin E staining in some normal or metaplastic epithelia, |
11420459 |
Human |
cdkn2a |
neurofibroma |
CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. |
11433531 |
Human |
ink4a |
leukaemia |
Overexpression of the polycomb group gene Bmi1 promotes cell proliferation and induces leukaemia through repression of Cdkn2a (also known as ink4a/Arf) tumour suppressors. |
15029199 |
Human |
cdkn2a |
leukaemia |
Overexpression of the polycomb group gene Bmi1 promotes cell proliferation and induces leukaemia through repression of Cdkn2a (also known as ink4a/Arf) tumour suppressors. |
15029199 |
Human |
arf |
leukaemia |
Overexpression of the polycomb group gene Bmi1 promotes cell proliferation and induces leukaemia through repression of Cdkn2a (also known as ink4a/Arf) tumour suppressors. |
15029199 |
Human |
p16 |
endometrial adenocarcinomas |
Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. |
15043304 |
Human |
p16 |
endometrial adenocarcinomas |
Most endocervical adenocarcinomas (ECAs) contain high-risk human papillomavirus (HPV) DNA, whereas endometrial adenocarcinomas (EMAs) rarely do. p16 is an inhibitor ofcyclin-dependent kinases, and overexpression of p16 has been observed in cervical intrae |
15043304 |
Human |
p16 |
insulinomas |
RT-PCR analysis revealed loss of expression of at least one of the tumor suppressor genes CDKN2A/p16, CDKN2B/p15, and CDKN2D/p14 with distinct genetic profiles, most frequently in nonfunctional pancreatic tumors (57%) and small intestinal carcinoids (44%) |
11479232 |
Human |
cdkn2a |
insulinomas |
RT-PCR analysis revealed loss of expression of at least one of the tumor suppressor genes CDKN2A/p16, CDKN2B/p15, and CDKN2D/p14 with distinct genetic profiles, most frequently in nonfunctional pancreatic tumors (57%) and small intestinal carcinoids (44%) |
11479232 |
Human |
p14 |
insulinomas |
RT-PCR analysis revealed loss of expression of at least one of the tumor suppressor genes CDKN2A/p16, CDKN2B/p15, and CDKN2D/p14 with distinct genetic profiles, most frequently in nonfunctional pancreatic tumors (57%) and small intestinal carcinoids (44%) |
11479232 |
Human |
p16 |
pancreatic tumors |
RT-PCR analysis revealed loss of expression of at least one of the tumor suppressor genes CDKN2A/p16, CDKN2B/p15, and CDKN2D/p14 with distinct genetic profiles, most frequently in nonfunctional pancreatic tumors (57%) and small intestinal carcinoids (44%) |
11479232 |
Human |
cdkn2a |
pancreatic tumors |
RT-PCR analysis revealed loss of expression of at least one of the tumor suppressor genes CDKN2A/p16, CDKN2B/p15, and CDKN2D/p14 with distinct genetic profiles, most frequently in nonfunctional pancreatic tumors (57%) and small intestinal carcinoids (44%) |
11479232 |
Human |
p14 |
pancreatic tumors |
RT-PCR analysis revealed loss of expression of at least one of the tumor suppressor genes CDKN2A/p16, CDKN2B/p15, and CDKN2D/p14 with distinct genetic profiles, most frequently in nonfunctional pancreatic tumors (57%) and small intestinal carcinoids (44%) |
11479232 |
Human |
cdkn2a |
atypical meningiomas |
We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppr |
11485924 |
Human |
cdkn2a |
benign meningiomas |
We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppr |
11485924 |
Human |
cdkn2a |
atypical meningioma |
Six anaplastic meningiomas (46%) and one atypical meningioma (3%) showed homozygous deletions of the CDKN2A, p14(ARF), and CDKN2B genes. |
11485924 |
Human |
cdkn2a |
benign meningioma |
One anaplastic meningioma, three atypical meningiomas, and one benign meningioma without a demonstrated homozygous deletion or mutation of CDKN2A, p14(ARF), or CDKN2B lacked detectable transcripts from at least one of these genes. |
11485924 |
Human |
cdkn2a |
atypical meningiomas |
One anaplastic meningioma, three atypical meningiomas, and one benign meningioma without a demonstrated homozygous deletion or mutation of CDKN2A, p14(ARF), or CDKN2B lacked detectable transcripts from at least one of these genes. |
11485924 |
Human |
p16 |
angiosarcoma of the liver |
This study was performed to determine whether alterations of p16 are involved in the development of angiosarcoma of the liver. |
11495043 |
Human |
mts1 |
mammary adenocarcinoma |
A composite enhancer that is active in murine mammary adenocarcinoma cells was previously identified in the first intron of the mts1/S100A4 gene. |
11504871 |
Mouse |
ink4a |
malignant pleural mesothelioma |
Genetic alterations of INK4a/ARF locus, which is a predominant event in malignant pleural mesothelioma, may result in loss of p14(ARF) and subsequent disruption of p53 pathway in cancer cells. |
11507034 |
Human |
arf |
malignant pleural mesothelioma |
Genetic alterations of INK4a/ARF locus, which is a predominant event in malignant pleural mesothelioma, may result in loss of p14(ARF) and subsequent disruption of p53 pathway in cancer cells. |
11507034 |
Human |
ink4a |
melanocytic nevi |
Here we evaluate 21 melanocytic lesions at various stages of malignant progression from common melanocytic nevi to metastatic melanomas and examine these lesions for Id1 and p16/Ink4a expression. |
11507043 |
Human |
p16 |
melanocytic nevi |
Here we evaluate 21 melanocytic lesions at various stages of malignant progression from common melanocytic nevi to metastatic melanomas and examine these lesions for Id1 and p16/Ink4a expression. |
11507043 |
Human |
ink4a |
melanoma in situ |
We demonstrate that Id1 expression correlates with loss of p16/Ink4a expression in melanoma in situ; however, more advanced stages of melanoma do not express Id1 except within perivascular regions, despite overall decreased p16/Ink4a expression in these l |
11507043 |
Human |
p16 |
melanoma in situ |
We demonstrate that Id1 expression correlates with loss of p16/Ink4a expression in melanoma in situ; however, more advanced stages of melanoma do not express Id1 except within perivascular regions, despite overall decreased p16/Ink4a expression in these l |
11507043 |
Human |
p16 |
metastatic bladder cancers |
DESIGN: The authors examined the pattern of allelic loss with polymorphic microsatellite markers on chromosome 9p21 (D9S161, D9S171, IFNA), regions of putative tumor suppressor gene p16, and on chromosome 17p13 (TP53), the p53 locus, in matched primary an |
11520271 |
Human |
p16 |
metastatic carcinoma |
CONCLUSIONS: The pattern of allelic loss at chromosome 9p21 (p16) and 17p13 (p53) was generally maintained during cancer progression to metastasis, and identical allelic loss in primary cancer was conserved in paired metastatic carcinoma. |
11520271 |
Human |
ink4a |
melanoma |
CDKN2A (INK4a/ARF) is frequently disrupted in various types of human cancer, and germline mutations of this locus can confer susceptibility to melanoma and other tumours. |
11544530 |
Human |
ink4a |
melanoma |
However, Ink4a*/Delta2,3 mice that are deficient for Ink4a and heterozygous for Arf spontaneously develop a wide spectrum of tumours, including melanoma. |
11544530 |
Mouse |
arf |
melanoma |
However, Ink4a*/Delta2,3 mice that are deficient for Ink4a and heterozygous for Arf spontaneously develop a wide spectrum of tumours, including melanoma. |
11544530 |
Mouse |
p 16 |
bone metastasis |
The genetic analysis of DNA from the original tumor, the bone metastasis and the autoptic brain tumor showed LOH of 1p; heterozygous deletion of CDKN2A/p 16 was detected as additional alteration in the metastasis and in the intracranial tumor at autopsy. |
15015656 |
Human |
cdkn2a |
bone metastasis |
The genetic analysis of DNA from the original tumor, the bone metastasis and the autoptic brain tumor showed LOH of 1p; heterozygous deletion of CDKN2A/p 16 was detected as additional alteration in the metastasis and in the intracranial tumor at autopsy. |
15015656 |
Human |
p 16 |
intracranial tumor |
The genetic analysis of DNA from the original tumor, the bone metastasis and the autoptic brain tumor showed LOH of 1p; heterozygous deletion of CDKN2A/p 16 was detected as additional alteration in the metastasis and in the intracranial tumor at autopsy. |
15015656 |
Human |
cdkn2a |
intracranial tumor |
The genetic analysis of DNA from the original tumor, the bone metastasis and the autoptic brain tumor showed LOH of 1p; heterozygous deletion of CDKN2A/p 16 was detected as additional alteration in the metastasis and in the intracranial tumor at autopsy. |
15015656 |
Human |
p16 |
breast adenocarcinomas |
ErbB2 was also a deciding factor in deregulation of cyclin D1-cdk4/6 in human tumors because no loss of pRb or p16 was found in tumors overexpressing erbB2, although erbB2-negative invasive breast adenocarcinomas frequently lacked expression of p16 or pRb |
14982856 |
Human |
p16 |
gallbladder adenomas |
STUDY DESIGN: Twenty-four gallbladder carcinomas, 20 gallbladder adenomas, and 18 chronic cholecystitis specimens were immunohistochemically and histopathologically investigated for the relation of p53, p16, and VEGF to Nevin staging and pathologic gradin |
11584965 |
Human |
p16 |
blastic nk-cell lymphoma |
In addition, homozygous deletions of p15, p16 and p14 genes in 5 out of 31 samples were detected; 3 were from nasal NK cell lymphoma and 2 from blastic NK cell lymphoma / leukemia. |
11676855 |
Human |
p14 |
blastic nk-cell lymphoma |
In addition, homozygous deletions of p15, p16 and p14 genes in 5 out of 31 samples were detected; 3 were from nasal NK cell lymphoma and 2 from blastic NK cell lymphoma / leukemia. |
11676855 |
Human |
ink4a |
primary central-nervous-system lymphoma |
Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type. |
11804283 |
Human |
arf |
primary central-nervous-system lymphoma |
Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type. |
11804283 |
Human |
p16 |
anaplastic tumors |
7/26 (27%) benign, 3/12 (25%) atypical but 4/7 (57%) anaplastic tumors lacked both, p16 and p15 protein expression. |
11859969 |
Human |
p16 |
waldenstrom macroglobulinemia |
MATERIALS AND METHODS: The methylation status of the p16 gene was analysed in a group of 159 patients with monoclonal gammopathies (40 monoclonal gammopathy of uncertain significance, eight Waldenström Macroglobulinemia, eight smoldering multiple myeloma |
11920239 |
Human |
p16 |
waldenstrom macroglobulinemia |
RESULTS: Forty-one of 98 MM patients (41.8%) as well as four of the five (80%) primary PCL patients showed methylation of the p16 gene, while none of the patients with monoclonal gammopathy of undetermined significance, Waldenström Macroglobulinemia or s |
11920239 |
Human |
p16 |
undifferentiated carcinoma |
The positive rate of p16 protein expression in mucoid carcinoma 10.00% (1/10) was significantly lower than that in poorly differentiated carcinoma 51.22% (21/41), undifferentiated carcinoma 57.69% (15/26) and signet ring cell carcinoma 62.50% (10/16) (P < |
11819820 |
Human |
p16 |
signet-ring-cell carcinoma |
The positive rate of p16 protein expression in mucoid carcinoma 10.00% (1/10) was significantly lower than that in poorly differentiated carcinoma 51.22% (21/41), undifferentiated carcinoma 57.69% (15/26) and signet ring cell carcinoma 62.50% (10/16) (P < |
11819820 |
Human |
p16 |
endometrial carcinomas |
Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. |
10656444 |
Human |
p16 |
endometrial carcinoma |
We therefore wanted to assess the pattern and prognostic impact of p16 protein expression and promoter region methylation in a population-based series of 316 endometrial carcinoma patients with long-term and complete follow-up. |
10656444 |
Human |
p16 |
intratumor microvessel density |
Loss of nuclear p16 staining was significantly associated with increased age, high FIGO (International Federation of Gynecology and Obstetrics) stage, serous papillary or clear cell histological types, high histological grade, aneuploidy, low estradiol an |
10656444 |
Human |
p16ink4 |
colorectal tumors |
Loss of p16INK4 tumor suppressor function in colorectal tumors was associated with proximal location in the gut. |
12963980 |
Human |
p14arf |
pediatric solid tumors |
Aberrations of p16INK4A, p14ARF and p15INK4B genes in pediatric solid tumors. |
12963998 |
Human |
p16 |
polypoid adenomas |
We analysed the methylation status of the tumor suppressor gene p16, the DNA mismatch repair gene hMLH1, and four CpG islands (MINT1, MINT2, MINT25, and MINT31) using methylation-specific polymerase chain reaction in 35 polypoid adenomas and 46 flat dyspl |
15064707 |
Human |
ink4a |
parathyroid adenomas |
The aim of the present study was to evaluate the alterations in the components of the pRB pathway in parathyroid adenomas and parathyroid aggressive tumors, including patterns of expression of pRB, Cyc D1, and p16/INK4A. |
10671696 |
Human |
p16 |
parathyroid adenomas |
The aim of the present study was to evaluate the alterations in the components of the pRB pathway in parathyroid adenomas and parathyroid aggressive tumors, including patterns of expression of pRB, Cyc D1, and p16/INK4A. |
10671696 |
Human |
cdkn2 |
uterine cervical cancer |
Alteration of the CDKN2/p16 gene is not required for HPV-positive uterine cervical cancer cell lines. |
10675486 |
Human |
p16 |
uterine cervical cancer |
Alteration of the CDKN2/p16 gene is not required for HPV-positive uterine cervical cancer cell lines. |
10675486 |
Human |
p16 |
high-grade lymphoma |
With time, a fraction of follicular lymphoma accumulates mutations of p53 and of p16 and evolves into a high grade lymphoma. |
10681729 |
Human |
cdkn2a |
plasmacytoma |
In contrast, mutations of the murine CDKN2A gene predispose BALB/c mice to pristane-induced plasmacytoma. |
10688850 |
Mouse |
p16 |
acral-lentiginous melanoma |
An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma. |
10657449 |
Human |
p16 |
acral-lentiginous melanomas |
These data suggest that p16 inactivation may play an important role in the development and progression of acral lentiginous melanomas. |
10657449 |
Human |
p16 |
mouse lymphomas |
Previously, we have reported frequent inactivation of the Cdkn2a/Cdkn2b loci encoding p16/p15 cyclin dependent kinase inhibitors in a subset of 2',3'-dideoxycytidine- and 1, 3-butadiene-induced mouse lymphomas (S.-M. Zhuang, A. Schippert, A. Hau |
10773403 |
Mouse |
cdkn2a |
mouse lymphomas |
Previously, we have reported frequent inactivation of the Cdkn2a/Cdkn2b loci encoding p16/p15 cyclin dependent kinase inhibitors in a subset of 2',3'-dideoxycytidine- and 1, 3-butadiene-induced mouse lymphomas (S.-M. Zhuang, A. Schippert, A. Hau |
10773403 |
Mouse |
p16 |
tubular adenomas |
We found that abnormal expression of p16 and p27 increased with the progression of tubular adenomas to advanced gastric cancers. |
10779641 |
Human |
ink4a |
germ-cell tumors |
Alterations of the INK4a/ARF locus in human intracranial germ cell tumors. |
10786670 |
Human |
arf |
germ-cell tumors |
Alterations of the INK4a/ARF locus in human intracranial germ cell tumors. |
10786670 |
Human |
ink4a |
nongerminomatous germ-cell tumors |
To evaluate whether genetic alterations of the INK4a/ARF locus occur in the genesis of ICGTs, we analyzed the INK4a/ARF genes in 21 ICGTs-10 pure germinomas and 11 nongerminomatous germ cell tumors. |
10786670 |
Human |
arf |
nongerminomatous germ-cell tumors |
To evaluate whether genetic alterations of the INK4a/ARF locus occur in the genesis of ICGTs, we analyzed the INK4a/ARF genes in 21 ICGTs-10 pure germinomas and 11 nongerminomatous germ cell tumors. |
10786670 |
Human |
ink4a |
germinoma |
These data suggested that INK4a/ARF gene abnormalities could play an important role in the genesis of ICGTs, especially in pure germinoma. |
10786670 |
Human |
arf |
germinoma |
These data suggested that INK4a/ARF gene abnormalities could play an important role in the genesis of ICGTs, especially in pure germinoma. |
10786670 |
Human |
ink4a |
high-grade lymphomas |
Because the cyclin-dependent kinase inhibitor p16/INK4a has been reported to be frequently inactivated in high-grade lymphomas, we evaluated 17 PT-LPD to determine whether p16/INK4a expression could be correlated to morphology, EBV detection, and a Ki-67 |
10793069 |
Human |
p16 |
high-grade lymphomas |
Because the cyclin-dependent kinase inhibitor p16/INK4a has been reported to be frequently inactivated in high-grade lymphomas, we evaluated 17 PT-LPD to determine whether p16/INK4a expression could be correlated to morphology, EBV detection, and a Ki-67 |
10793069 |
Human |
cyclin-dependent kinase inhibitor p16 |
high-grade lymphomas |
Because the cyclin-dependent kinase inhibitor p16/INK4a has been reported to be frequently inactivated in high-grade lymphomas, we evaluated 17 PT-LPD to determine whether p16/INK4a expression could be correlated to morphology, EBV detection, and a Ki-67 |
10793069 |
Human |
p14arf |
brain metastases |
Thus, in addition to these two genes, we determined the methylation status of the genes p16INK4a, glutathione S-transferase P1 (GSTP1), O6-methylguanine DNA methyltransferase (MGMT), thrombospondin-1 (THBS1), p14ARF, TP53, p73, and tissue inhibitor of met |
14654977 |
Human |
ink4a |
primary breast cancer |
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. |
10914724 |
Human |
p16 |
marginal zone b-cell lymphoma |
Analysis of the P53, RB/D13S25, and P16 tumor suppressor genes in marginal zone B-cell lymphoma: An interphase fluorescence in situ hybridization study. |
10913669 |
Human |
p16 |
colorectal adenocarcinomas |
Expression of thymidylate synthase in human gastric and colorectal adenocarcinomas is upregulated by p16/INK4. |
10919023 |
Human |
ink4 |
colorectal adenocarcinomas |
Expression of thymidylate synthase in human gastric and colorectal adenocarcinomas is upregulated by p16/INK4. |
10919023 |
Human |
p16 |
colorectal adenocarcinomas |
CONCLUSIONS: pTS expression regulation in human gastric and colorectal adenocarcinomas in complex, and upregulated by p16/INK4. |
10919023 |
Human |
ink4 |
colorectal adenocarcinomas |
CONCLUSIONS: pTS expression regulation in human gastric and colorectal adenocarcinomas in complex, and upregulated by p16/INK4. |
10919023 |
Human |
cdkn2a |
tumor |
Taken together, our data indicate that mutations of the PTEN and TP53 tumor suppressor genes, homozygous deletion of the CDKN2A gene as well as overexpression of the EGFR, p53 and Mdm2 proteins lack prognostic significance for overall survival time in pat |
11083071 |
Human |
p16 |
squamous-cell lung carcinoma |
By increasing the sensitivity of a PCR approach to detect methylated DNA sequences, we now demonstrate that aberrant methylation of the p16 and/or O6-methyl-guanine-DNA methyltransferase promoters can be detected in DNA from sputum in 100% of patients wit |
11085511 |
Human |
p16 |
primary cutaneous large-cell lymphoma |
Here, we provide the first evidence of the involvement of the tumor suppressor gene p16 in primary cutaneous large cell lymphoma. |
11121148 |
Human |
cdkn2a |
regional cancer |
We screened 80 individuals with at least two primary cutaneous melanomas, who were identified mainly by a search of a regional cancer registry, for germ-line CDKN2A mutations. |
11156381 |
Human |
p16 |
mature teratoma |
Total resection was performed, and histogenetical findings led to the diagnosis of a mature teratoma with normal p16 gene, whereas analysis of intracranial tumor showed p16 deletion. |
11155064 |
Human |
p16 |
intracranial tumor |
Total resection was performed, and histogenetical findings led to the diagnosis of a mature teratoma with normal p16 gene, whereas analysis of intracranial tumor showed p16 deletion. |
11155064 |
Human |
p16 |
squamous cell carcinoma in situ |
A total of 33 cases were examined for evidence of death-associated protein kinase and p16 hypermethylation and these consist of 9 cases of spongiotic dermatitis as nonneoplastic skin control, 9 cases of actinic keratosis, 8 cases of squamous cell carcinom |
12861061 |
Human |
p16 |
squamous cell carcinoma in situ |
P16 promoter methylation was detected in 1 case of invasive squamous cell carcinoma and 1 case of nonneoplastic skin control but none of the cases of squamous cell carcinoma in situ or actinic keratosis. |
12861061 |
Human |
p16 |
breast and ovarian cancer |
At present, the most useful methods of risk assessment are those performed on the following genes: BRCA1 and BRCA2 especially for hereditary breast and ovarian cancer, hMLH1 and hMSH2 for hereditary non polyposis colorectal cancer, APC for familial adenom |
11205230 |
Human |
p16 |
medullary-thyroid carcinoma |
At present, the most useful methods of risk assessment are those performed on the following genes: BRCA1 and BRCA2 especially for hereditary breast and ovarian cancer, hMLH1 and hMSH2 for hereditary non polyposis colorectal cancer, APC for familial adenom |
11205230 |
Human |
p16 |
salivary-gland carcinomas |
Analysis of chromosome 9p21 deletion and p16 gene mutation in salivary gland carcinomas. |
10534174 |
Human |
p16 |
salivary duct carcinoma |
In addition, another salivary duct carcinoma showed a homozygous deletion of p16 in differential polymerase chain reaction analysis. |
10534174 |
Human |
p16 |
salivary duct carcinomas |
These results suggest that inactivation of p16 is important in the development or progression of at least some salivary duct carcinomas, but we found no evidence that its alteration plays a role in the other subtypes examined. |
10534174 |
Human |
p16 |
invasive cancers |
Hypermethylation of p16 was localized only to the neoplastic cells in both in situ lesions and invasive cancers, and was associated with loss of p16 protein expression. |
10535995 |
Human |
p16 |
invasive cancer |
These data suggest that p16 inactivation is selected as the most effective mechanism of blocking the cyclin D-Rb pathway during the evolution of an invasive cancer from precursor lesions. |
10535995 |
Human |
p16 |
malignant brain tumors |
The frequency of the alteration of the p16 gene, either homozygous deletion or mutation accompanied with amino acid substitutions, increased in malignant brain tumors (grade III and IV) compared with that in low grade tumors (grade I and II) (p=0.0275), s |
10536183 |
Human |
p16 |
low-grade tumors |
The frequency of the alteration of the p16 gene, either homozygous deletion or mutation accompanied with amino acid substitutions, increased in malignant brain tumors (grade III and IV) compared with that in low grade tumors (grade I and II) (p=0.0275), s |
10536183 |
Human |
p16 |
neurofibromatosis 1 |
Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. |
10595918 |
Human |
cdkn2a |
neurofibromatosis 1 |
Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. |
10595918 |
Human |
p16 |
gastric adenosquamous carcinoma |
The expression of p53, p16 and RB proteins and their clinicopathologic correlation were investigated in 15 cases of primary gastric adenosquamous carcinoma and 2 cases of squamous cell carcinoma of the stomach. |
10605694 |
Human |
p16 |
squamous cell carcinoma of the stomach |
The expression of p53, p16 and RB proteins and their clinicopathologic correlation were investigated in 15 cases of primary gastric adenosquamous carcinoma and 2 cases of squamous cell carcinoma of the stomach. |
10605694 |
Human |
p16 |
angiomyolipoma |
In order to investigate a possible link between the two tumours, we investigated mutations in the p53-gene, loss of heterozygosity (LOH) at p53, Rb and p16, c-Myc expression, and the telomerase activity of the angiomyolipoma and the osteosarcoma. |
10605697 |
Human |
p16 |
angiomyolipoma |
Whilst the tibial osteosarcoma showed LOH at p16, no genetic alterations or increased telomerase activity were found in the angiomyolipoma. |
10605697 |
Human |
p16 |
small-bowel adenocarcinomas |
The levels of cyclin D1, cyclin E, p16, p21, p27, and p53 proteins were determined by immunohistochemistry in samples of normal small bowel (n = 16), small bowel adenomas (n = 20), and small bowel adenocarcinomas (n = 24). |
10613343 |
Human |
p16 |
salivary gland neoplasm |
Quantitative study on expression of p16 multiple tumor suppressor gene in salivary gland neoplasm. |
12840862 |
Human |
p16 |
parotid neoplasm |
The PU of p16 gene was higher in deep lobe of recurrent parotid neoplasm with incomplete capsule than that in shallow lobe of primary parotid neoplasm with complete capsule. |
12840862 |
Human |
p16 |
salivary gland tumors |
The findings suggests that p16 gene plays an equally important role in the salivary gland tumors and tumors in other part of the body. |
12840862 |
Human |
ink4a |
adult soft tissue sarcomas |
Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival. |
9890173 |
Human |
ink4a |
adult soft tissue sarcomas |
This study was undertaken to evaluate the frequency of INK4A and INK4B gene alterations in a cohort of adult soft tissue sarcomas. |
9890173 |
Human |
ink4a |
high-grade sarcomas |
The overall frequency of gene alteration (deletion or rearrangement) was approximately 15% for the INK4A and INK4B genes, with changes restricted to high-grade sarcomas. |
9890173 |
Human |
ink4a |
adult soft tissue sarcomas |
CONCLUSION/IMPLICATIONS: Coincident homozygous deletion of the INK4A and INK4B genes occurs frequently in adult soft tissue sarcomas. |
9890173 |
Human |
p16 |
female breast cancer |
We report the approximately tenfold increase in copy number of DNA from 9p23-24, which is far distal to P16/CDKN2A in female breast cancer cell line COLO 824, as revealed by fluorescence in situ hybridization, comparative genomic hybridization, and micros |
9892114 |
Human |
cdkn2a |
female breast cancer |
We report the approximately tenfold increase in copy number of DNA from 9p23-24, which is far distal to P16/CDKN2A in female breast cancer cell line COLO 824, as revealed by fluorescence in situ hybridization, comparative genomic hybridization, and micros |
9892114 |
Human |
p16 |
liver cancer |
Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. |
9892188 |
Human |
p16 |
ovarian epithelial tumor |
OBJECTIVE. The aim of this study was to test the hypothesis that DNA methylation is important for silencing the p16 tumor suppressor gene in ovarian epithelial tumors and to compare the prevalence of this mechanism among different ovarian epithelial tumor |
9889036 |
Human |
p16 |
ovarian epithelial tumors |
OBJECTIVE. The aim of this study was to test the hypothesis that DNA methylation is important for silencing the p16 tumor suppressor gene in ovarian epithelial tumors and to compare the prevalence of this mechanism among different ovarian epithelial tumor |
9889036 |
Human |
p16 |
non-small cell carcinoma |
p16 inactivation in small-sized lung adenocarcinoma: its association with poor prognosis. p16, an inhibitor of cell cycle machinery, is frequently inactivated in non-small cell carcinoma of the lung (NSCCL). |
9988232 |
Human |
p16 |
other cancers |
These results strongly support the hypothesis that the RB nuclear overexpression recently associated with poor prognosis in bladder cancer is also associated with loss of p16 function and implies that loss of p16 function could be equally deleterious as R |
10022125 |
Human |
p16 |
bladder cancer |
These results strongly support the hypothesis that the RB nuclear overexpression recently associated with poor prognosis in bladder cancer is also associated with loss of p16 function and implies that loss of p16 function could be equally deleterious as R |
10022125 |
Human |
ink4a |
papillomas |
The protein expression of cdk6 and ckis viz. p16/Ink4A, p21/Waf1 and p27/Kip1 did not show any significant change in UVB exposed skin, but significant upregulation was observed both in papillomas and carcinomas. |
10022811 |
Human |
p16 |
papillomas |
The protein expression of cdk6 and ckis viz. p16/Ink4A, p21/Waf1 and p27/Kip1 did not show any significant change in UVB exposed skin, but significant upregulation was observed both in papillomas and carcinomas. |
10022811 |
Human |
p16 |
acute leukemias |
Reports on homozygous deletion of p16 and p15 genes suggest the value of larger, prospective studies with standardized treatment protocols to definitively establish the prognostic utility of p15/p16 deletions in acute leukemias. |
10073286 |
Human |
p16 |
relapsed childhood all |
These findings indicate that loss of function of proteins encoded by p16 and/or p15 plays an important role in the biology of relapsed childhood ALL, and is associated with disease progression in a subset of cases. |
10090949 |
Human |
cdkn2a |
oropharyngeal squamous cell carcinomas |
DNA studies underestimate the major role of CDKN2A inactivation in oral and oropharyngeal squamous cell carcinomas. |
10221335 |
Human |
cdkn2a |
oropharyngeal squamous cell carcinomas |
Our data show that inactivation of the CDKN2A gene products is a near-universal step in the development of oral and oropharyngeal squamous cell carcinomas, and we suggest that homozygous deletion is the most common mechanism of inactivation. |
10221335 |
Human |
p16 |
verrucous carcinomas |
Immunohistochemical analysis of cell cycle-associated proteins p16, pRb, p53, p27 and Ki-67 in oral cancer and precancer with special reference to verrucous carcinomas. |
10226946 |
Human |
p16 |
invasive ductal breast cancer |
Using methylation-specific PCR, aberrant hypermethylation of p16 and CDH1 in tumor and plasma was analyzed and correlated with levels of serum protein markers, carcinoembryonic antigen (CEA) and carcinoma antigen 15-3 (CA15.3), in 36 patients with invasiv |
14534701 |
Human |
ink4a |
gastric stromal tumors |
Thirty-eight c-kit-positive gastric stromal tumors were subjected to methylation-specific polymerase chain reaction (MSP) to detect promoter methylation associated with 11 candidate tumor suppressor genes (p16/INK4a, APC, MGMT, hMLH1, p73, E-cadherin, RAR |
14675710 |
Human |
p16 |
gastric stromal tumors |
Thirty-eight c-kit-positive gastric stromal tumors were subjected to methylation-specific polymerase chain reaction (MSP) to detect promoter methylation associated with 11 candidate tumor suppressor genes (p16/INK4a, APC, MGMT, hMLH1, p73, E-cadherin, RAR |
14675710 |
Human |
p16 |
adenomatous polyps |
EXPERIMENTAL DESIGN: Methylation-specific PCR was used to detect p16 methylation in DNA extracted from 52 CRCs and matching serum samples and control serum samples from 34 patients with adenomatous polyps and 10 healthy individuals. |
11801557 |
Human |
p16 |
adenomatous polyps |
No methylated p16 sequences were detected in the peripheral serum of the other 32 CRC cases without these changes in the tumor, in 34 patients with adenomatous polyps, or in 10 healthy control subjects. |
11801557 |
Human |
ink4a |
extrahepatic bile duct cancers |
Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. |
11802210 |
Human |
arf |
extrahepatic bile duct cancers |
Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. |
11802210 |
Human |
ink4 |
spindle-cell tumor |
Gene deletion of the INK4 locus is associated with transformation to a highly invasive spindle cell tumor phenotype. |
10341708 |
Human |
p16 |
prostatic adenocarcinomas |
The purpose of the present study was to evaluate patterns of p16 expression in a well-characterized cohort of prostatic adenocarcinomas while exploring potential associations between alterations of p16 and clinicopathological variables. |
10353729 |
Human |
p16 |
metastatic prostate cancers |
Analysis of six independent lines from metastatic prostate cancers reveals a similar loss of either p16 or pRb. |
10383161 |
Human |
ink4 |
nervous system tumors |
BACKGROUND: A genetic syndrome of cutaneous malignant melanoma and nervous system tumors recently has been characterized and shown to be linked to the INK4 locus in the 9p21 region. |
10388473 |
Human |
cdkn2a |
plasma cell tumors |
The role of p16INK4a (Cdkn2a) in mouse plasma cell tumors. |
10396076 |
Mouse |
p16 |
sporadic colorectal cancers |
CIMP+ tumors also have a high incidence of p16 and THBS1 methylation, and they include the majority of sporadic colorectal cancers with microsatellite instability related to hMLH1 methylation. |
10411935 |
Human |
ink4a |
melanoma |
Here we show that melanoma genesis and maintenance are strictly dependent upon expression of H-RasV12G in a doxycycline-inducible H-Ras12G mouse melanoma model null for the tumour suppressor INK4a. |
10440378 |
Mouse |
p16 |
adrenocortical tumors |
Inactivation of the p16 tumor suppressor gene in adrenocortical tumors. |
10443678 |
Human |
p16 |
adrenocortical tumors |
Inactivation of the p16 tumor suppressor gene (p16INK4A), which encodes the cell cycle protein p16, was investigated in a series of 14 adrenocortical tumors. |
10443678 |
Human |
p16 |
adrenocortical tumors |
Immunohistochemistry showed the absence of p16 nuclear staining in all adrenocortical tumors with LOH within 9p21, and positive staining in all remaining tumors without LOH. |
10443678 |
Human |
p16 |
tumor angiogenesis |
Infection with a recombinant replication-defective adenovirus vector containing the cDNA of wild-type p16 significantly reduced the expression of vascular endothelial growth factor, which is thought to be a pivotal mediator of tumor angiogenesis, in p16-d |
10446996 |
Human |
p16 |
common acute lymphoblastic leukemia |
There were two patients who had DNA abnormalities in both 9p and 12p, one with common acute lymphoblastic leukemia (ALL) showed 9p LOH and the TEL/AML1 fusion gene on 12p and the other with common ALL and 12p RER had diminished expression of both the p27( |
10453181 |
Human |
p16 |
liver metastases |
To evaluate the clinical value of occult micrometastatic disease detection in lymph nodes, we tested genetic (K-ras and p53 gene mutations) and epigenetic (p16 promoter hypermethylation) molecular markers in the perihepatic lymph nodes from colorectal can |
10499618 |
Human |
p16 |
liver metastases |
Sixteen of the 21 (76%) liver metastases harbored either gene point mutations or p16 promoter hypermethylation. |
10499618 |
Human |
p16 |
actinic keratosis |
We searched for p16, Cdk4 and p53 gene mutations in 20 squamous cell carcinomas (SSCs), 1 actinic keratosis (AK), and 28 basal cell carcinomas (BCCs), using PCR-SSCP. |
10498902 |
Human |
arf |
metastatic cancers |
In combination, KrasG12D expression and Ink4a/Arf deficiency resulted in an earlier appearance of PanIN lesions and these neoplasms progressed rapidly to highly invasive and metastatic cancers, resulting in death in all cases by 11 weeks. |
14681207 |
Human |
ink4a |
metastatic cancers |
In combination, KrasG12D expression and Ink4a/Arf deficiency resulted in an earlier appearance of PanIN lesions and these neoplasms progressed rapidly to highly invasive and metastatic cancers, resulting in death in all cases by 11 weeks. |
14681207 |
Human |
mts1 |
gastrinoma |
In the present study, 12 gastrinoma and nonfunctioning pancreatic neuroendocrine tumor specimens were evaluated for genetic alterations of the p16/MTS1 tumor suppressor gene. |
9443399 |
Human |
p16 |
gastrinoma |
In the present study, 12 gastrinoma and nonfunctioning pancreatic neuroendocrine tumor specimens were evaluated for genetic alterations of the p16/MTS1 tumor suppressor gene. |
9443399 |
Human |
p16 |
intradermal nevi |
We have searched the frequency of p16 and p53 deletion in nine dysplastic nevi and 13 benign intradermal nevi with five microsatellite markers. |
9490270 |
Human |
cdkn2a |
plasmacytoma |
Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. |
9482902 |
Mouse |
p16 |
plasmacytoma |
When tested with wild-type (DBA/2) p16, both A134C and G232A BALB/c-specific variants of p16 were inefficient in their ability to inhibit the activity of cyclin D2/CDK4 in kinase assays with retinoblastoma protein, suggesting this defective, inherited all |
9482902 |
Mouse |
p16 |
invasive breast carcinoma |
The cell cycle-associated retinoblastoma protein (pRb) and p16 protein were demonstrated using immuno-histochemistry on paraffin sections from 192 cases of invasive breast carcinoma. |
9495362 |
Human |
cdkn2a |
thymic lymphomas |
We used this microsatellite to detect loss of heterozygosity of the Cdkn2A and Cdkn2B loci in gamma-irradiation-induced thymic lymphomas of C57BL/6J x RF/J F1 hybrids. |
9501299 |
Human |
mts1 |
atypical adenomatous hyperplasia |
Expression of cyclin D1, retinoblastoma gene protein, and p16 MTS1 protein in atypical adenomatous hyperplasia and adenocarcinoma of the lung. |
9531999 |
Human |
p16 |
atypical adenomatous hyperplasia |
Expression of cyclin D1, retinoblastoma gene protein, and p16 MTS1 protein in atypical adenomatous hyperplasia and adenocarcinoma of the lung. |
9531999 |
Human |
cdkn2a |
hepatoblastoma |
Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma. |
9537438 |
Human |
cdkn2a |
hepatoblastoma |
Structural analysis of the CDKN2A, CDKN2B, and CDKN2C genes in hepatoblastoma cases showed the absence of deletions and/or point mutations. |
9537438 |
Human |
cdkn2a |
hepatoblastoma |
Messenger RNA (mRNA) analysis showed that CDKN2C is expressed in all hepatoblastoma samples studied, while both CDKN2A and CDKN2B genes are not transcribed in the cancer specimens as well as in the matched normal liver tissues. |
9537438 |
Human |
cdkn2a |
human hepatoblastoma |
Our findings demonstrated the following: 1) CDKN2A, CDKN2B, and CDKN2C genes are structurally unmodified in human hepatoblastoma, and 2) CDKN2A (alpha-transcript) and CDKN2B are transcriptionally silenced in normal liver whereas CDKN2A (beta-transcript) a |
9537438 |
Human |
cdkn2a |
hepatoblastoma |
These results show that CDKN2A gene family alterations are not involved in hepatoblastoma development, whereas changes in cyclin D types might play a role in this type of tumor. |
9537438 |
Human |
cdkn2a |
stage i lung cancer |
We tested five gene promoters [CDKN2A (p16), O(6)-methylguanine-DNA-methyltransferase, glutathione S-transferase P1 (GSTP1), adenomatous polyposis coli (APC), and death-associated protein kinase (DAPK)] by real-time methylation-specific PCR in primary tum |
12684406 |
Human |
p16 |
stage i lung cancer |
We tested five gene promoters [CDKN2A (p16), O(6)-methylguanine-DNA-methyltransferase, glutathione S-transferase P1 (GSTP1), adenomatous polyposis coli (APC), and death-associated protein kinase (DAPK)] by real-time methylation-specific PCR in primary tum |
12684406 |
Human |
p16 |
testicular cancer |
The aim of our study was to examine TGCT and testicular cancer cell lines for deletions and mutations of the p15 and p16 genes. |
9554401 |
Human |
p16 |
testicular cancer |
For p15 no band shifts were observed for exons 1 to 2 in TGCT or testicular cancer cell lines; none of benign testicular tumors or normal control tissues demonstrated any band shifts for p15 or p16. |
9554401 |
Human |
p16 |
testicular tumors |
For p15 no band shifts were observed for exons 1 to 2 in TGCT or testicular cancer cell lines; none of benign testicular tumors or normal control tissues demonstrated any band shifts for p15 or p16. |
9554401 |
Human |
cdkn2 |
large-cell lymphoma |
Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. |
9591637 |
Human |
p16 |
adrenal cortical carcinomas |
Differentiation between benign and malignant tumors of the adrenal cortex was attempted by microdissection of nine cases of adrenal cortical hyperplasia, 10 cortical adenomas, and 18 adrenal cortical carcinomas with subsequent polymerase chain reaction (P |
9596277 |
Human |
p16 |
high-grade malignant lymphomas |
Paraffin sections of 9 reactive lymph nodes and 43 low-grade and 60 high-grade malignant lymphomas were reacted with antibodies against pRB and p16. |
9620022 |
Human |
p16 |
high-grade lymphomas |
Loss of p16 was identified in 14 of 55 evaluable high-grade lymphomas but not in any of the low-grade lesions. |
9620022 |
Human |
p16 |
diffuse large cell lymphomas |
While loss of RB function was a rare event in human lymphomagenesis, p16 was absent in some 25% of high-grade non-Hodgkin's lymphomas; diffuse large cell lymphomas were the primary target of tumor suppressor gene inactivation. |
9620022 |
Human |
ink4 |
nervous system tumors |
Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. |
9622062 |
Human |
p16 |
adenocarcinoma of the uterine cervix |
METHODS: In 40 cases of adenocarcinoma of the uterine cervix and 10 normal cervices, expression of estrogen receptor and cell cycle regulatory gene products (cyclin E, p16, p21WAF1/CIP1, p27, p53, and Ki-67) was studied using immunohistochemical technique |
9635534 |
Human |
p19 |
human leukemia-lymphoma |
Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. |
9639410 |
Human |
ink4 |
human leukemia-lymphoma |
Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. |
9639410 |
Human |
p16 |
human leukemia-lymphoma |
Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. |
9639410 |
Human |
p16 |
primary carcinoma |
The results revealed that nuclear expression of beta-catenin, p16 and c-myc was quantitatively increased from normal mucosa to premalignant adenoma, primary carcinoma and lymph node metastatic carcinoma; the frequency of nuclear overexpression of beta-cat |
14601048 |
Human |
p16 |
metastatic carcinoma |
The results revealed that nuclear expression of beta-catenin, p16 and c-myc was quantitatively increased from normal mucosa to premalignant adenoma, primary carcinoma and lymph node metastatic carcinoma; the frequency of nuclear overexpression of beta-cat |
14601048 |
Human |
cdkn2a |
soft-tissue tumors |
Gene alterations at the CDKN2A (p16/MTS1) locus in soft tissue tumors. |
9664128 |
Human |
mts1 |
soft-tissue tumors |
Gene alterations at the CDKN2A (p16/MTS1) locus in soft tissue tumors. |
9664128 |
Human |
p16 |
soft-tissue tumors |
Gene alterations at the CDKN2A (p16/MTS1) locus in soft tissue tumors. |
9664128 |
Human |
cdkn2a |
soft-tissue tumors |
Presumably, alterations of the CDKN2A gene do not contribute to the oncogenesis in the majority of soft tissue tumors. |
9664128 |
Human |
p16 |
t-cell childhood acute lymphoblastic leukaemias |
As a high proportion of T-cell childhood acute lymphoblastic leukaemias have deletions of both p15 and p16, our data suggest that inactivation of these genes makes it possible for leukemic cells to avoid senescence. |
9704925 |
Human |
ink4a |
low-grade lymphomas |
This loss of p16/INK4A was found more frequently in cases showing tumor progression from mucosa-associated lymphoid tissue low-grade lymphomas (31 of 37) or follicular lymphomas (4 of 4) into diffuse large B-cell lymphomas. |
9736037 |
Human |
p16 |
low-grade lymphomas |
This loss of p16/INK4A was found more frequently in cases showing tumor progression from mucosa-associated lymphoid tissue low-grade lymphomas (31 of 37) or follicular lymphomas (4 of 4) into diffuse large B-cell lymphomas. |
9736037 |
Human |
cdkn2a |
secondary tumors |
By comparing the genetic changes in the primary and corresponding secondary tumors, we found that additional loss of CDKN2A and/or RB1, encoding important components of the cell cycle regulatory pathway, was the most frequent genetic change in both types |
9739018 |
Human |
p16 |
adenomas |
In the rat, 94% of adenocarcinomas induced by the tobacco specific carcinogen 4-methylnitrosamino-1-(3-pyridyl)-1-butanone were hypermethylated at the p16 gene promoter; most important, this methylation change was frequently detected in precursor lesions |
9751761 |
Rat |
p16 |
carcinoma in situ |
The timing for p16 methylation was recapitulated in human SCCs where the p16 gene was coordinately methylated in 75% of carcinoma in situ lesions adjacent to SCCs harboring this change. |
9751761 |
Rat |
p16 |
carcinosarcoma |
This loss associated with carcinosarcoma of the urinary bladder is in agreement with previous studies, suggesting a possible role for the tumor suppressor gene p16 in the pathogenesis of this tumor. |
14692829 |
Human |
cdkn2 |
esophageal tumors |
p53 and p16/CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa. |
9808520 |
Human |
p16 |
esophageal tumors |
p53 and p16/CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa. |
9808520 |
Human |
p16 |
inherited cancer syndromes |
Frequent allelic losses on chromosome 9 are seen in a wide variety of human tumors; moreover, two genes (P16 and PTC) whose mutant alleles confer predispositions to some inherited cancer syndromes have been identified on this chromosome. |
9818027 |
Human |
p16 |
undifferentiated carcinoma |
Undifferentiated carcinoma (FRO) cells had a nonsense point mutation at codon 72 (CGA-TGA, Arg-Stop) of p16, whereas the poorly differentiated papillary carcinoma (NPA) line harbored a point mutation at the exon 1-intron 1 boundary that altered the donor |
9827724 |
Human |
p16 |
condylomata acuminata |
Condylomata acuminata and low-grade squamous intraepithelial lesions with infection by low-risk HPV such as HPV-6/11 showed focal and weak immunohistochemical staining for p16. |
9846965 |
Human |
p16 |
leiomyosarcoma |
Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis. |
14595762 |
Human |
p16 |
pleomorphic adenoma of the parotid gland |
Deletion of the p16 gene and microsatellite instability in carcinoma arising in pleomorphic adenoma of the parotid gland. |
9917133 |
Human |
p16 |
carcinosarcoma |
Cyclin D1 gene amplification and p16 gene deletion in patients with esophageal carcinosarcoma. |
9990483 |
Human |
p16 |
carcinosarcoma |
Because inactivation of p16 gene (which is a putative tumor suppressor gene) is thought to have similar oncogenic effects with CD1 gene amplification, DPCR was used to examine whether p16 homozygous deletion occurs in esophageal carcinosarcoma. |
9990483 |
Human |
p16 |
carcinosarcoma |
These results suggest that homozygous deletion of the p16 gene occurs less frequently than CD1 gene amplification in esophageal carcinosarcoma. |
9990483 |
Human |
p16 |
esophageal tumors |
To determine the role and mode of inactivation of the p16 and p15 genes in human esophageal tumors, we examined alterations and expression of the alpha and beta forms of the p16 gene, 5' CpG island methylation of p16 exon 1 alpha, and alterations of |
9033652 |
Human |
p16 |
juvenile pilocytic astrocytoma |
We screened human primary and recurrent malignant glioma, juvenile pilocytic astrocytoma, medulloblastoma, and meningioma tissue specimens for alterations in p16 gene structure. |
9049826 |
Human |
cdkn2a |
ovarian adenocarcinomas |
To determine the role of the CDKN2A gene in the development of ovarian adenocarcinomas, we examined a large series of benign, low malignant potential (LMP) and invasive ovarian neoplasms for evidence of loss of heterozygosity (LOH), homozygous deletions, |
9052747 |
Human |
cdkn2a |
ovarian adenocarcinomas |
No evidence of hypermethylation of the CDKN2A gene was found in 50 primary ovarian adenocarcinomas nor in 3 ovarian cancer cell lines. |
9052747 |
Human |
p14arf |
salivary-gland carcinomas |
Alterations of p14ARF and p16INK4a genes in salivary gland carcinomas. |
12684623 |
Human |
p16 |
malt lymphomas |
These results indicate that p16 gene methylation is a frequent event in NHLs, mainly in MALT lymphomas, and suggest that it could be an important mechanism of inactivation of this gene. |
9067584 |
Human |
p16 |
plasmacytoma |
Moreover, hypermethylation of p16/p15 was associated with blastic disease and concomitant hypermethylation of both genes may be pathogenetically related to plasmacytoma development. |
9116295 |
Human |
p16 |
metastatic prostate cancer |
METHODS: Five metastatic prostate cancer cell lines were analyzed for p16 gene structure and its expression by Southern and Northern blot analyses. |
9122044 |
Human |
p16 |
low-grade tumors |
Aberrant expression of p16 protein, detected by immunohistochemistry, occurred in 22 of 60 tumors, more frequently in low-grade tumors, and had significant correlation with low p16 mRNA expression. |
9133447 |
Human |
p16 |
ovarian epithelial tumors |
We conclude that inactivation of p16, by loss of p16 mRNA and protein expression as a consequence of hypermethylation of the 5'-CpG island, rather than by gene deletion or point mutation, may play an important role in the genesis of human ovarian epi |
9133447 |
Human |
cdkn2 |
metastatic prostate cancer |
Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. |
9171999 |
Human |
mts1 |
metastatic prostate cancer |
Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. |
9171999 |
Human |
p16 |
metastatic prostate cancer |
Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. |
9171999 |
Human |
p16 |
lymph-node metastasis |
METHODS: p53 and p16 expression status, the Ki-67 LI, and int-2/cyclin D1 amplification were assessed by immunohistochemical staining and slot blot analysis in pretreatment endoscopic biopsy specimens of 41 patients with T4 or M1 Lym (distant lymph node m |
12900371 |
Human |
p16 |
barrett's adenocarcinomas |
Only a minority of Barrett's adenocarcinomas with 9p21 LOH have a somatic mutation in the remaining p16 allele, and none have been found to have homozygous deletions. |
9205067 |
Human |
p16 |
esophageal adenocarcinomas |
To determine whether p16 promoter hypermethylation may be an alternative mechanism for p16 inactivation in esophageal adenocarcinomas, we examined the methylation status of the p16 promoter in flow-sorted aneuploid cell populations from 21 patients with p |
9205067 |
Human |
mts1 |
pituitary adenomas |
Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. |
9205080 |
Human |
p16 |
barrett's adenocarcinomas |
The aim of our study was to determine, in 26 Barrett's adenocarcinomas and 20 squamous-cell carcinomas of the esophagus, the prevalence of loss of heterozygosity on chromosome 9 by typing of microsatellite loci and mutation of p16 by direct sequencin |
9212218 |
Human |
p16 |
benign melanocytic nevi |
To investigate the role of the alterations of p16 expression in melanoma, we evaluated by immunohistochemistry the p16 expression and cell proliferation in 79 primary CMM and 10 benign melanocytic nevi (BMN). |
9221801 |
Human |
p16 |
spindle cell neoplasms |
In contrast, no fibromatoses and other spindle cell neoplasms of low malignant potential displayed abnormal p16 expression, and only 4 of 23 cases showed loss of pRB expression. |
9269824 |
Human |
mts1 |
testicular germ-cell tumors |
Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors. |
9284835 |
Human |
p16ink4 |
testicular germ-cell tumors |
Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors. |
9284835 |
Human |
p16 |
hepatoblastoma |
Hypermethylation of the p16 gene and lack of p16 expression in hepatoblastoma. |
12748249 |
Human |
p16 |
hepatoblastoma |
Aberrant methylation of 5' CpG islands of p16 was present in 12 of 24 (50.0%) cases of hepatoblastoma. |
12748249 |
Human |
p16 |
hepatoblastoma |
Nine of 12 (75.0%) unmethylated cases of hepatoblastoma displayed diffuse immunoreactivity, whereas 3 cases of unmethylated hepatoblastoma were not immunostained for p16. |
12748249 |
Human |
p16ink4 |
bone sarcoma |
Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients. |
9309118 |
Human |
p16ink4 |
bone sarcomas |
As the molecular events leading to the development of pediatric bone sarcomas remain unclear, we analyzed 75 osteosarcoma and Ewing sarcoma samples from 43 pediatric patients to search for alterations at the TP53 or p16INK4 tumor suppressor genes. |
9309118 |
Human |
cdkn2 |
thymic carcinoma |
p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. |
9398039 |
Human |
p16ink4 |
thymic carcinoma |
p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. |
9398039 |
Human |
cdkn2 |
thymic carcinomas |
Subsequently, we examined the 36 thymomas and 4 thymic carcinomas for mutations in p53 and CDKN2 genes, using PCR-SSCP and direct-sequencing analyses. |
9398039 |
Human |
cdkn2 |
thymic carcinoma |
We searched for hypermethylation in the promoter region of CDKN2, observing it in 4 thymomas and 1 thymic carcinoma. |
9398039 |
Human |
mts1 |
b16 melanoma |
Here we have examined the expression of CD44v6 in metastatic variants of the B16 melanoma with different levels of 18A2/mts1 expression. |
9413186 |
Human |
p16 |
lung adenomas |
Allelic loss of the p16 tumor suppressor gene also is a frequent event, occurring in about 50% of mouse lung adenocarcinomas, but rarely in lung adenomas, suggesting that it may play a role in malignant conversion or progression of lung tumors. |
9589349 |
Mouse |
cdkn2 |
benign prostatic hyperplasias |
Markedly reduced expression of CDKN2 mRNA was found in 43% (26 of 60) of untreated primary carcinomas, whereas no alteration was observed in 10 benign prostatic hyperplasias. |
9815578 |
Human |
cdkn2 |
primary carcinomas |
Markedly reduced expression of CDKN2 mRNA was found in 43% (26 of 60) of untreated primary carcinomas, whereas no alteration was observed in 10 benign prostatic hyperplasias. |
9815578 |
Human |
cdkn2 |
primary carcinomas |
Alteration of CDKN2 was observed in each prostate tumor cell line, including one with a missense mutation, and in one of three xenograft tumor tissues derived from primary carcinomas. |
9815578 |
Human |
cdkn2 |
primary carcinomas |
Analysis of genomic DNA indicated that altered CDKN2 expression in primary carcinomas of the prostate was more frequently due to down-regulation of transcription (five of seven) than deletion of the gene (two of seven). |
9815578 |
Human |
p16 |
plasma-cell leukemia (pcl) |
However, the frequency and significance of p16 abnormalities in multiple myeloma (MM) and the more aggressive phase of plasma cell leukemia (PCL) have not been well defined. |
9815612 |
Human |
cdkn2 |
differentiated thyroid cancers |
Infrequent CDKN2 mutation in human differentiated thyroid cancers. |
8561866 |
Human |
cdkn2 |
anaplastic thyroid cancers |
We examined the frequency of cyclin-dependent kinase (CDK) N2 alterations in differentiated and anaplastic thyroid cancers to assess the involvement of CDKN2 in the development of these cancers. |
8561866 |
Human |
cdkn2 |
papillary cancers |
LOH in the region of CDKN2 is seen in a significant proportion of follicular and anaplastic but not papillary cancers. |
8561866 |
Human |
cdkn2a |
ocular melanoma |
Ocular melanoma is not associated with CDKN2A or MC1R variants--a population-based study. |
12883368 |
Human |
cdkn2a |
ocular melanoma |
Our findings argue against an important predisposing effect of the MC1R and CDKN2A genes for ocular melanoma. |
12883368 |
Human |
p16 |
myxofibrosarcoma |
In this study, we evaluated the expression of p53, MDM2, MIB-1 (Ki-67), p21, p27, p16, cyclin A, cyclin D1, and cyclin E by immunohistochemistry in 45 cases of myxofibrosarcoma. |
14608538 |
Human |
p16 |
myxofibrosarcoma |
Among 43 cases of myxofibrosarcoma for which immunohistochemical findings were available, high MIB-1 labeling index (LI) (cutoffs of 10 and 22.5 on average), high cyclin A LI (cutoffs 10% and 13.8% on average), low p21 LI (cutoffs 10 and 20.7 on average), |
14608538 |
Human |
p16 |
meningiomas |
In this study, p15, p16, CDK4 and cyclin D1 genes were analyzed in 69 nonastrocytic human brain tumors, including 17 oligodendrogliomas, 16 medulloblastomas/primitive neuroectodermal tumors (PNETs), 14 ependymomas and 22 meningiomas. |
8621248 |
Human |
mts1 |
mouse adenocarcinoma |
The expression level of this gene correlates with the hypomethylation of the mts1 first intron sequence in mouse adenocarcinoma cells. |
8622894 |
Mouse |
cdkn2 |
undifferentiated carcinoma |
These results that p16/CDKN2 gene alteration is not required for malignant transformation in the thyroid, while p53 gene mutations may play a role in the progression from differentiated to undifferentiated carcinoma. |
8625287 |
Human |
p16 |
undifferentiated carcinoma |
These results that p16/CDKN2 gene alteration is not required for malignant transformation in the thyroid, while p53 gene mutations may play a role in the progression from differentiated to undifferentiated carcinoma. |
8625287 |
Human |
p16ink4 |
t-cell lymphoblastic lymphoma |
A T cell lymphoblastic lymphoma patient with two malignant cell populations carrying different 9p deletions including the p16INK4 and p15INK4B genes: Clinical response to interferon-alpha therapy in one of the subclones. |
8656689 |
Human |
p16ink4 |
malignant brain tumor |
Alterations in P16ink4 or in the gene encoding one of its ligands, cyclin-dependent kinase 4 (CDK4), have been reported in human glioma cell lines and primary tumors but not in primitive neuroectodermal tumors (PNETs), the most common malignant brain tumo |
8847566 |
Human |
p16 |
compound nevi |
Surprisingly, p16 deletions were also detected in 8/8 benign compound nevi and in 1/3 normal human melanocyte isolates. |
8649798 |
Human |
cdkn2a |
childhood rhabdomyosarcoma |
Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. p16INK4A, p15INK4B, and p18 proteins are highly specific inhibitors of cyclin-dependent serine/threonine kinase (CDK) activities required for G |
8703847 |
Human |
p16 |
nasopharyngeal carcinoma |
Hypermethylation of the p16 gene in nasopharyngeal carcinoma. |
8665502 |
Human |
p16ink4 |
thyroid tumors |
Status and expression of the p16INK4 gene in human thyroid tumors and thyroid-tumor cell lines. |
8690521 |
Human |
p16ink4 |
thyroid tumors |
We have examined the status of the p16INK4 gene in 31 thyroid tumors and 7 thyroid cell lines. |
8690521 |
Human |
cdkn2 |
myxoid chondrosarcoma |
Partial deletions of the CDKN2 and MTS2 putative tumor suppressor genes in a myxoid chondrosarcoma. |
8689636 |
Human |
cdkn2 |
myxoid chondrosarcoma |
We have previously reported a similar 9p21 abnormality and deletions of the CDKN2 and MTS2 genes in a myxoid chondrosarcoma cell line and its subclones. |
8689637 |
Human |
p14arf |
low-grade tumors |
Some differences may be established regarding the methylation profiles of specific genes and tumor types: MGMT, THBS1, TIMP-3, and p16INK4A appear hypermethylated in low-grade tumors (at least in 45% of cases), whereas GSTP1, DAPK, and p14ARF are mostly c |
12579314 |
Human |
p16 |
recurrent tumors |
The primary and recurrent tumors in Group A did not show structural alterations in the p16, p15 or CDK4 genes, whereas homozygous codeletion of p16 and p15 was observed in both primary and recurrent tumors in Group B. |
8760309 |
Human |
cdkn2 |
meningothelial meningioma |
The 1 meningioma with a CDKN2/p16 deletion was a meningothelial meningioma, without atypical or malignant features. |
8834533 |
Human |
p16 |
meningothelial meningioma |
The 1 meningioma with a CDKN2/p16 deletion was a meningothelial meningioma, without atypical or malignant features. |
8834533 |
Human |
p16 |
gastric carcinomas |
To evaluate the preferential histological type of MI-associated mutations in the development of gastric carcinoma, mutations of TGF-beta RII, p53, and p16 were analyzed for the two types of primary gastric carcinomas showing MI. |
8840981 |
Human |
p16 |
gastric carcinoma |
To evaluate the preferential histological type of MI-associated mutations in the development of gastric carcinoma, mutations of TGF-beta RII, p53, and p16 were analyzed for the two types of primary gastric carcinomas showing MI. |
8840981 |
Human |
p16 |
parathyroid adenomas |
Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas. |
8855819 |
Human |
p16 |
parathyroid adenomas |
Because inactivation of the p16 or p15 genes might be expected to result in oncogenic consequences similar to those from cyclin D1 overexpression, we examined 25 parathyroid adenomas for 1) allelic loss of polymorphic DNA loci on chromosome arm 9p, 2) hom |
8855819 |
Human |
p16 |
parathyroid tumors |
However, single strand conformational polymorphism analysis of all 3 exons of the p16 gene and both exons of the p15 gene failed to demonstrate mutation in any of the 25 cases, and homozygous deletions of the p16 and p15 genes, which are present in some h |
8855819 |
Human |
p16 |
parathyroid adenomas |
These observations indicate that inactivating mutations or homozygous deletions of the p16 and p15 genes occur uncommonly, if ever, in parathyroid adenomas; however, loss of a different tumor suppressor gene (or genes) on 9p appears to contribute to the p |
8855819 |
Human |
cdkn2 |
ovarian adenocarcinomas |
To establish the frequency of CDKN2 gene abnormalities in ovarian tumour specimens, we have studied this gene in five ovarian cancer cell lines and in 32 primary and five metastatic ovarian adenocarcinomas. |
8855976 |
Human |
cdkn2 |
sporadic breast cancer |
Frequent allele loss on 9p21-22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer. |
8889502 |
Human |
p16 |
esophageal tumors |
Alterations in the p16 and p15 cyclin kinase inhibitors, including point mutation and homozygous deletion, have been reported in primary esophageal tumors and/or tumor-derived cell lines. |
8893331 |
Human |
p16 |
thyroid carcinomas |
The involvement of Cdk inhibitors in carcinogenesis has been demonstrated by the studies of p16. p53 is frequently mutated in thyroid carcinomas and p21/Waf1 is a downstream effector of p53. |
8912526 |
Human |
p16 |
inverted papillomas |
Cuboidal and squamous metaplasia in inverted papillomas showed increased p16 expression in surface cells compared to columnar epithelium in inverted papillomas (p < 0.05 between squamous metaplasia and columnar epithelium). |
12507294 |
Human |
p16 |
inverted papillomas |
Cuboidal and squamous metaplasia in inverted papillomas involves downregulation of pRb expression along with increased p16 expression in surface cells. |
12507294 |
Human |
p19 |
burkitt-like lymphoma |
Using Southern blot analysis, one homozygous deletion of the p19 gene was detected in a human immunodeficiency virus (HIV)-related Burkitt-like lymphoma sample. |
8946928 |
Human |
mts1 |
primary carcinomas |
The multiple tumor suppressor 1 (MTS1) and 2 (MTS2) genes, located on chromosome 9p21, have been reported to be deleted or mutated in many malignant cell lines and in a high percentage of some primary carcinomas. |
8957063 |
Human |
multiple tumor suppressor 1 |
primary carcinomas |
The multiple tumor suppressor 1 (MTS1) and 2 (MTS2) genes, located on chromosome 9p21, have been reported to be deleted or mutated in many malignant cell lines and in a high percentage of some primary carcinomas. |
8957063 |
Human |
mts-1 |
thyroid tumors |
RESULTS: We failed to demonstrate homozygous deletions of MTS-1 and MTS-2 in thyroid tumors, but we demonstrated a highly frequent base pair exchange of the MTS-2 gene 27 codons upstream the 5' end of exon 2. |
8957499 |
Human |
mts1 |
gallbladder carcinoma |
Effects of E-cadherin transfection on gene expression of a gallbladder carcinoma cell line: repression of MTS1/S100A4 gene expression. |
12532418 |
Human |
mts1 |
malignant blue nevus |
We performed a molecular analysis for loss of heterozygosity on microdissected samples from the spectrum of benign to malignant blue nevus, using a panel of eight genes (MTS1, MXI1, CMM1, p53, NF1, L-myc hOGG1, and MCC), many of which are commonly associa |
12544095 |
Human |
cdkn2 |
squamous cancer |
MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. |
7845688 |
Human |
mts-1 |
squamous cancer |
MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. |
7845688 |
Human |
cdkn2 |
primary glioblastoma |
Using this probe, FISH analysis of primary glioblastoma tumors revealed homozygous deletions of the CDKN2 region in 6 of 9 tumors (67%) whereas a yeast artificial chromosome probe containing the interferon type I (IFN) gene cluster was deleted in only 4 c |
7867008 |
Human |
mts1 |
female breast carcinomas |
Analysis of MTS1/CDK4 in female breast carcinomas. |
7889533 |
Human |
mts1 |
breast adenocarcinomas |
Using PCR-SSCP, we analyzed exons one (126 bp) and two (307 bp) of the MTS1 gene to determine the incidence of mutation in a population of 50 primary breast adenocarcinomas and corresponding normal tissue. |
7889533 |
Human |
p16 |
blast crisis |
We have used a semiquantitative multiplex polymerase chain reaction assay to search for deletions of the p16 gene in 34 patients with chronic myeloid leukemia in blast crisis (CML BC), 19 patients with acute lymphoblastic leukemia (ALL), and 25 patients w |
7718873 |
Human |
mts1 |
metastatic cancers |
The mts1 gene codes for a 101 amino acid protein which belongs to the subfamily of S100 Ca(2+)-binding proteins and is overexpressed in metastatic cancers as compared to their nonmetastatic counterparts. |
7731714 |
Human |
p16 |
nasopharyngeal carcinoma |
p16 gene alterations in nasopharyngeal carcinoma. |
7743498 |
Human |
p16 |
gastric adenoma |
For instance, p16 methylation was found in 2.7% of normal gastric epithelium (n = 36), 16.7% of chronic atrophy gastritis (n = 24), 37.5% of dysplasia (n = 24), 67.4% of gastric adenoma (n = 43), and 85.2% of gastric carcinoma (n = 27). |
12547284 |
Human |
p16 |
large-cell carcinoma |
METHODS: p16 and p53 expression were detected by immunohistochemical analysis of 90 paraffin specimens of resected NSCLC, including 35 squamous cell carcinoma, 47 adenocarcinoma, and eight large cell carcinoma, between stages I and IV. |
12559346 |
Human |
p16 |
gastric adenomas |
The significance of p16 mutations in gastric tumorigenesis was examined by assessing p16 mutations as well as loss of heterozygosity (LOH) on 9p in 13 gastric adenomas and 45 adenocarcinomas. |
7775254 |
Human |
p16 |
gastric adenomas |
Although we found a sequence polymorphism at the second position of codon 99 (CGC/CAC) of the p16 in one gastric adenoma patient, no somatic mutations were detected in any of the gastric adenomas or adenocarcinomas. |
7775254 |
Human |
p16 |
gastric adenoma |
Although we found a sequence polymorphism at the second position of codon 99 (CGC/CAC) of the p16 in one gastric adenoma patient, no somatic mutations were detected in any of the gastric adenomas or adenocarcinomas. |
7775254 |
Human |
cdkn2 |
central nervous system primitive neuroectodermal tumor |
To investigate the possible role of this gene in the genesis of the central nervous system primitive neuroectodermal tumor (PNET), four established PNET cell lines and 18 PNET surgical specimens were studied for deletions and mutations of the MTS1/CDKN2 g |
7791990 |
Human |
mts1 |
central nervous system primitive neuroectodermal tumor |
To investigate the possible role of this gene in the genesis of the central nervous system primitive neuroectodermal tumor (PNET), four established PNET cell lines and 18 PNET surgical specimens were studied for deletions and mutations of the MTS1/CDKN2 g |
7791990 |
Human |
mts1 |
secondary tumors |
Two out of 5 (40%) secondary tumors showed evidence of homozygous deletion of MTS1. |
7794250 |
Human |
cdkn2 |
biliary tract cancers |
Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. p16Ink4 and p15Ink4B are cyclin-dependent kinase 4 inhibitors and link to the regulation of cell cycle in mammalian cells. |
7796400 |
Human |
p16ink4 |
biliary tract cancers |
Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. p16Ink4 and p15Ink4B are cyclin-dependent kinase 4 inhibitors and link to the regulation of cell cycle in mammalian cells. |
7796400 |
Human |
cdkn2 |
gastric cancer |
We report a highly frequent homozygous deletion of the p16/CDKN2 gene in the esophageal cancer cell line and a relatively high frequency of homozygous deletion in gastric cancer cell lines. |
7614482 |
Human |
cdkn2 |
adult solid tumors |
Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene have been found at high frequency in cell lines derived from a variety of adult solid tumors. |
7630190 |
Human |
mts1 |
adult solid tumors |
Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene have been found at high frequency in cell lines derived from a variety of adult solid tumors. |
7630190 |
Human |
p16ink4 |
adult solid tumors |
Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene have been found at high frequency in cell lines derived from a variety of adult solid tumors. |
7630190 |
Human |
cdkn2 |
squamous cell carcinoma of the bladder |
High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. |
7658499 |
Human |
p16ink4 |
cutaneous malignant melanoma |
BACKGROUND. A gene on chromosome 9p, p16INK4, has been implicated in the pathogenesis of cutaneous malignant melanoma in 19 melanoma-prone families. |
7666916 |
Human |
cdkn2 |
colon tumors |
It was striking to find that this region was extensively methylated and the gene not expressed in the normal colonic mucosa of 6 of 10 (60%) patients with colon cancer, whereas 5 of the corresponding colon tumors showed no methylation and high levels of p |
7553622 |
Human |
p16 |
testicular tumor |
MATERIALS AND METHODS: We examined alterations of p16 in 78 primary genital tumors (42 testicular, 21 ovarian and 15 endometrial cancers) and mononuclear cells from 2 patients with Lynch syndrome II as well as 5 testicular tumor cell lines by single-stran |
7563391 |
Human |
p16 |
testicular tumors |
RESULTS: The DNA from the p16 gene of 2 testicular tumors (5%), an ovarian cancer (4%) and a testicular tumor cell line (20%) had altered migration in gel electrophoresis as shown by SSCP. |
7563391 |
Human |
p16 |
testicular tumor |
RESULTS: The DNA from the p16 gene of 2 testicular tumors (5%), an ovarian cancer (4%) and a testicular tumor cell line (20%) had altered migration in gel electrophoresis as shown by SSCP. |
7563391 |
Human |
p16 |
endometrial tumors |
CONCLUSIONS: Taken together, these results suggest that p16 alterations probably are not important for tumorigenesis of testicular, ovarian and endometrial tumors. |
7563391 |
Human |
p16 |
small-lymphocytic lymphoma |
We identified the homozygous deletion of P15 and P16 genes in 13 tumors from 12 patients, all belonging to diffuse large-cell histology; 10 had this diagnosis made on presentation, 1 had transformed from small lymphocytic lymphoma, and 1 had transformed f |
7579381 |
Human |
p16 |
borderline ovarian tumors |
Southern blot analysis revealed no losses of the p16 gene in either the invasive or borderline ovarian tumors. |
7478544 |
Human |
p16 |
acute promyelocytic leukemia |
Neither p16 mRNA nor its protein expression are regulated during the cell cycle of normal phytohemagglutinin-stimulated lymphocytes, retinoblastoma protein-negative cells, papilloma virus-transformed cells, and acute promyelocytic leukemia cells. p16 mRNA |
7589458 |
Human |
cdkn2 |
chronic phase cml |
Whereas none of 22 chronic phase CML cases examined showed alterations, we found that 3/17 total blast crisis examined (18%) showed a homozygous deletion of the CDKN2 gene. |
8555065 |
Human |
cdk4i |
common acute lymphoblastic leukaemias |
We found that none of acute myeloblastic leukaemias (four cases) showed the CDK4I alteration, whereas 6/13 (46%) common acute lymphoblastic leukaemias (ALLs) displayed homozygous deletions. |
8555068 |
Human |
mts1 |
metastatic cancers |
Mts1 is overexpressed in metastatic cancers as compared to their nonmetastatic counterparts, and although mts1 is known to be involved in the metastatic phenotype (Davies et al., 1993; Grigorian et al., 1993), the role mts1 plays in this process is not cl |
7478526 |
Human |
ink4a |
colon tumor |
Inhibition of colon tumor progression and angiogenesis by the Ink4a/Arf locus. |
12591718 |
Human |
arf |
colon tumor |
Inhibition of colon tumor progression and angiogenesis by the Ink4a/Arf locus. |
12591718 |
Human |
ink4a |
colon tumors |
Colon tumors in 3-month-old Min mice that were null for the Ink4a/Arf locus (-/-) were moderately larger than in Ink4a/Arf-wild-type (+/+) animals (P = 0.032). |
12591718 |
Mouse |
p14arf |
neurofibroma |
Identification of a splice acceptor site mutation in p16INK4A/p14ARF within a breast cancer, melanoma, neurofibroma prone kindred. |
12920094 |
Human |
p16ink4 |
dedifferentiated chondrosarcoma |
We found p16INK4 and E-cadherin promotor methylation in the low grade chondroid compartment of the dedifferentiated chondrosarcoma. |
12924447 |
Human |
cdkn2a |
conjunctival melanoma |
CONCLUSION: Evidence for comorbid OM and CM exists in patients with strong phenotypic expression of atypical nevi and conjunctival melanoma, although CDKN2A mutations have not been documented in patients with OM. |
12925397 |
Human |
p16 |
advanced prostate cancer |
Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10. |
12947069 |
Human |
p16 |
small cell carcinoma of the uterine cervix |
P16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. |
14506638 |
Human |
p16 |
gastric tubular adenomas |
Loss of p27kip1 and p16Ink4a (p16) expression, another CDI, has been reported during the progression of gastric tubular adenomas to advanced gastric cancer. |
12603618 |
Human |
p16 |
neuroendocrine tumors |
The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. |
12612881 |
Human |
p16 |
adenoid-cystic carcinoma |
Expression of p16 protein and hypermethylation status of its promoter gene in adenoid cystic carcinoma of the head and neck. |
12624503 |
Human |
p16 |
adenoid-cystic carcinomas (acc) |
To explore the role of p16 in the biological behavior of adenoid cystic carcinomas (ACC), we investigated the immunohistochemical expression of p16 protein in 38 ACC tumors (32 primary, 3 recurrent, and 3 metastatic tumors) and the methylation status of i |
12624503 |
Human |
p14arf |
meningiomas |
Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome. |
12640680 |
Human |
p14arf |
meningiomas |
We investigated the prognostic significance of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression by immunohistochemical analysis of 271 meningiomas. |
12640680 |
Human |
p16 |
human malignant mesothelioma |
To determine whether p16 is altered in human malignant mesothelioma (MM), molecular analysis of multiple 9p loci was performed on 40 cell lines and 23 primary tumors from 42 MM patients. |
7923195 |
Human |
mts1 |
esophageal tumors |
The MTS1 gene is frequently mutated in primary human esophageal tumors. |
7970734 |
Human |
p14arf |
intestinal-type adenocarcinoma |
TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. |
12673679 |
Human |
p14 |
mucinous cystic neoplasms |
In this study, we compared methylation status of p16, p14, VHL, and ppENK genes by methylation-specific PCR (MSP), and genetic alterations including K-ras and beta-catenin gene mutations, chromosome 3p loss, and microsatellite instability in 15 mucinous c |
14614047 |
Human |
p16 |
mucinous cystic neoplasms |
In this study, we compared methylation status of p16, p14, VHL, and ppENK genes by methylation-specific PCR (MSP), and genetic alterations including K-ras and beta-catenin gene mutations, chromosome 3p loss, and microsatellite instability in 15 mucinous c |
14614047 |
Human |
p14 |
mucinous cystic neoplasms |
There were no significant differences between mucinous cystic neoplasms and serous microcystic adenomas in methylation of p16 (14%, 2/14 and 12%, 2/16), p14 (15%, 2/13 and 37%, 6/16), VHL (0/14 and 7%, 1/14), and ppENK (0/14 and 0/13), respectively. |
14614047 |
Human |
p16 |
mucinous cystic neoplasms |
There were no significant differences between mucinous cystic neoplasms and serous microcystic adenomas in methylation of p16 (14%, 2/14 and 12%, 2/16), p14 (15%, 2/13 and 37%, 6/16), VHL (0/14 and 7%, 1/14), and ppENK (0/14 and 0/13), respectively. |
14614047 |
Human |
p16 |
non-small cell carcinomas |
The authors evaluated 5 noninvasive dysplasias and 33 invasive gallbladder carcinomas (6 small cell carcinomas, 27 non-small cell carcinomas, of which 16 were accompanied by an in situ carcinoma component) for expression of the protein products of the p16 |
12692194 |
Human |
p16 |
squamous cervical cancer |
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis. |
12694668 |
Human |
p16 |
squamous cervical cancer |
OBJECTIVE: To examine the prognostic significance of the protein expression of the cyclin-dependent kinase (cdk) inhibitors p27, p21, and p16 in early squamous cervical cancer (SCC). |
12694668 |
Human |
p16 |
plasma cell tumors |
BALB/c mice are susceptible to the development of pristane-induced plasma cell tumors, and have a rare allelic variant in the coding region of the p16(INK4a) (p16) tumor suppressor gene that produces a protein with impaired activity. |
12700664 |
Mouse |
p16 |
recurrent colorectal cancer |
Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. |
12712439 |
Human |
p14 |
duodenal carcinomas |
RESULTS: Duodenal carcinomas were methylated more frequently or had increased methylation densities than biliary carcinomas at p14 (P = 0.04), hMLH1 (P = 0.04), MGMT (P = 0.01), MINT1 (P = 0.01), MINT25 (P = 0.01), MINT27 (P = 0.001), RAR beta (P = 0.03), |
12730870 |
Human |
mts1 |
intraductal papillary-mucinous tumors |
P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas. |
12749268 |
Human |
p16 |
intraductal papillary-mucinous tumors |
P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas. |
12749268 |
Human |
p19 |
sezary syndrome |
Antibodies reactive with human T-cell leukemia virus type I (HTLV-I) proteins p19, p24, gp46, p56, and gp68 were detected in four of 27 patients with mycosis fungoides/Sezary syndrome (MF/SS) and one patient with Kaposi's sarcoma using radioimmunopre |
1353704 |
Human |
p16 |
hyperplastic polyps |
METHODOLOGY: To evaluate the possible p16 role in the development of colonic neoplasms, the authors studied p16 immunohistochemical expression of 84 lesions of colorectal cancers, 6 lesions of hyperplastic polyps, 59 lesions of adenomas and 8 lesions of c |
14696398 |
Human |
p16 |
hyperplastic polyps |
RESULTS: Compared with normal colonic mucosa, in which virtually no p16 expression was observed, p16 was overexpressed in hyperplastic polyps (33%:2/6) adenomas (46%:27/59), carcinoma in adenoma (88%:7/8) and in adenocarcinomas (98%:82/84). |
14696398 |
Human |
mts1 |
mouse tumor |
Structure of gene mts1, transcribed in metastatic mouse tumor cells. |
2332170 |
Mouse |
cdkn2a |
primary testicular lymphoma |
We studied the methylation status of E-cadherin, CDKN2B, CDKN2A, BRCA1, RB1, VHL, RASSF1A, RARB, and GSTP1 by use of TGCT tissues and testicular malignant lymphoma tissues (25 primary TGCT tissues and three primary testicular lymphoma tissues). |
12874790 |
Human |
cdkn2a |
testicular lymphoma |
In contrast, all three (100%) of the testicular lymphoma tissues demonstrated hypermethylation of E-cadherin, RASSF1A, and RARB, but not CDKN2B, CDKN2A, BRCA1, RB1, VHL, and GSTP1. |
12874790 |
Human |
p16 |
small bowel adenomas |
The levels of cyclin D1, cyclin E, p16, p21, p27, and p53 proteins were determined by immunohistochemistry in samples of normal small bowel (n = 16), small bowel adenomas (n = 20), and small bowel adenocarcinomas (n = 24). |
10613343 |
Human |
p16 |
dcis |
Three of these proteins, cyclin D1, pRb and p16, were analysed by immunohistochemistry on archival paraffin sections to determine whether expression patterns were different in preinvasive ductal carcinoma in situ (DCIS) and invasive breast tumours relativ |
9652762 |
Human |
p16 |
dcis |
We therefore characterised the cell cycle regulators cyclin E, cyclin D1, p27 and p16 in a material of DCIS cases arranged in a tissue microarray. |
14612904 |
Human |
p16 |
ductal carcinoma in situ |
Three of these proteins, cyclin D1, pRb and p16, were analysed by immunohistochemistry on archival paraffin sections to determine whether expression patterns were different in preinvasive ductal carcinoma in situ (DCIS) and invasive breast tumours relativ |
9652762 |
Human |
p16 |
mucinous adenocarcinoma |
In the broad field of cervical glandular lesions, topics covered include: the value of markers such as MIB1, p16 and bcl-2 in distinguishing adenocarcinoma in situ and glandular dysplasia from benign mimics; markers of mesonephric lesions, including CD10; |
17365826 |
Human |
p16 |
benign ovarian tumors |
METHODS: We examined the promoter methylation status of 9 tumor suppressor genes (RARbeta2, TMS1, RIZ1, P15, P16, PTEN, MINT31, APC and HIC1) in 89 ovarian cancers, 16 borderline ovarian tumors, 19 benign ovarian tumors, 16 normal ovarian tissue and 5 ova |
17177027 |
Human |
p14 |
lynch syndrome |
We found MLH1 and p14(ARF) are methylated in 53 and 60% of the Lynch syndrome adenomas and in 4 and 20% of sporadic adenomas, whereas CDKN2A/p16 and MGMT are methylated in 6 and 14% of the Lynch syndrome adenomas versus 50 and 64% of sporadic adenomas. |
17278092 |
Human |
p16 |
monoclonal gammopathy of undetermined significance |
In this comprehensive study, using methylation-specific PCR (MS-PCR), we show that p16 methylation is relatively common and occurs in monoclonal gammopathy of undetermined significance (MGUS; n=17), smoldering multiple myeloma (SMM; n=40), and MM (n=522) |
16840723 |
Human |
p16 |
mgus |
In this comprehensive study, using methylation-specific PCR (MS-PCR), we show that p16 methylation is relatively common and occurs in monoclonal gammopathy of undetermined significance (MGUS; n=17), smoldering multiple myeloma (SMM; n=40), and MM (n=522) |
16840723 |
Human |
ink4a |
figo stage iib ovarian carcinoma |
We performed immunohistochemical analysis of p16(INK4a) and pRb expression and correlated with survival in a series of 300 patients with FIGO stage IIb-IV ovarian carcinoma which were enrolled in a randomized prospective trial evaluating two different pla |
17242700 |
Human |
p16ink4a |
recurrent respiratory papillomatosis |
Protein expression of the tumor suppressors p16INK4A and p53 and disease progression in recurrent respiratory papillomatosis. |
17277618 |
Human |
p16 |
sporadic breast cancer |
MATERIAL AND METHODS: The hypermethylation status of BRCA1, p16 and 14-3-3sigma in cancerous tissues and the paired serum of 38 sporadic breast cancer patients was examined by methylation-specific PCR (MSP) assay. |
17264521 |
Human |
ink4a |
adenocarcinoma in situ of the uterine cervix |
IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. |
17192788 |
Human |
ink4a |
follicular lymphoma |
These data identify CBX7 as a chromobox protein causally linked to cancer development and may help explain the low frequency of INK4a/ARF mutations observed in human follicular lymphoma. |
17374722 |
Human |
ink4a |
sarcoma |
Furthermore, in contrast to accelerated cancer onset and increased epithelial cancers of late-generation mTerc-/- p53 mutant mice, late-generation mTerc-/- Ink4a/Arf mutant mice experienced a delayed tumor onset and maintained the lymphoma and sarcoma spe |
17360455 |
Mouse |
p16 |
borderline ovarian tumors |
METHODS: We examined the promoter methylation status of 9 tumor suppressor genes (RARbeta2, TMS1, RIZ1, P15, P16, PTEN, MINT31, APC and HIC1) in 89 ovarian cancers, 16 borderline ovarian tumors, 19 benign ovarian tumors, 16 normal ovarian tissue and 5 ova |
17177027 |
Human |
p16 |
adenocarcinoma in situ of the uterine cervix |
IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. |
17192788 |
Human |
p14 |
lynch syndrome |
Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14(ARF) in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a "second hit&qu |
17278092 |
Human |
p16 |
lynch syndrome |
Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14(ARF) in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a "second hit&qu |
17278092 |
Human |
p16 |
polyp |
Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14(ARF) in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a "second hit&qu |
17278092 |
Human |
p16 |
oropharyngeal cancer |
Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. |
17236202 |
Human |
p14 |
polyp |
Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14(ARF) in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a "second hit&qu |
17278092 |
Human |
arf |
polyp |
Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14(ARF) in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a "second hit&qu |
17278092 |
Human |
p14arf |
papillary carcinomas |
Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. |
17117177 |
Human |
p14arf |
follicular adenomas |
These deregulations were statistically significant for pl6INK4a (P=0.006) in follicular adenomas and close to statistical significance for p14ARF in follicular adenomas (P=0.06) and in papillary carcinomas (P=0.05). |
17117177 |
Human |
p16 |
familial uveal melanoma |
Familial uveal melanoma: absence of germline mutations involving the cyclin-dependent kinase-4 inhibitor gene (p16). |
8740697 |
Human |
cdkn2 |
familial uveal melanoma |
CDKN2 gene, a cutaneous melanoma predisposition gene, is probably not a uveal melanoma predisposition gene as evidenced by the lack of somatic mutations involving this gene in uveal melanoma samples and the absence of germline mutations in familial uveal |
8970601 |
Human |
arf |
germ cell tumors |
Alterations of the INK4a/ARF locus in human intracranial germ cell tumors. |
10786670 |
Human |
arf |
medulloblastoma |
Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. |
11212243 |
Mouse |
arf |
malignant ependymoma |
We found that: (1) the polyclonal FL-132 antibody seems to be suitable for studying pl4ARF protein status in routinely processed and paraffin-embedded specimens; (2) decreasing pl4ARF protein expression is associated with patterns of ependymoma biological |
11585252 |
Human |
arf |
ependymal neoplasms |
We found that: (1) the polyclonal FL-132 antibody seems to be suitable for studying pl4ARF protein status in routinely processed and paraffin-embedded specimens; (2) decreasing pl4ARF protein expression is associated with patterns of ependymoma biological |
11585252 |
Human |
arf |
asap |
Here predictions for these two mechanisms were tested for the Arf1 effector GGA and ASAP family Arf GAPs. |
12376537 |
Human |
arf |
cerebellar tumors |
Unlike p53, loss of the Arf tumor suppressor did not contribute to the appearance of vascular or cerebellar tumors. |
14500377 |
Mouse |
arf |
low-grade tumours |
For CDKN2B and p14 ARF, methylation was more frequent in low-grade tumours; the reverse was observed for CDKN2A. |
14636164 |
Human |
arf |
pediatric medulloblastomas |
We analyzed the TP53 and INK4A/ARF loci in 29 pediatric medulloblastomas. |
14969745 |
Human |
arf |
kidney cancer |
We examined the tumor and the matched urine and serum DNA for aberrant methylation of nine gene promoters (CDH1, APC, MGMT, RASSF1A, GSTP1, p16, RAR-beta2, and ARF) from 17 patients with primary kidney cancer by quantitative fluorogenic real-time PCR. |
15289362 |
Human |
arf |
genitourinary cancer |
Urine samples from 91 control subjects without evidence of genitourinary cancer revealed no methylation of the MGMT, GSTP1, p16, and ARF genes, whereas methylation of RAR-beta2, RASSF1A, CDH1, APC, and TIMP3 was detected at low levels in a few control sub |
15289362 |
Human |
arf |
alveolar rhabdomyosarcomas |
Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. |
15489287 |
Mouse |
arf |
high-grade prostatic intraepithelial neoplasias |
EXPERIMENTAL DESIGN: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 b |
15623627 |
Human |
arf |
myelofibrosis |
We analyzed the promoter methylation status of eight tumor-associated genes (p14 ARF, p15 INK4B, p16 INK4A, Rb, hMLH1, hMSH2, APC, and DAPK) in 30 patients with myelofibrosis with myeloid metaplasia (MMM) by methylation specific PCR. |
15755503 |
Human |
arf |
mantle-cell lymphomas |
CDK4 and MDM2 Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-type INK4a/ARF Locus. |
15781632 |
Human |
arf |
amelanotic melanoma |
OBJECTIVE: To characterize a murine model of spontaneous amelanotic melanoma arising in the uvea of transgenic mice bearing a targeted deletion of the Ink4a/Arf tumor suppressor locus (exons 2 and 3) and expressing human H-ras controlled by the human tyro |
16087843 |
Mouse |
arf |
malignant mesotheliomas |
Human malignant mesotheliomas accumulate multiple somatic genetic alterations, including inactivation of the NF2 and CDKN2A/ARF tumor suppressor genes. |
16166281 |
Human |
arf |
malignant mesotheliomas |
Remarkably, similar to human malignant mesotheliomas, tumors from Nf2 (+/-) mice showed frequent homologous deletions of the Cdkn2a/Arf locus and adjacent Cdkn2b tumor suppressor gene, as well as reciprocal inactivation of Tp53 in a subset of tumors that |
16166281 |
Mouse |
arf |
genitourinary cancer |
Urine samples from the 91 controls without evidence of genitourinary cancer revealed no methylation of the p16, ARF, MGMT, and GSTP1 gene promoters, whereas methylation of RARbeta2, TIMP3, CDH1, Rassf1A, and APC was detected at low levels. |
16170165 |
Human |
cdk4i |
squamous cell carcinomas of the larynx |
We have examined the presence of p16MTS1/CDK4I gene deletions, mutations and methylation status, and 9p21-23 deletions in a series of 46 squamous cell carcinomas of the larynx and paired normal mucosa previously characterized for cyclin D1 gene amplificat |
9333020 |
Human |
cdkn2 |
anaplastic astrocytomas |
Forty-six glioblastomas, 16 anaplastic astrocytomas, and 8 astrocytomas were studied for the loss of the CDKN2 (p16/MTS1) gene on 9p. |
7987821 |
Human |
cdkn2 |
cervical tumor |
In this aspect, the potential role of the CDKN2 gene at 9p21-p22 in ovarian carcinogenesis was assessed in an extended panel of ovarian tumors, 11 human ovarian carcinoma cell lines, and 1 cervical tumor cell line. |
7743516 |
Human |
cdkn2 |
ovarian tumors |
In this aspect, the potential role of the CDKN2 gene at 9p21-p22 in ovarian carcinogenesis was assessed in an extended panel of ovarian tumors, 11 human ovarian carcinoma cell lines, and 1 cervical tumor cell line. |
7743516 |
Human |
cdkn2 |
central nervous system pnet |
The genesis of the human central nervous system PNET does not involve deletion or mutation of the MTS1/CDKN2 gene. |
7791990 |
Human |
cdkn2 |
stage iv nsclc |
Homozygous CDKN2 deletion was detected in 13 (28%) of 46 tumor cell lines from patients with stage III or stage IV NSCLC, compared with zero of 10 tumor cell lines from patients with stage I or stage II NSCLC. |
7563154 |
Human |
cdkn2 |
anaplastic astrocytomas |
By using comparative multiplex PCR, homozygous deletions of the CDKN2/p16 gene were detected in 24 GBMs (57%) and in 2 anaplastic astrocytomas. |
8548755 |
Human |
cdkn2 |
hemangiopericytomas |
Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas. |
8834533 |
Human |
cdkn2 |
bronchogenic carcinoma |
[Expression of CDKN2 gene product in human bronchogenic carcinoma] OBJECTIVE: To examine the expression of P16 protein in bronchogenic carcinoma and normal tissue adjacent to carcinoma and to determine the relationship between the gene and bronchogenic ca |
9388844 |
Human |
cdkn2 |
thymomas |
Subsequently, we examined the 36 thymomas and 4 thymic carcinomas for mutations in p53 and CDKN2 genes, using PCR-SSCP and direct-sequencing analyses. |
9398039 |
Human |
cdkn2 |
thymomas |
We searched for hypermethylation in the promoter region of CDKN2, observing it in 4 thymomas and 1 thymic carcinoma. |
9398039 |
Human |
cdkn2 |
prostate tumor |
Alteration of CDKN2 was observed in each prostate tumor cell line, including one with a missense mutation, and in one of three xenograft tumor tissues derived from primary carcinomas. |
9815578 |
Human |
cdkn2 |
head and neck carcinomas |
[Mutation and methylation of CDKN2 gene in human head and neck carcinomas] OBJECTIVE: To study mutations of CDKN2 gene in human head and neck carcinomas (HNC) and to elucidate the role of this gene in tumorigenesis. |
10072856 |
Human |
cdkn2 |
carcinoid |
DNA was extracted and polymerase chain reaction (PCR) was performed to evaluate loss of heterozygosity and microsatellite alterations using primers flanking 22 polymorphic microsatellite markers from 9 chromosomal regions, including genes associated with |
10679642 |
Human |
cdkn2 |
seminoma |
To assess whether the aberrant p16INK4A expression could be related to the alterations in CDKN2 regulatory sequence, we screened seminoma DNAs from 19 patients for the promoter mutations. |
15734211 |
Human |
cdkn2 |
seminoma |
These data suggest that in addition to previously characterized anomalies, the identified CDKN2 promoter mutation may be relevant for altered p16INK4A protein expressions in at least some seminoma. |
15734211 |
Human |
cdkn2a |
benign epithelial tumours |
Paraffin sections from 190 epithelial ovarian tumours, including 159 malignant and 31 benign epithelial tumours, were analysed immunohistochemically for expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16INK4A (p16). |
9036870 |
Human |
cdkn2a |
anaplastic oligodendrogliomas |
LOH for 9p and/or deletion of the CDKN2A gene occurred in 15 of these 55 tumors, and 11 of these cases were among the 24 (42%) anaplastic oligodendrogliomas. |
10433931 |
Human |
cdkn2a |
anaplastic oligodendrogliomas |
These findings demonstrate that oligodendroglial neoplasms usually have loss of 1p and 19q whereas astrocytomas of the progressive type frequently contain mutations of the TP53 gene, and that 9p loss and CDKN2A deletions are associated with progression fr |
10433931 |
Human |
cdkn2a |
head and neck tumors |
We tested 30 patients with primary head and neck tumors using methylation-specific PCR searching for promoter hypermethylation of the tumor suppressor gene p16 (CDKN2A), the DNA repair gene O6-methylguanine-DNA-methyltransferase (MGMT) and the putative me |
11221887 |
Human |
cdkn2a |
anaplastic meningiomas |
Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. |
11485924 |
Human |
cdkn2a |
anaplastic meningiomas |
We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppr |
11485924 |
Human |
cdkn2a |
anaplastic meningiomas |
Six anaplastic meningiomas (46%) and one atypical meningioma (3%) showed homozygous deletions of the CDKN2A, p14(ARF), and CDKN2B genes. |
11485924 |
Human |
cdkn2a |
anaplastic meningiomas |
Two anaplastic meningiomas carried somatic point mutations in CDKN2A (c.262G>T: E88X and c.262G>A: E88K) and p14(ARF) (c.305G>T: G102V and c.305G>A: G102E). |
11485924 |
Human |
cdkn2a |
anaplastic meningiomas |
However, the majority of anaplastic meningiomas either show homozygous deletions of CDKN2A, p14(ARF), and CDKN2B, mutations in CDKN2A and p14(ARF), or lack of expression of one or more of these genes. |
11485924 |
Human |
cdkn2a |
supratentorial primitive neuroectodermal tumours |
Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. |
12175345 |
Human |
cdkn2a |
myeloid tumors |
The effectiveness of large-scale insertional mutagenesis in a sensitized genetic background is demonstrated by the preference for activation of MAP kinase signaling, collaborating with Cdkn2a loss in generating the lymphoid and myeloid tumors. |
12185367 |
Human |
cdkn2a |
mammary tumor |
Differences in mammary tumor occurrence among genotypes for Prkdc and Cdkn2a in N2 mice were not statistically significant. |
12750252 |
Human |
cdkn2a |
ependymal tumours |
CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. |
14636164 |
Human |
cdkn2a |
low-grade tumours |
For CDKN2B and p14 ARF, methylation was more frequent in low-grade tumours; the reverse was observed for CDKN2A. |
14636164 |
Human |
cdkn2a |
kidney tumors |
Using sensitive methylation-specific PCR, we screened matched tumor DNA and sediment DNA from preoperative urine specimens obtained in 50 patients with kidney tumors, representing all major histological types, for hypermethylation status of a panel of six |
14695183 |
Human |
cdkn2a |
glioblastoma |
EXPERIMENTAL DESIGN: In this series of 140 consecutive cases of glioblastoma treated at a single center, we analyzed the frequency, age dependency and prognostic effects of TP53 mutation, CDKN2A/p16 deletion, EGFR amplification, as well as loss of chromos |
14734474 |
Human |
cdkn2a |
hereditary breast-ovarian cancer syndrome |
This article traces the historical aspects of hereditary cancer dealing with identification and ultimate molecular genetic confirmation of commonly occurring cancers, particularly of the colon in the case of familial adenomatous polyposis and its attenuat |
15264268 |
Human |
cdkn2a |
barrett's esophagus |
We measured p16 (CDKN2A/INK4A) lesions (loss of heterozygosity, mutations, and CpG island methylation), p53 (TP53) lesions (loss of heterozygosity, mutation) and ploidy abnormalities (aneuploidy, tetraploidy) within each Barrett's esophagus segment o |
15492292 |
Human |
cdkn2a |
high-grade prostatic intraepithelial neoplasias |
EXPERIMENTAL DESIGN: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 b |
15623627 |
Human |
cdkn2a |
invasive cervical cancers |
Flow cytometry on primary CVX and NCK and immunohistochemical staining of formalin fixed paraffin-embedded tumor specimens from which primary CVX cultures were derived as well as from a separate set of invasive cervical cancers confirmed differential expr |
15629771 |
Human |
cdkn2a |
colon polyps |
Aberrantly Methylated CDKN2A, MGMT, and MLH1 in Colon Polyps and in Fecal DNA from Patients with Colorectal Polyps. |
15709190 |
Human |
cdkn2a |
hyperplastic polyps |
Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the pot |
15709190 |
Human |
cdkn2a |
colon adenomas |
Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the pot |
15709190 |
Human |
cdkn2a |
hyperplastic polyps |
We have found that methylated MGMT, CDKN2A, and MLH1 occur in 49%, 34%, and 7% of adenomas and in 5%, 10%, and 7% of hyperplastic polyps, respectively, and that they are more common in histologically advanced adenomas. |
15709190 |
Human |
cdkn2a |
invasive ductal carcinomas |
Expressions of DUSP6, CDKN2A, TP53, and SMAD4 were investigated by immunohistochemistry in a total of 206 lesions of dysplastic ductal precursors and carcinomas retrieved from 52 pancreata with invasive ductal carcinomas and 51 of those with intraductal p |
15832194 |
Human |
cdkn2a |
malignant mesotheliomas |
Human malignant mesotheliomas accumulate multiple somatic genetic alterations, including inactivation of the NF2 and CDKN2A/ARF tumor suppressor genes. |
16166281 |
Human |
cdkn2a |
malignant mesotheliomas |
Remarkably, similar to human malignant mesotheliomas, tumors from Nf2 (+/-) mice showed frequent homologous deletions of the Cdkn2a/Arf locus and adjacent Cdkn2b tumor suppressor gene, as well as reciprocal inactivation of Tp53 in a subset of tumors that |
16166281 |
Mouse |
cdkn2a |
gastrointestinal stromal tumors |
Prognostic Role of E2F1 and Members of the CDKN2A Network in Gastrointestinal Stromal Tumors. |
16166437 |
Human |
ink4 |
digestive tract tumor |
CONCLUSION: The role of DNA methylation in the silence of p16/INK4 may different between these two types of upper digestive tract tumor. |
15612883 |
Human |
ink4a |
liver tumors |
Induction of mutations in Ki-ras and INK4a in liver tumors of mice exposed in utero to 3-methylcholanthrene. |
9667743 |
Mouse |
ink4a |
liver tumors |
Approximately 12% (3/26) of the liver tumors exhibited point mutations in exon 1 of the INK4a gene, with each of the three tumors exhibiting two point mutations. |
9667743 |
Mouse |
ink4a |
lung tumor |
To provide further evidence that hypermethylation is involved in the loss of p16 (Ink4a) gene expression, three mouse lung tumor cell lines (C10, sp6c and CMT64) displaying complete methylation at seven promoter CpG sites and no p16 (Ink4a) expression wer |
10964101 |
Mouse |
ink4a |
liver tumors |
Using the transplacental carcinogenesis model, which results in the induction of both lung and liver tumors following in utero exposure to MC, the results of this and our previous studies show that alterations in the Ink4a locus occur in only 15 and 27% o |
11595130 |
Human |
ink4a |
liver tumors |
These results imply that damage to the Ink4a gene is not a frequent pathway to malignant progression in mouse lung and liver tumors following in utero exposure to environmental carcinogens. |
11595130 |
Mouse |
ink4a |
pediatric medulloblastomas |
We analyzed the TP53 and INK4A/ARF loci in 29 pediatric medulloblastomas. |
14969745 |
Human |
ink4a |
malignant ovarian germ cell tumours |
Significance of beta-catenin and pRB pathway components in malignant ovarian germ cell tumours: INK4A promoter CpG island methylation is associated with cell proliferation. |
15476271 |
Human |
ink4a |
barrett's esophagus |
We measured p16 (CDKN2A/INK4A) lesions (loss of heterozygosity, mutations, and CpG island methylation), p53 (TP53) lesions (loss of heterozygosity, mutation) and ploidy abnormalities (aneuploidy, tetraploidy) within each Barrett's esophagus segment o |
15492292 |
Human |
ink4a |
alveolar rhabdomyosarcomas |
Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. |
15489287 |
Mouse |
ink4a |
neurofibroma |
In Part I of this review, we discussed findings demonstrating that a loss of NF1 tumor suppressor gene function in neoplastic Schwann cells is a key early step in neurofibroma formation and that progression from neurofibroma to MPNST is associated with ab |
15715079 |
Human |
ink4a |
melanoma |
The mutation of genes associated with melanoma, such as INK4a or BRAF that would affect either Mitf cooperation with Rb1 or Mitf stability respectively, would impair Mitf-mediated cell cycle control. |
15716956 |
Human |
ink4a |
myelofibrosis |
We analyzed the promoter methylation status of eight tumor-associated genes (p14 ARF, p15 INK4B, p16 INK4A, Rb, hMLH1, hMSH2, APC, and DAPK) in 30 patients with myelofibrosis with myeloid metaplasia (MMM) by methylation specific PCR. |
15755503 |
Human |
ink4a |
mantle-cell lymphomas |
CDK4 and MDM2 Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-type INK4a/ARF Locus. |
15781632 |
Human |
ink4a |
amelanotic melanoma |
OBJECTIVE: To characterize a murine model of spontaneous amelanotic melanoma arising in the uvea of transgenic mice bearing a targeted deletion of the Ink4a/Arf tumor suppressor locus (exons 2 and 3) and expressing human H-ras controlled by the human tyro |
16087843 |
Mouse |
mlm |
hamartomas |
To investigate the molecular mechanisms of tuberous sclerosis (TSC) histopathologic lesions, we have tested for loss of heterozygosity the two TSC loci (TSC1 and TSC2) and seven tumor suppressor gene-containing regions (TP53, NF1, NF2, BRCA1, APC, VHL, an |
8824721 |
Human |
mts1 |
metastatic tumors |
The mts1 gene is specifically expressed in certain metastatic tumors but not in their nonmetastatic counterparts. |
1329089 |
Human |
mts1 |
anaplastic astrocytomas |
After controlling for the contamination of tumor samples with normal cells, homozygous loss of MTS1 was found in 13 of 25 anaplastic astrocytomas (WHO grade III) and in 27 of 46 cases of glioblastomas (WHO grade IV) but in none of seven astrocytomas (WHO |
7805033 |
Human |
mts1 |
central nervous system pnet |
The genesis of the human central nervous system PNET does not involve deletion or mutation of the MTS1/CDKN2 gene. |
7791990 |
Human |
mts1 |
tumors of the central nervous system |
In this study we have examined the status of the MTS1 gene in a variety of non-astrocytic tumors of the central nervous system. |
7794250 |
Human |
mts1 |
t-cell neoplasms |
We observed a higher frequency of MTS1 deletions in ALL than in NHL (P < 0.001) and in T-cell neoplasms compared to B-cell neoplasms (67% v 6%; P = 0.001). |
8547074 |
Human |
mts1 |
common tumor |
The genes p16 (or MTS1) and TEL/AML1 are now respectively recognized as the most common tumor suppressor and fusion genes in childhood acute lymphoblastic leukemia. |
9372085 |
Human |
mts1 |
testicular germ cell tumors |
Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors. |
9284835 |
Human |
mts1 |
mesenchymal neoplasms |
BACKGROUND AND OBJECTIVES: Tumor suppressor gene MTS1/p16 (cyclin-dependent kinase-4 inhibitor) and a putative tumor metastasis suppressor gene nm23 (nucleoside diphosphate A kinase) have been identified in a variety of human tumors but have not been well |
11223831 |
Human |
mts1 |
minimal residual disease |
We evaluated the incidence of MTS1/p16 deletions by loss of heterozygosity (LOH) analysis in 36 non-high risk B-cell precursor childhood acute lymphoblastic leukemia (BCP-ALL) and correlated these results with clinical features and with the presence of mi |
12127556 |
Human |
mts1 |
mrd |
We evaluated the incidence of MTS1/p16 deletions by loss of heterozygosity (LOH) analysis in 36 non-high risk B-cell precursor childhood acute lymphoblastic leukemia (BCP-ALL) and correlated these results with clinical features and with the presence of mi |
12127556 |
Human |
mts1 |
adenocarcinomas of the uterine cervix |
The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with internati |
14584070 |
Human |
mts1 |
rectal carcinomas |
[The expression of MTS1 gene product in transitional mucosa adjacent to rectal carcinomas and its clinical significance] OBJECTIVE: To study the property of transitional mucosa (TM) adjacent to rectal carcinoma and the clinical significance of MTS1 gene d |
11829899 |
Human |
mts1 |
rectal carcinoma |
METHODS: We used the immunohistochemical methods to observe the range of TM adjacent to rectal carcinoma, and the immunohistochemical method to observe the expression of MTS1 gene product on TM, using normal mucosa and carcinoma tissue as control. |
11829899 |
Human |
mts1 |
rectal carcinoma |
TM is related to MTS1 gene expression deficit of rectal carcinoma, showing that MTS1 gene expression deficit or mutation may be a factor inducing transitional change adjacent to carcinoma. |
11829899 |
Human |
mts1 |
pulmonary metastasis |
Microarray Analysis of Metastasis-Associated Gene Expression Profiling in a Murine Model of Thyroid Carcinoma Pulmonary Metastasis: Identification of S100A4 (Mts1) Gene Overexpression as a Poor Prognostic Marker for Thyroid Carcinoma. |
15579771 |
Human |
p14 |
prostate tumors |
RESULTS: Overexpression of p16 mRNA was found in 6/9 (67) of prostate tumors compared to the adjacent normal prostate, whereas elevated p14 and p15 levels were only observed in 2/9 (22) and 1/6 (17) of prostate cases, respectively. |
10797499 |
Human |
p14 |
prostate tumors |
Exon 2 of p16/p14 is methylated in a majority of prostate tumors compared to the unmethylated upstream 5' region, and may be a potential tumor marker for human prostate cancer. |
10797499 |
Human |
p14 |
malignant ependymoma |
We found that: (1) the polyclonal FL-132 antibody seems to be suitable for studying pl4ARF protein status in routinely processed and paraffin-embedded specimens; (2) decreasing pl4ARF protein expression is associated with patterns of ependymoma biological |
11585252 |
Human |
p14 |
ependymal neoplasms |
We found that: (1) the polyclonal FL-132 antibody seems to be suitable for studying pl4ARF protein status in routinely processed and paraffin-embedded specimens; (2) decreasing pl4ARF protein expression is associated with patterns of ependymoma biological |
11585252 |
Human |
p14 |
advanced cancers |
Inactivation of both p16 and p14 genes may result in a malignant change in colorectal cancer cells, leading to advanced cancers with a smaller size than those with p16 or p14 activity. |
12716465 |
Human |
p14 |
carcinoid tumors |
Carcinoid tumors were frequently methylated at RARbeta, MGMT, p16, COX2, p14, THBS1, and ER ranging from 25 to 63% of tumors. |
12584572 |
Human |
p14 |
carcinoid tumors |
Methylation was more frequent in carcinoid tumors than PETs at MGMT (25 versus 0%, p = 0.03), THBS1 (44 versus 9%, p = 0.04), p14 (44 versus 9%, p = 0.04) and RARbeta (25 versus 0%, p = 0.03). |
12584572 |
Human |
p14 |
low-grade tumours |
For CDKN2B and p14 ARF, methylation was more frequent in low-grade tumours; the reverse was observed for CDKN2A. |
14636164 |
Human |
p14 |
colon adenoma |
To address changes in the methylation profiles of multiple genes during colorectal carcinogenesis, we investigated the methylation of 12 genes (APC, COX-2, DAP-kinase, E-cadherin, GSTP1, hMLH1, MGMT, p14, p16, RASSF1A, THBS1, and TIMP3) in normal colon (n |
15122305 |
Human |
p14 |
relapsed childhood acute lymphoblastic leukemia |
Methylation profile was analyzed in nine cases of relapsed childhood acute lymphoblastic leukemia (ALL) for p14, p15, p16, Rb, MGMT, APC, hMLH1, RARbeta, RIZ, DAPK, and FHIT genes by using methylation specific polymerase chain reaction (MSP) analysis. |
15201966 |
Human |
p14 |
nodular melanomas |
Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. |
15547691 |
Human |
p14 |
nodular melanomas |
Strong staining of p14 was found in 63% of nodular melanomas and was associated with strong p53 expression (p=0.014), and with high levels of CDK4 (p<0.0001). |
15547691 |
Human |
p14 |
uterine cervical cancer |
METHODS: We analyzed CpG island hypermethylation in 15 genes (APC, CDH1, COX2, DAPK, FHIT, GSTP1, HLTF1, hMLH1, MGMT, p14, p16, RASSF1A, RUNX3, THBS1, and TIMP3) and its association with the methylene-tetrahydrofolate reductase (MTHFR) C677T and A1298C an |
15589597 |
Human |
p14 |
high-grade prostatic intraepithelial neoplasias |
EXPERIMENTAL DESIGN: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 b |
15623627 |
Human |
p14 |
myelofibrosis |
We analyzed the promoter methylation status of eight tumor-associated genes (p14 ARF, p15 INK4B, p16 INK4A, Rb, hMLH1, hMSH2, APC, and DAPK) in 30 patients with myelofibrosis with myeloid metaplasia (MMM) by methylation specific PCR. |
15755503 |
Human |
p14arf |
pediatric astrocytomas |
Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas. |
10665922 |
Human |
p14arf |
stage i adenocarcinomas of the lung |
Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung. |
11940214 |
Human |
p14arf |
laryngeal tumor |
[Effect of p14ARF gene on cell growth of human laryngeal tumor cells and expression of endogenous p53 protein] OBJECTIVE: To explore the inhibitory effect of p14ARF on the cell growth of laryngeal carcinoma and the expression on endogenous p53. |
12761983 |
Human |
p14arf |
familial cancers |
They are "classical" tumor suppressor genes with associated familial cancers (BRCA1, hMLH1, p16INK4a, VHL, etc.) and putative new tumor suppressor genes which loss may contribute to the transformed phenotype (MGMT, p14ARF, GSTP1, RARB2, etc.). |
12908548 |
Human |
p14arf |
neurofibromatosis |
p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. |
14519636 |
Human |
p14arf |
diffuse astrocytomas |
Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. |
14581362 |
Human |
p14arf |
ependymal tumours |
CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. |
14636164 |
Human |
p14arf |
kidney tumors |
Using sensitive methylation-specific PCR, we screened matched tumor DNA and sediment DNA from preoperative urine specimens obtained in 50 patients with kidney tumors, representing all major histological types, for hypermethylation status of a panel of six |
14695183 |
Human |
p14arf |
well-differentiated liposarcomas |
Distinct MDM2 and P14ARF expression and centrosome amplification in well-differentiated liposarcomas. |
14695989 |
Human |
p14arf |
clear cell sarcoma |
Alterations of the p16INK4a/p14ARF pathway in clear cell sarcoma. |
15298727 |
Human |
p14arf |
melanocytic neoplasm |
Alterations in the p16INK4a/p14ARF gene are common in malignant melanoma, which is the prototypical melanocytic neoplasm. |
15298727 |
Human |
p14arf |
barrett's adenocarcinoma |
To study the contribution of each pathway to the carcinogenesis of Barrett's adenocarcinoma, we analysed the alterations of p14ARF and p16INK4a in preneoplastic and neoplastic lesions of this disease. |
15185075 |
Human |
p14arf |
invasive breast cancers |
p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2. |
15318938 |
Human |
p14arf |
nsclc |
Using genetic and epigenetic analyses, we examined various molecular alterations including the loss of protein and mRNA expression, and 5'CpG hypermethylation, allelic imbalance, and mutation of the p14ARF gene in a series of 102 NSCLC samples, in pa |
15269146 |
Human |
p14arf |
occupational bladder cancer |
An analysis of the effects of lifestyle and occupational bladder cancer risk factors revealed that TCC of smokers showed a 2-fold elevated expression of MDM2 mRNA and an approximately 2-fold lower expression of P14ARF mRNA, whereas the activity of the p73 |
15492852 |
Human |
p14arf |
aggressive nk-cell leukemia |
We found methylation of the first exon of the p16INK4A gene in two cases (one aggressive, one blastic), and methylation of the p14ARF gene in one aggressive NK cell leukemia. |
15813917 |
Human |
p14arf |
aggressive nk-cell leukemia |
It has been reported that tumor suppressor genes are inactivated by DNA methylation of the promoter region and/or first exon of the genes in a variety of human cancers. |
15813917 |
Human |
p14arf |
squamous cell carcinoma of the anterior tongue |
p14ARF Protein Expression Is a Predictor of Both Relapse and Survival in Squamous Cell Carcinoma of the Anterior Tongue. |
15930346 |
Human |
p16 |
brain tumors |
Deletion of p16 and p15 genes in brain tumors. |
7987828 |
Human |
p16 |
medulloblastomas |
We found that p16 and a neighboring gene, p15, were often homozygously deleted in glioblastoma multiformes but not in medulloblastomas or ependymomas. |
7987828 |
Human |
p16 |
primary tumours |
Screening of primary tumours and linkage analysis of familial melanoma pedigrees have identified many potential mutations in p16, but the functional significance of these sequence variants has remained unclear. |
7777061 |
Human |
p16 |
melanomas in situ |
Our results suggest that loss of p16 protein expression is (a) not necessary for tumor initiation in malignant melanoma because all melanomas in situ and the majority of primary invasive melanomas retain expression of this protein; and (b) potentially mor |
7796391 |
Human |
p16 |
hodgkin's disease |
We identified the homozygous deletion of P15 and P16 genes in 13 tumors from 12 patients, all belonging to diffuse large-cell histology; 10 had this diagnosis made on presentation, 1 had transformed from small lymphocytic lymphoma, and 1 had transformed f |
7579381 |
Human |
p16 |
anaplastic astrocytomas |
By using comparative multiplex PCR, homozygous deletions of the CDKN2/p16 gene were detected in 24 GBMs (57%) and in 2 anaplastic astrocytomas. |
8548755 |
Human |
p16 |
hemangiopericytomas |
Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas. |
8834533 |
Human |
p16 |
common tumor |
The genes p16 (or MTS1) and TEL/AML1 are now respectively recognized as the most common tumor suppressor and fusion genes in childhood acute lymphoblastic leukemia. |
9372085 |
Human |
p16 |
trophoblastic tumors |
[The expressions of p16, CDK4 and PCNA proteins in trophoblastic tumors] OBJECTIVE: To evaluate the relationship between the regulatory factors in G1 phase of cell cycle and the cacrinogenesis of the trophoblastic cells. |
10681785 |
Human |
p16 |
trophoblastic tumors |
RESULTS: The expressions of p16 protein between malignant trophoblastic tumors and normal villi were significantly different (P < 0.05). |
10681785 |
Human |
p16 |
ovarian serous cystadenocarcinoma |
[A study on P16 and P53 protein expressions in ovarian serous cystadenocarcinoma] An immunohistochemical method utilizing avidin-biontin complex (ABC) technique was used in this study to detect P16 and P53 protein expressions in 40 ovarian serous cystaden |
10683958 |
Human |
p16 |
cll |
Several cases of CLL manifested LOH at a locus telomeric to the p15 and p16 tumor suppressor genes, all being early to intermediate stage disease. |
9018124 |
Human |
p16 |
benign epithelial tumours |
Paraffin sections from 190 epithelial ovarian tumours, including 159 malignant and 31 benign epithelial tumours, were analysed immunohistochemically for expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16INK4A (p16). |
9036870 |
Human |
p16 |
benign tumours |
Most benign tumours showed no p16 expression in the tumour cells, whereas only 11% of malignant cancers were p16 negative. |
9036870 |
Human |
p16 |
gastric tumors |
Quantitative reverse transcription PCR (RT-PCR) was used to measure gene expressions (relative mRNA levels) of p16 and the alternate transcript pl6beta in esophageal and gastric tumors. p16 gene expression was undetectable in 13 of 25 esophageal squamous |
9333024 |
Human |
p16 |
neck tumors |
Expression of p16 protein was negative or weak in 9% of the cases, and this tended to be less frequent in head/neck tumors compared with the others (0% vs. 12%). |
9355977 |
Human |
p16 |
prostate tumor |
Results of the study show that whereas universal promoters, such as Cytomegalovirus (CMV) and Rous Sarcoma Virus (RSV) promoter-driven tumor suppressors (e.g. p53, p21, and p16), were effective in inhibiting prostate tumor growth, the advantages of drivin |
9436028 |
Human |
p16 |
benign testicular tumors |
For p15 no band shifts were observed for exons 1 to 2 in TGCT or testicular cancer cell lines; none of benign testicular tumors or normal control tissues demonstrated any band shifts for p15 or p16. |
9554401 |
Human |
p16 |
b-cell non-hodgkin's lymphomas |
Detection of single and associated lesions of the Bcl-1, Bcl-2, Bcl-6, c-myc, p53 and p16 genes in B-cell non-Hodgkin's lymphomas: value of molecular analysis for a better assignment of the histologic subtype. |
9573674 |
Human |
p16 |
low-grade squamous intraepithelial lesions |
Condylomata acuminata and low-grade squamous intraepithelial lesions with infection by low-risk HPV such as HPV-6/11 showed focal and weak immunohistochemical staining for p16. |
9846965 |
Human |
p16 |
cystadenomas |
All six cases of normal pancreas and all but 1 of 20 cases of chronic pancreatitis expressed p16 protein, whereas 37.5% (3 of 8) of cystadenomas and 41. 9% (26 of 62) of PCs lost p16 expression. |
9815833 |
Human |
p16 |
cervical tumor |
MSP-ISH reveals that p16 hypermethylation occurs heterogeneously within early cervical tumor cell populations that are separate from those expressing viral E7 transcripts. |
10535995 |
Human |
p16 |
gliomas |
Alternatively, since the p16, retinoblastoma (RB), and CDK4 genes have been implicated in malignant progression, detection of losses or amplifications of these genes in gliomas could be diagnostically, prognostically, and therapeutically important. |
10587703 |
Human |
p16 |
premalignant condition |
Loss of heterozygosity (LOH) at 9p21 and 17p13 chromosomes (locations for p16 and p53 genes, respectively) is frequently observed in the premalignant condition, Barrett's esophagus. |
10601379 |
Human |
p16 |
adenocarcinomas of the prostate |
METHODS: The levels of p16 and CDK4 proteins were quantitated by immunofluorescence flow cytometry, using paraffin embedded material, in 104 adenocarcinomas of the prostate after radical prostatectomy. |
10640976 |
Human |
p16 |
bph |
RESULTS: In prostatic carcinoma specimens, p16 protein was elevated significantly compared with BPH, with a median fluorescence index (FI) of 15.4 versus 10.7, respectively (P = 0.010). |
10640976 |
Human |
p16 |
bph |
This was not the case for CDK4 protein, although p16 protein expression correlated significantly with CDK4 protein expression in BPH (Spearman rank correlation [R(S)] = 0.63) and carcinoma (R(S) = 0.78). |
10640976 |
Human |
p16 |
secondary glioblastomas |
Primary (de novo) glioblastomas develop in older patients and are characterized by epidermal growth factor (EGF) receptor amplification/overexpression, p16 deletion, and PTEN mutations, whereas secondary glioblastomas that progressed from low-grade or ana |
10666371 |
Human |
p16 |
cartilaginous tumour |
The role of two important tumour suppressor genes, p16 and p53, was evaluated in cartilaginous tumour tissues. |
10709095 |
Human |
p16 |
prostate tumor |
Replacement of p16 inhibits prostate tumor cell growth, but the mechanism is not known. |
10713671 |
Human |
p16 |
prostate tumors |
RESULTS: Overexpression of p16 mRNA was found in 6/9 (67) of prostate tumors compared to the adjacent normal prostate, whereas elevated p14 and p15 levels were only observed in 2/9 (22) and 1/6 (17) of prostate cases, respectively. |
10797499 |
Human |
p16 |
prostate tumors |
Diminished RB levels in prostate tumors that had upregulated p16 mRNA were found, although absent RB was also detected in tumors without elevated p16 levels. |
10797499 |
Human |
p16 |
prostate tumors |
Exon 2 of p16/p14 is methylated in a majority of prostate tumors compared to the unmethylated upstream 5' region, and may be a potential tumor marker for human prostate cancer. |
10797499 |
Human |
p16 |
prostate tumors |
Moreover, prostate tumors injected with Adp16 expressed p16 and the adenoviral vector expressed the transgene for up to 14 days. |
10854145 |
Human |
p16 |
astrocytomas |
Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy. |
10896207 |
Human |
p16 |
lung tumor |
To provide further evidence that hypermethylation is involved in the loss of p16 (Ink4a) gene expression, three mouse lung tumor cell lines (C10, sp6c and CMT64) displaying complete methylation at seven promoter CpG sites and no p16 (Ink4a) expression wer |
10964101 |
Mouse |
p16 |
adrenocortical neoplasms |
While the mechanisms of tumorigenesis for adrenocortical neoplasms remain unknown, several genes, such as Gsalpha, ACTH receptor (MC2-R), p53, and p16 tumor suppressor genes, are considered to be candidates for adrenocortical neoplasms. |
11075727 |
Human |
p16 |
hereditary breast and ovarian cancer |
At present, the most useful methods of risk assessment are those performed on the following genes: BRCA1 and BRCA2 especially for hereditary breast and ovarian cancer, hMLH1 and hMSH2 for hereditary non polyposis colorectal cancer, APC for familial adenom |
11205230 |
Human |
p16 |
transitional cell carcinoma of urinary bladder |
[Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder] OBJECTIVE: To study the relationship between the expression of proto-oncogene bcl-2 and MTS1/p16 in transitional cell carcinoma of bladder and prognosis. |
11831985 |
Human |
p16 |
cystadenomas |
Lack of p16 expression was present in 7 of 16 cystadenomas, 4 of 13 LMP tumors, and 22 of 29 carcinomas (P [LMPs versus carcinomas] = 0. 01) and correlated with methylation changes in LMP tumors (P = 0.05). p16 expression was correlated with mucinous diff |
9889036 |
Human |
p16 |
cystadenomas |
Changes in DNA methylation may be more important for inactivation of this gene (and perhaps other tumor suppressor genes) in LMP tumors, which lack many of the alternative mechanisms present in carcinomas. p16 expression is primarily related to mucinous d |
9889036 |
Human |
p16 |
uterine tumours |
Alteration of p16 and p15 genes in human uterine tumours. |
10408854 |
Human |
p16 |
endometrial tumours |
Reduced expression of p16 protein, detected by immunohistochemistry, occurred even more frequently, in nine of 33 (27%) cervical and seven of 37 (19%) endometrial tumours. |
10408854 |
Human |
p16 |
pediatric all |
These results confirm and extend the authors' previous findings that homozygous deletion of p16 in pediatric ALL patients is an independent prognostic indicator of outcome from therapy. |
11154239 |
Human |
p16 |
mzbcl |
DESIGN AND METHODS: Fourteen cases of MZBCL diagnosed according to the REAL classification were studied by conventional chromosome analysis (CCA) and by interphase fluorescence in situ hybridization (FISH) using the following probes: 3q27/BCL6, 6q21, 7q31 |
11146573 |
Human |
p16 |
head and neck tumors |
We tested 30 patients with primary head and neck tumors using methylation-specific PCR searching for promoter hypermethylation of the tumor suppressor gene p16 (CDKN2A), the DNA repair gene O6-methylguanine-DNA-methyltransferase (MGMT) and the putative me |
11221887 |
Human |
p16 |
mesenchymal neoplasms |
BACKGROUND AND OBJECTIVES: Tumor suppressor gene MTS1/p16 (cyclin-dependent kinase-4 inhibitor) and a putative tumor metastasis suppressor gene nm23 (nucleoside diphosphate A kinase) have been identified in a variety of human tumors but have not been well |
11223831 |
Human |
p16 |
minimal residual disease |
PURPOSE: To investigate the frequency of p15 and p16 gene promoter methylation in acute promyelocytic leukemia (APL), and to define its value in the detection of minimal residual disease (MRD) and treatment prognostication. |
11283136 |
Human |
p16 |
mrd |
PURPOSE: To investigate the frequency of p15 and p16 gene promoter methylation in acute promyelocytic leukemia (APL), and to define its value in the detection of minimal residual disease (MRD) and treatment prognostication. |
11283136 |
Human |
p16 |
apl |
CONCLUSION: In APL, p15 but not p16 gene methylation is frequent. |
11283136 |
Human |
p16 |
ptcl |
Fifty-seven cases of T-cell lymphomas (TCL) including 5 lymphoblastic (T-LBL) and 52 peripheral TCL (PTCL) were analyzed by immunohistochemistry for the expression of p53, mdm2, p21, Rb, cyclin D1, cyclin A, cyclin B1, and Ki67/MIB1 proteins and 39/52 PTC |
11332692 |
Human |
p16 |
basal cell nevus syndrome |
Expression of cyclin D1 and p16 protein was detected in the basal and parabasal cells in lining epithelium of OKCs and was found more frequently in basal cell nevus syndrome (BCNS)-associated OKCs than in primary or recurrent OKCs. |
11488422 |
Human |
p16 |
pnet |
Given that EWS/FLI1 is only able to transform immortalized 3T3 fibroblasts and that 30% of ES/PNET tumors contain a homozygous deletion of the p16 locus, it is likely that other genetic events are required for EWS/FLI1 oncogenesis. |
11709708 |
Human |
p16 |
mucoepidermoid carcinoma of salivary glands |
[Detection of proteins and mRNA of p16, p53 and nm23 in mucoepidermoid carcinoma of salivary glands and their prognostic significance] OBJECTIVE: To disclose the relationship between the expression of p16, p53 and nm23 and the significant morphologic char |
11758216 |
Human |
p16 |
parotid tumor |
[A qualititative study on p16 mutiple tumor suppressor gene, ras oncogene p21 and DNA content in parotid tumor and its' contiguous acini] OBJECTIVE: To determine the biologic characteristics of tumor's contiguous acini and the relationship of re |
11769651 |
Human |
p16 |
gastric malt lymphoma |
We performed a prospective study to evaluate the outcome of patients with low-grade gastric MALT lymphoma and the expression of p16 hypermethylation. |
11824795 |
Human |
p16 |
nsclc |
To identify the molecular basis for this p16 immunohistochemical negativity further, we performed a genetic and epigenetic study of p16(INK4a) status in a series of 115 NSCLC samples parallel to the clinicopathologic and prognostic analyses. |
11920642 |
Human |
p16 |
malignant eyelid tumors |
Expression of P16 protein and Bcl-2 protein in malignant eyelid tumors. |
11930651 |
Human |
p16 |
malignant eyelid tumors |
OBJECTIVE: To investigate the relationship between P16 gene (the tumor suppressor gene) and the bcl-2 gene (the apoptosis inhibitor gene) and the incidence and development of malignant eyelid tumors. |
11930651 |
Human |
p16 |
malignant eyelid tumors |
METHODS: The streptavidin-biotin-peroxidase complex immunohistochemistry method was used to study the expression of P16 gene and the bcl-2 gene in 96 cases of malignant eyelid tumors. |
11930651 |
Human |
p16 |
mucoid carcinoma |
The positive rate of p16 protein expression in mucoid carcinoma 10.00% (1/10) was significantly lower than that in poorly differentiated carcinoma 51.22% (21/41), undifferentiated carcinoma 57.69% (15/26) and signet ring cell carcinoma 62.50% (10/16) (P < |
11819820 |
Human |
p16 |
stage i adenocarcinomas of the lung |
Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung. |
11940214 |
Human |
p16 |
minimal residual disease |
Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia. |
12127556 |
Human |
p16 |
minimal residual disease |
We evaluated the incidence of MTS1/p16 deletions by loss of heterozygosity (LOH) analysis in 36 non-high risk B-cell precursor childhood acute lymphoblastic leukemia (BCP-ALL) and correlated these results with clinical features and with the presence of mi |
12127556 |
Human |
p16 |
mrd |
We evaluated the incidence of MTS1/p16 deletions by loss of heterozygosity (LOH) analysis in 36 non-high risk B-cell precursor childhood acute lymphoblastic leukemia (BCP-ALL) and correlated these results with clinical features and with the presence of mi |
12127556 |
Human |
p16 |
mrd |
A slower response to the induction treatment (MRD) was associated with LOH of p16 and worse clinical outcome. |
12127556 |
Human |
p16 |
familial cancers |
Based on our observations, the spectrum of familial cancers associated with p16 mutations should include a new clinical entity, familial HNSCC. |
12352668 |
Human |
p16 |
cin 3 |
Expression of p16 was restricted to CIN 2/CIN 3, CIN 1 associated with high-risk human papillomavirus, or cervical cancer. p16 immunostaining allowed precise identification of even small CIN or cervical cancer lesions in biopsy sections and helped to redu |
12409715 |
Human |
p16 |
advanced cancers |
Inactivation of both p16 and p14 genes may result in a malignant change in colorectal cancer cells, leading to advanced cancers with a smaller size than those with p16 or p14 activity. |
12716465 |
Human |
p16 |
laryngeal papilloma |
[Human papilloma virus infection and expression of p16 protein in laryngeal papilloma and laryngeal carcinoma] OBJECTIVE: To evaluate the role of human papilloma virus (HPV) infection and inactivation of p16 gene in laryngeal papilloma (LP) and laryngeal |
12761910 |
Human |
p16 |
carcinoid tumors |
Carcinoid tumors were frequently methylated at RARbeta, MGMT, p16, COX2, p14, THBS1, and ER ranging from 25 to 63% of tumors. |
12584572 |
Human |
p16 |
carcinoid tumors |
Loss of p16 protein expression correlated with methylation of p16 gene in carcinoid tumors (p = 0.006). |
12584572 |
Human |
p16 |
neuroendocrine tumors of the lung |
The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. |
12612881 |
Human |
p16 |
apl |
In this study, methylation-specific polymerase chain reaction (MSP) was used to define the methylation status of a panel of nine genes, comprising p15, p16, RARbeta, oestrogen receptor (ER), E-cadherin (E-CAD), p73, caspase 8 (CASP8), VHL and MGMT, in 29 |
12899712 |
Human |
p16 |
apl |
In APL, p15, p16, ER and RARbeta were most frequently methylated. |
12899712 |
Human |
p16 |
tongue squamous cell carcinoma |
[Expression of p15 and p16 proteins in tongue squamous cell carcinoma and their significances] BACKGROUND & OBJECTIVE: Abnormal expression of p15 and p16 were commonly found in many kinds of primary tumors, but the possible correlation between p15 and p16 |
14613656 |
Human |
p16 |
ganglioglioma |
The present case is unusual in four aspects: (i) it arose from a low-grade ganglioglioma in the absence of previous radiation or chemotherapy, which is the fourth reported case; (ii) the original tumor showed a high proliferative index on flow cytometry b |
14629754 |
Human |
p16 |
skin metastasis |
In contrast, all cells of melanoma metastases, except one skin metastasis, lacked nuclear staining for p16. |
14576937 |
Human |
p16 |
mmmt |
Three consecutive cases of primary peritoneal MMMT were examined by paraffin immunohistochemistry for expression of p53, p16, BCL2, CerbB2, and classical cadherins E-cadherin, P-cadherin, and N-cadherin. |
14675326 |
Human |
p16 |
mmmt |
We conclude that p16 may be a common tumor suppressor gene expressed in peritoneal MMMT. |
14675326 |
Human |
p16 |
common tumor |
We conclude that p16 may be a common tumor suppressor gene expressed in peritoneal MMMT. |
14675326 |
Human |
p16 |
pancreatic adenocarcinoma |
A pancreatic adenocarcinoma cell line (PaCa44), which contains, among other alterations, a methylated p16 promoter, was treated with a chemoterapeutic agent, 5-aza-2'-deoxycytidine (DAC), in order to evaluate the effect of this drug on cell growth an |
14679576 |
Human |
p16 |
oral tumor |
The incidence of hypermethylation in oral tumor and adjacent mucosa for p16 gene was 66.7 and 50%, for DAPK was 68.3 and 60%, and MGMT gene was 51.7 and 26.7%, respectively. |
14693237 |
Human |
p16 |
kidney tumors |
Using sensitive methylation-specific PCR, we screened matched tumor DNA and sediment DNA from preoperative urine specimens obtained in 50 patients with kidney tumors, representing all major histological types, for hypermethylation status of a panel of six |
14695183 |
Human |
p16 |
oropharyngeal tumors |
P16 expression in the node metastases also correlated with site of tumor origin: 24 of 31 oropharyngeal tumors were p16 positive, whereas only 1 of 37 nonoropharyngeal tumors was p16 positive (77% versus 3%; P < 0.001; Fisher's exact). |
14695150 |
Human |
p16 |
glioblastoma |
EXPERIMENTAL DESIGN: In this series of 140 consecutive cases of glioblastoma treated at a single center, we analyzed the frequency, age dependency and prognostic effects of TP53 mutation, CDKN2A/p16 deletion, EGFR amplification, as well as loss of chromos |
14734474 |
Human |
p16 |
cin grade 3 |
Immunohistochemistry revealed that all HSIL and invasive carcinoma cases contained p16-positive cells in the liquid-based Pap smears and diffuse p16 staining was observed in all high-grade lesions with greater than CIN Grade 3 cervical intraepithelial neo |
15098254 |
Human |
p16 |
cervical tumor |
RESULTS: Promotor CpG island methylation of DAPK, p16, and MGMT was detectable, respectively, in 60%, 28.2%, and 18.8% of cases of cervical tumor DNA; and in 40%, 10%, and 7.5% of cases of patients' plasma DNA. |
15099958 |
Human |
p16 |
spitz nevus |
An analysis of cell-cycle inhibitory proteins including p16, p21, and p27 showed that the majority of Spitz nevus cells expressed high levels of p16, with cells of the cases that had increased copy number of 11p expressing significantly higher levels than |
15111324 |
Human |
p16 |
barrett's esophagus |
Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. |
15150093 |
Human |
p16 |
salivary gland tumors |
[Expression of p16 and nm23 genes in salivary gland tumors] OBJECTIVE: To study the expression of p16 and nm23 genes in salivary gland tumors and the relation of P16 and nm23 proteins with fumorigenesis of salivary gland tumors. |
15190803 |
Human |
p16 |
salivary gland tumors |
METHODS: Expression of P16 and nm23 proteins was examined by SABC immunohistochemical method in 39 cases of paraffin blocks of normal salivary gland tissues and salivary gland tumors. |
15190803 |
Human |
p16 |
colon adenoma |
To address changes in the methylation profiles of multiple genes during colorectal carcinogenesis, we investigated the methylation of 12 genes (APC, COX-2, DAP-kinase, E-cadherin, GSTP1, hMLH1, MGMT, p14, p16, RASSF1A, THBS1, and TIMP3) in normal colon (n |
15122305 |
Human |
p16 |
small cell carcinoma of the uterine cervix |
In this study, 22 cases of primary small cell carcinoma of the uterine cervix were subjected to broad-spectrum HPV DNA amplification and typing, and immunohistochemically examined for the expression of p16, Rb, and p53 proteins. |
15223960 |
Human |
p16 |
cervical tumors |
While similar p16 and Rb expression patterns were observed in these HPV-negative tumors, a different expression pattern for p53 was noted where strong nuclear staining was seen in 8 cases (47%; P = 0.0004 compared with cervical tumors). |
15223960 |
Human |
p16 |
endometrial adenocarcinomas |
Re: Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papilloma virus (HPV) DNA detection. |
15223971 |
Human |
p16 |
hereditary breast-ovarian cancer syndrome |
This article traces the historical aspects of hereditary cancer dealing with identification and ultimate molecular genetic confirmation of commonly occurring cancers, particularly of the colon in the case of familial adenomatous polyposis and its attenuat |
15264268 |
Human |
p16 |
kidney cancer |
We examined the tumor and the matched urine and serum DNA for aberrant methylation of nine gene promoters (CDH1, APC, MGMT, RASSF1A, GSTP1, p16, RAR-beta2, and ARF) from 17 patients with primary kidney cancer by quantitative fluorogenic real-time PCR. |
15289362 |
Human |
p16 |
genitourinary cancer |
Urine samples from 91 control subjects without evidence of genitourinary cancer revealed no methylation of the MGMT, GSTP1, p16, and ARF genes, whereas methylation of RAR-beta2, RASSF1A, CDH1, APC, and TIMP3 was detected at low levels in a few control sub |
15289362 |
Human |
p16 |
vulvar squamous cell carcinomas |
METHODS: A total of 224 vulvar squamous cell carcinomas were immunohistochemically investigated for expression of p16, p21, and p27 using the biotin-streptavidin-peroxidase method and the OptiMax Plus automated cell staining system. |
15385108 |
Human |
p16 |
colorectal carcinomas |
This study aimed to identify potential abnormalities of retinoblastoma protein (pRb) and p16(INK4a) (p16) expression in resectable colorectal carcinomas (CRCs) and to assess the prognostic significance of pRb and p16 levels in patients with CRC. |
15492985 |
Human |
p16 |
eyelid tumors |
[A study on the expression of p16 protein and bcl-2 protein in cutaneous eyelid tumors] OBJECTIVE: To investigate the relationship between p16 (tumor suppressor) and bcl-2 (apoptosis inhibitor) gene expression and the incidence and development of eyelid m |
11853608 |
Human |
p16 |
skin carcinoma |
Monitoring of the expression of p16, p21(WAF1/CIP1) and Cyclin D1 proteins may be valuable for early detection and early treatment and prognostic assessment of skin carcinoma caused by coal-burning. |
11860939 |
Human |
p16 |
hepatitis b virus-related hepatocellular carcinoma |
[Effect of p16 gene on carcinogenesis of hepatitis B virus related hepatocellular carcinoma] OBJECTIVE: To investigate the relation between p16 gene expression and the carcinogenesis and progress of hepatitis B virus (HBV) related hepatocellular carcinoma |
12921565 |
Human |
p16 |
invasive carcinomas |
RARbeta, p16, and MGMT genes showed the highest incidences of methylation in premalignant and invasive carcinomas. |
15173091 |
Human |
p16 |
relapsed childhood acute lymphoblastic leukemia |
Methylation profile was analyzed in nine cases of relapsed childhood acute lymphoblastic leukemia (ALL) for p14, p15, p16, Rb, MGMT, APC, hMLH1, RARbeta, RIZ, DAPK, and FHIT genes by using methylation specific polymerase chain reaction (MSP) analysis. |
15201966 |
Human |
p16 |
hpv-related carcinomas |
Recently, the tumor suppressor protein p16 has been shown to be specifically overexpressed in HPV-related carcinomas and premalignant lesions of the uterine cervix, oral cavity, and anus, but the presence of p16 vulvar squamous lesions has not been examin |
15213596 |
Human |
p16 |
ameloblastic carcinoma |
There were 12 ameloblastomas (two peripheral, eight solid, and two unicystic) and three ameloblastic carcinoma studied for loss of heterozygosity of tumor suppressor genes on chromosomes 1p, 3p, 9p,10q, and 17p (L-myc, hOGG1, p16, pten, and p53). |
15133474 |
Human |
p16 |
oropharyngeal squamous cell carcinoma |
In this study, we sought to determine whether p16 expression is of prognostic importance in oropharyngeal squamous cell carcinoma. |
15355894 |
Human |
p16 |
oropharyngeal squamous cell carcinoma |
CONCLUSIONS: In patients with oropharyngeal squamous cell carcinoma, overexpression of p16 as determined by immunohistochemistry is associated with significantly improved prognosis and lower local recurrence rates. |
15355894 |
Human |
p16 |
large-cell neuroendocrine carcinomas |
Loss of Rb and p16 expression, respectively, was observed in no and 14% typical carcinoids, no and 40% atypical carcinoids, 49 and 18% large-cell neuroendocrine carcinomas, 84 and 8% small-cell carcinomas. |
15154011 |
Human |
p16 |
carcinoid tumors |
Rb pathway aberration was mostly attributed to Rb loss in small-cell carcinomas, while p16 loss and/or cyclin D1 overexpression besides Rb loss also played an important role in large-cell neuroendocrine carcinomas, while cyclin D1 overexpression was the o |
15154011 |
Human |
p16 |
large-cell neuroendocrine carcinomas |
Rb pathway aberration was mostly attributed to Rb loss in small-cell carcinomas, while p16 loss and/or cyclin D1 overexpression besides Rb loss also played an important role in large-cell neuroendocrine carcinomas, while cyclin D1 overexpression was the o |
15154011 |
Human |
p16 |
malignant germ cell tumours of the ovary |
To clarify the mechanisms underlying cell cycle promotion in malignant germ cell tumours of the ovary (MGCTOs), beta-catenin and components of the pRB pathway, cyclin D1 and p16, were analysed in relation to cell proliferation. |
15476271 |
Human |
p16 |
esophageal adenocarcinoma |
The size of a clone with a p16 lesion is not a significant predictor of esophageal adenocarcinoma when we controlled for p53 loss of heterozygosity status. |
15492292 |
Human |
p16 |
hydatidiform moles |
We investigated the methylation status of the promoter regions of six genes, p16, HIC-1, TIMP3, GSTP1, death-associated protein kinase (DAPK), and E-cadherin in 54 hydatidiform moles, five choriocarcinomas, and 10 first trimester placenta by methylation-s |
15507671 |
Human |
p16 |
choriocarcinomas |
We investigated the methylation status of the promoter regions of six genes, p16, HIC-1, TIMP3, GSTP1, death-associated protein kinase (DAPK), and E-cadherin in 54 hydatidiform moles, five choriocarcinomas, and 10 first trimester placenta by methylation-s |
15507671 |
Human |
p16 |
choriocarcinoma |
Among the six genes examined, the promoter region of four genes (E-cadherin, HIC-1, p16, TIMP3) in choriocarcinoma and three genes (E-cadherin, HIC-1, p16) in hydatidiform mole exhibited aberrant methylation whereas none was hypermethylated in normal plac |
15507671 |
Human |
p16 |
gestational trophoblastic neoplasia |
Hypermethylation of multiple genes, especially p16, might be related to the subsequent development of gestational trophoblastic neoplasia. |
15507671 |
Human |
p16 |
nodular melanomas |
Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. |
15547691 |
Human |
p16 |
smooth muscle tumors |
Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. |
15589581 |
Human |
p16 |
smooth muscle tumor |
In the present study, we compared the expression of p16 protein in cases with leiomyoma, uterine smooth muscle tumor of uncertain malignant potential (STUMP), and leiomyosarcoma (LMS). |
15589581 |
Human |
p16 |
leiomyoma |
In the present study, we compared the expression of p16 protein in cases with leiomyoma, uterine smooth muscle tumor of uncertain malignant potential (STUMP), and leiomyosarcoma (LMS). |
15589581 |
Human |
p16 |
leiomyoma |
METHODS: P16 expression was investigated by immunohistochemistry from paraffin-embedded tissue in 26 patients with leiomyoma, in 24 patients with STUMP, and in 21 patients with LMS. |
15589581 |
Human |
p16 |
leiomyoma |
A statistically significant difference regarding the frequency of p16 protein expression was observed between LMS and STUMP (P < 0.05) as well as between LMS and leiomyoma (P < 0.05), but not between STUMP and leiomyoma (P > 0.05). |
15589581 |
Human |
p16 |
leiomyoma |
CONCLUSIONS: We found that p16 was more frequently and more strongly expressed in LMS compared to STUMP and leiomyoma. |
15589581 |
Human |
p16 |
smooth muscle tumors |
Furthermore, p16 might be a useful immunohistochemical marker, which could help to distinguish cases of smooth muscle tumors in which histologic features are ambiguous or borderline, but the use of p16 in a diagnostic setting should await further clinical |
15589581 |
Human |
p16 |
uterine cervical cancer |
METHODS: We analyzed CpG island hypermethylation in 15 genes (APC, CDH1, COX2, DAPK, FHIT, GSTP1, HLTF1, hMLH1, MGMT, p14, p16, RASSF1A, RUNX3, THBS1, and TIMP3) and its association with the methylene-tetrahydrofolate reductase (MTHFR) C677T and A1298C an |
15589597 |
Human |
p16 |
digestive tract tumor |
CONCLUSION: The role of DNA methylation in the silence of p16/INK4 may different between these two types of upper digestive tract tumor. |
15612883 |
Human |
p16 |
vin 3 |
Ninety-five percent of VIN 3 and basaloid or warty SCCs (76/80) and 4% of keratinizing SCC (2/48) were moderately to strongly immunopositive for p16, which localized to nucleus and cytoplasm; 52/58 analyzed (90%) contained HPV 16 transcripts. |
15619206 |
Human |
p16 |
vin 3 |
The positive predictive value (PPV) of moderate to strong diffuse p16 immunostaining and HPV positivity for the diagnosis of VIN 3 and of basaloid or warty SCC was 97% and 95%, respectively. |
15619206 |
Human |
p16 |
vulvar carcinomas |
These disparate patterns of p16 expression underscore 2 different mechanisms for p16 expression in HPV-related and HPV-unrelated vulvar carcinomas. |
15619206 |
Human |
p16 |
papillary neoplasm |
Frequent p16ink4a inactivation is an early and frequent event of intraductal papillary neoplasm of the liver arising in hepatolithiasis. |
15619210 |
Human |
p16 |
oropharyngeal tumors |
Loss of P16 protein was less common in oropharyngeal tumors than at other HNSCC locations (P = 0.02). |
15623629 |
Human |
p16 |
high-grade prostatic intraepithelial neoplasias |
EXPERIMENTAL DESIGN: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 b |
15623627 |
Human |
p16 |
invasive cervical cancers |
Flow cytometry on primary CVX and NCK and immunohistochemical staining of formalin fixed paraffin-embedded tumor specimens from which primary CVX cultures were derived as well as from a separate set of invasive cervical cancers confirmed differential expr |
15629771 |
Human |
p16 |
gallbladder adenoma |
METHODS: Forty-one gallbladder carcinoma, 7 gallbladder adenoma and 14 chronic cholecystitis specimens were immunohistochemically and histopathologically investigated for the relation of cyclin D1, p16 and Rb with Nevin staging and pathologic grading. |
15655836 |
Human |
p16 |
squamous papillomas |
Metachronous squamous cell carcinomas evolving from independent oropharyngeal and pulmonary squamous papillomas: Association with human papillomavirus 11 and lack of aberrant p53, Rb, and p16 protein expression. |
15668901 |
Human |
p16 |
gastrointestinal stromal tumors |
Loss of p16 Protein Defines High-Risk Patients with Gastrointestinal Stromal Tumors: A Tissue Microarray Study. |
15701851 |
Human |
p16 |
epithelioma |
Cervical adenoid basal tumors comprised of adenoid basal epithelioma associated with various types of invasive carcinoma: Clinicopathologic features, human papillomavirus DNA detection, and P16 expression. |
15712186 |
Human |
p16 |
liposarcomas |
In this study, the methylation status of RASSF1A, p16, MLH1, MSH2 and ERalpha was investigated in 84 primary soft tissue sarcomas (STSs), including 22 liposarcomas, 18 malignant fibrous histiocytomas (MFHs), 18 leiomyosarcomas, 6 rhabdomyosarcomas, 6 neur |
15551306 |
Human |
p16 |
soft-tissue sarcomas (stss) |
In this study, the methylation status of RASSF1A, p16, MLH1, MSH2 and ERalpha was investigated in 84 primary soft tissue sarcomas (STSs), including 22 liposarcomas, 18 malignant fibrous histiocytomas (MFHs), 18 leiomyosarcomas, 6 rhabdomyosarcomas, 6 neur |
15551306 |
Human |
p16 |
fibroadenoma |
Conversely, protein p16 expression, although heterogeneously distributed within the section, is considerably higher in breast carcinoma as compared to fibroadenoma in both tumoral and non-tumoral epithelia and stroma. |
15578730 |
Human |
p16 |
fibroadenoma |
Furthermore, in a subset of fibroadenoma with higher proliferative activity, p16 protein expression was substantially decreased as compared to those showing lower proliferation. |
15578730 |
Human |
p16 |
papillary tumors |
Low-grade superficial papillary tumors induced by activated H-ras had no detectable Rb family proteins (Rb, p107, and p130) and late cell cycle cyclins and kinases (cyclin A, E, and CDK1), but had increased level of p16, p53, and MDM2. |
15734997 |
Human |
p16 |
bronchioloalveolar carcinomas |
Role of cdk4, p16INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomas. |
15753637 |
Human |
p16 |
juvenile myelomonocytic leukaemia |
Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia. |
15755284 |
Human |
p16 |
juvenile myelomonocytic leukaemia |
This is the first report to investigate the methylation status of p15 and p16, cell cycle regulatory genes, in children with MDS (n = 9) and juvenile myelomonocytic leukaemia (JMML; n = 18) by using a methylation-specific polymerase chain reaction. |
15755284 |
Human |
p16 |
jmml |
This is the first report to investigate the methylation status of p15 and p16, cell cycle regulatory genes, in children with MDS (n = 9) and juvenile myelomonocytic leukaemia (JMML; n = 18) by using a methylation-specific polymerase chain reaction. |
15755284 |
Human |
p16 |
jmml |
Aberrant methylation of p16 was not detected in children with either MDS or JMML. |
15755284 |
Human |
p16 |
jmml |
Since p15 and p16 genes were unmethylated in two children with JMML, in whom the disease had progressed with an increased number of blasts, a condition referred to as blastic crisis, we infer that the aberrant methylation of these genes is not responsible |
15755284 |
Human |
p16 |
myelofibrosis |
We analyzed the promoter methylation status of eight tumor-associated genes (p14 ARF, p15 INK4B, p16 INK4A, Rb, hMLH1, hMSH2, APC, and DAPK) in 30 patients with myelofibrosis with myeloid metaplasia (MMM) by methylation specific PCR. |
15755503 |
Human |
p16 |
mucoid carcinoma |
The positive rate of P16 protein expression in mucoid carcinoma (10%, 1/10) was significantly lower than that in poorly differentiated carcinoma (51%, 21/41), undifferentiated carcinoma (58%, 15/26) and signet ring cell carcinoma (62%, 10/16) (P<0.05). |
15818729 |
Human |
p16 |
undifferentiated carcinoma |
The positive rate of P16 protein expression in mucoid carcinoma (10%, 1/10) was significantly lower than that in poorly differentiated carcinoma (51%, 21/41), undifferentiated carcinoma (58%, 15/26) and signet ring cell carcinoma (62%, 10/16) (P<0.05). |
15818729 |
Human |
p16 |
signet-ring-cell carcinoma |
The positive rate of P16 protein expression in mucoid carcinoma (10%, 1/10) was significantly lower than that in poorly differentiated carcinoma (51%, 21/41), undifferentiated carcinoma (58%, 15/26) and signet ring cell carcinoma (62%, 10/16) (P<0.05). |
15818729 |
Human |
p16 |
endocrine tumours |
AIMS: p16 and p27, the inhibitors of cyclin-dependent kinases, have been reportedly decreased in certain human tumours, including a few endocrine tumours. |
15841692 |
Human |
p16 |
glucagonoma |
Insulinomas, glucagonoma, PP-omas and non-functioning tumours were weakly stained for cdk6 and p16. |
15841692 |
Human |
p16 |
endocrine tumours |
This decreased cdk6 and p16 in pancreatic endocrine neoplasms may be a part of the cell cycle event in tumour transformation and progression, and the same process may involve other endocrine tumours. |
15841692 |
Human |
p16 |
leukoplakia |
METHODS: 20 patients of leukoplakia with hyperplasia, 11 patients of leukoplakia with mild dysplasia, 10 patients of leukoplakia with moderate dysplasia, 9 patients of leukoplakia with severe dysplasia, 10 patients with OSCC in low grade, 12 patients with |
15842853 |
Human |
p16 |
leukoplakia |
RESULTS: Rates of p16 methylation were 0 for normal individuals, 5% for patients of leukoplakia with hyperplasia, 18% for patients of leukoplakia with mild dysplasia, 10% for patients of leukoplakia with moderate dysplasia, 22% for patients of leukoplakia |
15842853 |
Human |
p16 |
leukoplakia |
CONCLUSIONS: It was first reported that p16 methylation occurred in every stage of leukoplakia cancerization and OSCC progression. p16 can be one of the important molecular biological markers for leukoplakia cancerization and OSCC progression. p16 methyla |
15842853 |
Human |
p16 |
peritoneal malignant mesothelioma |
P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. |
15867227 |
Human |
p16 |
peritoneal malignant mesothelioma |
CONCLUSIONS: Biphasic histology, increased mitotic rate, and p16 loss were independently associated with poorer survival in peritoneal malignant mesothelioma. |
15867227 |
Human |
p16 |
melanoma |
BRAF mutation and p16 inactivation accompanied MITF amplification in melanoma cell lines. |
16001072 |
Human |
p16 |
malignant thyroid tumors |
Design: Quantitative hypermethylation of Rassf1A, TSHR, RAR-beta2, DAPK, S100, p16, CDH1, CALCA, TIMP3, TGF-beta, and GSTpi was tested on a cohort of 82 benign and malignant thyroid tumors and five thyroid cancer cell lines. |
15840741 |
Human |
p16 |
ovarian adenocarcinoma |
We have evaluated the use of Ad5/3-Delta24, a serotype 3 receptor targeted Rb/p16 pathway selective CRAd, in combination with gemcitabine against human ovarian adenocarcinoma. |
15800658 |
Human |
p16 |
cystadenomas |
The mean methylation index was highest in invasive tumors [0.20 versus 0.065 (LMP) and 0.033 (cystadenomas); P = 0.001]. |
16061849 |
Human |
p16 |
invasive carcinomas |
LMP tumors also showed p16 (22%) and E-cadherin (17%) methylation, in addition to RARbeta (9%) and H-cadherin (4%). |
16061849 |
Human |
p16 |
cystadenomas |
LMP tumors also showed p16 (22%) and E-cadherin (17%) methylation, in addition to RARbeta (9%) and H-cadherin (4%). |
16061849 |
Human |
p16 |
cystadenomas |
All eight genes were hypermethylated in invasive cancers at a frequency of 9% to 30%. |
16061849 |
Human |
p16 |
de novo myelodysplastic syndromes |
Absence of p16 and p27 gene rearrangements and mutations in de novo myelodysplastic syndromes. |
16104874 |
Human |
p16 |
genitourinary cancer |
Urine samples from the 91 controls without evidence of genitourinary cancer revealed no methylation of the p16, ARF, MGMT, and GSTP1 gene promoters, whereas methylation of RARbeta2, TIMP3, CDH1, Rassf1A, and APC was detected at low levels. |
16170165 |
Human |
p16ink4 |
esophageal cancer |
[Analysis of the p16INK4, p15INK4B genes abnormality and the amplification of cyclin D1 gene in esophageal cancer] To evaluate the prognostic significance of gene amplification and overexpression of cyclin D1 in the patients of esophageal squamous cancer, |
8920671 |
Human |
p16ink4 |
testicular germ cell tumors |
Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors. |
9284835 |
Human |
p16ink4 |
bone tumors |
These data support the hypothesis that TP53 alterations may play a role in the development of pediatric bone tumors and that the primary mechanism of inactivation of p16INK4 seems to be homozygous deletion rather than point mutation. |
9309118 |
Human |
p16ink4 |
bone tumours |
[Analysis of the involvement of the tumour suppressor genes TP53, p16INK4, p21WAF1, RB1 and the drugs metabolizing enzymes in the development of bone tumours in children] BACKGROUND: Several tumor suppressor genes such as p16INK4, TP53, RB1 y p21WAF1 are |
12886318 |
Human |
p16ink4 |
adenocarcinomas of the uterine cervix |
The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with internati |
14584070 |
Human |
p16ink4 |
bronchioloalveolar carcinomas |
Role of cdk4, p16INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomas. |
15753637 |
Human |
p16ink4a |
hairy-cell leukemia (hcl) |
We analyzed p16INK4A and p15INK4B genes in 178 cases of primary leukemias including 81 cases of chronic lymphocytic leukemia (CLL), seven of hairy cell leukemia (HCL), seven of chronic myelogenous leukemia (CML), 43 of acute myelogenous leukemia (AML), 27 |
7795238 |
Human |
p16ink4a |
skin tumors |
Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. p16INK4a and p15INK4b are cell cycle regulators that specifically bind to and inhibit the cyclin D-dependent kinases, cdk4 and cdk6. |
7585567 |
Mouse |
p16ink4a |
papillary tumors |
Fine mapping at 9p21 demonstrated that CIS also displayed a high frequency of homozygous deletion surrounding the p16INK4A locus, like superficial papillary tumors, the other form of noninvasive lesion found in the bladder. |
7585577 |
Human |
p16ink4a |
tumor syndrome |
Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. |
8841025 |
Human |
p16ink4a |
benign epithelial tumours |
Paraffin sections from 190 epithelial ovarian tumours, including 159 malignant and 31 benign epithelial tumours, were analysed immunohistochemically for expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16INK4A (p16). |
9036870 |
Human |
p16ink4a |
hematological malignancies |
Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. |
9041182 |
Human |
p16ink4a |
hematological malignancies |
We have analyzed both modes of inactivation of p15INK4B and p16INK4A in the major types of adult and pediatric hematological malignancies. |
9041182 |
Human |
p16ink4a |
adult acute myelogenous leukemia |
Hypermethylation of p15INK4B, without alteration of p16INK4A, was an almost universal finding in adult acute myelogenous leukemia, and occurred very frequently in adult acute lymphocytic leukemia and pediatric acute myelogenous leukemia and acute lymphocy |
9041182 |
Human |
p16ink4a |
pediatric acute myelogenous leukemia |
Hypermethylation of p15INK4B, without alteration of p16INK4A, was an almost universal finding in adult acute myelogenous leukemia, and occurred very frequently in adult acute lymphocytic leukemia and pediatric acute myelogenous leukemia and acute lymphocy |
9041182 |
Human |
p16ink4a |
adult acute lymphocytic leukemia |
Hypermethylation of p15INK4B, without alteration of p16INK4A, was an almost universal finding in adult acute myelogenous leukemia, and occurred very frequently in adult acute lymphocytic leukemia and pediatric acute myelogenous leukemia and acute lymphocy |
9041182 |
Human |
p16ink4a |
non-hodgkin's lymphoma |
Hypermethylation of p16INK4A, often without alterations of p15INK4B, was found in non-Hodgkin's lymphoma and was much more frequent in cases with high-grade than low-grade histology. |
9041182 |
Human |
p16ink4a |
hematological malignancies |
Remarkably distinct patterns of inactivation of p15INK4B and p16INK4A characterize different types of hematological malignancy, and alterations in these tumor suppressor genes are one of the most common alterations in hematological malignancies. |
9041182 |
Human |
p16ink4a |
thymomas |
To investigate the expression of p16INK4A, RB, p53 and cyclin D1 in thymomas, we first examined 36 thymomas (non-invasive type, 16 cases; invasive type, 20 cases) and 3 thymic carcinomas, using immunohistochemistry. |
9398039 |
Human |
p16ink4a |
thymic carcinomas |
To investigate the expression of p16INK4A, RB, p53 and cyclin D1 in thymomas, we first examined 36 thymomas (non-invasive type, 16 cases; invasive type, 20 cases) and 3 thymic carcinomas, using immunohistochemistry. |
9398039 |
Human |
p16ink4a |
invasive thymomas |
Only a subgroup of invasive thymomas and thymic carcinomas showed an inverse correlation between p16INK4A and RB expression. |
9398039 |
Human |
p16ink4a |
thymic carcinomas |
Only a subgroup of invasive thymomas and thymic carcinomas showed an inverse correlation between p16INK4A and RB expression. |
9398039 |
Human |
p16ink4a |
thymic carcinoma |
However, inactivation of p16INK4A and RB may play a role in the progression of thymoma and thymic carcinoma. |
9398039 |
Human |
p16ink4a |
mouse lymphomas |
The p16INK4a (alpha and beta form) and p15INK4b genes were analysed for homozygous deletion, hypermethylation and point mutation in B6C3F1 mouse lymphomas induced by 2',3'-dideoxycytidine or 1,3-butadiene. |
9488045 |
Human |
p16ink4a |
plasmacytoma |
Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. |
9482902 |
Mouse |
p16ink4a |
mesenchymal tumours |
This study investigates p16INK4A gene status and expression in mesenchymal tumours, in particular soft tissue sarcomas (STSs). |
9582521 |
Human |
p16ink4a |
histiocytic lymphoma |
Human histiocytic lymphoma U937 cells were treated with onconase and expression of cyclins D3 and E, as well as of the cyclin-dependent kinase inhibitors (CKIs) p16INK4A, p21WAF1/CIP1 and p27KIP1 (all detected immunocytochemically) was measured by multipa |
9697879 |
Human |
p16ink4a |
sporadic colon cancer |
Recent evidence shows that transcriptional silencing as a consequence of hypermethylation of CpG islands is the predominant mechanism of p16INK4a gene inactivation in sporadic colon cancer. |
9731506 |
Human |
p16ink4a |
thyroid neoplasms |
METHODS: The authors examined 20 thyroid neoplasms (12 papillary carcinomas and 8 follicular adenomas) and 4 human thyroid carcinoma cell lines for gene mutations and epigenetic modifications of the p15INK4b and p16INK4a genes by Southern blot analysis, s |
9827724 |
Human |
p16ink4a |
undifferentiated carcinoma |
Undifferentiated carcinoma (FRO) cells had a nonsense point mutation at codon 72 (CGA-TGA, Arg-Stop) of p16, whereas the poorly differentiated papillary carcinoma (NPA) line harbored a point mutation at the exon 1-intron 1 boundary that altered the donor |
9827724 |
Human |
p16ink4a |
oral squamous-cell carcinoma |
Hence, it was possible to restore a functional pRB pathway in an oral squamous cell carcinoma line by inducing re-expression of endogenous p16ink4a in response to treatment with a demethylating agent. |
10030668 |
Human |
p16ink4a |
carcinoma of the anterior tongue |
Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. |
10537346 |
Human |
p16ink4a |
squamous cell carcinoma of the anterior tongue |
Thus, we sought to determine the relationship between cyclin D1 and/or p16INK4A expression and disease outcome in squamous cell carcinoma of the anterior tongue. |
10537346 |
Human |
p16ink4a |
tongue cancers |
Immunohistochemical detection of nuclear proteins cyclin D1, p53, and p16INK4A, and the Ki-67 labeling index was undertaken in tissue sections from 148 tongue cancers treated by surgical resection. |
10537346 |
Human |
p16ink4a |
tongue cancer |
Multivariate analysis confirmed that in addition to pathological stage and regional lymph node status, cyclin D1 overexpression and loss of p16INK4A expression are independent predictors of death from tongue cancer. |
10537346 |
Human |
p16ink4a |
anaplastic ependymomas |
P16INK4a mRNA was found in all pilocytic astrocytomas (7/7), in all grade II and III astrocytomas (7/7 and 4/4, respectively), in 4/12 glioblastomas, 8/8 oligodendrogliomas, 10/11 anaplastic oligodendrogliomas, 4/7 ependymomas and 3/3 anaplastic ependymom |
10564531 |
Human |
p16ink4a |
acute adult t-cell lymphoma leukemia |
Deletion of the p16INK4A gene in ex vivo acute adult T cell lymphoma/leukemia cells and methylation of the p16INK4A promoter in HTLV type I-infected T cell lines. |
10826477 |
Human |
p16ink4a |
primary breast cancer |
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. |
10914724 |
Human |
p16ink4a |
adenoid-cystic carcinomas (acc) |
In this study, the expressions of Rb, p16INK4A, and cyclin D1 alternations were analyzed by immunohistochemical assay in 5 specimens of normal salivary glands and twenty-two cases of adenoid cystic carcinomas (ACC). |
10928172 |
Human |
p16ink4a |
aggressive non-hodgkin's lymphoma |
Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. |
11021747 |
Human |
p16ink4a |
gastrinoma |
The presence or absence of methylation of the p16INK4a gene did not correlate with clinical characteristics of the gastrinoma, biological behavior (gastrin release and basal or maximal acid output), the presence or absence of known prognostic factors (tum |
11095446 |
Human |
p16ink4a |
gastrinoma |
Furthermore, because it is independent of disease stage it is probably an early event in the pathogenesis and because it is independent of the primary gastrinoma location, which is now thought to have different origins, methylation of the p16INK4a gene is |
11095446 |
Human |
p16ink4a |
glomus tumor |
p53 and p16INK4A mutations during the progression of glomus tumor. |
10079377 |
Human |
p16ink4a |
glomus tumors |
In spite of this possibility, the missense point mutations in conserved region of p53 and p16INK4A genes may indicate the role of p53 and p16INK4A in tumor progression of glomus tumors. |
10079377 |
Human |
p16ink4a |
scrotal cancer |
Cumulation of TP53 mutations and p16INK4A/p15INK4B homozygous deletions in human papilloma virus type 16 positive scrotal cancer. |
10087941 |
Human |
p16ink4a |
scrotal carcinoma |
Here, the mutation pattern of TP53, p16INK4A, and p15INK4B genes and the homo/hemizygous deletion patterns of p16INK4A/p15INK4B genes are presented in four scrotal carcinoma cases. |
10087941 |
Human |
p16ink4a |
scrotal carcinoma |
Homozygous deletion in p16INK4A/p15INK4B genes and a codon 259 missense point mutation (GAC-->TAC; Asp-->Tyr) in the TP53 gene were observed in one human papilloma positive scrotal carcinoma case. |
10087941 |
Human |
p16ink4a |
scrotal carcinoma |
The homozygous deletion in p16INK4A/p15INK4B genes was observed in another human papilloma positive scrotal carcinoma case. |
10087941 |
Human |
p16ink4a |
scrotal carcinoma |
The cumulation of TP53 mutations and p16INK4A/p15INK4B homozygous deletions in human papilloma virus type 16 positive scrotal carcinoma cases indicate that the alterations of TP53, p16INK4A, and p15INK4B genes have an important role in the progression of |
10087941 |
Human |
p16ink4a |
scrotal cancers |
The cumulation of TP53 mutations and p16INK4A/p15INK4B homozygous deletions in human papilloma virus type 16 positive scrotal carcinoma cases indicate that the alterations of TP53, p16INK4A, and p15INK4B genes have an important role in the progression of |
10087941 |
Human |
p16ink4a |
scrotal cancer |
The molecular alteration of TP53, p16INK4A, and p15INK4B genes may be useful as a prognostic marker in scrotal cancer. |
10087941 |
Human |
p16ink4a |
plasma cell tumors |
The role of p16INK4a (Cdkn2a) in mouse plasma cell tumors. |
10396076 |
Mouse |
p16ink4a |
adrenocortical tumors |
Inactivation of the p16 tumor suppressor gene (p16INK4A), which encodes the cell cycle protein p16, was investigated in a series of 14 adrenocortical tumors. |
10443678 |
Human |
p16ink4a |
seminoma |
Existence of the P16INK4A mutation and the hereditary TP53 mutation with or without loss of heterozygosity in the TP53 gene (seminoma/medulloblastoma) may be evidence for a common mechanism involved in tumorogenesis. |
10484981 |
Human |
p16ink4a |
primary mediastinal b-cell lymphoma |
Molecular features of primary mediastinal B-cell lymphoma: involvement of p16INK4A, p53 and c-myc. |
10520030 |
Human |
p16ink4a |
aggressive lymphomas |
Based on reports that p16INK4A gene, located on this chromosomal arm, is frequently altered in aggressive lymphomas, we analysed for alterations of this gene in 27 cases of PMBL, which were part of a series of 32 PMBL cases that have been characterized fo |
10520030 |
Human |
p16ink4a |
plasma cell dyscrasia |
Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia. |
11243384 |
Human |
p16ink4a |
extramedullary plasmacytoma |
Many patients whose BM-MNC showed dense methylation of the p16INK4A gene had extramedullary plasmacytoma (extra-PC), and all available extra-PC samples showed alterations of the p16INK4A gene (4; dense methylation, 1; homozygous deletion). |
11243384 |
Human |
p16ink4a |
liver tumors |
p16INK4a and beta-catenin alterations in rat liver tumors induced by NNK. |
11238187 |
Rat |
p16ink4a |
high-grade prostatic intraepithelial neoplasia |
Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. |
11297246 |
Human |
p16ink4a |
anaplasia |
In one tumor containing distinct areas with and without anaplasia, p14ARF hypermethylation was detected in the WHO grade II area, while homozygous co-deletion of p14ARF and p16INK4a was found in the region with anaplastic features (grade III). |
11307615 |
Human |
p16ink4a |
metastatic melanoma |
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. |
11544530 |
Mouse |
p16ink4a |
hyperplasia |
Mice lacking p16Ink4a were born with the expected mendelian distribution and exhibited normal development except for thymic hyperplasia. |
11544531 |
Mouse |
p16ink4a |
smzl |
The mean proliferative index (MIB1 staining) in initial SMZL specimens of cases with LBCL transformation was 28.6%, higher than that of MIB1 staining in the overall SMZL series (21.8%), although not statistically significantly so. p53 or p16INK4a inactiva |
11688461 |
Human |
p16ink4a |
smzl |
It seems that progression in SMZL is mainly independent of p53 or p16INK4a inactivation. |
11688461 |
Human |
p16ink4a |
colorectal adenocarcinomas |
The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. |
11696421 |
Human |
p16ink4a |
colorectal adenocarcinomas |
However, invasion front of well-differentiated colorectal adenocarcinomas are known to be zones of low proliferation and express the cell cycle inhibitor p16INK4A. |
11696421 |
Human |
p16ink4a |
colorectal adenocarcinomas |
Therefore, we investigated the expression profiles of nuclear beta-catenin, cyclin D1, p16INK4A, and the Ki-67 antigen, a marker for proliferation, in serial sections of well-differentiated colorectal adenocarcinomas. |
11696421 |
Human |
p16ink4a |
primary-effusion lymphoma |
p16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma. |
11896614 |
Human |
p16ink4a |
primary-effusion lymphoma (pel) |
To address this we investigated whether KSHV associated primary effusion lymphoma (PEL) derived cell lines are resistant to growth inhibition by p16INK4a. |
11896614 |
Human |
p16ink4a |
pel |
Importantly, endogenous p16INK4a expression is not detected in six PEL derived cell lines and four primary PEL samples and examination of the p16INK4a locus shows deletion in two out of six and hypermethylation in four out of six PEL lines. |
11896614 |
Human |
p16ink4a |
pel |
Taken together these results suggest that p16INK4a loss may be a cellular change frequently associated with PEL. |
11896614 |
Human |
p16ink4a |
vin |
Co-incident methylation, accompanied by loss of expression, of sigma and p16INK4a was commonly detected in both SCC and VIN III, suggesting that epigenetic silencing of these two genes is an early and important event in vulval neoplasia. |
11896620 |
Human |
p16ink4a |
b-cell acute lymphoblastic leukaemia |
We examined deletion and methylation of the p15INK4B (p15) and p16INK4A (p16) genes, using Southern blotting and methylation-specific polymerase chain reaction (PCR), in 70 untreated adult patients with precursor B-cell acute lymphoblastic leukaemia (PBC- |
12028019 |
Human |
p16ink4a |
pediatric tumor |
Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. |
12149641 |
Human |
p16ink4a |
large-cell lymphoma |
We investigated the response of SUDHL-1 and L428 cells, derived from t(2;5)-anaplastic large cell lymphoma (ALCL) and Hodgkin's disease (HD), respectively, to recombinant adenoviruses expressing cyclin-dependent kinase inhibitors (CDKIs) p27Kip1 (Adp |
12153002 |
Human |
p16ink4a |
xeroderma pigmentosum |
After characterization of the xeroderma pigmentosum C complementation group, we found unexpectedly that this patient also carried a germline mutation of the INK4a-ARF locus affecting the p16INK4A reading frame. |
12485439 |
Human |
p16ink4a |
mucinous cystadenocarcinomas |
METHODOLOGY: Seven serous cystadenomas (SCA) and seven malignant mucinous cystadenocarcinomas (MCC) were analyzed for alterations in the tumor suppressor genes p16INK4a, p53, and DPC4 by single-strand conformational variant analysis, direct sequencing, an |
12499916 |
Human |
p16ink4a |
serous cystadenomas |
METHODOLOGY: Seven serous cystadenomas (SCA) and seven malignant mucinous cystadenocarcinomas (MCC) were analyzed for alterations in the tumor suppressor genes p16INK4a, p53, and DPC4 by single-strand conformational variant analysis, direct sequencing, an |
12499916 |
Human |
p16ink4a |
low-grade tumors |
Some differences may be established regarding the methylation profiles of specific genes and tumor types: MGMT, THBS1, TIMP-3, and p16INK4A appear hypermethylated in low-grade tumors (at least in 45% of cases), whereas GSTP1, DAPK, and p14ARF are mostly c |
12579314 |
Human |
p16ink4a |
gastric tubular adenomas |
Loss of p27kip1 and p16Ink4a (p16) expression, another CDI, has been reported during the progression of gastric tubular adenomas to advanced gastric cancer. |
12603618 |
Human |
p16ink4a |
cin 3 |
The control HSIL case with a CIN 3 biopsy was diffusely positive for P16INK4A, and the control negative case with biopsy diagnosis of squamous metaplasia was negative. |
12630076 |
Human |
p16ink4a |
meningiomas |
Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome. |
12640680 |
Human |
p16ink4a |
meningiomas |
We investigated the prognostic significance of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression by immunohistochemical analysis of 271 meningiomas. |
12640680 |
Human |
p16ink4a |
intestinal-type adenocarcinoma |
TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. |
12673679 |
Human |
p16ink4a |
salivary-gland carcinomas |
Alterations of p14ARF and p16INK4a genes in salivary gland carcinomas. |
12684623 |
Human |
p16ink4a |
adenoid-cystic carcinomas |
A total of 5 (14%) SGCs demonstrated homozygous deletion (1 case) or methylation (4 cases) of p16INK4a, all but one being adenoid cystic carcinomas. |
12684623 |
Human |
p16ink4a |
neurofibromatosis 1 |
We found that loss of p16INK4A coincided with transformation of neurofibromas to malignant peripheral nerve sheath tumors in neurofibromatosis 1 patients. |
12812137 |
Human |
p16ink4a |
plexiform neurofibroma |
We have determined the methylation status of the CpG island of 11 tumour-related genes (RB1, p14ARF, p16INK4a, p73, TIMP-3, MGMT, DAPK, THBS1, caspase 8, TP53 and GSTP1) in 18 neurofibromas (including one plexiform neurofibroma) and three neurofibrosarcom |
12883734 |
Human |
p16ink4a |
familial cancers |
They are "classical" tumor suppressor genes with associated familial cancers (BRCA1, hMLH1, p16INK4a, VHL, etc.) and putative new tumor suppressor genes which loss may contribute to the transformed phenotype (MGMT, p14ARF, GSTP1, RARB2, etc.). |
12908548 |
Human |
p16ink4a |
neurofibroma |
Identification of a splice acceptor site mutation in p16INK4A/p14ARF within a breast cancer, melanoma, neurofibroma prone kindred. |
12920094 |
Human |
p16ink4a |
penile carcinoma |
Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. |
12950023 |
Human |
p16ink4a |
pediatric solid tumors |
Aberrations of p16INK4A, p14ARF and p15INK4B genes in pediatric solid tumors. |
12963998 |
Human |
p16ink4a |
glandular neoplasms |
Approximately 80% of glandular neoplasms showed overexpression of p16INK4a. |
14501820 |
Human |
p16ink4a |
neurofibromatosis |
p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. |
14519636 |
Human |
p16ink4a |
leiomyosarcoma |
Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis. |
14595762 |
Human |
p16ink4a |
adenocarcinoma in situ |
The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. |
14648656 |
Human |
p16ink4a |
brain metastases |
Thus, in addition to these two genes, we determined the methylation status of the genes p16INK4a, glutathione S-transferase P1 (GSTP1), O6-methylguanine DNA methyltransferase (MGMT), thrombospondin-1 (THBS1), p14ARF, TP53, p73, and tissue inhibitor of met |
14654977 |
Human |
p16ink4a |
brain metastases |
Our data suggest an important role for gene methylation in the development of brain metastases, primarily involving epigenetic silencing of DAP-kinase, THBS1 and the cell-cycle regulators RB1/p16INK4a. |
14654977 |
Human |
p16ink4a |
oropharyngeal squamous cell carcinomas |
Mutations of the cell cycle regulatory genes p16INK4A and p21WAF1 and the metastasis-inducing gene S100A4 are infrequent and unrelated to p53 tumour suppressor gene status and data on survival in oropharyngeal squamous cell carcinomas. |
14981901 |
Human |
p16ink4a |
b16 melanoma |
In the spontaneous B16 melanoma cell lines, expression of p16Ink4a and p19Arf tumor suppressor proteins was lost as a consequence of a large deletion spanning Ink4a/Arf exons 1alpha, 1beta, and 2. |
14743208 |
Human |
p16ink4a |
clear cell sarcoma |
Alterations of the p16INK4a/p14ARF pathway in clear cell sarcoma. |
15298727 |
Human |
p16ink4a |
melanocytic neoplasm |
Alterations in the p16INK4a/p14ARF gene are common in malignant melanoma, which is the prototypical melanocytic neoplasm. |
15298727 |
Human |
p16ink4a |
barrett's adenocarcinoma |
To study the contribution of each pathway to the carcinogenesis of Barrett's adenocarcinoma, we analysed the alterations of p14ARF and p16INK4a in preneoplastic and neoplastic lesions of this disease. |
15185075 |
Human |
p16ink4a |
barrett's adenocarcinomas |
RESULTS: We detected 9p21 LOH, p16INK4a methylation and p16INK4a mutations in Barrett's adenocarcinomas in 5 of 15 (33%), 8 of 15 (53%) and 1 of 15 (7%) patients, respectively. |
15185075 |
Human |
p16ink4a |
mfh |
The growth inhibition rate was the greatest for lung adenocarcinoma cells, lacking p16INK4a expression associated with methylation-mediated gene silencing; 83% at a concentration of 300 nM for 72-h treatment; while the growth of osteosarcoma and MFH cells |
15069542 |
Human |
p16ink4a |
cin 3 |
When the time interval for disease progression from initial biopsy to CIN 3 or invasive cancer was compared with states of p16INK4A expression, cases stained positive for p16INK4A progressed within 64.2 months as compared with 122.3 months among those sta |
15073118 |
Human |
p16ink4a |
colorectal tumours |
Furthermore, p16INK4a promoter hypermethylation leading to gene silencing has been shown to occur in advanced colorectal tumours and has been associated with patient survival. p16INK4a is polymorphic, with variant alleles being associated with tumour prog |
15492837 |
Human |
p16ink4a |
squamous cell carcinoma in situ |
Retinoblastoma protein function and p16INK4a expression in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma of the skin and links between p16INK4a expression and infiltrative behavior. p16INK4a is involved in many im |
15257310 |
Human |
p16ink4a |
papillary neoplasm |
Frequent p16ink4a inactivation is an early and frequent event of intraductal papillary neoplasm of the liver arising in hepatolithiasis. |
15619210 |
Human |
p16ink4a |
cervical squamous intraepithelial lesions |
Immunohistochemical Expression of p16INK4a and bcl-2 According to HPV Type and to the Progression of Cervical Squamous Intraepithelial Lesions. |
15805425 |
Human |
p16ink4a |
seminoma |
Human male germ-cell tumors of seminoma type display aberrant expression of INK4-family inhibitors of the cell cycle including CDKN2-encoded p16INK4A. |
15734211 |
Human |
p16ink4a |
seminoma |
To assess whether the aberrant p16INK4A expression could be related to the alterations in CDKN2 regulatory sequence, we screened seminoma DNAs from 19 patients for the promoter mutations. |
15734211 |
Human |
p16ink4a |
seminoma |
These data suggest that in addition to previously characterized anomalies, the identified CDKN2 promoter mutation may be relevant for altered p16INK4A protein expressions in at least some seminoma. |
15734211 |
Human |
p16ink4a |
aggressive nk-cell leukemia |
We found methylation of the first exon of the p16INK4A gene in two cases (one aggressive, one blastic), and methylation of the p14ARF gene in one aggressive NK cell leukemia. |
15813917 |
Human |
p16ink4a |
aggressive nk-cell leukemia |
It has been reported that tumor suppressor genes are inactivated by DNA methylation of the promoter region and/or first exon of the genes in a variety of human cancers. |
15813917 |
Human |
p16ink4a |
phyllodes tumor |
We studied cell cycle-regulating proteins in phyllodes tumor pathogenesis by immunohistochemical analysis for Ki-67, cyclin A, cyclin D1, retinoblastoma protein (pRb), p53, p16INK4A, bcl-2, and p21waf1 in the epithelium and stroma of 40 primary (benign, 2 |
15981808 |
Human |
p16ink4a |
ovarian cancer |
Methylation and Messenger RNA Expression of p15INK4b but Not p16INK4a Are Independent Risk Factors for Ovarian Cancer. |
16000597 |
Human |
the p16 gene |
blast crisis |
We have used a semiquantitative multiplex polymerase chain reaction assay to search for deletions of the p16 gene in 34 patients with chronic myeloid leukemia in blast crisis (CML BC), 19 patients with acute lymphoblastic leukemia (ALL), and 25 patients w |
7718873 |
Human |
the p16 gene |
myeloid tumors |
Loss of the p16 gene is frequent in and highly specific to lymphoid malignancies (54 of 183 [30%] in lymphoid tumor v2 of 219 [1%] in myeloid tumors; P < .0001). |
7632963 |
Human |
the p16 gene |
testicular tumors |
RESULTS: The DNA from the p16 gene of 2 testicular tumors (5%), an ovarian cancer (4%) and a testicular tumor cell line (20%) had altered migration in gel electrophoresis as shown by SSCP. |
7563391 |
Human |
the p16 gene |
testicular tumor |
RESULTS: The DNA from the p16 gene of 2 testicular tumors (5%), an ovarian cancer (4%) and a testicular tumor cell line (20%) had altered migration in gel electrophoresis as shown by SSCP. |
7563391 |
Human |
the p16 gene |
borderline ovarian tumors |
Southern blot analysis revealed no losses of the p16 gene in either the invasive or borderline ovarian tumors. |
7478544 |
Human |
the p16 gene |
nasopharyngeal carcinoma |
Hypermethylation of the p16 gene in nasopharyngeal carcinoma. |
8665502 |
Human |
the p16 gene |
parathyroid tumors |
However, single strand conformational polymorphism analysis of all 3 exons of the p16 gene and both exons of the p15 gene failed to demonstrate mutation in any of the 25 cases, and homozygous deletions of the p16 and p15 genes, which are present in some h |
8855819 |
Human |
the p16 gene |
esophageal tumors |
To determine the role and mode of inactivation of the p16 and p15 genes in human esophageal tumors, we examined alterations and expression of the alpha and beta forms of the p16 gene, 5' CpG island methylation of p16 exon 1 alpha, and alterations of |
9033652 |
Human |
the p16 gene |
adrenal cortical carcinomas |
Differentiation between benign and malignant tumors of the adrenal cortex was attempted by microdissection of nine cases of adrenal cortical hyperplasia, 10 cortical adenomas, and 18 adrenal cortical carcinomas with subsequent polymerase chain reaction (P |
9596277 |
Human |
the p16 gene |
adrenal cortical hyperplasia |
Differentiation between benign and malignant tumors of the adrenal cortex was attempted by microdissection of nine cases of adrenal cortical hyperplasia, 10 cortical adenomas, and 18 adrenal cortical carcinomas with subsequent polymerase chain reaction (P |
9596277 |
Human |
the p16 gene |
malignant tumors of the adrenal cortex |
Differentiation between benign and malignant tumors of the adrenal cortex was attempted by microdissection of nine cases of adrenal cortical hyperplasia, 10 cortical adenomas, and 18 adrenal cortical carcinomas with subsequent polymerase chain reaction (P |
9596277 |
Human |
the p16 gene |
adenomas |
In the rat, 94% of adenocarcinomas induced by the tobacco specific carcinogen 4-methylnitrosamino-1-(3-pyridyl)-1-butanone were hypermethylated at the p16 gene promoter; most important, this methylation change was frequently detected in precursor lesions |
9751761 |
Rat |
the p16 gene |
carcinoma in situ |
The timing for p16 methylation was recapitulated in human SCCs where the p16 gene was coordinately methylated in 75% of carcinoma in situ lesions adjacent to SCCs harboring this change. |
9751761 |
Rat |
the p16 gene |
neuroblastoma |
We previously reported that loss of heterozygosity (LOH) on chromosome 9p21 correlates with poor prognosis of neuroblastoma and the p16 gene is not expressed in approximately two thirds of neuroblastoma cell lines. |
9872329 |
Human |
the p16 gene |
pleomorphic adenoma of the parotid gland |
Deletion of the p16 gene and microsatellite instability in carcinoma arising in pleomorphic adenoma of the parotid gland. |
9917133 |
Human |
the p16 gene |
carcinoma in pleomorphic adenoma |
Results of this study suggest that two different genetic alterations, the inactivation of the p16 gene and genetic instability, play roles in the malignant transformation of carcinoma in pleomorphic adenoma. |
9917133 |
Human |
the p16 gene |
carcinosarcoma |
These results suggest that homozygous deletion of the p16 gene occurs less frequently than CD1 gene amplification in esophageal carcinosarcoma. |
9990483 |
Human |
the p16 gene |
malignant brain tumors |
The frequency of the alteration of the p16 gene, either homozygous deletion or mutation accompanied with amino acid substitutions, increased in malignant brain tumors (grade III and IV) compared with that in low grade tumors (grade I and II) (p=0.0275), s |
10536183 |
Human |
the p16 gene |
low-grade tumors |
The frequency of the alteration of the p16 gene, either homozygous deletion or mutation accompanied with amino acid substitutions, increased in malignant brain tumors (grade III and IV) compared with that in low grade tumors (grade I and II) (p=0.0275), s |
10536183 |
Human |
the p16 gene |
ovarian cystadenomas |
METHOD. Methylation-specific PCR was used to analyze the p16 gene for DNA methylation in 20 ovarian cystadenomas, 15 low malignant potential (LMP) tumors, and 37 carcinomas. p16 expression was determined immunohistochemically in 58 of these tumors (16 cys |
9889036 |
Human |
the p16 gene |
endometrial tumours |
Hypermethylation of a site within the 5'-CpG island of the p16 gene was detected in only one of 32 (3%) cervical tumours and none of 26 endometrial tumours. |
10408854 |
Human |
the p16 gene |
cervical tumours |
Hypermethylation of a site within the 5'-CpG island of the p16 gene was detected in only one of 32 (3%) cervical tumours and none of 26 endometrial tumours. |
10408854 |
Human |
the p16 gene |
uterine tumours |
PCR-SSCP (single-strand conformation polymorphism) analysis detected point mutations in the p16 gene in six (8%) of 78 uterine tumours (four of 40 (10%) cervical tumours and two of 38 (5%) endometrial tumours). |
10408854 |
Human |
the p16 gene |
endometrial tumours |
PCR-SSCP (single-strand conformation polymorphism) analysis detected point mutations in the p16 gene in six (8%) of 78 uterine tumours (four of 40 (10%) cervical tumours and two of 38 (5%) endometrial tumours). |
10408854 |
Human |
the p16 gene |
cervical tumours |
PCR-SSCP (single-strand conformation polymorphism) analysis detected point mutations in the p16 gene in six (8%) of 78 uterine tumours (four of 40 (10%) cervical tumours and two of 38 (5%) endometrial tumours). |
10408854 |
Human |
the p16 gene |
uterine tumours |
These observations suggest that inactivation of the p16 gene, either by homologous deletion, mutation or loss of expression, occurs in a subset of uterine tumours. |
10408854 |
Human |
the p16 gene |
common acute lymphoblastic leukemia |
There were two patients who had DNA abnormalities in both 9p and 12p, one with common acute lymphoblastic leukemia (ALL) showed 9p LOH and the TEL/AML1 fusion gene on 12p and the other with common ALL and 12p RER had diminished expression of both the p27( |
10453181 |
Human |
the p16 gene |
extrahepatic bile duct cancers |
In conclusion, inactivation of the p16 gene is a frequent event in primary sporadic extrahepatic bile duct cancers, 9p21 LOH and promoter hypermethylation being the principal inactivating mechanisms. |
11802210 |
Human |
the p16 gene |
macroglobulinemia |
MATERIALS AND METHODS: The methylation status of the p16 gene was analysed in a group of 159 patients with monoclonal gammopathies (40 monoclonal gammopathy of uncertain significance, eight Waldenström Macroglobulinemia, eight smoldering multiple myeloma |
11920239 |
Human |
the p16 gene |
macroglobulinemia |
RESULTS: Forty-one of 98 MM patients (41.8%) as well as four of the five (80%) primary PCL patients showed methylation of the p16 gene, while none of the patients with monoclonal gammopathy of undetermined significance, Waldenström Macroglobulinemia or s |
11920239 |
Human |
the p16 gene |
tumour |
These findings showed methylation of the p16 gene was a frequent event inMM patients at diagnosis, and was associated with an increased proliferative rate of plasma cells and a poor prognosis, indicating an important role for p16 gene in the cell cycle re |
12199782 |
Human |
the p16 gene |
multiple myeloma |
These findings showed methylation of the p16 gene was a frequent event inMM patients at diagnosis, and was associated with an increased proliferative rate of plasma cells and a poor prognosis, indicating an important role for p16 gene in the cell cycle re |
12199782 |
Human |
the p16 gene |
hepatoblastoma |
Hypermethylation of the p16 gene and lack of p16 expression in hepatoblastoma. |
12748249 |
Human |
the p16 gene |
corticotroph adenomas |
EXPERIMENTAL DESIGN: Tissue from 31 corticotroph adenomas and 16 nonadenomatous pituitaries were subject to methylation-sensitive PCR to determine the methylation status of the p16 gene CpG island. |
15014032 |
Human |
the p16 gene |
primary gastric lymphomas |
Promoter hypermethylation and protein expression of the p16 gene: analysis of 43 cases of B-cell primary gastric lymphomas from China. |
14976529 |
Human |
the p16 gene |
primary gastric lymphomas |
In this study, we characterize protein expression and promoter hypermethylation of the p16 gene in B-cell primary gastric lymphomas from China. |
14976529 |
Human |
the p16 gene |
metastatic cancers |
Homozygous deletions of the p16 gene were observed in 2 of the 5 primary colorectal carcinomas and in 1 of the matching liver metastatic cancers. |
11677769 |
Human |
the p16 gene |
lung adenocarcinoma |
CONCLUSIONS: Aberrant methylation of the promoter region of the p16 gene and loss of expression of its product were in accord with the multistep progression of peripheral-type lung adenocarcinoma, and these alterations were associated closely with poor pr |
15612080 |
Human |
the p16 gene |
polyposis |
BRAF mutation status in patients with multiple/large HPs and/or hyperplastic polyposis correlated with HPs from the same patient (odds ratio, 5.8; P = 0.0002) but associated with younger age (odds ratio, 0.83; P = 0.006 compared to older age), with a larg |
15793287 |
Human |
the p16 mrna |
aml |
The p16 mRNA expression in 12 AML at diagnosis or relapse was significantly lower than that in 4 long term remission cases and normal controls. p16 mRNA expression was significantly higher in a case of AML with p53 mutation. |
10921094 |
Human |
the p16 protein |
intraductal carcinomas |
In 33 (9%) invasive and two (4%) intraductal carcinomas, a cytoplasmic accumulation of the p16 protein was seen. |
9862580 |
Human |
the p16 protein |
malignant eyelid tumors |
CONCLUSIONS: The expression of the P16 protein was related to the occurrence and degree of differentiation of malignant eyelid tumors. |
11930651 |
Human |
the p16 protein |
primary gastric lymphoma |
However, the p16 protein expression in primary gastric lymphoma has not been studied. |
14976529 |
Human |
the p19 gene |
burkitt-like lymphoma |
Using Southern blot analysis, one homozygous deletion of the p19 gene was detected in a human immunodeficiency virus (HIV)-related Burkitt-like lymphoma sample. |
8946928 |
Human |
p16ink4a |
high grade cervical intraepithelial neoplasia |
[The p16INK4a protein: a cytological marker for detecting high grade intraepithelial neoplasia of the uterine cervix] The identification of a small percentage of high grade cervical intraepithelial neoplasia (HGCIN) among patients with a diagnosis of atyp |
17255929 |
Human |
p16ink4a |
squamous papillomas |
DESIGN: Immunohistochemistry of p16INK4A and p53 was performed on biopsies of recurrent squamous papillomas and invasive lesions in nine patients. |
17277618 |
Human |
p16 |
figo stage iib ovarian carcinoma |
We performed immunohistochemical analysis of p16(INK4a) and pRb expression and correlated with survival in a series of 300 patients with FIGO stage IIb-IV ovarian carcinoma which were enrolled in a randomized prospective trial evaluating two different pla |
17242700 |
Human |
p16ink4a |
high grade intraepithelial neoplasia |
[The p16INK4a protein: a cytological marker for detecting high grade intraepithelial neoplasia of the uterine cervix] The identification of a small percentage of high grade cervical intraepithelial neoplasia (HGCIN) among patients with a diagnosis of atyp |
17255929 |
Human |
p14arf |
follicular adenomas |
Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. |
17117177 |
Human |
p14arf |
oncocytic adenomas |
Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. |
17117177 |
Human |
p14 |
tumour infiltrating lymphocytes |
Methylation of the MLH1, P16, TIMP3 and P14 genes was associated with tumour infiltrating lymphocytes (p < 0.05), microsatellite instability (p < 0.001), BRAF mutation (p < 0.0001) and elevated concentrations of the methyl group carriers tetrahydrofolate |
16981189 |
Human |
cdkn2a |
familial atypical multiple mole melanoma |
Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. |
11815963 |
Human |
p19 |
thymoma |
Quantitative measurements of cultured human and murine thymic, and human thymoma reticuloepithelial cells (REC), immunolabeled by different antibodies (Ab) (TE3, TE4, anti-HTLV p19(p19), lu5, K11 and Aks) and by thymic hormones (thymulin and thymosin alph |
2649289 |
Human |
cdkn2a |
penile intraepithelial neoplasia |
OBJECTIVES: To investigate the role of CDKN2A and p53 in the pathogenesis of EGCs and their precursor lesions vulval intraepithelial neoplasia (VIN3), penile intraepithelial neoplasia and lichen sclerosus (LS). |
17300232 |
Human |
p16ink4a |
thyroid tumour |
The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression. |
17117177 |
Human |
p16 |
head and neck carcinomas |
The main aim of this study was to investigate the relationship between HPV presence and p16 expression in a representative collection of 60 head and neck carcinomas by tissue microarrays. |
17352245 |
Human |
cdkn2a |
egc |
BACKGROUND: p53 has been extensively studied in external genital carcinoma (EGC), and is frequently inactivated, but little is known about the role of the CDKN2A tumour suppressor gene in the oncogenesis of EGC. |
17300232 |
Human |
p16 |
oligodendrogliomas |
Therefore, in oligodendrogliomas, the absence of the combined deletion of 1p and 19q and the aberrant expression of p53 or loss of p16 could be used as poor prognostic markers. |
17319279 |
Human |
p16 |
ameloblastoma |
[Expression of cyclin D1 and its inhibitors and hTERT in ameloblastoma] OBJECTIVE: To investigate the expression of human telomerase reverse transcripase (hTERT), cyclin D1 mRNA, p16(INK4), p21(WAF1) mRNA and p27(KIP1) protein in human ameloblastoma (ABs) |
17334067 |
Human |
arf |
sarcoma |
Furthermore, in contrast to accelerated cancer onset and increased epithelial cancers of late-generation mTerc-/- p53 mutant mice, late-generation mTerc-/- Ink4a/Arf mutant mice experienced a delayed tumor onset and maintained the lymphoma and sarcoma spe |
17360455 |
Mouse |
p16ink4a |
solid carcinomas |
BACKGROUND: BMI-1 is involved in the maintenance of stem cells and functions as an oncogene in both lymphomas and solid carcinomas, acting by downregulation of p16ink4a. |
17244030 |
Human |
ink4 |
ameloblastoma |
[Expression of cyclin D1 and its inhibitors and hTERT in ameloblastoma] OBJECTIVE: To investigate the expression of human telomerase reverse transcripase (hTERT), cyclin D1 mRNA, p16(INK4), p21(WAF1) mRNA and p27(KIP1) protein in human ameloblastoma (ABs) |
17334067 |
Human |
p16ink4a |
mucoepidermoid carcinoma of the salivary glands |
Alterations of p16INK4a tumour suppressor gene in mucoepidermoid carcinoma of the salivary glands. |
17223311 |
Human |
p14arf |
follicular carcinomas |
Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. |
17117177 |
Human |
p14arf |
papillary carcinomas |
These deregulations were statistically significant for pl6INK4a (P=0.006) in follicular adenomas and close to statistical significance for p14ARF in follicular adenomas (P=0.06) and in papillary carcinomas (P=0.05). |
17117177 |
Human |
ink4a |
low grade dysplasia |
CDC6 may be a biomarker of high grade and invasive lesions of the cervix, with limited use in low grade dysplasia. p16(INK4A) was the most reliable marker of cervical dysplasia. |
15858126 |
Human |
p14arf |
colorectal adenomas |
In primary colorectal carcinomas, p14ARF promoter hypermethylation was found in 31 of 110 (28%) of the tumors and observed in 13 of 41 (32%) colorectal adenomas but was not present in any normal tissues. p14ARF methylation appears in the context of an adj |
10646864 |
Human |
p14arf |
anaplastic astrocytomas |
To investigate the roles of the G1-S transition control system and the p14ARF/MDM2/p53 pathway in the development of astrocytic gliomas, we examined abnormalities of genes involved in these regulatory pathways in a total of 190 primary human astrocytic gl |
10667596 |
Human |
p14arf |
meningiomas |
Immunoreactivity of p14ARF, p27KIP1 and p73 did not show any differences between meningiomas of various histology and clinical outcomes. |
12640680 |
Human |
p14arf |
salivary gland carcinomas |
Alterations of p14ARF and p16INK4a genes in salivary gland carcinomas. |
12684623 |
Human |
p14arf |
tumors |
Our results suggest that abnormal expression of the p16 and/or p14ARF may be associated with a poor prognosis in these 3 tumors. |
12963998 |
Human |
p14arf |
invasive cervical cancer |
Serial consecutive biopsies representing normal cervical epithelium to cervical intraepithelial neoplasia and/or invasive cervical cancer were stained with immunohistochemistry for p16INK4A, p14ARF and proliferating cell nuclear antigen. |
15502810 |
Human |
p14arf |
nk cell leukemia |
We found methylation of the first exon of the p16INK4A gene in two cases (one aggressive, one blastic), and methylation of the p14ARF gene in one aggressive NK cell leukemia. |
15813917 |
Human |
p19 |
hepatic tumor |
Resistance of primary cultured mouse hepatic tumor cells to cellular senescence despite expression of p16(Ink4a), p19(Arf), p53, and p21(Waf1/Cip1). |
11568971 |
Mouse |
p19 |
breast tumors |
Several disease-implicated regulators of p19(ARF) are known to date, among which are the T-box genes TBX2, which resides on an amplicon in primary breast tumors, and TBX3, which is mutated in the human developmental disorder Ulnar-Mammary syndrome. |
12000749 |
Human |
p19 |
neurofibromatosis |
The tumor types observed were characteristic of p19(ARF) null animals, not those associated with neurofibromatosis or those observed with NF1(+/-)/p53(+/-) mice. |
12118376 |
Mouse |
p19 |
mouse tumor |
Recent evidence emerging from mouse tumor models distinguishes the activities of p16(Ink4a) and p19(Arf) in regulating tumor onset and identifies differences in their responsiveness to drugs. |
12573439 |
Mouse |
p14 |
aggressive lymphomas |
Aggressive lymphomas with p14(ARF) inactivation and p53 wild type showed a significantly lower p53 protein expression than tumors with no alteration in any of these genes. |
10854221 |
Human |
p14 |
neurofibroma |
CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. |
11433531 |
Human |
p14 |
chondrosarcoma |
Changes in p14(ARF) do not play a primary role in human chondrosarcoma tissues. |
11477582 |
Human |
p14 |
chondrosarcoma |
In this study, the first unique exon, exon 1 beta, of p14(ARF), has been studied in 22 chondrosarcoma tissues using polymerase chain reaction, DNA sequencing and methylation-specific polymerase chain reaction. |
11477582 |
Human |
p14 |
chondrosarcoma |
This indicates that genetic changes of p14(ARF) are a rare event in chondrosarcoma. |
11477582 |
Human |
p14 |
anaplastic meningiomas |
Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. |
11485924 |
Human |
p14 |
atypical meningiomas |
We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppr |
11485924 |
Human |
p14 |
benign meningiomas |
We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppr |
11485924 |
Human |
p14 |
benign meningioma |
One anaplastic meningioma, three atypical meningiomas, and one benign meningioma without a demonstrated homozygous deletion or mutation of CDKN2A, p14(ARF), or CDKN2B lacked detectable transcripts from at least one of these genes. |
11485924 |
Human |
p14 |
malignant pleural mesothelioma |
Genetic alterations of INK4a/ARF locus, which is a predominant event in malignant pleural mesothelioma, may result in loss of p14(ARF) and subsequent disruption of p53 pathway in cancer cells. |
11507034 |
Human |
p14 |
common tumor |
p14(ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. p14(ARF), the alternative product from the human INK4a/ARF locus, antagonizes Hdm2 and mediates p53 activation in response t |
11830494 |
Human |
p14 |
myeloproliferative disorders |
A broad spectrum of tumor suppressor gene alterations do occur in hematological malignancies, especially structural alterations of p15(INK4A), p15(INK4B) and p14(ARF) in acute lymphoblastic leukemia as well as methylation of these genes in several myelopr |
12032783 |
Human |
p14 |
primary carcinomas |
RESULTS: Altogether inactivation (methylation, loss of heterozygosity and mutation of exon 1beta) of p14(ARF) was found in 29 of all 68 (43%) carcinomas, with a significant difference in primary [8 of 29 (28%)] relative to second primary carcinomas [21 of |
12189502 |
Human |
p14 |
recurrent carcinomas |
Mutations of p53 were found in 32 of 68 HNSCCs (44%), evenly distributed among primary and recurrent carcinomas. p14(ARF) alterations showed no relationship to p53 mutations. |
12189502 |
Human |
p14 |
recurrent carcinomas |
The significantly higher rate of p14(ARF) alterations in recurrent (respective second primary) carcinomas suggests a further acquired genetic aberration during the development of the recurrent carcinomas. |
12189502 |
Human |
p14 |
pleomorphic adenomas |
To study the contribution of each pathway in pleomorphic adenomas, this study analysed alterations of p14(ARF), p16(INK4a), p53, and pRb in these tumours. |
12375265 |
Human |
p14 |
pleomorphic adenomas |
Methylation of p14(ARF) was found in 1/42 cases and alterations of p16(INK4a) occurred in 12/42 of pleomorphic adenomas, which correlated with loss of mRNA transcription. |
12375265 |
Human |
p14 |
pleomorphic adenoma |
The observation that alterations of p14(ARF) and p16(INK4a), and also p53 mutations, occurred exclusively in the epithelial and transitional components of pleomorphic adenoma supports the theory that these areas are prone to malignant transformation to ca |
12375265 |
Human |
p14 |
liver angiosarcoma |
Alterations of p14(ARF), p16(INKa), and p53 in primary liver angiosarcoma from 19 patients were analyzed by methylation-specific polymerase chain reaction (MSP), restriction enzyme-related polymerase chain reaction (RE-PCR), microsatellite analysis, and D |
12378512 |
Human |
p14 |
gastric adenoma (ga) |
Five different classes of methylation behaviors were found: (a). genes methylated in GC only (GSTP1 and RASSF1A), (b). genes showing low methylation frequency (<12%) in CG, IM, and gastric adenoma (GA) but significantly higher methylation frequency in GC |
12695555 |
Human |
p14 |
sporadic breast cancer |
[Abnormal methylation of several tumor suppressor genes in sporadic breast cancer] Multiplex methylation-sensitive PCR was employed in studying the methylation of CpG islands in the RB1, p16/CDKN2A, p15/CDKN2B, p14/ARF, CDH1, MGMT, HIC1, and N33 promoter |
12942643 |
Human |
p14 |
schwannomas |
EXPERIMENTAL DESIGN: We examined the DNA methylation status of 12 tumor-related genes (NF2, RB1, p14(ARF), p16(INK4a), p73, TIMP-3, MGMT, DAPK, THBS1, caspase-8, TP53, and GSTP1) in 44 sporadic and/or NF2-associated schwannomas using methylation-specific |
14654541 |
Human |
p14 |
mec |
Late-passage hTERT-immortalized MEC express p53 but down-regulate p14(ARF). |
14966292 |
Human |
p14 |
gallbladder tumors |
RESULTS: p16 gene alterations including silent mutations were present in 61.8% gallbladder cancers, 54.5% bile duct cancers, and 70.6% ampullary cancers. p16 gene nonsilent mutations, p16 methylation, and loss of chromosome 9p21-22 that targets p14, p15, |
15014024 |
Human |
p14 |
benign meningiomas |
We found methylation of p14(ARF) gene in five of 58 cases of benign meningiomas (8.6%), two of 10 cases of atypical meningiomas (20%), and two of four cases of anaplastic meningiomas (50%). |
15073599 |
Human |
p14 |
odontogenic tumors |
BACKGROUND: To clarify the roles of the p53-MDM2-p14(ARF) cell cycle regulation system in oncogenesis and cytodifferentiation of odontogenic tumors, p53 gene status and expression of p53, MDM2, and p14(ARF) proteins was analyzed in ameloblastomas as well |
15078490 |
Human |
p14 |
ameloblastoma |
Markedly decreased reactivity for p53, MDM2, and p14(ARF) was detected in keratinizing and granular cells in ameloblastoma subtypes. |
15078490 |
Human |
p14 |
ameloblastoma |
Basal cell ameloblastoma showed slightly higher reactivity for p53, MDM2, and p14(ARF) as compared with other subtypes. |
15078490 |
Human |
p14 |
ameloblastoma |
Immunoreactivity for p53, MDM2, and p14(ARF) in ameloblastoma variants suggests that these factors might be associated with tissue structuring and cytodifferentiation of ameloblastomas. |
15078490 |
Human |
p14 |
endometrial hyperplasias |
Thus expression levels of p14 were higher in G1 tumors than in normal endometria or endometrial hyperplasias, and the frequency of its staining in endometrioid carcinomas was inversely correlated with histologic grade. |
15213599 |
Human |
p14 |
endometrioid adenocarcinoma |
In conclusion, p14 expression correlated with histologic grade and Ki-67, but not other prognostic factors in endometrioid adenocarcinoma. |
15213599 |
Human |
p14 |
fundic gland polyps (fgps) |
We studied methylation of 2 tumor suppressor genes (p14, p16) and 4 MINT (methylated in tumor) clones (MINT1, MINT2, MINT25, MINT31) among 51 fundic gland polyps (FGPs) and 27 normal gastric body biopsy samples using bisulfite treatment of genomic DNA fol |
15491970 |
Human |
p14 |
b-cell lymphoblastic leukemia |
[Abnormal methylation of p16/CDKN2A AND p14/ARF genes GpG Islands in non-small cell lung cancer and in acute lymphoblastic leukemia] Multiplex methylation-sensitive PCR and methylation-specific PCR were employed in studying the methylation of CpG islands |
15612580 |
Human |
p14 |
b-cell lymphoblastic leukemia |
High level of the p16/CDKN2A first exon CpC island methylation was revealed in non-small cell lung cancer (68%) and in acute B-cell lymphoblastic leukemia (55%) and the CpG island of p14/ARF first exon was nonmethylated in these types of tumors. |
15612580 |
Human |
p14 |
benign prostatic hyperplasias (bph) |
EXPERIMENTAL DESIGN: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 b |
15623627 |
Human |
p14 |
scc of the tongue |
CONCLUSIONS: These data show that in patients with SCC of the tongue, combined nuclear and nucleolar expression of p14(ARF) protein predicts for improved DFS and OS independent of established prognostic markers. |
15930346 |
Human |
p14 |
immunoblastic lymphoma |
Current data indicate that the transformation of chronic lymphocytic leukemia to a large-cell or immunoblastic lymphoma is associated with abnormalities in cell cycle regulation (e.g., loss of the cell cycle inhibitors p16(INK4a) and p27(KIP1) ) and DNA r |
16053658 |
Human |
cyclin-dependent kinase inhibitor p16 |
t-cell acute lymphoblastic leukemia |
The cyclin-dependent kinase inhibitor p16(INK4A) is frequently inactivated in childhood T-cell acute lymphoblastic leukemia. |
11278393 |
Human |
cyclin-dependent kinase inhibitor p16 |
t-cell acute lymphoblastic leukemia |
The cyclin-dependent kinase inhibitor p16(INK4A) is frequently inactivated in childhood T-cell acute lymphoblastic leukemia. |
11441822 |
Human |
mts1 |
mucinous tumors |
p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. |
9495360 |
Human |
mts1 |
atypical adenomatous hyperplasia |
An immunohistochemical analysis. To clarify the events leading to the disruption of cell growth control that occurs during the development of pulmonary adenocarcinoma (AC), we used immunohistochemistry to evaluate the expression of G1 cycle regulators, cy |
9531999 |
Human |
mts1 |
soft tissue tumors |
Gene alterations at the CDKN2A (p16/MTS1) locus in soft tissue tumors. |
9664128 |
Human |
mts1 |
mouse adenocarcinoma |
Here we present a detailed analysis of the structure and function of this enhancer in the Mts1/S100A4-expressing CSML100 and non-expressing CSML0 mouse adenocarcinoma cell lines. |
11504871 |
Human |
mts1 |
transitional cell carcinoma of bladder |
[Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder] OBJECTIVE: To study the relationship between the expression of proto-oncogene bcl-2 and MTS1/p16 in transitional cell carcinoma of bladder and prognosis. |
11831985 |
Human |
mts1 |
transitional cell carcinoma of urinary bladder |
[Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder] OBJECTIVE: To study the relationship between the expression of proto-oncogene bcl-2 and MTS1/p16 in transitional cell carcinoma of bladder and prognosis. |
11831985 |
Human |
mts1 |
bladder cancer |
CONCLUSIONS: Over-expression of bcl-2 appears to be common in bladder cancer; over-expression of proto-oncogene bcl-2 and inactivation of the MTS1/p16 gene are likely to be contributing factors for primary bladder cancer; and they can be the prognostic in |
11831985 |
Human |
mts1 |
transitional cell carcinoma of urinary bladder |
CONCLUSIONS: Over-expression of bcl-2 appears to be common in bladder cancer; over-expression of proto-oncogene bcl-2 and inactivation of the MTS1/p16 gene are likely to be contributing factors for primary bladder cancer; and they can be the prognostic in |
11831985 |
Human |
mts1 |
transitional cell carcinomas (tcc) |
Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de |
15161057 |
Human |
ink4a |
megakaryoblastic leukemia |
In a human megakaryoblastic leukemia cell line, CMK, that showed some degree of megakaryocytic differentiation after culture with TPO, the cyclin-dependent kinase (Cdk) inhibitor p21(WAF1/Cip1), but not p27(Kip1), p16(INK4A), p15(INK4B), or p18(INK4C), wa |
9111365 |
Human |
ink4a |
plasmacytoma |
When tested with wild-type (DBA/2) p16, both A134C and G232A BALB/c-specific variants of p16 were inefficient in their ability to inhibit the activity of cyclin D2/CDK4 in kinase assays with retinoblastoma protein, suggesting this defective, inherited all |
9482902 |
Mouse |
ink4a |
plasmacytoma |
When tested with wild-type (DBA/2) p16, both A134C and G232A BALB/c-specific variants of p16 were inefficient in their ability to inhibit the activity of cyclin D2/CDK4 in kinase assays with retinoblastoma protein, suggesting this defective, inherited all |
9482902 |
Mouse |
ink4a |
indolent lymphomas |
Hypermethylation of the gene was also examined in a subset of tumors with lack of protein expression but without mutations or deletions of the gene. p16(INK4a) gene alterations were detected in 3 out of 64 (5%) indolent lymphomas but in 16 out of 48 (33%) |
9531609 |
Human |
ink4a |
low-grade tumors |
In the low-grade tumors, p16(INK4a) alterations were detected in 1 (4%) chronic lymphocytic leukemia (hemizygous missense mutation), 1 (6%) follicular lymphoma (homozygous deletion), and 1 (5%) typical mantle cell lymphoma (homozygous deletion). |
9531609 |
Human |
ink4a |
anaplastic large cell lymphomas |
In the aggressive tumors, p16(INK4a) gene alterations were observed in 2 (29%) Richter's syndromes (2 homozygous deletions), 3 (33%) transformed follicular lymphomas (1 homozygous deletion and 2 nonsense mutations), 3 (43%) blastoid mantle cell lymph |
9531609 |
Human |
ink4a |
large-cell lymphomas |
In the aggressive tumors, p16(INK4a) gene alterations were observed in 2 (29%) Richter's syndromes (2 homozygous deletions), 3 (33%) transformed follicular lymphomas (1 homozygous deletion and 2 nonsense mutations), 3 (43%) blastoid mantle cell lymph |
9531609 |
Human |
ink4a |
lymphoblastic lymphomas |
In the aggressive tumors, p16(INK4a) gene alterations were observed in 2 (29%) Richter's syndromes (2 homozygous deletions), 3 (33%) transformed follicular lymphomas (1 homozygous deletion and 2 nonsense mutations), 3 (43%) blastoid mantle cell lymph |
9531609 |
Human |
ink4a |
large-cell lymphoma |
Sequential samples of the indolent and transformed phase of three cases showed the presence of p16(INK4a) deletions in the Richter's syndrome but not in the CLL component of two cases, whereas in a follicular lymphoma the deletion was present in both |
9531609 |
Human |
ink4a |
plasma cell leukemia |
Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia. |
9815612 |
Human |
ink4a |
advanced carcinomas |
PATIENTS AND METHODS: The expression patterns and their possible prognostic relevance of the cell cycle regulatory proteins p53, p21(WAF/CIP1), Rb, p16(INK4A), CDK4 and Cyclin D1, MIB1 (Ki-67) and BCL-2 were analysed in pretreatment tumor biopsies from 43 |
10525606 |
Human |
ink4a |
neuroendocrine tumors of the lung |
Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung. |
10649246 |
Human |
ink4a |
adult t-cell leukemia |
The transactivator protein Tax of human T-cell leukemia virus type I plays an important role in the development of adult T-cell leukemia probably through modulation of growth regulatory molecules including p16(INK4a). |
10753922 |
Human |
ink4a |
human t-cell leukemia |
The transactivator protein Tax of human T-cell leukemia virus type I plays an important role in the development of adult T-cell leukemia probably through modulation of growth regulatory molecules including p16(INK4a). |
10753922 |
Human |
ink4a |
indolent lymphomas |
To determine the role of these genes in the pathogenesis of human non-Hodgkin's lymphomas we have analyzed exon 1beta, 1alpha, and 2 of the INK4a/ARF locus and p53 gene aberrations in 97 tumors previously characterized for p16(INK4a) alterations. p53 |
10854221 |
Human |
ink4a |
leukoplakia |
Immunohistochemical analysis of Rb, p16(INK4A) and cyclin D1 expression was performed on 78 oral squamous cell carcinoma (SCC), 46 leukoplakia, and 20 normal mucosa. |
11098077 |
Human |
ink4a |
leukoplakia |
Rb and p16(INK4A) expression were observed in all normal mucosa and most of leukoplakia. |
11098077 |
Human |
ink4a |
marginal zone lymphomas |
Chronic antigenic stimulation at these sites or in response to infection with Hepatitis C provides the milieu for mutations at FAS, API2/ML, TP53 and INK4a/p19ARF and the development of marginal zone lymphomas (MZL) in node, spleen and MALT. |
11166833 |
Human |
ink4a |
mzl |
Chronic antigenic stimulation at these sites or in response to infection with Hepatitis C provides the milieu for mutations at FAS, API2/ML, TP53 and INK4a/p19ARF and the development of marginal zone lymphomas (MZL) in node, spleen and MALT. |
11166833 |
Human |
ink4a |
pediatric osteosarcomas |
Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas. |
11241308 |
Human |
ink4a |
pediatric osteosarcomas |
We examined a series of 38 pediatric osteosarcomas for abnormal expression of pRB, p16(INK4a) and cyclin D1 by immunohistochemical analysis of archival biopsy specimens. |
11241308 |
Human |
ink4a |
metastasis |
There was an inverse correlation between loss of pRB and p16(INK4a) expression (p = 0.07). pRB and p16(INK4a) abnormalities were independent of site of disease, presence of metastasis at diagnosis and percentage of tumor necrosis in the resection specimen |
11241308 |
Human |
ink4a |
tumor necrosis |
There was an inverse correlation between loss of pRB and p16(INK4a) expression (p = 0.07). pRB and p16(INK4a) abnormalities were independent of site of disease, presence of metastasis at diagnosis and percentage of tumor necrosis in the resection specimen |
11241308 |
Human |
ink4a |
pediatric osteosarcomas |
Immunohistochemical analysis of p16(INK4a) expression in pediatric osteosarcomas may be a useful adjunctive marker of prognosis. |
11241308 |
Human |
ink4a |
t-cell acute lymphoblastic leukemia |
The cyclin-dependent kinase inhibitor p16(INK4A) is frequently inactivated in childhood T-cell acute lymphoblastic leukemia. |
11278393 |
Human |
ink4a |
t-cell acute lymphoblastic leukemia |
To investigate possible consequences of this genetic alteration for tumor development, we conditionally expressed p16(INK4A) in the T-cell acute lymphoblastic leukemia line CCRF-CEM, which carries a homozygous deletion of this gene. |
11278393 |
Human |
ink4a |
cin ii |
In line with this hypothesis, we observed marked overexpression of p16(INK4a) in all cervical intraepithelial neoplasm (CIN) I lesions (n = 47) except those associated with low-risk HPV types (n = 7), all CIN II lesions (n = 32), all CIN III lesions (n = |
11291057 |
Human |
ink4a |
intraepithelial neoplasm |
In line with this hypothesis, we observed marked overexpression of p16(INK4a) in all cervical intraepithelial neoplasm (CIN) I lesions (n = 47) except those associated with low-risk HPV types (n = 7), all CIN II lesions (n = 32), all CIN III lesions (n = |
11291057 |
Human |
ink4a |
invasive cervical cancers |
In line with this hypothesis, we observed marked overexpression of p16(INK4a) in all cervical intraepithelial neoplasm (CIN) I lesions (n = 47) except those associated with low-risk HPV types (n = 7), all CIN II lesions (n = 32), all CIN III lesions (n = |
11291057 |
Human |
ink4a |
monoclonal gammopathy of undetermined significance |
p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. p15(INK4b) and p16(INK4a) proteins are cell cycle regulators involved in the inhibition of G1 phase progression. |
11418489 |
Human |
ink4a |
uveal melanoma |
Treatment of uveal melanoma cell lines with 5-aza-2'-deoxycytidine results in demethylation of p16(INK4a) and in reexpression of p16(INK4a) mRNA, which is maintained upon withdrawal of the 5-aza-2'-deoxycytidine. |
11431374 |
Human |
ink4a |
t-cell acute lymphoblastic leukemia |
To investigate possible consequences of this genetic alteration for tumor development, we conditionally expressed p16(INK4A) in the T-cell acute lymphoblastic leukemia line CCRF-CEM, which carries a homozygous deletion of this gene. |
11441822 |
Human |
ink4a |
hcl |
The latter DNA probes and probes hybridizing to chromosomal regions, which are frequently deleted in other subtypes of non-Hodgkin lymphomas (NHL), namely 9p21/ P16(INK4A), 13q14/D13S25, and 17p13/P53 were subsequently applied to all 14 cases of HCL, but |
11463458 |
Human |
ink4a |
lymphoid tumors |
Interestingly, whereas p53 mutations or loss of heterozygosity did not account for the accelerated development of lymphoid tumors in UV-irradiated p53(+/-) mice, deletions in the p16(INK4a) gene were quite common. |
11481437 |
Mouse |
ink4a |
hepatic tumor |
Resistance of primary cultured mouse hepatic tumor cells to cellular senescence despite expression of p16(Ink4a), p19(Arf), p53, and p21(Waf1/Cip1). |
11568971 |
Mouse |
ink4a |
vulvar epidermoid carcinoma |
To determine whether this difference can be translated into a therapeutic advantage to protect normal cells from adverse cytotoxicity caused by chemotherapy, we established cell model systems for ecdysone-inducible expression of p16(Ink4a), p21(Waf1), and |
11593424 |
Human |
ink4a |
barrett's esophagus |
Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma, a cancer of which the incidence has been increasing at an alarming rate in Western countries. p16(INK4a) lesions occur frequently in esophageal adenocarcinomas but the |
11719461 |
Human |
ink4a |
esophageal adenocarcinoma |
Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma, a cancer of which the incidence has been increasing at an alarming rate in Western countries. p16(INK4a) lesions occur frequently in esophageal adenocarcinomas but the |
11719461 |
Human |
ink4a |
primary central nervous system lymphoma |
Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type. |
11804283 |
Human |
ink4a |
endometrial hyperplasia |
Ink4a/Arf deficiency reduced tumor-free survival and shortened the latency of neoplasias associated with Pten heterozygosity, specifically pheochromocytoma, prostatic intraepithelial neoplasia, and endometrial hyperplasia. |
11818530 |
Mouse |
ink4a |
pheochromocytoma |
Ink4a/Arf deficiency reduced tumor-free survival and shortened the latency of neoplasias associated with Pten heterozygosity, specifically pheochromocytoma, prostatic intraepithelial neoplasia, and endometrial hyperplasia. |
11818530 |
Mouse |
ink4a |
prostatic intraepithelial neoplasia |
Ink4a/Arf deficiency reduced tumor-free survival and shortened the latency of neoplasias associated with Pten heterozygosity, specifically pheochromocytoma, prostatic intraepithelial neoplasia, and endometrial hyperplasia. |
11818530 |
Mouse |
ink4a |
pheochromocytoma |
Functional synergy between Ink4a/Arf and Pten manifested most prominently in the development of pheochromocytoma, prompting an analysis of genes and loci implicated in this rare human neoplasm. |
11818530 |
Mouse |
ink4a |
pheochromocytoma |
The classical pheochromocytoma genes Ret, Vhl, and Nf-1 remained intact, a finding consistent with the intersection of these genes with pathways engaged by Pten and Ink4a/Arf. |
11818530 |
Mouse |
ink4a |
common tumor |
p14(ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. p14(ARF), the alternative product from the human INK4a/ARF locus, antagonizes Hdm2 and mediates p53 activation in response t |
11830494 |
Human |
ink4a |
nsclc |
To identify the molecular basis for this p16 immunohistochemical negativity further, we performed a genetic and epigenetic study of p16(INK4a) status in a series of 115 NSCLC samples parallel to the clinicopathologic and prognostic analyses. |
11920642 |
Human |
ink4a |
invasive ductal adenocarcinoma |
Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. |
12010891 |
Human |
ink4a |
angiosarcomas |
In vivo, mice doubly deficient for p16(INK4a) and p53 showed an increased rate of tumor formation with particular susceptibility to aggressive angiosarcomas. |
12019151 |
Mouse |
ink4a |
myeloproliferative disorders |
A broad spectrum of tumor suppressor gene alterations do occur in hematological malignancies, especially structural alterations of p15(INK4A), p15(INK4B) and p14(ARF) in acute lymphoblastic leukemia as well as methylation of these genes in several myelopr |
12032783 |
Human |
ink4a |
thyroid tumors |
Additionally, we analyzed the methylation frequency of the CpG island of cell cycle inhibitor p16(INK4a) in the same thyroid tumors. |
12097277 |
Human |
ink4a |
oral cancer |
We reported previously that acquisition of the immortal phenotype is an early event in oral cancer development (F. McGregor et al., Cancer Res., 57: 3886-3889, 1997); our current data indicate that about half of oral dysplasia cultures are immortal, and t |
12183435 |
Human |
ink4a |
pleomorphic adenomas |
To study the contribution of each pathway in pleomorphic adenomas, this study analysed alterations of p14(ARF), p16(INK4a), p53, and pRb in these tumours. |
12375265 |
Human |
ink4a |
pleomorphic adenomas |
Methylation of p14(ARF) was found in 1/42 cases and alterations of p16(INK4a) occurred in 12/42 of pleomorphic adenomas, which correlated with loss of mRNA transcription. |
12375265 |
Human |
ink4a |
pleomorphic adenoma |
The observation that alterations of p14(ARF) and p16(INK4a), and also p53 mutations, occurred exclusively in the epithelial and transitional components of pleomorphic adenoma supports the theory that these areas are prone to malignant transformation to ca |
12375265 |
Human |
ink4a |
common neoplasms |
Loss of p16(INK4a) expression has also been frequently observed in more common neoplasms such as lung cancer as well. |
12399123 |
Human |
ink4a |
mesothelioma |
This methylation in these mesothelioma cells could be reversed, resulting in re-expression of p16(INK4a) protein, following the treatment of the cells with cytidine analogs, which are known inhibitors of DNA methylation. |
12399123 |
Human |
ink4a |
lobular carcinomas |
Oestrogen and progesterone receptors, tumour proliferative activity, the expression of cyclin A, p16(ink4A), p27(kip1), p21(waf1), p53, bcl-2, and levels of vascular endothelial growth factor and hypoxia-inducible factor-1alpha (HIF-1alpha) were evaluated |
12402149 |
Human |
ink4a |
oral cancer |
In an attempt to model oral cancer in a human cell-based system, we analyzed normal oral epithelial keratinocytes with the pRB pathway dysregulated by loss of expression of the cyclin-dependent kinase (cdk) 4/cdk6 inhibitor p16(INK4A) and/or ectopic expre |
12543805 |
Human |
ink4a |
mouse tumor |
Recent evidence emerging from mouse tumor models distinguishes the activities of p16(Ink4a) and p19(Arf) in regulating tumor onset and identifies differences in their responsiveness to drugs. |
12573439 |
Mouse |
ink4a |
aggressive fibromatosis |
Importantly, exogenous p16(INK4a) introduced by cotransfection is sufficient to reduce GR activity in FS cells, without affecting GR activity in p16-positive aggressive fibromatosis cells. |
12624188 |
Human |
ink4a |
liver tumors |
Additionally, we analysed the methylation status of p16(INK4a) and other cancer-related genes in the same liver tumors. |
12660822 |
Human |
ink4a |
hca |
In conclusion, our results demonstrate that RASSF1A and p16(INK4a) inactivation by methylation are frequent events in hepatocellular carcinoma, but not in HCA, which is in contrast to HCC without cirrhosis, viral hepatitis, storage diseases, or genetic ba |
12660822 |
Human |
ink4a |
plasma cell tumors |
BALB/c mice are susceptible to the development of pristane-induced plasma cell tumors, and have a rare allelic variant in the coding region of the p16(INK4a) (p16) tumor suppressor gene that produces a protein with impaired activity. |
12700664 |
Mouse |
ink4a |
basal cell carcinoma |
Invade or proliferate? Two contrasting events in malignant behavior governed by p16(INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma. |
12702553 |
Human |
ink4a |
basal cell carcinomas |
Using immunohistochemistry and Western blotting of microdissected parts of basal cell carcinomas, we showed that p16(INK4a) was up-regulated at the invasive front of the majority of basal cell carcinomas with infiltrative growth patterns, followed by ceas |
12702553 |
Human |
ink4a |
neuroendocrine tumors |
Additionally, we analysed the aberrant methylation frequency of cell cycle inhibitor p16(INK4a) and K-ras gene mutations in the pancreatic samples. p16 inactivation was detected in 43% of adenocarcinomas, in 17% of neuroendocrine tumors, in 18% of pancrea |
12802288 |
Human |
ink4a |
tonsil cancers |
In our study 86 tonsil cancers were analysed for HPV status by sequence analysis of polymerase chain reaction products and for the expression of cell cycle proteins (p53, p21(CIP1/WAF1), pRb, p16(INK4A), cyclin D1 and p27(KIP1)) by immunohistochemistry. |
12845651 |
Human |
ink4a |
squamous cell carcinoma of the cervix |
Carcinogenesis of cervical cancer has been investigated, and p16(INK4a) overexpression in squamous cell carcinoma of the cervix has been reported as a result of infection by human papillomavirus (HPV) (eg, HPV 16), and the consequence of the retinoblastom |
14506638 |
Human |
ink4a |
small cell carcinoma of the cervix |
However, to our knowledge, there have been no studies on the relation between p16(INK4a) overexpression associated with HPV and small cell carcinoma of the cervix, which behaves more aggressively clinically than squamous cell carcinoma. |
14506638 |
Human |
ink4a |
small cell carcinoma |
The purpose of this study was to determine whether p16(INK4a) is overexpressed in small cell carcinoma, and if p16(INK4a) is overexpressed, the types of HPV that are related to this cancer. |
14506638 |
Human |
ink4a |
small cell carcinoma |
We reviewed 10 cases of small cell carcinoma and examined them for p16(INK4a) overexpression by immunohistochemistry. |
14506638 |
Human |
ink4a |
small cell carcinoma |
In conclusion, p16(INK4a) was overexpressed and HPV 18 was frequently detected in an integrated form in small cell carcinoma. |
14506638 |
Human |
ink4a |
schwannomas |
EXPERIMENTAL DESIGN: We examined the DNA methylation status of 12 tumor-related genes (NF2, RB1, p14(ARF), p16(INK4a), p73, TIMP-3, MGMT, DAPK, THBS1, caspase-8, TP53, and GSTP1) in 44 sporadic and/or NF2-associated schwannomas using methylation-specific |
14654541 |
Human |
ink4a |
hsil |
Comparison of the number of p16(INK4a) immunoreactive cells/1,000 cells exhibited a significantly higher mean count in HSIL (8.80 +/- 1.13) than other cytological groups. |
14712490 |
Human |
ink4a |
transitional cell carcinomas (tcc) |
Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de |
15161057 |
Human |
ink4a |
cysts |
Immunohistochemical staining was performed for p16(INK4a) and pRb in formalin-fixed, paraffin-embedded tissue sections of the uterine cervix using an indirect immunoperoxidase method. p16(INK4a) staining was detected in 7 of 108 sections (6.5%) of normal |
15188135 |
Human |
ink4a |
non-small cell carcinomas |
In two additional cases originally interpreted as small cell carcinoma, high molecular weight keratin highlighted small numbers of neoplastic large cells, leading to reclassification as combined small cell and non-small cell carcinomas. p16(INK4A) express |
15309021 |
Human |
ink4a |
cervical cancer |
The present data confirm the role of p16(INK4A) as a highly specific marker of CIN and HR-HPV type, but expression of this protein does not seem to be of any prognostic value in cervical cancer or in predicting the clearance of HR-HPV after treatment of C |
15381905 |
Human |
ink4a |
cin |
The present data confirm the role of p16(INK4A) as a highly specific marker of CIN and HR-HPV type, but expression of this protein does not seem to be of any prognostic value in cervical cancer or in predicting the clearance of HR-HPV after treatment of C |
15381905 |
Human |
ink4a |
colorectal carcinomas |
This study aimed to identify potential abnormalities of retinoblastoma protein (pRb) and p16(INK4a) (p16) expression in resectable colorectal carcinomas (CRCs) and to assess the prognostic significance of pRb and p16 levels in patients with CRC. |
15492985 |
Human |
ink4a |
fibroadenoma |
The potential role of p16(INK4a) methylation in breast cancer is controversial whereas there are no data on fibroadenoma. |
15578730 |
Human |
ink4a |
fibroadenoma |
To assess if inactivation of p16(INK4a) by promoter hypermethylation occurs in this hyperproliferative benign breast lesion or, on the contrary, it is strictly related to the carcinogenic process, we have tested the different histological components of 15 |
15578730 |
Human |
ink4a |
salivary gland carcinomas (sgcs) |
As combinations of genetic and/or epigenetic alterations occurring during salivary gland carcinogenesis are largely unknown, we here analyzed 36 salivary gland carcinomas (SGCs) for changes in INK4a/ARF, RB1, p21, p27, PTEN, p53, MDM2 and O6-MGMT genes us |
15695118 |
Human |
ink4a |
mantle cell lymphomas |
CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. |
15781632 |
Human |
ink4a |
mcl |
To determine the role of these genes in MCL, we have examined their gene status and expression and their relationship to INK4a/ARF and p53 gene aberrations in 69 tumors. |
15781632 |
Human |
ink4a |
oligodendroglial tumors |
Remarkably, 9 of 10 murine oligodendroglial tumors (from p53+/- or ink4a/arf+/- animals transgenic for S100beta-v-erbB) showed a similar tumor-specific down-regulation of mSLC5A8, the highly conserved mouse homologue. |
15867356 |
Mouse |
ink4a |
vin 3 |
RESULTS: p16(INK4a) immunoreactivity was different in VIN 1, VIN 2, VIN 3, and squamous cell carcinoma. |
15870532 |
Human |
ink4a |
vin 3 |
Strong expression of p16(INK4a) protein was observed in 92% (22 of 24) of VIN 2 and VIN 3 lesions and 100% (4 of 4) of invasive SCCs. |
15870532 |
Human |
ink4a |
condyloma acuminatum |
No p16(INK4a) immunoreactivity was observed in any of the benign/reactive and condyloma acuminatum lesions. |
15870532 |
Human |
ink4a |
condyloma acuminatum |
CONCLUSIONS: Upregulation of INK4a gene occurs in vulvar carcinogenesis. p16(INK4a) is not a sensitive marker for differentiation of benign vulvar squamous epithelium from condyloma acuminatum or VIN 1 lesions because most VIN 1 lesions are p16(INK4a) neg |
15870532 |
Human |
ink4a |
cervical polyp |
METHODS: A total of 188 consecutive and unselected colposcopically directed cervical biopsies and a single contemporaneous cervical polyp were accessioned prospectively over a 3-month period, step-serially sectioned and examined by H&E and immunostained f |
16028838 |
Human |
ink4a |
cervical polyp |
Diffuse strong parabasal immunostaining for p16(INK4a), suggestive of integrated high-risk HPV DNA into the host genome, was observed in 81 biopsies (42.9%, including the cervical polyp) and correlated (>90%) with HGSIL in the H&E sections. |
16028838 |
Human |
ink4a |
immunoblastic lymphoma |
Current data indicate that the transformation of chronic lymphocytic leukemia to a large-cell or immunoblastic lymphoma is associated with abnormalities in cell cycle regulation (e.g., loss of the cell cycle inhibitors p16(INK4a) and p27(KIP1) ) and DNA r |
16053658 |
Human |
ink4a |
amelanotic melanoma |
Spontaneous uveal amelanotic melanoma in transgenic Tyr-RAS+ Ink4a/Arf-/- mice. |
16087843 |
Mouse |
mts-1 |
ductal adenocarcinomas |
Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. |
8640773 |
Human |
cdkn2 |
biliary tract cancers |
Twenty-five primary biliary tract cancers were examined for somatic mutations in p16Ink4/CDKN2, p15Ink4B/MTS2, p53, and K-ras genes and allelic loss of 9p21 by microsatellite analysis. |
7796400 |
Human |
cdkn2 |
biliary tract cancer |
We found frequent homozygous deletions in p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in the biliary tract cancer cell lines. |
7796400 |
Human |
cdkn2 |
ampullary cancers |
One of three intrahepatic bile duct cancers, one of two common bile duct cancers, and one of two ampullary cancers had mutations in the p16Ink4/CDKN2 gene. |
7796400 |
Human |
cdkn2 |
bile duct cancers |
One of three intrahepatic bile duct cancers, one of two common bile duct cancers, and one of two ampullary cancers had mutations in the p16Ink4/CDKN2 gene. |
7796400 |
Human |
cdkn2 |
lymphoblastic lymphoma |
In the primary tumors, homozygous deletions of both CDKN2 and MTS2 were found in 35% of the T-ALL/lymphoblastic lymphoma (8 of 23). |
7882348 |
Human |
cdkn2 |
lymphoblastic lymphoma |
These results are consistent with a role for CDKN2 and/or MTS2 in the pathogenesis of some lymphoid leukemia/lymphomas, particularly in T-ALL/lymphoblastic lymphoma. |
7882348 |
Human |
cdkn2 |
bronchogenic carcinoma |
CONCLUSIONS: The results suggested that CDKN2 gene was a tumor suppressor gene, the inactivation of which were involved in the carcinogenesis of bronchogenic carcinoma and implicated in tumor differentiation. |
9388844 |
Human |
cdkn2 |
thymoma |
p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. |
9398039 |
Human |
cdkn2 |
thymoma |
A polymorphism in the 3' untranslated region of exon 3 of CDKN2 was detected in 5 cases of thymoma. |
9398039 |
Human |
cdkn2 |
neurofibromatosis |
Mutations of p16 (CDKN2), p53, ras, neurofibromatosis type I gene (NF-1), bcl2 and the retinoblastoma gene have been described, but none are common. |
10427507 |
Human |
cdkn2 |
transitional cell carcinomas (tcc) |
Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de |
15161057 |
Human |
p16 |
small lymphocytic lymphoma |
We identified the homozygous deletion of P15 and P16 genes in 13 tumors from 12 patients, all belonging to diffuse large-cell histology; 10 had this diagnosis made on presentation, 1 had transformed from small lymphocytic lymphoma, and 1 had transformed f |
7579381 |
Human |
p16 |
myeloid tumors |
Loss of the p16 gene is frequent in and highly specific to lymphoid malignancies (54 of 183 [30%] in lymphoid tumor v2 of 219 [1%] in myeloid tumors; P < .0001). |
7632963 |
Human |
p16 |
lymphoblastic lymphomas |
None of the lymphoid tumors studied possessed deletions of p18, including a group of lymphoblastic lymphomas which we previously reported to have deletions of p16 and p15. |
8637248 |
Human |
p16 |
ductal adenocarcinomas |
Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. |
8640773 |
Human |
p16 |
papillary cancer |
Homozygous deletion of the entire p16 coding sequence was observed in two of three follicular and two of four papillary cancer cell lines, but not in normal tissue or normal cells immortalised by SV40 T antigen. |
8822272 |
Human |
p16 |
differentiated thyroid cancer |
Given the co-existence of p16 abnormalities in primary tumours and cell lines observed in other tumour types, this high frequency of deletion suggests that p16 is a key tumour suppressor gene in the genesis of differentiated thyroid cancer. |
8822272 |
Human |
p16 |
advanced cancer |
In cancer in adenoma pRB and cdk2 were overexpressed with high frequency, and cdk4 overexpression was detected in advanced cancer. p16 overexpression was detected in almost all cancers, but in contrast p21 overexpression was rare event. |
8920658 |
Human |
p16 |
liposarcoma |
Using one microsatellite marker distal to p16(D9S171) and one intragenic sequence-tagged site (STS) marker (c5.1), we observed LOH in only one liposarcoma and one malignant schwannoma (2.6%). |
9049181 |
Human |
p16 |
megakaryoblastic leukemia |
In a human megakaryoblastic leukemia cell line, CMK, that showed some degree of megakaryocytic differentiation after culture with TPO, the cyclin-dependent kinase (Cdk) inhibitor p21(WAF1/Cip1), but not p27(Kip1), p16(INK4A), p15(INK4B), or p18(INK4C), wa |
9111365 |
Human |
p16 |
pancreatic neoplasms |
In half of the patients, two or more unique K-ras mutations were identified among distinct PILs, which is evidence for the separate clonal evolution of multiple pancreatic neoplasms within individual patients. p16 alterations (one homozygous deletion and |
9187111 |
Human |
p16 |
gastric adenocarcinomas |
Among 34 esophageal adenocarcinomas and 11 gastric adenocarcinomas, only one tumor lacked p16 expression and all tumors expressed p16beta. p16 sequences were not detectable by PCR in genomic DNA from tumors lacking both p16 and p16beta mRNA, suggesting th |
9333024 |
Human |
p16 |
bronchogenic carcinoma |
[Expression of CDKN2 gene product in human bronchogenic carcinoma] OBJECTIVE: To examine the expression of P16 protein in bronchogenic carcinoma and normal tissue adjacent to carcinoma and to determine the relationship between the gene and bronchogenic ca |
9388844 |
Human |
p16 |
ewing tumors |
Our data indicate that, despite the absence of cytogenetically detectable 9p21 chromosomal aberrations, p16 deletions constitute the most frequent secondary molecular aberration in Ewing tumors so far. |
9393981 |
Human |
p16 |
bladder tumor |
The remaining tumor lines expressed p16 at constant levels before and after 5-Aza-CdR treatment and showed minimal p16 promoter methylation, suggesting that other growth-regulatory genes may have been silenced by de novo methylation in these cells. p16 ex |
9426064 |
Human |
p16 |
plasmacytoma |
When tested with wild-type (DBA/2) p16, both A134C and G232A BALB/c-specific variants of p16 were inefficient in their ability to inhibit the activity of cyclin D2/CDK4 in kinase assays with retinoblastoma protein, suggesting this defective, inherited all |
9482902 |
Mouse |
p16 |
mucinous tumors |
p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. |
9495360 |
Human |
p16 |
oral tumors |
In this paper, we present results of our examination of a series of 80 oral squamous cell carcinomas for p53 exons 5-9 and p16 exons 1-2 mutations, and the potential association of these mutations with specific genotyping patterns. p53 mutation prevalence |
9525287 |
Human |
p16 |
oral tumors |
A significant association was not observed between the prevalence of p16 mutations in oral tumors and tobacco use, or CYP1A1 [val] or GSTM1 (0/0) genotypes. |
9525287 |
Human |
p16 |
indolent lymphomas |
Hypermethylation of the gene was also examined in a subset of tumors with lack of protein expression but without mutations or deletions of the gene. p16(INK4a) gene alterations were detected in 3 out of 64 (5%) indolent lymphomas but in 16 out of 48 (33%) |
9531609 |
Human |
p16 |
low-grade tumors |
In the low-grade tumors, p16(INK4a) alterations were detected in 1 (4%) chronic lymphocytic leukemia (hemizygous missense mutation), 1 (6%) follicular lymphoma (homozygous deletion), and 1 (5%) typical mantle cell lymphoma (homozygous deletion). |
9531609 |
Human |
p16 |
anaplastic large cell lymphomas |
In the aggressive tumors, p16(INK4a) gene alterations were observed in 2 (29%) Richter's syndromes (2 homozygous deletions), 3 (33%) transformed follicular lymphomas (1 homozygous deletion and 2 nonsense mutations), 3 (43%) blastoid mantle cell lymph |
9531609 |
Human |
p16 |
large-cell lymphomas |
In the aggressive tumors, p16(INK4a) gene alterations were observed in 2 (29%) Richter's syndromes (2 homozygous deletions), 3 (33%) transformed follicular lymphomas (1 homozygous deletion and 2 nonsense mutations), 3 (43%) blastoid mantle cell lymph |
9531609 |
Human |
p16 |
lymphoblastic lymphomas |
In the aggressive tumors, p16(INK4a) gene alterations were observed in 2 (29%) Richter's syndromes (2 homozygous deletions), 3 (33%) transformed follicular lymphomas (1 homozygous deletion and 2 nonsense mutations), 3 (43%) blastoid mantle cell lymph |
9531609 |
Human |
p16 |
large-cell lymphoma |
Sequential samples of the indolent and transformed phase of three cases showed the presence of p16(INK4a) deletions in the Richter's syndrome but not in the CLL component of two cases, whereas in a follicular lymphoma the deletion was present in both |
9531609 |
Human |
p16 |
atypical adenomatous hyperplasia |
An immunohistochemical analysis. To clarify the events leading to the disruption of cell growth control that occurs during the development of pulmonary adenocarcinoma (AC), we used immunohistochemistry to evaluate the expression of G1 cycle regulators, cy |
9531999 |
Human |
p16 |
b-cell lymphoma |
The p16 gene is frequently mutated or deleted in many types of cancer cell lines as well as in certain types of primary tumors. p16 knockout mice are viable but predisposed to sarcoma and B-cell lymphoma. |
9563903 |
Mouse |
p16 |
adrenal cortical hyperplasia |
Differentiation between benign and malignant tumors of the adrenal cortex was attempted by microdissection of nine cases of adrenal cortical hyperplasia, 10 cortical adenomas, and 18 adrenal cortical carcinomas with subsequent polymerase chain reaction (P |
9596277 |
Human |
p16 |
malignant tumors of the adrenal cortex |
Differentiation between benign and malignant tumors of the adrenal cortex was attempted by microdissection of nine cases of adrenal cortical hyperplasia, 10 cortical adenomas, and 18 adrenal cortical carcinomas with subsequent polymerase chain reaction (P |
9596277 |
Human |
p16 |
soft tissue tumors |
Gene alterations at the CDKN2A (p16/MTS1) locus in soft tissue tumors. |
9664128 |
Human |
p16 |
large cell carcinomas |
To observe the expression of p16, pRb, cdk4 and cyclinD1 in non-small cell lung cancers, 104 cases of resected lung cancers were collected, which included squamous cell carcinomas, adenocarcinomas and large cell carcinomas. |
9751261 |
Human |
p16 |
plasma cell leukemia |
Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia. |
9815612 |
Human |
p16 |
plasma cell leukemia (pcl) |
However, the frequency and significance of p16 abnormalities in multiple myeloma (MM) and the more aggressive phase of plasma cell leukemia (PCL) have not been well defined. |
9815612 |
Human |
p16 |
intraductal carcinomas |
In 33 (9%) invasive and two (4%) intraductal carcinomas, a cytoplasmic accumulation of the p16 protein was seen. |
9862580 |
Human |
p16 |
cystadenomas |
METHOD. Methylation-specific PCR was used to analyze the p16 gene for DNA methylation in 20 ovarian cystadenomas, 15 low malignant potential (LMP) tumors, and 37 carcinomas. p16 expression was determined immunohistochemically in 58 of these tumors (16 cys |
9889036 |
Human |
p16 |
ovarian cystadenomas |
METHOD. Methylation-specific PCR was used to analyze the p16 gene for DNA methylation in 20 ovarian cystadenomas, 15 low malignant potential (LMP) tumors, and 37 carcinomas. p16 expression was determined immunohistochemically in 58 of these tumors (16 cys |
9889036 |
Human |
p16 |
carcinoma in pleomorphic adenoma |
Results of this study suggest that two different genetic alterations, the inactivation of the p16 gene and genetic instability, play roles in the malignant transformation of carcinoma in pleomorphic adenoma. |
9917133 |
Human |
p16 |
invasive carcinoma |
In contrast, p16 expression was lost in moderate dysplasia (12%) and in CIS (30%) in patients with lung cancer. p16 loss occurred exclusively in patients who displayed loss of p16 expression in their related invasive carcinoma. |
10037171 |
Human |
p16 |
invasive carcinoma |
Our results indicate that Rb protein function can be invalidated before invasion through alteration of the Rb phosphorylation pathway, by p16 inhibition, and/or by cyclin D1 overexpression and suggest a role for p16 and cyclin D1 deregulation in progressi |
10037171 |
Human |
p16 |
colonic adenomas |
CONCLUSIONS: p16 methylation occurs frequently in human colonic adenomas and cancers and is closely associated with K-ras mutations. |
10220498 |
Human |
p16 |
verrucous carcinomas (vcs) |
In this study, the expression of the cell cycle-associated proteins p16, pRb, p53, p27 and Ki-67 were examined by immunohistochemistry in precancerous and cancerous oral lesions, including verrucous carcinomas (VCs). |
10226946 |
Human |
p16 |
agnogenic myeloid metaplasia (amm) |
P16 gene deletions and point mutations in patients with agnogenic myeloid metaplasia (AMM). |
10400184 |
Human |
p16 |
agnogenic myeloid metaplasia (amm) |
Studies of p16 alterations with homozygous deletions and mutation analysis were done in 32 patients with agnogenic myeloid metaplasia (AMM) including six patients in leukemic phase. |
10400184 |
Human |
p16 |
endometrial tumours |
The roles of the p16 and p15 inhibitor of cyclin-dependent kinase tumour suppressor genes were examined in human uterine cervical and endometrial cancers. p16 mRNA, examined by reverse transcription polymerase chain reaction (RT-PCR), was significantly re |
10408854 |
Human |
p16 |
cervical tumours |
Hypermethylation of a site within the 5'-CpG island of the p16 gene was detected in only one of 32 (3%) cervical tumours and none of 26 endometrial tumours. |
10408854 |
Human |
p16 |
cervical tumours |
Homozygous p16 gene deletion, evaluated by differential PCR analysis, was found in four of 40 (10%) cervical tumours and one of 38 (3%) endometrial tumours. |
10408854 |
Human |
p16 |
endometrial tumours |
Homozygous p16 gene deletion, evaluated by differential PCR analysis, was found in four of 40 (10%) cervical tumours and one of 38 (3%) endometrial tumours. |
10408854 |
Human |
p16 |
cervical tumours |
PCR-SSCP (single-strand conformation polymorphism) analysis detected point mutations in the p16 gene in six (8%) of 78 uterine tumours (four of 40 (10%) cervical tumours and two of 38 (5%) endometrial tumours). |
10408854 |
Human |
p16 |
endometrial tumours |
PCR-SSCP (single-strand conformation polymorphism) analysis detected point mutations in the p16 gene in six (8%) of 78 uterine tumours (four of 40 (10%) cervical tumours and two of 38 (5%) endometrial tumours). |
10408854 |
Human |
p16 |
uterine tumours |
PCR-SSCP (single-strand conformation polymorphism) analysis detected point mutations in the p16 gene in six (8%) of 78 uterine tumours (four of 40 (10%) cervical tumours and two of 38 (5%) endometrial tumours). |
10408854 |
Human |
p16 |
uterine tumours |
These observations suggest that inactivation of the p16 gene, either by homologous deletion, mutation or loss of expression, occurs in a subset of uterine tumours. |
10408854 |
Human |
p16 |
neurofibromatosis |
Mutations of p16 (CDKN2), p53, ras, neurofibromatosis type I gene (NF-1), bcl2 and the retinoblastoma gene have been described, but none are common. |
10427507 |
Human |
p16 |
basaloid carcinomas |
In order to assess the frequency and the prognostic value of these abnormalities in NSCLC, immunohistochemical analysis of Rb, p16(INK4), and cyclin D1 has been performed on 168 cases of NSCLC including 77 squamous cell carcinomas, 43 adenocarcinomas, and |
10440744 |
Human |
p16 |
nsclc |
In order to assess the frequency and the prognostic value of these abnormalities in NSCLC, immunohistochemical analysis of Rb, p16(INK4), and cyclin D1 has been performed on 168 cases of NSCLC including 77 squamous cell carcinomas, 43 adenocarcinomas, and |
10440744 |
Human |
p16 |
squamous cell carcinomas |
In order to assess the frequency and the prognostic value of these abnormalities in NSCLC, immunohistochemical analysis of Rb, p16(INK4), and cyclin D1 has been performed on 168 cases of NSCLC including 77 squamous cell carcinomas, 43 adenocarcinomas, and |
10440744 |
Human |
p16 |
basaloid carcinoma |
In univariate analysis, Rb-negative adenocarcinomas at stages I-II had a significantly shorter survival than Rb-positive cases ( p = 0.04) and stages I-II p16-positive cases had a shorter survival than p16-negative cases ( p = 0.02), which was more signif |
10440744 |
Human |
p16 |
advanced carcinomas |
PATIENTS AND METHODS: The expression patterns and their possible prognostic relevance of the cell cycle regulatory proteins p53, p21(WAF/CIP1), Rb, p16(INK4A), CDK4 and Cyclin D1, MIB1 (Ki-67) and BCL-2 were analysed in pretreatment tumor biopsies from 43 |
10525606 |
Human |
p16 |
salivary gland carcinomas |
Analysis of chromosome 9p21 deletion and p16 gene mutation in salivary gland carcinomas. |
10534174 |
Human |
p16 |
small bowel adenocarcinomas |
The levels of cyclin D1, cyclin E, p16, p21, p27, and p53 proteins were determined by immunohistochemistry in samples of normal small bowel (n = 16), small bowel adenomas (n = 20), and small bowel adenocarcinomas (n = 24). |
10613343 |
Human |
p16 |
neuroendocrine tumors of the lung |
Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung. |
10649246 |
Human |
p16 |
acral lentiginous melanoma |
An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma. |
10657449 |
Human |
p16 |
acral lentiginous melanomas |
These data suggest that p16 inactivation may play an important role in the development and progression of acral lentiginous melanomas. |
10657449 |
Human |
p16 |
high grade lymphoma |
With time, a fraction of follicular lymphoma accumulates mutations of p53 and of p16 and evolves into a high grade lymphoma. |
10681729 |
Human |
p16 |
hydatidiform mole |
METHODS: The expressions of p16, cyclin-dependent kinase 4 (CDK4), proliferation cell nuclear antigen (PCNA) proteins in 18 cases of trophoblastic tumors, 30 cases of hydatidiform mole and 30 cases of normal villi were studied by immunohistochemical metho |
10681785 |
Human |
p16 |
trophoblastic tumors |
METHODS: The expressions of p16, cyclin-dependent kinase 4 (CDK4), proliferation cell nuclear antigen (PCNA) proteins in 18 cases of trophoblastic tumors, 30 cases of hydatidiform mole and 30 cases of normal villi were studied by immunohistochemical metho |
10681785 |
Human |
p16 |
endometrial hyperplasias (eh) |
We analysed p16 gene alteration and p16, cyclin-dependent kinase 4 (CDK4), CDK6, cyclin D1, cyclin D2, cyclin D3 and retinoblastoma protein (pRb) expression in ten normal endometriums (PE), 18 endometrial hyperplasias (EH) and 35 endometrial cancers (EC). |
10682682 |
Human |
p16 |
ovarian serous cystadenocarcinomas |
[A study on P16 and P53 protein expressions in ovarian serous cystadenocarcinoma] An immunohistochemical method utilizing avidin-biontin complex (ABC) technique was used in this study to detect P16 and P53 protein expressions in 40 ovarian serous cystaden |
10683958 |
Human |
p16 |
serous cystadenomas |
[A study on P16 and P53 protein expressions in ovarian serous cystadenocarcinoma] An immunohistochemical method utilizing avidin-biontin complex (ABC) technique was used in this study to detect P16 and P53 protein expressions in 40 ovarian serous cystaden |
10683958 |
Human |
p16 |
ovarian serous cystadenocarcinoma |
These results suggested that P16 and P53 protein expressions of the ovarian serous cystadenocarcinoma might be correlated with human organs, histological type of tumor, cyclin and cyclindependent kinase. |
10683958 |
Human |
p16 |
9l gliosarcoma |
We detected homozygous deletions of the p16/Cdkn2a/Ink4a gene locus in 4 of 5 glioma cell lines (C6, F98, RG2, and RGL.3), but not in the 9L gliosarcoma cell line or in a rat primary fibroblast cell line. |
10738182 |
Rat |
p16 |
indolent lymphomas |
To determine the role of these genes in the pathogenesis of human non-Hodgkin's lymphomas we have analyzed exon 1beta, 1alpha, and 2 of the INK4a/ARF locus and p53 gene aberrations in 97 tumors previously characterized for p16(INK4a) alterations. p53 |
10854221 |
Human |
p16 |
hereditary cancer syndrome |
[Mechanism of tumorigenesis caused by tumor suppressor gene] Hereditary cancer syndrome is mainly caused by tumor suppressor genes, such as p53 gene in Li-Fraumeni syndrome and p16 gene in familial melanoma. |
10879046 |
Human |
p16 |
aml |
The p16 mRNA expression in 12 AML at diagnosis or relapse was significantly lower than that in 4 long term remission cases and normal controls. p16 mRNA expression was significantly higher in a case of AML with p53 mutation. |
10921094 |
Human |
p16 |
squamous cell lung carcinoma |
By increasing the sensitivity of a PCR approach to detect methylated DNA sequences, we now demonstrate that aberrant methylation of the p16 and/or O6-methyl-guanine-DNA methyltransferase promoters can be detected in DNA from sputum in 100% of patients wit |
11085511 |
Human |
p16 |
leukoplakia |
Immunohistochemical analysis of Rb, p16(INK4A) and cyclin D1 expression was performed on 78 oral squamous cell carcinoma (SCC), 46 leukoplakia, and 20 normal mucosa. |
11098077 |
Human |
p16 |
leukoplakia |
Rb and p16(INK4A) expression were observed in all normal mucosa and most of leukoplakia. |
11098077 |
Human |
p16 |
pancreatic carcinoma |
CONCLUSION: The alteration of p16 gene and abnormal expression of P16 protein are significantly correlated with the biological behavior and clinical staging of pancreatic carcinoma and may hence be helpful to prognostication |
11110976 |
Human |
p16 |
medullary thyroid carcinoma |
At present, the most useful methods of risk assessment are those performed on the following genes: BRCA1 and BRCA2 especially for hereditary breast and ovarian cancer, hMLH1 and hMSH2 for hereditary non polyposis colorectal cancer, APC for familial adenom |
11205230 |
Human |
p16 |
pediatric osteosarcomas |
Loss of p16(INK4a) expression correlates with decreased survival in pediatric osteosarcomas. |
11241308 |
Human |
p16 |
pediatric osteosarcomas |
We examined a series of 38 pediatric osteosarcomas for abnormal expression of pRB, p16(INK4a) and cyclin D1 by immunohistochemical analysis of archival biopsy specimens. |
11241308 |
Human |
p16 |
metastasis |
There was an inverse correlation between loss of pRB and p16(INK4a) expression (p = 0.07). pRB and p16(INK4a) abnormalities were independent of site of disease, presence of metastasis at diagnosis and percentage of tumor necrosis in the resection specimen |
11241308 |
Human |
p16 |
tumor necrosis |
There was an inverse correlation between loss of pRB and p16(INK4a) expression (p = 0.07). pRB and p16(INK4a) abnormalities were independent of site of disease, presence of metastasis at diagnosis and percentage of tumor necrosis in the resection specimen |
11241308 |
Human |
p16 |
pediatric osteosarcomas |
Immunohistochemical analysis of p16(INK4a) expression in pediatric osteosarcomas may be a useful adjunctive marker of prognosis. |
11241308 |
Human |
p16 |
corticotroph adenomas |
Staining for p16 was only seen in 5 of 15 (33%) corticotroph, 3 of 13 (23%) somatotroph, 3 of 5 (60%) plurihormonal, and 1 of 19 (5%) null cell adenomas. p16 immunonegativity without CDKN2A methylation or deletion occurred in 22 tumours, including most so |
11276008 |
Human |
p16 |
corticotroph adenomas |
The mechanisms of p16 down-regulation probably involve CDKN2A methylation in most types, but remain to be determined in somatotroph and corticotroph adenomas. |
11276008 |
Human |
p16 |
acute promyelocytic leukemia (apl) |
PURPOSE: To investigate the frequency of p15 and p16 gene promoter methylation in acute promyelocytic leukemia (APL), and to define its value in the detection of minimal residual disease (MRD) and treatment prognostication. |
11283136 |
Human |
p16 |
mrd |
It is possible that p16 methylation is acquired during clonal evolution. p15 methylation is a potential marker of MRD and might be of prognostic significance. |
11283136 |
Human |
p16 |
cin ii |
In line with this hypothesis, we observed marked overexpression of p16(INK4a) in all cervical intraepithelial neoplasm (CIN) I lesions (n = 47) except those associated with low-risk HPV types (n = 7), all CIN II lesions (n = 32), all CIN III lesions (n = |
11291057 |
Human |
p16 |
intraepithelial neoplasm |
In line with this hypothesis, we observed marked overexpression of p16(INK4a) in all cervical intraepithelial neoplasm (CIN) I lesions (n = 47) except those associated with low-risk HPV types (n = 7), all CIN II lesions (n = 32), all CIN III lesions (n = |
11291057 |
Human |
p16 |
invasive cervical cancers |
In line with this hypothesis, we observed marked overexpression of p16(INK4a) in all cervical intraepithelial neoplasm (CIN) I lesions (n = 47) except those associated with low-risk HPV types (n = 7), all CIN II lesions (n = 32), all CIN III lesions (n = |
11291057 |
Human |
p16 |
invasive ductal carcinoma of the breast |
Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast. |
11329139 |
Human |
p16 |
uveal melanoma |
Treatment of uveal melanoma cell lines with 5-aza-2'-deoxycytidine results in demethylation of p16(INK4a) and in reexpression of p16(INK4a) mRNA, which is maintained upon withdrawal of the 5-aza-2'-deoxycytidine. |
11431374 |
Human |
p16 |
neurofibroma |
CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. |
11433531 |
Human |
p16 |
hcl |
The latter DNA probes and probes hybridizing to chromosomal regions, which are frequently deleted in other subtypes of non-Hodgkin lymphomas (NHL), namely 9p21/ P16(INK4A), 13q14/D13S25, and 17p13/P53 were subsequently applied to all 14 cases of HCL, but |
11463458 |
Human |
p16 |
lymphoid tumors |
Interestingly, whereas p53 mutations or loss of heterozygosity did not account for the accelerated development of lymphoid tumors in UV-irradiated p53(+/-) mice, deletions in the p16(INK4a) gene were quite common. |
11481437 |
Mouse |
p16 |
adult acute myeloid leukemia |
In this study, we used sodium bisulfite sequencing to obtain a complete map of the 5-methylcytosine status of 80 CpGs covering approximately 900 bp in the 5' p15 CpG island, and 53 CpGs covering approximately 700 bp in the 5' p16 CpG island in t |
11532526 |
Human |
p16 |
hepatic tumor |
Resistance of primary cultured mouse hepatic tumor cells to cellular senescence despite expression of p16(Ink4a), p19(Arf), p53, and p21(Waf1/Cip1). |
11568971 |
Mouse |
p16 |
vulvar epidermoid carcinoma |
To determine whether this difference can be translated into a therapeutic advantage to protect normal cells from adverse cytotoxicity caused by chemotherapy, we established cell model systems for ecdysone-inducible expression of p16(Ink4a), p21(Waf1), and |
11593424 |
Human |
p16 |
metastatic cancers |
Homozygous deletions of the p16 gene were observed in 2 of the 5 primary colorectal carcinomas and in 1 of the matching liver metastatic cancers. |
11677769 |
Human |
p16 |
barrett's esophagus |
Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma, a cancer of which the incidence has been increasing at an alarming rate in Western countries. p16(INK4a) lesions occur frequently in esophageal adenocarcinomas but the |
11719461 |
Human |
p16 |
esophageal adenocarcinoma |
We conclude that most Barrett's metaplasia contains genetic and/or epigenetic p16 lesions and has the ability to undergo clonal expansion, creating a field in which other abnormalities can arise that can lead to esophageal adenocarcinoma. |
11719461 |
Human |
p16 |
metaplasia |
We conclude that most Barrett's metaplasia contains genetic and/or epigenetic p16 lesions and has the ability to undergo clonal expansion, creating a field in which other abnormalities can arise that can lead to esophageal adenocarcinoma. |
11719461 |
Human |
p16 |
parotid tumor |
CONCLUSIONS: When p16 multiple tumor suppressor gene is lost and oncogene p21 is mutated, the tumor's contiguous acini maybe in the condition of "paraneoplasm" after parotid tumor removal, and it has a strong ability of preliferation, which |
11769651 |
Human |
p16 |
atypical hyperplasia |
METHODS: Methylation status of p16 gene was determined by methylation-sensitive restriction enzymes, PCR and p16 mRNA expression was evaluated by RT-PCR in a series of 8 specimens with normal endometrium(NE), 6 with simple and complex hyperplasia(SCH), 6 |
11778238 |
Human |
p16 |
sch |
In 1 of the 6 AH and 13 of the 38(34.21%) EC, there was methylation of p16 exon 1; 5 of the 6 SCH showed overexpression of p16 mRNA, 4 of the 6 AH and 27 of the 38 (71.05%) EC exhibited decrease or loss of p16 mRNA expression. |
11778238 |
Human |
p16 |
extrahepatic bile duct carcinomas |
We investigated their role in the pathogenesis of 9 bile tract cancer cell lines and 21 primary sporadic extrahepatic bile duct carcinomas. p53 and p16 protein expression was examined by Western blot analysis and immunohistochemistry. |
11802210 |
Human |
p16 |
extrahepatic bile duct cancers |
In conclusion, inactivation of the p16 gene is a frequent event in primary sporadic extrahepatic bile duct cancers, 9p21 LOH and promoter hypermethylation being the principal inactivating mechanisms. |
11802210 |
Human |
p16 |
recurrent breast carcinoma |
Fourteen patients (12.2%) of 114 patients whose tumors did not show p16 expression died of recurrent breast carcinoma, whereas 18 patients (23.1%) of 78 patients with p16 expressing tumor died during the follow-up period. |
11804184 |
Human |
p16 |
signet ring cell carcinoma |
The positive rate of p16 protein expression in mucoid carcinoma 10.00% (1/10) was significantly lower than that in poorly differentiated carcinoma 51.22% (21/41), undifferentiated carcinoma 57.69% (15/26) and signet ring cell carcinoma 62.50% (10/16) (P < |
11819820 |
Human |
p16 |
transitional cell carcinoma of bladder |
[Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder] OBJECTIVE: To study the relationship between the expression of proto-oncogene bcl-2 and MTS1/p16 in transitional cell carcinoma of bladder and prognosis. |
11831985 |
Human |
p16 |
bladder cancer |
CONCLUSIONS: Over-expression of bcl-2 appears to be common in bladder cancer; over-expression of proto-oncogene bcl-2 and inactivation of the MTS1/p16 gene are likely to be contributing factors for primary bladder cancer; and they can be the prognostic in |
11831985 |
Human |
p16 |
transitional cell carcinoma of urinary bladder |
CONCLUSIONS: Over-expression of bcl-2 appears to be common in bladder cancer; over-expression of proto-oncogene bcl-2 and inactivation of the MTS1/p16 gene are likely to be contributing factors for primary bladder cancer; and they can be the prognostic in |
11831985 |
Human |
p16 |
agnogenic myeloid metaplasia(amm) |
Hypermethylation of p15 and p16 genes was determined in 32 patients with agnogenic myeloid metaplasia(AMM), also known as idiopathic myelofibrosis (MF). |
11849214 |
Human |
p16 |
differentiated carcinoma |
The p16 positive rate was negatively correlated to the degree of tumor histological differentiation, and the rate difference between the high differentiated carcinoma and the low differentiated one was significant (P < 0.05). bcl-2 protein positive expres |
11853608 |
Human |
p16 |
endometrioid carcinomas |
Endometrioid carcinomas frequently show microsatellite instability (MIN), PTEN and K-ras mutation but infrequently p53 mutations, loss of p16 expression and her2/neu amplification, respectively. |
11873308 |
Human |
p16 |
serous carcinomas |
In contrast, serous carcinomas show a high frequency of p53 mutations and often loss of p16 expression whereas MIN and PTEN and K-ras mutations are uncommon. |
11873308 |
Human |
p16 |
atypical endometrial hyperplasia |
During the progression of endometrioid carcinoma PTEN mutations and MIN are considered early changes since they are present in a high frequency in atypical endometrial hyperplasia whereas p53 mutations, loss of p16 expression and her2/neu amplification ar |
11873308 |
Human |
p16 |
endometrioid carcinoma |
During the progression of endometrioid carcinoma PTEN mutations and MIN are considered early changes since they are present in a high frequency in atypical endometrial hyperplasia whereas p53 mutations, loss of p16 expression and her2/neu amplification ar |
11873308 |
Human |
p16 |
macroglobulinemia |
MATERIALS AND METHODS: The methylation status of the p16 gene was analysed in a group of 159 patients with monoclonal gammopathies (40 monoclonal gammopathy of uncertain significance, eight Waldenström Macroglobulinemia, eight smoldering multiple myeloma |
11920239 |
Human |
p16 |
macroglobulinemia |
RESULTS: Forty-one of 98 MM patients (41.8%) as well as four of the five (80%) primary PCL patients showed methylation of the p16 gene, while none of the patients with monoclonal gammopathy of undetermined significance, Waldenström Macroglobulinemia or s |
11920239 |
Human |
p16 |
malignant eyelid tumors |
CONCLUSIONS: The expression of the P16 protein was related to the occurrence and degree of differentiation of malignant eyelid tumors. |
11930651 |
Human |
p16 |
invasive ductal adenocarcinoma |
Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. |
12010891 |
Human |
p16 |
angiosarcomas |
In vivo, mice doubly deficient for p16(INK4a) and p53 showed an increased rate of tumor formation with particular susceptibility to aggressive angiosarcomas. |
12019151 |
Mouse |
p16 |
relapsed childhood acute lymphoblastic leukemia |
Deletion analysis of p16(INKa) and p15(INKb) in relapsed childhood acute lymphoblastic leukemia. |
12036898 |
Human |
p16 |
teratomas |
Twenty-five primary intracranial germ cell tumors (11 germinomas, 5 teratomas, 5 mixed teratomas-germinomas. 1 mixed choriocarcinoma-teratoma, 1 yolk sac tumor, 1 mixed yolk sac tumor-teratoma, and 1embryonal carcinoma; from 24 males and 1 female) were st |
12071636 |
Human |
p16 |
yolk sac tumor |
Twenty-five primary intracranial germ cell tumors (11 germinomas, 5 teratomas, 5 mixed teratomas-germinomas. 1 mixed choriocarcinoma-teratoma, 1 yolk sac tumor, 1 mixed yolk sac tumor-teratoma, and 1embryonal carcinoma; from 24 males and 1 female) were st |
12071636 |
Human |
p16 |
liver tumor |
On the other hand, circulating liver tumor DNA such as p16 and p15 methylation and mitochondrial mutations in the plasma and serum of liver cancer patients might be useful for monitoring, similar to the tumor markers. |
12094698 |
Human |
p16 |
thyroid tumors |
Additionally, we analyzed the methylation frequency of the CpG island of cell cycle inhibitor p16(INK4a) in the same thyroid tumors. |
12097277 |
Human |
p16 |
hereditary breast-ovarian cancer syndrome |
Hereditary pancreatic cancer. Hereditary pancreatic cancer (PC) appears to be exceedingly heterogeneous, as evidenced by its association with a variety of integrally associated diverse cancers and/or differing mendelian inherited cancer syndromes, which i |
12120226 |
Human |
p16 |
hereditary pancreatic cancer |
Hereditary pancreatic cancer. Hereditary pancreatic cancer (PC) appears to be exceedingly heterogeneous, as evidenced by its association with a variety of integrally associated diverse cancers and/or differing mendelian inherited cancer syndromes, which i |
12120226 |
Human |
p16 |
inherited cancer syndromes |
Hereditary pancreatic cancer. Hereditary pancreatic cancer (PC) appears to be exceedingly heterogeneous, as evidenced by its association with a variety of integrally associated diverse cancers and/or differing mendelian inherited cancer syndromes, which i |
12120226 |
Human |
p16 |
polyposis |
Hereditary pancreatic cancer. Hereditary pancreatic cancer (PC) appears to be exceedingly heterogeneous, as evidenced by its association with a variety of integrally associated diverse cancers and/or differing mendelian inherited cancer syndromes, which i |
12120226 |
Human |
p16 |
nerve sheath tumors |
Hemizygous or homozygous p16 deletions were detected in 75% of MPNSTs, but not in benign nerve sheath tumors (p < 0.001). |
12152785 |
Human |
p16 |
idiopathic pulmonary fibrosis |
MYCL1, FHIT, SPARC, p16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis. |
12169206 |
Human |
p16 |
oral cancer |
We reported previously that acquisition of the immortal phenotype is an early event in oral cancer development (F. McGregor et al., Cancer Res., 57: 3886-3889, 1997); our current data indicate that about half of oral dysplasia cultures are immortal, and t |
12183435 |
Human |
p16 |
mds |
We examined p15 and p16 methylation status in bone marrow mononuclear cells from patients with high-risk MDS during treatment with decitabine, using a methylation-sensitive primer extension assay (Ms-SNuPE) to quantitate methylation, and denaturing gradie |
12351408 |
Human |
p16 |
pleomorphic adenomas |
To study the contribution of each pathway in pleomorphic adenomas, this study analysed alterations of p14(ARF), p16(INK4a), p53, and pRb in these tumours. |
12375265 |
Human |
p16 |
liver angiosarcoma |
Alterations of p14(ARF), p16(INKa), and p53 in primary liver angiosarcoma from 19 patients were analyzed by methylation-specific polymerase chain reaction (MSP), restriction enzyme-related polymerase chain reaction (RE-PCR), microsatellite analysis, and D |
12378512 |
Human |
p16 |
common neoplasms |
Loss of p16(INK4a) expression has also been frequently observed in more common neoplasms such as lung cancer as well. |
12399123 |
Human |
p16 |
mesothelioma |
This methylation in these mesothelioma cells could be reversed, resulting in re-expression of p16(INK4a) protein, following the treatment of the cells with cytidine analogs, which are known inhibitors of DNA methylation. |
12399123 |
Human |
p16 |
lobular carcinomas |
Oestrogen and progesterone receptors, tumour proliferative activity, the expression of cyclin A, p16(ink4A), p27(kip1), p21(waf1), p53, bcl-2, and levels of vascular endothelial growth factor and hypoxia-inducible factor-1alpha (HIF-1alpha) were evaluated |
12402149 |
Human |
p16 |
human erythroleukemia |
Changes of biophysical behavior of k562 cells for p16 gene transfer. p16 gene was transferred into human erythroleukemia cell line K562 that had been subjected to p16 deletion. |
12454374 |
Human |
p16 |
vulvar carcinoma |
Alterations of the p16/Rb/cyclin-D1 pathway in vulvar carcinoma, vulvar intraepithelial neoplasia, and lichen sclerosus. |
12454817 |
Human |
p16 |
vulvar carcinoma (vc) |
Three different alterations in the p16/pRb/cyclin-D1 pathway (p16(INK4a)-promoter hypermethylation and expression of pRb and cyclin-D1) were investigated in a series of 38 cases of vulvar carcinoma (VC), 13 cases of vulvar intraepithelial neoplasia (VIN), |
12454817 |
Human |
p16 |
oral cancer |
In an attempt to model oral cancer in a human cell-based system, we analyzed normal oral epithelial keratinocytes with the pRB pathway dysregulated by loss of expression of the cyclin-dependent kinase (cdk) 4/cdk6 inhibitor p16(INK4A) and/or ectopic expre |
12543805 |
Human |
p16 |
cervical glandular intraepithelial neoplasia |
A total of 45 surgical specimens, including 18 cases of invasive carcinoma, 8 cases of adenocarcinoma in situ, 4 cases of endocervical glandular atypia (cervical glandular intraepithelial neoplasia), and 15 reactive lesions of the endocervical glands were |
12548164 |
Human |
p16 |
large cell carcinoma |
METHODS: p16 and p53 expression were detected by immunohistochemical analysis of 90 paraffin specimens of resected NSCLC, including 35 squamous cell carcinoma, 47 adenocarcinoma, and eight large cell carcinoma, between stages I and IV. |
12559346 |
Human |
p16 |
mouse tumor |
Recent evidence emerging from mouse tumor models distinguishes the activities of p16(Ink4a) and p19(Arf) in regulating tumor onset and identifies differences in their responsiveness to drugs. |
12573439 |
Mouse |
p16 |
aggressive fibromatosis |
Importantly, exogenous p16(INK4a) introduced by cotransfection is sufficient to reduce GR activity in FS cells, without affecting GR activity in p16-positive aggressive fibromatosis cells. |
12624188 |
Human |
p16 |
adenoid cystic carcinoma |
Expression of p16 protein and hypermethylation status of its promoter gene in adenoid cystic carcinoma of the head and neck. |
12624503 |
Human |
p16 |
adenoid cystic carcinomas (acc) |
To explore the role of p16 in the biological behavior of adenoid cystic carcinomas (ACC), we investigated the immunohistochemical expression of p16 protein in 38 ACC tumors (32 primary, 3 recurrent, and 3 metastatic tumors) and the methylation status of i |
12624503 |
Human |
p16 |
atypical adenomatous hyperplasia |
In the case of adenocarcinoma, we investigated the utility of hnRNP B1 for both detection of early adenocarcinoma and discrimination of non-invasive lesion, atypical adenomatous hyperplasia (AAH) from adenocarcinoma. hnRNP B1, cyclin D1, p16, and Ki-67 we |
12660006 |
Human |
p16 |
liver tumors |
Additionally, we analysed the methylation status of p16(INK4a) and other cancer-related genes in the same liver tumors. |
12660822 |
Human |
p16 |
hca |
In conclusion, our results demonstrate that RASSF1A and p16(INK4a) inactivation by methylation are frequent events in hepatocellular carcinoma, but not in HCA, which is in contrast to HCC without cirrhosis, viral hepatitis, storage diseases, or genetic ba |
12660822 |
Human |
p16 |
gastric adenoma (ga) |
Five different classes of methylation behaviors were found: (a). genes methylated in GC only (GSTP1 and RASSF1A), (b). genes showing low methylation frequency (<12%) in CG, IM, and gastric adenoma (GA) but significantly higher methylation frequency in GC |
12695555 |
Human |
p16 |
basal cell carcinoma |
Invade or proliferate? Two contrasting events in malignant behavior governed by p16(INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma. |
12702553 |
Human |
p16 |
basal cell carcinomas |
Using immunohistochemistry and Western blotting of microdissected parts of basal cell carcinomas, we showed that p16(INK4a) was up-regulated at the invasive front of the majority of basal cell carcinomas with infiltrative growth patterns, followed by ceas |
12702553 |
Human |
p16 |
laryngeal papilloma (alp) |
METHODS: HPV consensus primers direct in situ polymerase chain reaction (ISPCR) and immunohistochemical method were applied to detect the presence of HPV genomes (1, 6, 8, 11, 13, 16, 18, 30, 31, 32, 33, 45, 51) and the expression of p16 protein respectiv |
12761910 |
Human |
p16 |
neuroendocrine tumors |
Additionally, we analysed the aberrant methylation frequency of cell cycle inhibitor p16(INK4a) and K-ras gene mutations in the pancreatic samples. p16 inactivation was detected in 43% of adenocarcinomas, in 17% of neuroendocrine tumors, in 18% of pancrea |
12802288 |
Human |
p16 |
tonsil cancers |
In our study 86 tonsil cancers were analysed for HPV status by sequence analysis of polymerase chain reaction products and for the expression of cell cycle proteins (p53, p21(CIP1/WAF1), pRb, p16(INK4A), cyclin D1 and p27(KIP1)) by immunohistochemistry. |
12845651 |
Human |
p16 |
hepatitis b virus related hepatocellular carcinoma |
[Effect of p16 gene on carcinogenesis of hepatitis B virus related hepatocellular carcinoma] OBJECTIVE: To investigate the relation between p16 gene expression and the carcinogenesis and progress of hepatitis B virus (HBV) related hepatocellular carcinoma |
12921565 |
Human |
p16 |
sporadic breast cancer |
[Abnormal methylation of several tumor suppressor genes in sporadic breast cancer] Multiplex methylation-sensitive PCR was employed in studying the methylation of CpG islands in the RB1, p16/CDKN2A, p15/CDKN2B, p14/ARF, CDH1, MGMT, HIC1, and N33 promoter |
12942643 |
Human |
p16 |
tumors |
Our results suggest that abnormal expression of the p16 and/or p14ARF may be associated with a poor prognosis in these 3 tumors. |
12963998 |
Human |
p16 |
squamous cell carcinoma of the cervix |
Carcinogenesis of cervical cancer has been investigated, and p16(INK4a) overexpression in squamous cell carcinoma of the cervix has been reported as a result of infection by human papillomavirus (HPV) (eg, HPV 16), and the consequence of the retinoblastom |
14506638 |
Human |
p16 |
small cell carcinoma of the cervix |
However, to our knowledge, there have been no studies on the relation between p16(INK4a) overexpression associated with HPV and small cell carcinoma of the cervix, which behaves more aggressively clinically than squamous cell carcinoma. |
14506638 |
Human |
p16 |
tongue neoplasms |
[Expression of p15 and p16 proteins in tongue squamous cell carcinoma and their significances] BACKGROUND & OBJECTIVE: Abnormal expression of p15 and p16 were commonly found in many kinds of primary tumors, but the possible correlation between p15 and p16 |
14613656 |
Human |
p16 |
tongue squamous cell carcinoma |
This study was designed to investigate the expression of p15 and p16 proteins and their possible correlation with clinicopathology and prognosis of tongue squamous cell carcinoma (TSCC). |
14613656 |
Human |
p16 |
papillomatosis |
METHODS: Immunohistochemistry was used to examine the protein expression of CyclinD1, p16, E2F-1 and Rb in 4 groups (196 cases) with mild papillomatosis (MP), moderate papillomatosis (MoP), serious papillomatosis (SP) and ductal carcinoma in situ (DCIS). |
14642081 |
Human |
p16 |
schwannomas |
EXPERIMENTAL DESIGN: We examined the DNA methylation status of 12 tumor-related genes (NF2, RB1, p14(ARF), p16(INK4a), p73, TIMP-3, MGMT, DAPK, THBS1, caspase-8, TP53, and GSTP1) in 44 sporadic and/or NF2-associated schwannomas using methylation-specific |
14654541 |
Human |
p16 |
head and neck carcinomas |
Due to heterozygous p16-Leiden constitution, our proband with multiple head and neck carcinomas was a suitable model for studying the type of p16 inactivation according to the Knudson-two-hit model. |
14740307 |
Human |
p16 |
adenoid cystic carcinoma (acc) |
Samples of NSG, pleomorphic adenoma (PA), adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), epithelial-myoepithelial carcinoma (EMC), malignant myoepithelioma (MEM), carcinoma ex pleomorphic adenoma (CEPA), and polymorphous, low-grade adenoc |
14747065 |
Human |
p16 |
carcinoma ex pleomorphic adenoma (cepa) |
Samples of NSG, pleomorphic adenoma (PA), adenoid cystic carcinoma (ACC), mucoepidermoid carcinoma (MEC), epithelial-myoepithelial carcinoma (EMC), malignant myoepithelioma (MEM), carcinoma ex pleomorphic adenoma (CEPA), and polymorphous, low-grade adenoc |
14747065 |
Human |
p16 |
gallbladder tumors |
RESULTS: p16 gene alterations including silent mutations were present in 61.8% gallbladder cancers, 54.5% bile duct cancers, and 70.6% ampullary cancers. p16 gene nonsilent mutations, p16 methylation, and loss of chromosome 9p21-22 that targets p14, p15, |
15014024 |
Human |
p16 |
corticotroph adenomas |
EXPERIMENTAL DESIGN: Tissue from 31 corticotroph adenomas and 16 nonadenomatous pituitaries were subject to methylation-sensitive PCR to determine the methylation status of the p16 gene CpG island. |
15014032 |
Human |
p16 |
laryngeal cancer |
Our purpose was to investigate 9p21 LOH and expression of p16 protein and their possible prognostic value in laryngeal cancer. |
15101277 |
Human |
p16 |
transitional cell carcinomas (tcc) |
Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de |
15161057 |
Human |
p16 |
cysts |
Immunohistochemical staining was performed for p16(INK4a) and pRb in formalin-fixed, paraffin-embedded tissue sections of the uterine cervix using an indirect immunoperoxidase method. p16(INK4a) staining was detected in 7 of 108 sections (6.5%) of normal |
15188135 |
Human |
p16 |
malignant salivary gland tumors |
Positive rate of P16 protein expression was 76.9% (10/13) and 40.9% (9/22) in benign and malignant salivary gland tumors, respectively. |
15190803 |
Human |
p16 |
salivary gland tumors |
There was no correlation of the expression of P16 and nm23 in salivary gland tumors was found (P > 0.05). |
15190803 |
Human |
p16 |
malignant salivary gland tumors |
CONCLUSION: p16 and nm23 genes may play an important role in different sides in salivary gland tumorigenesis and the reduce of the expression of p16 and nm23 genes may contribute to the generation of malignant salivary gland tumors. |
15190803 |
Human |
p16 |
keratinizing squamous cell carcinoma |
In contrast, p16 was almost consistently negative in normal skin, squamous cell hyperplasia (0/20), lichen sclerosus (0/19), differentiated (simplex) VIN3 (0/11), verrucous carcinoma (0/2), and keratinizing squamous cell carcinoma (3/33, 9%). |
15213596 |
Human |
p16 |
verrucous carcinoma |
In contrast, p16 was almost consistently negative in normal skin, squamous cell hyperplasia (0/20), lichen sclerosus (0/19), differentiated (simplex) VIN3 (0/11), verrucous carcinoma (0/2), and keratinizing squamous cell carcinoma (3/33, 9%). |
15213596 |
Human |
p16 |
keratinizing squamous cell carcinomas |
One of the keratinizing squamous cell carcinomas positive for p16 occurred in a 25-year-old woman and the other two were associated with small foci of basaloid VIN3 adjacent to the tumor, suggesting a probable relationship with HPV. p16 was positive in 6 |
15213596 |
Human |
p16 |
non-small cell carcinomas |
In two additional cases originally interpreted as small cell carcinoma, high molecular weight keratin highlighted small numbers of neoplastic large cells, leading to reclassification as combined small cell and non-small cell carcinomas. p16(INK4A) express |
15309021 |
Human |
p16 |
chl |
The aim of the present study was to assess expression of cyclin D2, Ki67, cyclin A, cyclin B1, cyclin D1, cyclin D3, cyclin E, p53, Rb, p16 and p27 proteins in order to gain further insight into the proliferation profile of cHL. |
15354186 |
Human |
p16 |
cervical cancer |
The present data confirm the role of p16(INK4A) as a highly specific marker of CIN and HR-HPV type, but expression of this protein does not seem to be of any prognostic value in cervical cancer or in predicting the clearance of HR-HPV after treatment of C |
15381905 |
Human |
p16 |
cin |
The present data confirm the role of p16(INK4A) as a highly specific marker of CIN and HR-HPV type, but expression of this protein does not seem to be of any prognostic value in cervical cancer or in predicting the clearance of HR-HPV after treatment of C |
15381905 |
Human |
p16 |
fundic gland polyps (fgps) |
We studied methylation of 2 tumor suppressor genes (p14, p16) and 4 MINT (methylated in tumor) clones (MINT1, MINT2, MINT25, MINT31) among 51 fundic gland polyps (FGPs) and 27 normal gastric body biopsy samples using bisulfite treatment of genomic DNA fol |
15491970 |
Human |
p16 |
hydatidiform mole |
Among the six genes examined, the promoter region of four genes (E-cadherin, HIC-1, p16, TIMP3) in choriocarcinoma and three genes (E-cadherin, HIC-1, p16) in hydatidiform mole exhibited aberrant methylation whereas none was hypermethylated in normal plac |
15507671 |
Human |
p16 |
soft tissue sarcomas (stss) |
In this study, the methylation status of RASSF1A, p16, MLH1, MSH2 and ERalpha was investigated in 84 primary soft tissue sarcomas (STSs), including 22 liposarcomas, 18 malignant fibrous histiocytomas (MFHs), 18 leiomyosarcomas, 6 rhabdomyosarcomas, 6 neur |
15551306 |
Human |
p16 |
fibroadenoma |
The potential role of p16(INK4a) methylation in breast cancer is controversial whereas there are no data on fibroadenoma. |
15578730 |
Human |
p16 |
fibroadenoma |
To assess if inactivation of p16(INK4a) by promoter hypermethylation occurs in this hyperproliferative benign breast lesion or, on the contrary, it is strictly related to the carcinogenic process, we have tested the different histological components of 15 |
15578730 |
Human |
p16 |
lung adenocarcinoma |
CONCLUSIONS: Aberrant methylation of the promoter region of the p16 gene and loss of expression of its product were in accord with the multistep progression of peripheral-type lung adenocarcinoma, and these alterations were associated closely with poor pr |
15612080 |
Human |
p16 |
b-cell lymphoblastic leukemia |
[Abnormal methylation of p16/CDKN2A AND p14/ARF genes GpG Islands in non-small cell lung cancer and in acute lymphoblastic leukemia] Multiplex methylation-sensitive PCR and methylation-specific PCR were employed in studying the methylation of CpG islands |
15612580 |
Human |
p16 |
b-cell lymphoblastic leukemia |
High level of the p16/CDKN2A first exon CpC island methylation was revealed in non-small cell lung cancer (68%) and in acute B-cell lymphoblastic leukemia (55%) and the CpG island of p14/ARF first exon was nonmethylated in these types of tumors. |
15612580 |
Human |
p16 |
benign prostatic hyperplasias (bph) |
EXPERIMENTAL DESIGN: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 b |
15623627 |
Human |
p16 |
gallbladder adenocarcinomas |
RESULTS: Of 38 gallbladder adenocarcinomas analyzed by IHC, 11 cases (29%) were negative for p16 protein. |
15693199 |
Human |
p16 |
polyposis |
BRAF mutation status in patients with multiple/large HPs and/or hyperplastic polyposis correlated with HPs from the same patient (odds ratio, 5.8; P = 0.0002) but associated with younger age (odds ratio, 0.83; P = 0.006 compared to older age), with a larg |
15793287 |
Human |
p16 |
colon cancer |
Loss of MGMT protein expression was associated with the MSI-L phenotype but was not a prognostic factor for overall survival in colon cancer. p16 methylation was significantly less frequent in MSI-L than in MSI-H and MSS tumors and was not associated with |
15800322 |
Human |
p16 |
tumors |
Loss of MGMT protein expression was associated with the MSI-L phenotype but was not a prognostic factor for overall survival in colon cancer. p16 methylation was significantly less frequent in MSI-L than in MSI-H and MSS tumors and was not associated with |
15800322 |
Human |
p16 |
signet ring cell carcinoma |
The positive rate of P16 protein expression in mucoid carcinoma (10%, 1/10) was significantly lower than that in poorly differentiated carcinoma (51%, 21/41), undifferentiated carcinoma (58%, 15/26) and signet ring cell carcinoma (62%, 10/16) (P<0.05). |
15818729 |
Human |
p16 |
leukoplakia |
[The p16 methylation in oral leukoplakia and oral squamous cell carcinoma] OBJECTIVE: To investigate p16 gene methylation in normal mucosa, leukoplakia with hyperplasia and dysplasia and oral squamous cell carcinoma. |
15842853 |
Human |
p16 |
vin 3 |
RESULTS: p16(INK4a) immunoreactivity was different in VIN 1, VIN 2, VIN 3, and squamous cell carcinoma. |
15870532 |
Human |
p16 |
vin 3 |
Strong expression of p16(INK4a) protein was observed in 92% (22 of 24) of VIN 2 and VIN 3 lesions and 100% (4 of 4) of invasive SCCs. |
15870532 |
Human |
p16 |
condyloma acuminatum |
No p16(INK4a) immunoreactivity was observed in any of the benign/reactive and condyloma acuminatum lesions. |
15870532 |
Human |
p16 |
condyloma acuminatum |
CONCLUSIONS: Upregulation of INK4a gene occurs in vulvar carcinogenesis. p16(INK4a) is not a sensitive marker for differentiation of benign vulvar squamous epithelium from condyloma acuminatum or VIN 1 lesions because most VIN 1 lesions are p16(INK4a) neg |
15870532 |
Human |
p16 |
cervical polyp |
METHODS: A total of 188 consecutive and unselected colposcopically directed cervical biopsies and a single contemporaneous cervical polyp were accessioned prospectively over a 3-month period, step-serially sectioned and examined by H&E and immunostained f |
16028838 |
Human |
p16 |
cervical polyp |
Diffuse strong parabasal immunostaining for p16(INK4a), suggestive of integrated high-risk HPV DNA into the host genome, was observed in 81 biopsies (42.9%, including the cervical polyp) and correlated (>90%) with HGSIL in the H&E sections. |
16028838 |
Human |
p16 |
immunoblastic lymphoma |
Current data indicate that the transformation of chronic lymphocytic leukemia to a large-cell or immunoblastic lymphoma is associated with abnormalities in cell cycle regulation (e.g., loss of the cell cycle inhibitors p16(INK4a) and p27(KIP1) ) and DNA r |
16053658 |
Human |
p16 |
chronic myelomonocytic leukemias (cmml) |
To determine whether genetic alterations of p16 and p27 genes play an important role in MDS pathogenesis, we examined DNA from 51 patients classified as 17 refractory anemias (RA), four refractory anemias with ringed sideroblasts (RARS), 19 refractory ane |
16104874 |
Human |
p16 |
nodular melanoma |
To evaluate the importance of ID1 in malignant melanoma, tumour cell expression was examined by immunohistochemistry in 119 cases of nodular melanoma using tissue microarray technique, and related to multiple tumour markers including proliferation, p16 ex |
16189525 |
Human |
p16 |
squamous cell carcinoma of conjunctiva |
Expression of cell cycle-regulatory proteins, MIB-1, p16, p53, and p63, in squamous cell carcinoma of conjunctiva: not associated with human papillomavirus infection. |
16328355 |
Human |
p16 |
keratoacanthoma |
Further, the loss of MMP-19 and p16 could aid in making the differential diagnosis between well-differentiated SCC and keratoacanthoma. |
16699496 |
Human |
p16 |
verrucous carcinoma |
METHODS: Promoter hypermethylation status of p16 and MGMT genes were examined by the methylation-specific PCR (MSP) in OSCC (n = 51), verrucous carcinoma (n = 2), and carcinoma in situ (n = 2) tissues. |
16791592 |
Human |
p16 |
invasive ductal carcinomas (idcs) |
MATERIALS AND METHODS: To evaluate the biological importance of 14-3-3 sigma expression in pancreatic carcinogenesis, immunohistochemistry for 14-3-3 sigma, CDX2, MUC1, MUC2, p53, p16 and Ki-67 was carried out on 33 IPMTs and the results were compared wit |
16886641 |
Human |
p16 |
bowenoid papulosis |
Expression of p16 and hTERT protein is associated with the presence of high-risk human papillomavirus in Bowenoid papulosis. |
16919029 |
Human |
p16 |
bowenoid papulosis (bp) |
The expression of p16 and hTERT protein in Bowenoid papulosis (BP) has not been studied. |
16919029 |
Human |
cdk4i |
squamous cell carcinoma of the larynx |
p16MTS1/CDK4I mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx. |
9333020 |
Human |
cdk4i |
squamous cell carcinomas of larynx |
These findings indicate that p16MTS1/CDK4I is frequently inactivated by gene mutation, hypermethylation, and allelic deletions in a significant subset of squamous cell carcinomas of larynx. |
9333020 |
Human |
multiple tumor suppressor 1 |
central nervous system primitive neuroectodermal tumor |
The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor. |
7791990 |
Human |
arf |
indolent lymphomas |
To determine the role of these genes in the pathogenesis of human non-Hodgkin's lymphomas we have analyzed exon 1beta, 1alpha, and 2 of the INK4a/ARF locus and p53 gene aberrations in 97 tumors previously characterized for p16(INK4a) alterations. p53 |
10854221 |
Human |
arf |
aggressive lymphomas |
Aggressive lymphomas with p14(ARF) inactivation and p53 wild type showed a significantly lower p53 protein expression than tumors with no alteration in any of these genes. |
10854221 |
Human |
arf |
neurofibroma |
CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. |
11433531 |
Human |
arf |
chondrosarcoma |
Changes in p14(ARF) do not play a primary role in human chondrosarcoma tissues. |
11477582 |
Human |
arf |
chondrosarcoma |
In this study, the first unique exon, exon 1 beta, of p14(ARF), has been studied in 22 chondrosarcoma tissues using polymerase chain reaction, DNA sequencing and methylation-specific polymerase chain reaction. |
11477582 |
Human |
arf |
anaplastic meningiomas |
Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. |
11485924 |
Human |
arf |
atypical meningiomas |
We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppr |
11485924 |
Human |
arf |
benign meningiomas |
We investigated 67 meningothelial tumors (20 benign meningiomas, 34 atypical meningiomas, and 13 anaplastic meningiomas) for losses of genetic information from chromosome arms 1p and 9p, as well as for deletion, mutation, and expression of the tumor suppr |
11485924 |
Human |
arf |
benign meningioma |
One anaplastic meningioma, three atypical meningiomas, and one benign meningioma without a demonstrated homozygous deletion or mutation of CDKN2A, p14(ARF), or CDKN2B lacked detectable transcripts from at least one of these genes. |
11485924 |
Human |
arf |
hepatic tumor |
Resistance of primary cultured mouse hepatic tumor cells to cellular senescence despite expression of p16(Ink4a), p19(Arf), p53, and p21(Waf1/Cip1). |
11568971 |
Mouse |
arf |
primary central nervous system lymphoma |
Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type. |
11804283 |
Human |
arf |
endometrial hyperplasia |
Ink4a/Arf deficiency reduced tumor-free survival and shortened the latency of neoplasias associated with Pten heterozygosity, specifically pheochromocytoma, prostatic intraepithelial neoplasia, and endometrial hyperplasia. |
11818530 |
Mouse |
arf |
prostatic intraepithelial neoplasia |
Ink4a/Arf deficiency reduced tumor-free survival and shortened the latency of neoplasias associated with Pten heterozygosity, specifically pheochromocytoma, prostatic intraepithelial neoplasia, and endometrial hyperplasia. |
11818530 |
Mouse |
arf |
common tumor |
p14(ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. p14(ARF), the alternative product from the human INK4a/ARF locus, antagonizes Hdm2 and mediates p53 activation in response t |
11830494 |
Human |
arf |
breast tumors |
Several disease-implicated regulators of p19(ARF) are known to date, among which are the T-box genes TBX2, which resides on an amplicon in primary breast tumors, and TBX3, which is mutated in the human developmental disorder Ulnar-Mammary syndrome. |
12000749 |
Human |
arf |
myeloproliferative disorders |
A broad spectrum of tumor suppressor gene alterations do occur in hematological malignancies, especially structural alterations of p15(INK4A), p15(INK4B) and p14(ARF) in acute lymphoblastic leukemia as well as methylation of these genes in several myelopr |
12032783 |
Human |
arf |
neurofibromatosis |
The tumor types observed were characteristic of p19(ARF) null animals, not those associated with neurofibromatosis or those observed with NF1(+/-)/p53(+/-) mice. |
12118376 |
Mouse |
arf |
primary carcinomas |
RESULTS: Altogether inactivation (methylation, loss of heterozygosity and mutation of exon 1beta) of p14(ARF) was found in 29 of all 68 (43%) carcinomas, with a significant difference in primary [8 of 29 (28%)] relative to second primary carcinomas [21 of |
12189502 |
Human |
arf |
recurrent carcinomas |
Mutations of p53 were found in 32 of 68 HNSCCs (44%), evenly distributed among primary and recurrent carcinomas. p14(ARF) alterations showed no relationship to p53 mutations. |
12189502 |
Human |
arf |
recurrent carcinomas |
The significantly higher rate of p14(ARF) alterations in recurrent (respective second primary) carcinomas suggests a further acquired genetic aberration during the development of the recurrent carcinomas. |
12189502 |
Human |
arf |
liver angiosarcoma |
Alterations of p14(ARF), p16(INKa), and p53 in primary liver angiosarcoma from 19 patients were analyzed by methylation-specific polymerase chain reaction (MSP), restriction enzyme-related polymerase chain reaction (RE-PCR), microsatellite analysis, and D |
12378512 |
Human |
arf |
mouse tumor |
Recent evidence emerging from mouse tumor models distinguishes the activities of p16(Ink4a) and p19(Arf) in regulating tumor onset and identifies differences in their responsiveness to drugs. |
12573439 |
Mouse |
arf |
sporadic breast cancer |
[Abnormal methylation of several tumor suppressor genes in sporadic breast cancer] Multiplex methylation-sensitive PCR was employed in studying the methylation of CpG islands in the RB1, p16/CDKN2A, p15/CDKN2B, p14/ARF, CDH1, MGMT, HIC1, and N33 promoter |
12942643 |
Human |
arf |
schwannomas |
EXPERIMENTAL DESIGN: We examined the DNA methylation status of 12 tumor-related genes (NF2, RB1, p14(ARF), p16(INK4a), p73, TIMP-3, MGMT, DAPK, THBS1, caspase-8, TP53, and GSTP1) in 44 sporadic and/or NF2-associated schwannomas using methylation-specific |
14654541 |
Human |
arf |
mec |
Late-passage hTERT-immortalized MEC express p53 but down-regulate p14(ARF). |
14966292 |
Human |
arf |
benign meningiomas |
We found methylation of p14(ARF) gene in five of 58 cases of benign meningiomas (8.6%), two of 10 cases of atypical meningiomas (20%), and two of four cases of anaplastic meningiomas (50%). |
15073599 |
Human |
arf |
odontogenic tumors |
BACKGROUND: To clarify the roles of the p53-MDM2-p14(ARF) cell cycle regulation system in oncogenesis and cytodifferentiation of odontogenic tumors, p53 gene status and expression of p53, MDM2, and p14(ARF) proteins was analyzed in ameloblastomas as well |
15078490 |
Human |
arf |
ameloblastoma |
Markedly decreased reactivity for p53, MDM2, and p14(ARF) was detected in keratinizing and granular cells in ameloblastoma subtypes. |
15078490 |
Human |
arf |
ameloblastoma |
Basal cell ameloblastoma showed slightly higher reactivity for p53, MDM2, and p14(ARF) as compared with other subtypes. |
15078490 |
Human |
arf |
ameloblastoma |
Immunoreactivity for p53, MDM2, and p14(ARF) in ameloblastoma variants suggests that these factors might be associated with tissue structuring and cytodifferentiation of ameloblastomas. |
15078490 |
Human |
arf |
b-cell lymphoblastic leukemia |
[Abnormal methylation of p16/CDKN2A AND p14/ARF genes GpG Islands in non-small cell lung cancer and in acute lymphoblastic leukemia] Multiplex methylation-sensitive PCR and methylation-specific PCR were employed in studying the methylation of CpG islands |
15612580 |
Human |
arf |
b-cell lymphoblastic leukemia |
High level of the p16/CDKN2A first exon CpC island methylation was revealed in non-small cell lung cancer (68%) and in acute B-cell lymphoblastic leukemia (55%) and the CpG island of p14/ARF first exon was nonmethylated in these types of tumors. |
15612580 |
Human |
arf |
benign prostatic hyperplasias (bph) |
EXPERIMENTAL DESIGN: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 b |
15623627 |
Human |
arf |
salivary gland carcinomas (sgcs) |
As combinations of genetic and/or epigenetic alterations occurring during salivary gland carcinogenesis are largely unknown, we here analyzed 36 salivary gland carcinomas (SGCs) for changes in INK4a/ARF, RB1, p21, p27, PTEN, p53, MDM2 and O6-MGMT genes us |
15695118 |
Human |
arf |
mcl |
To determine the role of these genes in MCL, we have examined their gene status and expression and their relationship to INK4a/ARF and p53 gene aberrations in 69 tumors. |
15781632 |
Human |
arf |
scc of the tongue |
CONCLUSIONS: These data show that in patients with SCC of the tongue, combined nuclear and nucleolar expression of p14(ARF) protein predicts for improved DFS and OS independent of established prognostic markers. |
15930346 |
Human |
arf |
immunoblastic lymphoma |
Current data indicate that the transformation of chronic lymphocytic leukemia to a large-cell or immunoblastic lymphoma is associated with abnormalities in cell cycle regulation (e.g., loss of the cell cycle inhibitors p16(INK4a) and p27(KIP1) ) and DNA r |
16053658 |
Human |
ink4 |
spindle cell tumor |
Gene deletion of the INK4 locus is associated with transformation to a highly invasive spindle cell tumor phenotype. |
10341708 |
Human |
ink4 |
basaloid carcinomas |
In order to assess the frequency and the prognostic value of these abnormalities in NSCLC, immunohistochemical analysis of Rb, p16(INK4), and cyclin D1 has been performed on 168 cases of NSCLC including 77 squamous cell carcinomas, 43 adenocarcinomas, and |
10440744 |
Human |
ink4 |
nsclc |
In order to assess the frequency and the prognostic value of these abnormalities in NSCLC, immunohistochemical analysis of Rb, p16(INK4), and cyclin D1 has been performed on 168 cases of NSCLC including 77 squamous cell carcinomas, 43 adenocarcinomas, and |
10440744 |
Human |
ink4 |
squamous cell carcinomas |
In order to assess the frequency and the prognostic value of these abnormalities in NSCLC, immunohistochemical analysis of Rb, p16(INK4), and cyclin D1 has been performed on 168 cases of NSCLC including 77 squamous cell carcinomas, 43 adenocarcinomas, and |
10440744 |
Human |
ink4 |
testicular germ-cell tumours |
Lack of p19INK4d in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesis. p19INK4d, a member of the INK4 family of cyclin-dependent kinase inhibitors, negatively regulates the proto-oncogenic cyclin D/CDK4(6) com |
10962575 |
Human |
ink4 |
neurofibroma |
CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. |
11433531 |
Human |
ink4 |
idiopathic pulmonary fibrosis |
MYCL1, FHIT, SPARC, p16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis. |
12169206 |
Human |
ink4 |
ovarian granulosa cell tumors |
Evidence of a role for the INK4 family of cyclin-dependent kinase inhibitors in ovarian granulosa cell tumors. |
12203782 |
Human |
cdkn2a |
plasmacytoma |
Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. |
9482902 |
Mouse |
cdkn2a |
soft tissue tumors |
Gene alterations at the CDKN2A (p16/MTS1) locus in soft tissue tumors. |
9664128 |
Human |
cdkn2a |
soft tissue tumors |
Presumably, alterations of the CDKN2A gene do not contribute to the oncogenesis in the majority of soft tissue tumors. |
9664128 |
Human |
cdkn2a |
oropharyngeal squamous cell carcinoma (oscc) |
Loss of CDKN2A expression was demonstrated by immunohistochemistry in 87% of oral and oropharyngeal squamous cell carcinoma (OSCC) primary tumor samples. |
10221335 |
Human |
cdkn2a |
corticotroph adenomas |
Homozygous CDKN2A deletion was restricted to rare somatotroph (15%) and corticotroph adenomas (13%). |
11276008 |
Human |
cdkn2a |
corticotroph adenomas |
Staining for p16 was only seen in 5 of 15 (33%) corticotroph, 3 of 13 (23%) somatotroph, 3 of 5 (60%) plurihormonal, and 1 of 19 (5%) null cell adenomas. p16 immunonegativity without CDKN2A methylation or deletion occurred in 22 tumours, including most so |
11276008 |
Human |
cdkn2a |
corticotroph adenomas |
The mechanisms of p16 down-regulation probably involve CDKN2A methylation in most types, but remain to be determined in somatotroph and corticotroph adenomas. |
11276008 |
Human |
cdkn2a |
oral carcinomas |
In this longitudinal study, we examined changes in the CDKN2A gene locus in sequential epithelial dysplasias and oral carcinomas from 11 patients. |
11289098 |
Human |
cdkn2a |
teratomas |
Twenty-five primary intracranial germ cell tumors (11 germinomas, 5 teratomas, 5 mixed teratomas-germinomas. 1 mixed choriocarcinoma-teratoma, 1 yolk sac tumor, 1 mixed yolk sac tumor-teratoma, and 1embryonal carcinoma; from 24 males and 1 female) were st |
12071636 |
Human |
cdkn2a |
yolk sac tumor |
Twenty-five primary intracranial germ cell tumors (11 germinomas, 5 teratomas, 5 mixed teratomas-germinomas. 1 mixed choriocarcinoma-teratoma, 1 yolk sac tumor, 1 mixed yolk sac tumor-teratoma, and 1embryonal carcinoma; from 24 males and 1 female) were st |
12071636 |
Human |
cdkn2a |
hereditary breast-ovarian cancer syndrome |
Hereditary pancreatic cancer. Hereditary pancreatic cancer (PC) appears to be exceedingly heterogeneous, as evidenced by its association with a variety of integrally associated diverse cancers and/or differing mendelian inherited cancer syndromes, which i |
12120226 |
Human |
cdkn2a |
hereditary pancreatic cancer |
Hereditary pancreatic cancer. Hereditary pancreatic cancer (PC) appears to be exceedingly heterogeneous, as evidenced by its association with a variety of integrally associated diverse cancers and/or differing mendelian inherited cancer syndromes, which i |
12120226 |
Human |
cdkn2a |
inherited cancer syndromes |
Hereditary pancreatic cancer. Hereditary pancreatic cancer (PC) appears to be exceedingly heterogeneous, as evidenced by its association with a variety of integrally associated diverse cancers and/or differing mendelian inherited cancer syndromes, which i |
12120226 |
Human |
cdkn2a |
polyposis |
Hereditary pancreatic cancer. Hereditary pancreatic cancer (PC) appears to be exceedingly heterogeneous, as evidenced by its association with a variety of integrally associated diverse cancers and/or differing mendelian inherited cancer syndromes, which i |
12120226 |
Human |
cdkn2a |
metastatic pancreatic adenocarcinoma |
RESULTS: Sequence analysis confirmed a CDKN2A mutation, and immunohistochemical evaluation confirmed the diagnoses of metastatic melanoma and metastatic pancreatic adenocarcinoma. |
12925390 |
Human |
cdkn2a |
sporadic breast cancer |
[Abnormal methylation of several tumor suppressor genes in sporadic breast cancer] Multiplex methylation-sensitive PCR was employed in studying the methylation of CpG islands in the RB1, p16/CDKN2A, p15/CDKN2B, p14/ARF, CDH1, MGMT, HIC1, and N33 promoter |
12942643 |
Human |
cdkn2a |
b-cell lymphoblastic leukemia |
[Abnormal methylation of p16/CDKN2A AND p14/ARF genes GpG Islands in non-small cell lung cancer and in acute lymphoblastic leukemia] Multiplex methylation-sensitive PCR and methylation-specific PCR were employed in studying the methylation of CpG islands |
15612580 |
Human |
cdkn2a |
b-cell lymphoblastic leukemia |
High level of the p16/CDKN2A first exon CpC island methylation was revealed in non-small cell lung cancer (68%) and in acute B-cell lymphoblastic leukemia (55%) and the CpG island of p14/ARF first exon was nonmethylated in these types of tumors. |
15612580 |
Human |
cdkn2a |
benign prostatic hyperplasias (bph) |
EXPERIMENTAL DESIGN: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 b |
15623627 |
Human |
cdkn2a |
gallbladder adenocarcinomas |
MATERIAL AND METHODS: We analyzed the methylation status of the promoter region of the CDKN2A gene in gallbladder adenocarcinomas using methylation specific PCR (MSP). |
15693199 |
Human |
cdkn2a |
gastrointestinal stromal tumors (gist) |
PURPOSE: The aim of the current study was to examine the prognostic relevance of the CDKN2A tumor suppressor pathway in gastrointestinal stromal tumors (GIST). |
16166437 |
Human |
p16ink4a |
erythroleukemia |
In mouse MEL erythroleukemia cells, p16INK4a associates preferentially with cdk6 under conditions where cdk4 and cdk6 are coexpressed at equivalent levels. |
7651726 |
Mouse |
p16ink4a |
hairy cell leukemia (hcl) |
We analyzed p16INK4A and p15INK4B genes in 178 cases of primary leukemias including 81 cases of chronic lymphocytic leukemia (CLL), seven of hairy cell leukemia (HCL), seven of chronic myelogenous leukemia (CML), 43 of acute myelogenous leukemia (AML), 27 |
7795238 |
Human |
p16ink4a |
childhood rhabdomyosarcoma |
Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. p16INK4A, p15INK4B, and p18 proteins are highly specific inhibitors of cyclin-dependent serine/threonine kinase (CDK) activities required for G |
8703847 |
Human |
p16ink4a |
childhood rhabdomyosarcoma |
Our results strongly indicate that the p16INK4A (and/or p15INK4B) protein plays a key role in the development and/or progression of childhood rhabdomyosarcoma and suggest that this CDK-inhibitor protein might control proliferation and/or differentiation o |
8703847 |
Human |
p16ink4a |
thymoma |
However, inactivation of p16INK4A and RB may play a role in the progression of thymoma and thymic carcinoma. |
9398039 |
Human |
p16ink4a |
plasmacytoma |
Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. |
9482902 |
Mouse |
p16ink4a |
cml |
In this disease p53, p16INK4A, p15INK4B, p57KIP2 mutations and p15INK4B/p16INK4A homo/hemizygous deletions were analyzed in the initial diagnosis phase and during the treatment phase of twelve CML cases, in order to establish whether there was a consisten |
10069444 |
Human |
p16ink4a |
squamous cell carcinoma of the anterior tongue |
These data indicate that cyclin D1 overexpression and loss of p16INK4A expression predict early relapse and reduced survival in squamous cell carcinoma of the anterior tongue. |
10537346 |
Human |
p16ink4a |
anaplasia |
P16INK4a expression was not related to anaplasia in oligodendrogliomas and ependymomas. |
10564531 |
Human |
p16ink4a |
thymic lymphomas (tls) |
Frequent chromosome 4 LOH in mouse radiation-induced (C57BL/6 x RF/J) thymic lymphomas (TLs) is associated with promoter/exon 1 region hypermethylation of the remaining p15INK4b and p16INK4a alleles, so this may be common to mouse radiation myeloid and ly |
10602427 |
Mouse |
p16ink4a |
colorectal adenomas |
In primary colorectal carcinomas, p14ARF promoter hypermethylation was found in 31 of 110 (28%) of the tumors and observed in 13 of 41 (32%) colorectal adenomas but was not present in any normal tissues. p14ARF methylation appears in the context of an adj |
10646864 |
Human |
p16ink4a |
adenoid cystic carcinomas (acc) |
In this study, the expressions of Rb, p16INK4A, and cyclin D1 alternations were analyzed by immunohistochemical assay in 5 specimens of normal salivary glands and twenty-two cases of adenoid cystic carcinomas (ACC). |
10928172 |
Human |
p16ink4a |
aggressive lymphomas |
For the aggressive lymphomas, the Kaplan-Meier estimate of overall survival for cases with disruption of either p16INK4a or the ARF-p53 pathway was not different from cases with retention of both pathways (5 year survival 45% vs 35%; P= 0.85), suggesting |
11021747 |
Human |
p16ink4a |
skin tumors |
In skin tumors from (XP) patients, p16INK4a UV induced mutations occur more frequently, are often multiple, and significantly associated with the presence of p53 mutations. |
11741799 |
Human |
p16ink4a |
agnogenic myeloid metaplasia (amm) |
Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. |
11849214 |
Human |
p16ink4a |
primary effusion lymphoma |
p16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma. |
11896614 |
Human |
p16ink4a |
pel |
To address this we investigated whether KSHV associated primary effusion lymphoma (PEL) derived cell lines are resistant to growth inhibition by p16INK4a. |
11896614 |
Human |
p16ink4a |
primary effusion lymphoma |
To address this we investigated whether KSHV associated primary effusion lymphoma (PEL) derived cell lines are resistant to growth inhibition by p16INK4a. |
11896614 |
Human |
p16ink4a |
salivary gland carcinomas |
Alterations of p14ARF and p16INK4a genes in salivary gland carcinomas. |
12684623 |
Human |
p16ink4a |
adenoid cystic carcinomas |
A total of 5 (14%) SGCs demonstrated homozygous deletion (1 case) or methylation (4 cases) of p16INK4a, all but one being adenoid cystic carcinomas. |
12684623 |
Human |
p16ink4a |
seminomas |
To improve understanding of the role of this pathway in spermatogenesis, and its subversion in TGCTs, we examined immunohistochemical expression patterns of CDK4, p16INK4a, p15INK4b, and pRB, and established an in situ assay for cyclin D-mediated phosphor |
12754735 |
Human |
p16ink4a |
teratomas |
To improve understanding of the role of this pathway in spermatogenesis, and its subversion in TGCTs, we examined immunohistochemical expression patterns of CDK4, p16INK4a, p15INK4b, and pRB, and established an in situ assay for cyclin D-mediated phosphor |
12754735 |
Human |
p16ink4a |
uterine tumors |
An allelic loss was detected in 12 of 50 (24%) carcinomas with a higher incidence in advanced endometrial carcinomas than in early-stage uterine tumors. p16INK4A alterations were generally accompanied by gene silencing, confirmed by aberrant protein immun |
12920579 |
Human |
p16ink4a |
undifferentiated carcinomas |
The p16INK4A promotor status was compared with p16INK4A protein expression and patient-specific data. p16INK4A promotor hypermethylation was detected in 13% of non-tumorous tissue; in 33% of follicular adenomas; in 44% of papillary carcinomas; in 50% of f |
12924440 |
Human |
p16ink4a |
bowen's disease |
BACKGROUND: Progression of cutaneous squamous neoplasms from actinic keratosis (AK) to Bowen's disease (BD; squamous cell carcinoma in situ) has important implications for clinical management and treatment, thus requiring accurate diagnosis. p16INK4a |
14632806 |
Human |
p16ink4a |
squamous cell carcinoma in situ |
BACKGROUND: Progression of cutaneous squamous neoplasms from actinic keratosis (AK) to Bowen's disease (BD; squamous cell carcinoma in situ) has important implications for clinical management and treatment, thus requiring accurate diagnosis. p16INK4a |
14632806 |
Human |
p16ink4a |
squamous cell carcinoma in situ |
Expression of a paraffin-reactive p16INK4a marker has recently been shown to increase in cervical squamous neoplasms as lesions progress from low-grade dysplasia to squamous cell carcinoma in situ. p16INK4a expression in the progression of squamous cutane |
14632806 |
Human |
p16ink4a |
verruca vulgaris |
METHODS: Biopsies of 203 squamous cutaneous neoplasms with unequivocal features of AK (n = 87) and BD (n = 116) as well as a benign squamous control group (verruca vulgaris: n = 10; seborrhoeic keratosis: n = 11; scar tissue: n = 8) obtained between Janua |
14632806 |
Human |
p16ink4a |
osteosarcoma |
The growth inhibition rate was the greatest for lung adenocarcinoma cells, lacking p16INK4a expression associated with methylation-mediated gene silencing; 83% at a concentration of 300 nM for 72-h treatment; while the growth of osteosarcoma and MFH cells |
15069542 |
Human |
p16ink4a |
squamous cell carcinoma in situ |
We therefore characterized the expression of p16INK4a, Rb-phosphorylation and proliferation in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma with special reference to infiltrative behavior. |
15257310 |
Human |
p16ink4a |
invasive cervical cancer |
Serial consecutive biopsies representing normal cervical epithelium to cervical intraepithelial neoplasia and/or invasive cervical cancer were stained with immunohistochemistry for p16INK4A, p14ARF and proliferating cell nuclear antigen. |
15502810 |
Human |
p16ink4a |
nk cell leukemia |
We found methylation of the first exon of the p16INK4A gene in two cases (one aggressive, one blastic), and methylation of the p14ARF gene in one aggressive NK cell leukemia. |
15813917 |
Human |
p16ink4a |
colorectal tumors |
Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? |
16760277 |
Human |
p16ink4 |
ampullary cancers |
One of three intrahepatic bile duct cancers, one of two common bile duct cancers, and one of two ampullary cancers had mutations in the p16Ink4/CDKN2 gene. |
7796400 |
Human |
p16ink4 |
bile duct cancers |
One of three intrahepatic bile duct cancers, one of two common bile duct cancers, and one of two ampullary cancers had mutations in the p16Ink4/CDKN2 gene. |
7796400 |
Human |
p16ink4 |
metastatic lung cancer |
Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. |
7882351 |
Human |
p16ink4 |
melanocytic neoplasms |
To clarify any role for p16INK4 and CDK4 proteins in the development of human malignant melanoma, we have examined, immunohistochemically, the expression of these two proteins in melanocytic neoplasms including 19 primary lesions of non-familial melanoma. |
8746340 |
Human |
p16ink4 |
esophageal squamous cancer |
[Analysis of the p16INK4, p15INK4B genes abnormality and the amplification of cyclin D1 gene in esophageal cancer] To evaluate the prognostic significance of gene amplification and overexpression of cyclin D1 in the patients of esophageal squamous cancer, |
8920671 |
Human |
p16ink4 |
thymoma |
p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. |
9398039 |
Human |
p16ink4 |
pediatric osteosarcoma |
CONCLUSIONS: Mutations of the TP53 and deletion of p16INK4 tumor suppressor genes seem to be involved in the development of pediatric osteosarcoma. |
9586287 |
Human |
p16ink4 |
bone tumors |
CONCLUSIONS: Alteration of TP53, p16INK4 and p21WAF1 seems to be involved in the development of pediatric bone tumors and to be an unfavourable prognostic factor in this type of tumors. |
12886318 |
Human |
p14arf |
thyroid tumour |
The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression. |
17117177 |
Human |
cdkn2a |
nodular melanoma |
PURPOSE: In order to obtain better insight into the genetic background of nodular melanoma (NM), we aimed to analyse the frequency of CDKN2A and C-MYC copy number changes. |
16977458 |
Human |
p16 |
sporadic breast cancer |
CONCLUSIONS: Hypermethylation of BRCA1, p16 and 14-3-3sigma is present in all histologic types, stages and grades in sporadic breast cancer and can be detected in serum DNA. |
17264521 |
Human |
cdkn2a |
second cancer |
The obtained results allow us to conclude: (i) survival times of 500 C/G carriers vs. cumulating proportion surviving was not statistically significant; (ii) CDKN2a polymorphism 500 C/G correlated with Ala148Thr; (iii) no correlation was observed between |
17351674 |
Human |
p16 |
sporadic breast cancer |
Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients. |
17264521 |
Human |
cdkn2a |
nodular melanoma |
Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma. |
16977458 |
Human |
p16 |
oropharyngeal squamous cell carcinoma (oscc) |
Molecular prognostic indicators for oropharyngeal squamous cell carcinoma (OSCC), including HPV-DNA detection, epidermal growth factor receptor (EGFR) and p16 expression, have been suggested in the literature, but none of these are currently used in clini |
17236202 |
Human |
cdkn2a |
egc |
CONCLUSIONS: Our study shows a high prevalence of co-inactivating mutations of p53 and/or CDKN2A genes in EGC, that seem to occur preferentially in LS-derived tumours and late in oncogenesis. |
17300232 |
Human |
p19 |
ganglioglioma |
Direct analysis demonstrated loss of p19 expression and p53 mutation in the malignant areas, highly suggestive of these alterations being involved in the malignant progression of the ganglioglioma. |
17259542 |
Human |
p14arf |
large b cell lymphoma |
All patients with follicular lymphoma (FL), myeloma or acute myeloid leukemia (AML) expressed p14ARF while nine of 23 patients with diffuse large B cell lymphoma (DLBCL) lost p14ARF expression. |
10557050 |
Human |
p14arf |
condyloma |
All condyloma acuminata except one and low-grade dysplasia with HPV infection of low risk, such as HPV 6, immunohistochemically showed completely negative staining for p14ARF, also seen in non-neoplastic and mesenchymal cells. |
12100520 |
Human |
p14arf |
invasive ductal breast cancers |
This study examined p14ARF and p53/Hdm2 expression and subcellular localisation by using immunohistochemistry in a series of invasive ductal breast cancers (IDCs) with concomitant ductal carcinoma in situ (DCIS), to evaluate whether findings in vitro were |
15318938 |
Human |
p14 |
serous microcystic adenomas |
In this study, we compared methylation status of p16, p14, VHL, and ppENK genes by methylation-specific PCR (MSP), and genetic alterations including K-ras and beta-catenin gene mutations, chromosome 3p loss, and microsatellite instability in 15 mucinous c |
14614047 |
Human |
p14 |
serous microcystic adenomas |
There were no significant differences between mucinous cystic neoplasms and serous microcystic adenomas in methylation of p16 (14%, 2/14 and 12%, 2/16), p14 (15%, 2/13 and 37%, 6/16), VHL (0/14 and 7%, 1/14), and ppENK (0/14 and 0/13), respectively. |
14614047 |
Human |
p14 |
ampullary tumors |
RESULTS: p16 gene alterations including silent mutations were present in 61.8% gallbladder cancers, 54.5% bile duct cancers, and 70.6% ampullary cancers. p16 gene nonsilent mutations, p16 methylation, and loss of chromosome 9p21-22 that targets p14, p15, |
15014024 |
Human |
mts1 |
pancreatic neuroendocrine tumors |
Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. |
9443399 |
Human |
mts1 |
pancreatic neuroendocrine tumor |
In the present study, 12 gastrinoma and nonfunctioning pancreatic neuroendocrine tumor specimens were evaluated for genetic alterations of the p16/MTS1 tumor suppressor gene. |
9443399 |
Human |
mts1 |
primary bladder cancer |
CONCLUSIONS: Over-expression of bcl-2 appears to be common in bladder cancer; over-expression of proto-oncogene bcl-2 and inactivation of the MTS1/p16 gene are likely to be contributing factors for primary bladder cancer; and they can be the prognostic in |
11831985 |
Human |
mts1 |
intraductal papillary mucinous tumors |
P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas. |
12749268 |
Human |
ink4a |
nongerminomatous germ cell tumors |
To evaluate whether genetic alterations of the INK4a/ARF locus occur in the genesis of ICGTs, we analyzed the INK4a/ARF genes in 21 ICGTs-10 pure germinomas and 11 nongerminomatous germ cell tumors. |
10786670 |
Human |
ink4a |
metastatic breast carcinomas |
However, primary and metastatic breast carcinomas exhibited a relative hypomethylation of p16(INK4A), which is associated with expression, compared to normal breast tissue. |
11369056 |
Human |
ink4a |
intraductal papillary mucinous tumours |
Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. |
12010891 |
Human |
ink4a |
primary cutaneous b cell lymphoma |
Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma. |
12060387 |
Human |
ink4a |
primary cutaneous b cell lymphomas |
Our findings suggest that p15(INK4b) and p16(INK4a) biallelic gene abnormalities are common in primary cutaneous B cell lymphomas, most frequently as a result of promotor hypermethylation. |
12060387 |
Human |
cdkn2 |
advanced stage cancer |
CDKN2 is homozygously deleted in approximately 25% of nonsmall cell lung cancer (NSCLC) cell lines and these deletions are associated with advanced stage cancer. |
7478613 |
Human |
cdkn2 |
familial atypical multiple mole-melanoma (fammm) |
We have analysed CDKN2 coding sequences in 15 Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome pedigrees, and identified a 19 basepair (bp) germline deletion in 13 of them. |
7670475 |
Human |
cdkn2 |
common bile duct cancers |
One of three intrahepatic bile duct cancers, one of two common bile duct cancers, and one of two ampullary cancers had mutations in the p16Ink4/CDKN2 gene. |
7796400 |
Human |
p16 |
borderline ovarian tumor |
We also examined p16 gene expression and mutations in ovarian cancer cell lines and invasive and borderline ovarian tumor tissues. |
7478544 |
Human |
p16 |
pancreatic neuroendocrine tumors |
Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. |
9443399 |
Human |
p16 |
mixed mesodermal tumour |
No p16 deletion was found, and mutations were detected in only one tumour sample and Skut1B uterine mixed mesodermal tumour cells. |
10071231 |
Human |
p16 |
paraffin embedded tumor |
METHODS: p16 and Rb pretoin were immunostained by SP immunohistochemical method in the sections of formalin fixed paraffin embedded tumor tissue from 102 patients with astrocytoma brain tumors. |
10374322 |
Human |
p16 |
familial atypical multiple mole melanoma (fammm) |
A locus linked to p16 modifies melanoma risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families. |
10400925 |
Human |
p16 |
low grade tumors |
The frequency of the alteration of the p16 gene, either homozygous deletion or mutation accompanied with amino acid substitutions, increased in malignant brain tumors (grade III and IV) compared with that in low grade tumors (grade I and II) (p=0.0275), s |
10536183 |
Human |
p16 |
adenosquamous cell carcinoma (ascc) |
The rate of loss of P16 protein expression in adenocarcinoma (AC) was 28.47 +/- 16.33%, that in squamous cell carcinoma (SCC) was 35.95% +/- 17.36%, and that in adenosquamous cell carcinoma (ASCC) 57.88% +/- 10.18%. |
10684032 |
Human |
p16 |
familial atypical multiple mole melanoma |
Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). |
10956390 |
Human |
p16 |
primary brain lymphomas |
Recent reports indicate a high proportion of primary brain lymphomas show loss of CDKN2A/p16 gene expression. |
10976700 |
Human |
p16 |
familial atypical multiple mole melanoma (fammm) |
[From gene to disease; from p16 to melanoma] Approximately 10% of human cutaneous melanoma cases occur in families with the familial atypical multiple mole melanoma (FAMMM) syndrome, which is characterised by the familial occurrence of melanomas and atypi |
11103670 |
Human |
p16 |
large cell lymphoma |
Here, we provide the first evidence of the involvement of the tumor suppressor gene p16 in primary cutaneous large cell lymphoma. |
11121148 |
Human |
p16 |
metastatic breast carcinomas |
However, primary and metastatic breast carcinomas exhibited a relative hypomethylation of p16(INK4A), which is associated with expression, compared to normal breast tissue. |
11369056 |
Human |
p16 |
familial atypical multiple mole melanoma (fammm) |
BACKGROUND: Hereditary pancreatic carcinoma shows extant phenotypic and genotypic heterogeneity as evidenced by its integral association with a variety of hereditary cancer syndromes inclusive of the familial atypical multiple mole melanoma (FAMMM) syndro |
11815963 |
Human |
p16 |
hereditary cancer syndromes |
BACKGROUND: Hereditary pancreatic carcinoma shows extant phenotypic and genotypic heterogeneity as evidenced by its integral association with a variety of hereditary cancer syndromes inclusive of the familial atypical multiple mole melanoma (FAMMM) syndro |
11815963 |
Human |
p16 |
primary bladder cancer |
CONCLUSIONS: Over-expression of bcl-2 appears to be common in bladder cancer; over-expression of proto-oncogene bcl-2 and inactivation of the MTS1/p16 gene are likely to be contributing factors for primary bladder cancer; and they can be the prognostic in |
11831985 |
Human |
p16 |
ii lung cancers |
In stage I and II lung cancers, the obvious inactivation of tumor suppressor gene p16 or Rb was examined (32.6% or 28.3%); p16 inactivation was detected mainly in non-small cell lung cancers, and Rb inactivation mainly in small cell lung cancers. |
11832104 |
Human |
p16 |
sebaceous carcinomas |
RESULTS: In the 96 cases, including 40 cases of basal cell carcinoma (BCC), 33 squamous and 23 sebaceous carcinomas, their p16 protein positive (nuclear staining) rates were 70.0%, 54.6% and 56.5% respectively. |
11853608 |
Human |
p16 |
sebaceous carcinoma |
RESULTS: Among the 96 cases, there were 40 basal cell carcinomas (BCCs), 33 squamous carcinomas and 23 sebaceous carcinoma, with P16 protein positive (nuclear staining) rates 70%, 54.6% and 56.5%, respectively. |
11930651 |
Human |
p16 |
intraductal papillary mucinous tumours |
Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. |
12010891 |
Human |
p16 |
intraductal papillary-mucinous tumors |
p16 and p53 gene alterations and accumulations in the malignant evolution of intraductal papillary-mucinous tumors of the pancreas. |
12021900 |
Human |
p16 |
intraductal papillary-mucinous tumors |
CONCLUSIONS: The p16 and p53 gene alterations and accumulations observed are crucial events during the carcinogenesis and malignant progression of intraductal papillary-mucinous tumors of the pancreas. |
12021900 |
Human |
p16 |
primary cutaneous b cell lymphoma |
Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma. |
12060387 |
Human |
p16 |
primary cutaneous b cell lymphomas |
We analyzed DNA from 36 cases of primary cutaneous B cell lymphomas, four systemic B cell lymphomas, and six benign B cell lymphoproliferative infiltrates for abnormalities of p15 and p16 using microsatellite markers for 9p21, methylation specific polymer |
12060387 |
Human |
p16 |
primary cutaneous b cell lymphomas |
In primary cutaneous B cell lymphomas with allelic loss or promotor hypermethylation of either p15 or p16, loss of expression in tumor cells was identified in 5 of 8 and 9 of 10 cases, respectively. |
12060387 |
Human |
p16 |
primary cutaneous b cell lymphomas |
Our findings suggest that p15(INK4b) and p16(INK4a) biallelic gene abnormalities are common in primary cutaneous B cell lymphomas, most frequently as a result of promotor hypermethylation. |
12060387 |
Human |
p16 |
metastatic human prostate cancers |
We examined the status of a cell cycle checkpoint by immunohistochemically staining for p16 and pRb using multiple tissue arrays generated from 49 primary and 23 hormone-sensitive metastatic human prostate cancers. |
12169393 |
Human |
p16 |
intraductal papillary-mucinous tumors |
Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas. |
12469138 |
Human |
p16 |
lip cancers |
[Expression of VEGF, EGFR, p16 in lip cancers and oral squamous cell carcinomas and their clinic significance] OBJECTIVE: To detect the expression of vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), p16 protein in lip ca |
12475418 |
Human |
p16 |
lip cancers |
METHODS: Immunohistochemisty for expression VEGF, EGFR, P16 were carried out in 69 cases of lip cancers and OSCC. |
12475418 |
Human |
p16 |
lip cancers |
RESULTS: Expression of VEGF, EGFR, p16 protein in OSCC and lip cancers was respectively 71.01%, 46.37%, 28.98% and there were no significance between their positive expressions (P > 0.05) as well as in different sites of them (P > 0.05). |
12475418 |
Human |
p16 |
lip cancers |
CONCLUSIONS: The results show that there is no correlation to the expression of VEGF, EGFR and P16 protein in OSCC and lip cancers. |
12475418 |
Human |
p16 |
squamous cervical cancers |
In squamous cervical cancers, overexpression of p16 is induced by HPV and associated with the carcinogenesis of cervical epithelia. |
12548164 |
Human |
p16 |
digestive tract cancers |
PURPOSE AND EXPERIMENTAL DESIGN: To date, the presence of p16 gene promoter methylation associated with loss of protein expression has been demonstrated frequently in digestive tract cancers. |
12631606 |
Human |
p16 |
intraductal papillary mucinous tumors |
P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas. |
12749268 |
Human |
p16 |
intraductal papillary mucinous tumors |
The purpose of the study was to determine the prevalence of p53-, p16/MTS1- and K-ras mutations in benign and malignant intraductal papillary mucinous tumors with intent to value their importance for tumor progression. |
12749268 |
Human |
p16 |
lymph node metastasis |
METHODS: p53 and p16 expression status, the Ki-67 LI, and int-2/cyclin D1 amplification were assessed by immunohistochemical staining and slot blot analysis in pretreatment endoscopic biopsy specimens of 41 patients with T4 or M1 Lym (distant lymph node m |
12900371 |
Human |
p16 |
advanced prostate cancers |
We investigated the prognostic significance of both pRB and p16 expression in locally advanced prostate cancers, from patients treated on the Radiation Therapy Oncology Group (RTOG) protocol 86-10. |
12947069 |
Human |
p16 |
seborrhoeic keratosis |
Enhanced expression of p16 in seborrhoeic keratosis; a lesion of accumulated senescent epidermal cells in G1 arrest. |
14510989 |
Human |
p16 |
cervical lymph node metastasis |
CONCLUSION: The expression of p15 and p16 protein are closely associated with clinical stages and cervical lymph node metastasis of TSCC. p15 deletion, or both p15 and p16 co-deletion in TSCC can also predict a poor prognosis. p15 and p16 expression can b |
14613656 |
Human |
p16 |
serous microcystic adenomas |
In this study, we compared methylation status of p16, p14, VHL, and ppENK genes by methylation-specific PCR (MSP), and genetic alterations including K-ras and beta-catenin gene mutations, chromosome 3p loss, and microsatellite instability in 15 mucinous c |
14614047 |
Human |
p16 |
serous microcystic adenomas |
There were no significant differences between mucinous cystic neoplasms and serous microcystic adenomas in methylation of p16 (14%, 2/14 and 12%, 2/16), p14 (15%, 2/13 and 37%, 6/16), VHL (0/14 and 7%, 1/14), and ppENK (0/14 and 0/13), respectively. |
14614047 |
Human |
p16 |
primary gastric lymphomas |
Promoter hypermethylation and protein expression of the p16 gene: analysis of 43 cases of B-cell primary gastric lymphomas from China. |
14976529 |
Human |
p16 |
primary gastric lymphoma |
However, the p16 protein expression in primary gastric lymphoma has not been studied. |
14976529 |
Human |
p16 |
primary gastric lymphomas |
In this study, we characterize protein expression and promoter hypermethylation of the p16 gene in B-cell primary gastric lymphomas from China. |
14976529 |
Human |
p16 |
primary gastric lymphomas |
In conclusion, loss of p16 protein expression is frequent in those B-cell primary gastric lymphomas and approximately one-third of such loss correlated with promoter hypermethylation. |
14976529 |
Human |
p16 |
ampullary tumors |
RESULTS: p16 gene alterations including silent mutations were present in 61.8% gallbladder cancers, 54.5% bile duct cancers, and 70.6% ampullary cancers. p16 gene nonsilent mutations, p16 methylation, and loss of chromosome 9p21-22 that targets p14, p15, |
15014024 |
Human |
p16 |
squamous cell hyperplasia |
In contrast, p16 was almost consistently negative in normal skin, squamous cell hyperplasia (0/20), lichen sclerosus (0/19), differentiated (simplex) VIN3 (0/11), verrucous carcinoma (0/2), and keratinizing squamous cell carcinoma (3/33, 9%). |
15213596 |
Human |
p16 |
familial atypical multiple mole melanoma |
This article traces the historical aspects of hereditary cancer dealing with identification and ultimate molecular genetic confirmation of commonly occurring cancers, particularly of the colon in the case of familial adenomatous polyposis and its attenuat |
15264268 |
Human |
p16 |
bronchioloalveolar carcinomas (bacs) |
OBJECTIVES: Loss of p16(INK4) has been associated with a poor cancer prognosis, but its potential significance in bronchioloalveolar carcinomas (BACs) has not been explored. |
15753637 |
Human |
p16 |
muscle invasive bladder cancer |
METHODS: Fluorescence in situ hybridisation analysis was performed to evaluate chromosomes 3, 7, 9, and 17 and the 9p21 (p16), 17p13.1 (p53), 13q14 (RB1), and 17q11.2 (HER-2) chromosomal loci in 48 muscle invasive bladder cancer specimens and the adjacent |
15790699 |
Human |
p16 |
malignant rhabdoid tumor |
Establishment of a cell line from a malignant rhabdoid tumor of the liver lacking the function of two tumor suppressor genes, hSNF5/INI1 and p16. |
15796965 |
Human |
p16 |
rars |
To determine whether genetic alterations of p16 and p27 genes play an important role in MDS pathogenesis, we examined DNA from 51 patients classified as 17 refractory anemias (RA), four refractory anemias with ringed sideroblasts (RARS), 19 refractory ane |
16104874 |
Human |
p16 |
non-keratinizing carcinoma (nkc) |
METHODS: Immunohistochemical study for p16 protein was carried out in 90 cases of non-keratinizing carcinoma (NKC) of nasopharynx. |
16185507 |
Human |
p16 |
salivary adenoid cystic carcinoma |
[Mechanisms of p16 gene inactivation salivary adenoid cystic carcinoma] OBJECTIVE: To study the mechanism of p16 gene inactivation in salivary adenoid cystic carcinoma. |
16285551 |
Human |
p16 |
salivary adenoid cystic carcinomas |
Polymerase chain reaction (PCR) and single-stranded conformation polymorphism analysis of polymerase chain reaction products (PCR-SSCP) were used to detect deletion and mutation of p16 gene in salivary adenoid cystic carcinomas. |
16285551 |
Human |
p16 |
salivary adenoid cystic carcinomas |
RESULTS: The homozygous deletion, mutation and hypermethylation of p16 gene were noted in 16 cases (30.2%), 4 cases (7.5%) and 26 cases (49.1%) respectively in 53 cases of salivary adenoid cystic carcinomas. |
16285551 |
Human |
p16 |
salivary adenoid cystic carcinoma |
CONCLUSION: The main inactivation mechanisms of p16 gene in salivary adenoid cystic carcinoma were hypermethylation and homozygous deletion. |
16285551 |
Human |
p16 |
salivary adenoid cystic carcinoma |
The mutation p16 gene was rare in salivary adenoid cystic carcinoma. |
16285551 |
Human |
arf |
nongerminomatous germ cell tumors |
To evaluate whether genetic alterations of the INK4a/ARF locus occur in the genesis of ICGTs, we analyzed the INK4a/ARF genes in 21 ICGTs-10 pure germinomas and 11 nongerminomatous germ cell tumors. |
10786670 |
Human |
ink4 |
bronchioloalveolar carcinomas (bacs) |
OBJECTIVES: Loss of p16(INK4) has been associated with a poor cancer prognosis, but its potential significance in bronchioloalveolar carcinomas (BACs) has not been explored. |
15753637 |
Human |
cdkn2a |
large b cell lymphoma |
Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. |
10086736 |
Human |
cdkn2a |
somatotrophinoma |
In contrast, a single invasive methylated somatotrophinoma failed to express the CDKN2A protein. |
10092131 |
Human |
cdkn2a |
primary brain lymphomas |
Recent reports indicate a high proportion of primary brain lymphomas show loss of CDKN2A/p16 gene expression. |
10976700 |
Human |
cdkn2a |
inherited cancer syndrome |
Usually this occurs in the setting of a known inherited cancer syndrome caused by mutations in genes such as BRCA1/2 and CDKN2A. |
11291558 |
Human |
cdkn2a |
neuroendocrine (merkel cell) carcinoma |
CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin. |
11433400 |
Human |
cdkn2a |
familial atypical multiple mole melanoma (fammm) |
BACKGROUND: Hereditary pancreatic carcinoma shows extant phenotypic and genotypic heterogeneity as evidenced by its integral association with a variety of hereditary cancer syndromes inclusive of the familial atypical multiple mole melanoma (FAMMM) syndro |
11815963 |
Human |
cdkn2a |
hereditary cancer syndromes |
BACKGROUND: Hereditary pancreatic carcinoma shows extant phenotypic and genotypic heterogeneity as evidenced by its integral association with a variety of hereditary cancer syndromes inclusive of the familial atypical multiple mole melanoma (FAMMM) syndro |
11815963 |
Human |
cdkn2a |
familial atypical multiple mole melanoma |
This article traces the historical aspects of hereditary cancer dealing with identification and ultimate molecular genetic confirmation of commonly occurring cancers, particularly of the colon in the case of familial adenomatous polyposis and its attenuat |
15264268 |
Human |
p16ink4a |
digestive cancers |
Point mutations of p16ink4a have also been sequenced, especially in familial melanomas and digestive cancers but preferential mechanism of p16ink4a/p15ink4b inactivation seems to be biallelic deletion. |
8724524 |
Human |
p16ink4a |
cholangiocellular carcinomas |
We examined the genomic status of the p16INK4A (inhibitor of cyclin-dependent kinase 4 A) and cyclin-dependent kinase 4 (CDK4) genes in 62 human hepatocellular carcinomas (HCCs), 5 cholangiocellular carcinomas and 6 cell lines derived from human liver can |
8760583 |
Human |
p16ink4a |
metastatic breast carcinomas |
We show here that primary and metastatic breast carcinomas demonstrate hypomethylation of p16INK4a which is associated with expression of p16INK4a mRNA, as compared to normal breast tissue which demonstrates a relative hypermethylation of p16INK4a associa |
9652738 |
Human |
p16ink4a |
oral squamous cell carcinoma |
Hence, it was possible to restore a functional pRB pathway in an oral squamous cell carcinoma line by inducing re-expression of endogenous p16ink4a in response to treatment with a demethylating agent. |
10030668 |
Human |
p16ink4a |
large b cell lymphoma |
Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. |
10803523 |
Human |
p16ink4a |
epidermoid tumors |
P16INK4a UV induced mutations (CC:GG > TT:AA tandem transition or C:G > T:A transition at dipyrimidic site) are found in 12% of sporadic skin carcinomas, mainly in epidermoid tumors, and seem to occur independently of p53 mutations. |
11741799 |
Human |
p16ink4a |
large cell lymphoma |
We investigated the response of SUDHL-1 and L428 cells, derived from t(2;5)-anaplastic large cell lymphoma (ALCL) and Hodgkin's disease (HD), respectively, to recombinant adenoviruses expressing cyclin-dependent kinase inhibitors (CDKIs) p27Kip1 (Adp |
12153002 |
Human |
p16ink4a |
malignant rhabdoid tumor |
P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells. |
14604992 |
Human |
p16ink4a |
seborrhoeic keratosis |
METHODS: Biopsies of 203 squamous cutaneous neoplasms with unequivocal features of AK (n = 87) and BD (n = 116) as well as a benign squamous control group (verruca vulgaris: n = 10; seborrhoeic keratosis: n = 11; scar tissue: n = 8) obtained between Janua |
14632806 |
Human |
p16ink4a |
salivary adenoid cystic carcinoma |
Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. |
15959912 |
Human |
p16ink4 |
ampullary tumor |
CONCLUSIONS: The disruption of the pRb-p16NK4 pathway plays an important role in ampullary carcinogenesis, the absence of p16INK4 protein expression might be involved in ampullary tumor progression. |
15782994 |
Human |
p14arf |
papillary carcinomas |
In all histological types, except papillary carcinomas, we observed a statistically significant relationship between p14ARF and E2F1 (r=0.64 to 1, P<0.05). |
17117177 |
Human |
arf |
follicular lymphoma |
These data identify CBX7 as a chromobox protein causally linked to cancer development and may help explain the low frequency of INK4a/ARF mutations observed in human follicular lymphoma. |
17374722 |
Human |
p16 |
cancerous lesions |
Point mutations of p16(CDKN2A) exon 1 were found in all of the precancerous and cancerous lesions. |
17091472 |
Human |
p16 |
tumour infiltrating lymphocytes |
Methylation of the MLH1, P16, TIMP3 and P14 genes was associated with tumour infiltrating lymphocytes (p < 0.05), microsatellite instability (p < 0.001), BRAF mutation (p < 0.0001) and elevated concentrations of the methyl group carriers tetrahydrofolate |
16981189 |
Human |
p14arf |
sporadic breast carcinomas |
Since our earlier studies have shown lack of genetic alterations such as missense mutations and deletions in the tumor associated genes-p16, ras and p14ARF in sporadic breast tumors, the epigenetic alterations of the two genes reported in the present stud |
16480176 |
Human |
p14arf |
melanoma |
CGIs in putative promoter regions of 34 genes (ABHD9, BARHL1, CLIC5, CNNM1, COL2A1, CPT1C, DDIT4L, DERL3, DHRS3, DPYS, EFEMP2, FAM62C, FAM78A, FLJ33790, GBX2, GPR10, GPRASP1, HOXA9, HOXD11, HOXD12, HOXD13, p14ARF, PAX6, PRDX2, PTPRG, RASD1, RAX, REC8L1, S |
16778180 |
NA |
p14arf |
ovarian serous tumors |
We studied the immunoexpression of p14ARF, MDM2, and p53, in addition to relationships between those protein expressions and estrogen receptor (ER)alpha in ovarian serous tumors including benign (n= 23), borderline (n= 41), and malignant (n= 94). |
16803476 |
Human |
p14arf |
borderline tumors |
The expression of MDM2 was significantly higher in borderline tumors compared to benign (P= 0.04) and malignant (P < 0.01) tumors. p53 expression in borderline tumors was uncommon, and p14ARF expression loss was mainly observed in carcinomas. |
16803476 |
Human |
p19 |
lung adenomas |
Lung adenomas exhibited a 50% decrease and a 35-fold increase in expression of Rb and p19/ARF mRNA, respectively. |
16424006 |
Human |
p14 |
childhood ependymomas |
PROCEDURE: Primary ependymomas at diagnosis or relapse from 24 children were analyzed for p53 pathway, using a functional assay in yeast, RT-PCR, Western blot analysis, and/or immunohistochemistry for TP53 mutation, p14(ARF) deletion and promoter hypermet |
16086408 |
Human |
p14 |
ependymoma |
PROCEDURE: Primary ependymomas at diagnosis or relapse from 24 children were analyzed for p53 pathway, using a functional assay in yeast, RT-PCR, Western blot analysis, and/or immunohistochemistry for TP53 mutation, p14(ARF) deletion and promoter hypermet |
16086408 |
Human |
p14 |
ependymomas |
PROCEDURE: Primary ependymomas at diagnosis or relapse from 24 children were analyzed for p53 pathway, using a functional assay in yeast, RT-PCR, Western blot analysis, and/or immunohistochemistry for TP53 mutation, p14(ARF) deletion and promoter hypermet |
16086408 |
Human |
p14 |
round cell liposarcoma |
Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. |
16177957 |
Human |
p14 |
anaplastic lymphoma |
To understand better T-cell lymphomagenesis, we examined promoter CpG methylation and mRNA expression of closely related genes encoding p16, p15, and p14 tumor suppressor genes in cultured malignant T-cells that were derived from cutaneous, adult type, an |
16185764 |
Human |
p14 |
neuroendocrine tumors |
We therefore compared methylation of the RAS-association domain family 1, isoform A (RASSF1A), p14, p16 and O6-methyl-guanine methyltransferase genes in neuroendocrine tumors from 47 patients including 16 pancreatic, 15 nonileal and 16 ileal neuroendocrin |
16258509 |
Human |
p14 |
mpnst |
We found that MPNST lines are heterogeneous in their in vitro growth rates and exhibit diverse alterations in expression of pRb, p53, p14(Arf), and p16(INK4a) proteins. |
16510576 |
Human |
p14 |
round cell liposarcoma |
Frequent alteration of p16INK4a/p14ARF and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14ARF expression both correlate with poor prognosis. |
16622896 |
Human |
p14 |
supratentorial pnet |
High promoter hypermethylation frequency of p14/ARF in supratentorial PNET but not in medulloblastoma. |
16623784 |
Human |
p14 |
squamous cell carcinoma of the endometrium |
p16, p14, p53, cyclin D1, and steroid hormone receptor expression and human papillomaviruses analysis in primary squamous cell carcinoma of the endometrium. |
16844559 |
Human |
p14 |
malignant pleural mesothelioma |
p53-Induced Apoptosis Occurs in the Absence of p14(ARF) in Malignant Pleural Mesothelioma. |
16867217 |
Human |
p14 |
malignant pleural mesotheliomas |
Malignant pleural mesotheliomas (MPMs) are usually wild type for the p53 gene but contain homozygous deletions in the INK4A locus that encodes p14(ARF), an inhibitor of p53-MDM2 interaction. |
16867217 |
Human |
p-16 |
choriocarcinoma |
Numerous works on this subject are published and some recent important discoveries underline the roles of genes HOX, Tim P3, E-cad and p-16, and the recurrent chromosome anomalies 7q21+and 8p21- in the mole to choriocarcinoma processing. |
16005675 |
Human |
mts1 |
rectal carcinoma |
[The expression of MTS1 gene product in transitional mucosa adjacent to rectal carcinomas and its clinical significance] OBJECTIVE: To study the property of transitional mucosa (TM) adjacent to rectal carcinoma and the clinical significance of MTS1 gene d |
11829899 |
Human |
mts1 |
rectal carcinoma |
CONCLUSIONS: The inactivation of MTS1 gene is relative to the occurrence of rectal carcinoma, suggesting that the TM adjacent to rectal carcinoma possess as certain potential malignancy. |
11829899 |
Human |
ink4a |
tumors |
Our study indicates that a high frequency of hypermethylation for RARbeta2, p16(INK4A) and RASSF1A promoters is present in spiral CT-detected tumors, whereas promoter hypermethylation of this panel of genes in uninduced sputum has a limited diagnostic val |
16152615 |
Human |
ink4a |
hsil |
There was a higher mean number of p16(INK4A) and MIB-1 immunoreactive cells/1,000 cells in HSIL (4.06 +/- 1.93 and 11.13 +/- 2.83, respectively) compared to other cytological categories. |
16161049 |
Human |
ink4a |
keratoacanthoma |
As the phenotype worsens, with increasing hyperplasia and vascularization leading to keratoacanthoma, p16(INK4a) and matrix metalloproteinase 9 expression is induced. |
16204053 |
Mouse |
ink4a |
nasopharyngeal carcinoma |
These data are consistent with the cooperative effects seen between LMP1 and loss of the INK4a locus in transgenic mice and with the frequency of loss of this locus in EBV-associated nasopharyngeal carcinoma. |
16204053 |
Mouse |
ink4a |
hepatocellular carcinomas |
In contrast, strong induction of HSP90, CDC37, and E2F4 was paralleled by P16(INK4A) downregulation and high levels of HSP90-CDK4 and CDC37-CDK4 complexes in hepatocellular carcinomas with poorer prognosis. |
16317707 |
Human |
ink4a |
low-grade lymphomas |
To examine whether methylation of p16(INK4A) and p57(KIP2) is involved in the development and progression of gastric MALT lymphomas, 24 gastric low-grade lymphomas of MALT, 11 diffuse large B-cell lymphomas, and 10 each case of gastric lymphoid follicles |
16357845 |
Human |
ink4a |
mpnst |
We found that MPNST lines are heterogeneous in their in vitro growth rates and exhibit diverse alterations in expression of pRb, p53, p14(Arf), and p16(INK4a) proteins. |
16510576 |
Human |
ink4a |
skin tumors |
Induction of Nevi and Skin Tumors in Ink4a/Arf Xpa Knockout Mice by Neonatal, Intermittent, or Chronic UVB Exposures. |
16510579 |
Mouse |
ink4a |
xeroderma pigmentosum |
Nevi and melanomas correlate to childhood and intermittent solar UV exposure, xeroderma pigmentosum patients run increased risk, and p16(Ink4a) expression is often lost in malignant progression. |
16510579 |
Human |
ink4a |
skin tumors |
Ink4a/Arf(-/-) mice developed most skin tumors faster, but surprisingly developed nevi slower than their heterozygous counterparts especially after neonatal UV exposure. |
16510579 |
Mouse |
ink4a |
nevus |
Hence, although our experiments did not effectively emulate human melanoma, they provided clear evidence that intermittent UV overexposure strongly stimulates and the Ink4a/Arf(-/-) genotype may actually impair nevus development. |
16510579 |
Mouse |
ink4a |
pancreatic ductal adenocarcinoma |
Activating KRAS mutations and p16(Ink4a) inactivation are near universal events in human pancreatic ductal adenocarcinoma (PDAC). |
16585505 |
Human |
ink4a |
head and neck cancer |
The frequency and precise loss of CDKN2B(INK4b), CDKN2A(ARF, INK4a), and MTAP in the prognosis of 9p21-deleted HNSCC may provide impetus for use of these targets as therapeutic biomarkers in head and neck cancer. |
16618910 |
Human |
ink4a |
histiocytic sarcoma |
The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. |
16697958 |
Human |
ink4a |
breast tumor |
These results demonstrate a causal role of p16(INK4A) disruption in modulating DNA hypermethylation, and identify a dynamic and active process whereby epigenetic modulation of gene expression is activated as an early event in breast tumor progression. |
16766534 |
Human |
ink4a |
malignant pleural mesotheliomas |
Malignant pleural mesotheliomas (MPMs) are usually wild type for the p53 gene but contain homozygous deletions in the INK4A locus that encodes p14(ARF), an inhibitor of p53-MDM2 interaction. |
16867217 |
Human |
p16 |
lung cancer |
CONCLUSION: p16 gene mutation and abnormal expression may play an important role in the occurrence and development of lung cancer, and it is relative to CT appearances of lung cancer. p16 gene may be used as a predicting index for clinical diagnosis and p |
15898427 |
Human |
p16 |
tumors |
Our study indicates that a high frequency of hypermethylation for RARbeta2, p16(INK4A) and RASSF1A promoters is present in spiral CT-detected tumors, whereas promoter hypermethylation of this panel of genes in uninduced sputum has a limited diagnostic val |
16152615 |
Human |
p16 |
squamous cell carcinoma of the skin |
Samples of basal cell carcinoma and squamous cell carcinoma of the skin with either functional or non-functional Rb also exhibited at least two forms of p16. |
16161044 |
Human |
p16 |
hsil |
There was a higher mean number of p16(INK4A) and MIB-1 immunoreactive cells/1,000 cells in HSIL (4.06 +/- 1.93 and 11.13 +/- 2.83, respectively) compared to other cytological categories. |
16161049 |
Human |
p16 |
anaplastic lymphoma |
To understand better T-cell lymphomagenesis, we examined promoter CpG methylation and mRNA expression of closely related genes encoding p16, p15, and p14 tumor suppressor genes in cultured malignant T-cells that were derived from cutaneous, adult type, an |
16185764 |
Human |
p16 |
cutaneous t-cell lymphoma |
Extensive methylation of the p16 promoter was seen in six out of 10 cutaneous T-cell lymphoma patient samples and corresponded with lack of p16 protein expression in the cases examined. |
16185764 |
Human |
p16 |
keratoacanthoma |
As the phenotype worsens, with increasing hyperplasia and vascularization leading to keratoacanthoma, p16(INK4a) and matrix metalloproteinase 9 expression is induced. |
16204053 |
Mouse |
p16 |
hyperplastic polyps |
Two benign gastric hyperplastic polyps also had intact p16 and MTAP. |
16224217 |
Human |
p16 |
neuroendocrine tumors |
Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. |
16258509 |
Human |
p16 |
neuroendocrine tumors |
We therefore compared methylation of the RAS-association domain family 1, isoform A (RASSF1A), p14, p16 and O6-methyl-guanine methyltransferase genes in neuroendocrine tumors from 47 patients including 16 pancreatic, 15 nonileal and 16 ileal neuroendocrin |
16258509 |
Human |
p16 |
hepatocellular carcinomas |
In contrast, strong induction of HSP90, CDC37, and E2F4 was paralleled by P16(INK4A) downregulation and high levels of HSP90-CDK4 and CDC37-CDK4 complexes in hepatocellular carcinomas with poorer prognosis. |
16317707 |
Human |
p16 |
colorectal tumors |
p16 Gene Methylation in Colorectal Tumors: Correlation with Clinicopathological Features and Prognostic Value. |
16352895 |
Human |
p16 |
low-grade lymphomas |
To examine whether methylation of p16(INK4A) and p57(KIP2) is involved in the development and progression of gastric MALT lymphomas, 24 gastric low-grade lymphomas of MALT, 11 diffuse large B-cell lymphomas, and 10 each case of gastric lymphoid follicles |
16357845 |
Human |
p16 |
keratoses |
DESIGN: We studied the expression of p16 by immunohistochemistry in 24 KAs, 24 infiltrating SCCs of the skin, 4 histologically indeterminate lesions, and 8 nonmalignant keratoses. |
16390241 |
Human |
p16 |
keratoses |
No significant difference in measures of p16 expression was identified among the KAs, the SCCs, the indeterminate lesions, or the benign keratoses. |
16390241 |
Human |
p16 |
anal intraepithelial neoplasia |
The sensitivity and specificity of p16 immunoreactivity in the detection of anal intraepithelial neoplasia or carcinoma were 72% and 71%, respectively. |
16404747 |
Human |
p16 |
dlbcl |
CONCLUSIONS: Our results suggest that hypermethylation of the p16 promoter indicates a poor prognosis in high-intermediate-risk and high-risk DLBCL patients, and may be a useful marker for selection of appropriate treatment when used in conjunction with t |
16406514 |
Human |
p16 |
carcinomatosis |
We assessed the correlation of the clinicopathologic variables (previous surgical score, age, sex, performance status, previous systemic chemotherapy, carcinomatosis extension, completeness of cytoreduction, IPHP drug schedule, mitotic count [MC], nuclear |
16444562 |
Human |
p16 |
smooth muscle neoplasms |
In the uterus, p16 positivity is more common and widespread in leiomyosarcomas than leiomyomas, and this may be a useful aid to diagnosis, although problematic uterine smooth muscle neoplasms have not been extensively studied. |
16462152 |
Human |
p16 |
mucinous adenocarcinoma |
Metastatic cervical adenocarcinomas in the ovary are usually diffusely p16-positive, and because these may closely mimic a primary ovarian endometrioid or mucinous adenocarcinoma, this may be a valuable diagnostic aid, although p16 expression in primary o |
16462152 |
Human |
p16 |
ovarian adenocarcinomas |
Metastatic cervical adenocarcinomas in the ovary are usually diffusely p16-positive, and because these may closely mimic a primary ovarian endometrioid or mucinous adenocarcinoma, this may be a valuable diagnostic aid, although p16 expression in primary o |
16462152 |
Human |
p16 |
sporadic breast carcinomas |
We have employed a novel restriction digestion based multiplex PCR assay to analyse the methylation status of promoter regions of tumor suppressor genes (p16, hMLH1, MGMT and E-cadherin) in sporadic breast carcinomas of Indian women. |
16480176 |
Human |
p16 |
undifferentiated carcinomas |
Hypermethylation of tumor suppressor and tumor-related genes, including APC, CHFR, DAP-kinase, DCC, E-cadherin, GSTP1, hMLH1, p16, PTEN, RASSF1A, RUNX3, and TSLC1, can be detected in both differentiated and undifferentiated carcinomas at varying frequenci |
16482617 |
Human |
p16 |
mpnst |
We found that MPNST lines are heterogeneous in their in vitro growth rates and exhibit diverse alterations in expression of pRb, p53, p14(Arf), and p16(INK4a) proteins. |
16510576 |
Human |
p16 |
xeroderma pigmentosum |
Nevi and melanomas correlate to childhood and intermittent solar UV exposure, xeroderma pigmentosum patients run increased risk, and p16(Ink4a) expression is often lost in malignant progression. |
16510579 |
Human |
p16 |
cervical squamous intraepithelial lesions |
BACKGROUND/AIM: It is generally assumed that similar pathways are involved in human papillomavirus (HPV) induced pathogenesis of cervical squamous intraepithelial lesions (SILs) and cancers and a subset of conjunctival intraepithelial neoplasm (CIN)-that |
16540490 |
Human |
p16 |
pleural mesotheliomas |
Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and P16/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic Prediction. |
16540645 |
Human |
p16 |
villous adenomas |
METHODS: Immunohistochemistry with the antibodies p16, p53, and p63 was performed in tubular, tubular-villous, and villous adenomas (n = 30) and in well, moderately, and poorly differentiated adenocarcinomas (n = 30). |
16575619 |
Human |
p16 |
colorectal neoplasms |
CONCLUSIONS: Despite both p16 and p53 having been detected in colorectal neoplasms, they were not related to the different histologic variables nor to the expression of p63. |
16575619 |
Human |
p16 |
pancreatic ductal adenocarcinoma |
Activating KRAS mutations and p16(Ink4a) inactivation are near universal events in human pancreatic ductal adenocarcinoma (PDAC). |
16585505 |
Human |
p16 |
stage i non-small cell lung cancer |
Cohypermethylation of p16 and FHIT Promoters as a Prognostic Factor of Recurrence in Surgically Resected Stage I Non-Small Cell Lung Cancer. |
16618724 |
Human |
p16 |
stage i nsclc |
In conclusion, the present study suggests that cohypermethylation of p16 and FHIT genes in patients with stage I NSCLC may be a valuable biomarker for predicting the recurrence-associated prognosis of the disease. |
16618724 |
Human |
p16 |
atypical endometrial hyperplasia |
MATERIALS AND METHODS: Hypermethylation in the promoter region of the p16 gene and the expression of the p16 protein in 51 specimens, including 8 endometrial cancer cell lines, 7 normal endometrial tissues, 12 atypical endometrial hyperplasia tissues and |
16619479 |
Human |
p16 |
carcinosarcoma |
In total, 92% of serous carcinomas expressed p16 strongly compared to weak-to-moderate expression of p16 in 7-67% of other tumors (FIGO grades 1 and 2 carcinoma and carcinosarcoma, respectively). |
16648864 |
Human |
p16 |
serous carcinomas |
In total, 92% of serous carcinomas expressed p16 strongly compared to weak-to-moderate expression of p16 in 7-67% of other tumors (FIGO grades 1 and 2 carcinoma and carcinosarcoma, respectively). |
16648864 |
Human |
p16 |
breast tumor |
These results demonstrate a causal role of p16(INK4A) disruption in modulating DNA hypermethylation, and identify a dynamic and active process whereby epigenetic modulation of gene expression is activated as an early event in breast tumor progression. |
16766534 |
Human |
p16 |
cin 3 |
There was no observed association of methylation of the p16INK4a gene with either CIN grading (P=0.0698) or HPV status (P=0.2811): specifically 42.9% (3/7) was found in CIN 1, 57.1% (8/14) in CIN 2, and 52.9% (9/17) in CIN 3. |
16778587 |
Human |
p16 |
leukoplakia of buccal mucosa |
RESULTS: The methylation of p16 gene was found in 15 of 30 cases SCC and 1 of 10 cases of leukoplakia of buccal mucosa (P < 0.05). |
16784614 |
Human |
p16 |
scc of buccal mucosa |
Methylation of p16 gene in SCC of buccal mucosa was not related with age, sex, cell differentiation and clinical stage. |
16784614 |
Human |
p16 |
scc of buccal mucosa |
CONCLUSIONS: The methylation of p16 gene leaded to the inactivation of p16 gene and was related with the carcinogenesis and progress of SCC of buccal mucosa. |
16784614 |
Human |
p16 |
monocytic leukemia |
Suppression of U937 human monocytic leukemia cell growth by dideoxypetrosynol A, a polyacetylene from the sponge Petrosia sp., via induction of Cdk inhibitor p16 and down-regulation of pRB phosphorylation. |
16786142 |
Human |
p16 |
tumors of the uterus |
Loss of p16 in recurrent malignant mixed müllerian tumors of the uterus. |
16803529 |
Human |
p16 |
mmmt |
Five cases of recurrent uterine MMMT were examined by paraffin immunohistochemistry for the expression of p53, p16, P-cadherin, and Cerb-B2. |
16803529 |
Human |
p16 |
common tumor |
P53, p16, and P-cadherin are common tumor suppressor genes expressed in uterine MMMT. |
16803529 |
Human |
p16 |
mmmt |
P53, p16, and P-cadherin are common tumor suppressor genes expressed in uterine MMMT. |
16803529 |
Human |
p16 |
oral tumour |
As proof of principle, we illustrate MEP using assays of p16 and cyclin A1 promoters in a methylated DNA dilution matrix and also in a clinical setting using paired saliva and oral tumour specimens. |
16807314 |
Human |
p16 |
condylomas |
After discrepancies were resolved and concurrence was achieved by at least 2 of 3 reviewing pathologists, the diagnoses were as follows: 37 negative, 12 condylomas without overt dysplasia, 14 AIN I, 25 AIN II, and 16 AIN III. p16 and Ki67 expression was e |
16819320 |
Human |
p16 |
condylomas |
None of the condylomas and only 1 of the negative cases showed a band of p16 positive staining. |
16819320 |
Human |
p16 |
adenomatous polyps |
We investigated the methylation status in the promoter regions of the CDKN2A/p16, hMLH1, and MGMT genes in human non-neoplastic rectal mucosa and evaluated whether these methylation markers may predict the presence of adenomatous polyps in the colon. |
16820927 |
Human |
p16 |
squamous cell carcinoma of the endometrium |
p16, p14, p53, cyclin D1, and steroid hormone receptor expression and human papillomaviruses analysis in primary squamous cell carcinoma of the endometrium. |
16844559 |
Human |
arf |
childhood ependymomas |
PROCEDURE: Primary ependymomas at diagnosis or relapse from 24 children were analyzed for p53 pathway, using a functional assay in yeast, RT-PCR, Western blot analysis, and/or immunohistochemistry for TP53 mutation, p14(ARF) deletion and promoter hypermet |
16086408 |
Human |
arf |
ependymoma |
PROCEDURE: Primary ependymomas at diagnosis or relapse from 24 children were analyzed for p53 pathway, using a functional assay in yeast, RT-PCR, Western blot analysis, and/or immunohistochemistry for TP53 mutation, p14(ARF) deletion and promoter hypermet |
16086408 |
Human |
arf |
ependymomas |
PROCEDURE: Primary ependymomas at diagnosis or relapse from 24 children were analyzed for p53 pathway, using a functional assay in yeast, RT-PCR, Western blot analysis, and/or immunohistochemistry for TP53 mutation, p14(ARF) deletion and promoter hypermet |
16086408 |
Human |
arf |
round cell liposarcoma |
Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. |
16177957 |
Human |
arf |
lung adenomas |
Lung adenomas exhibited a 50% decrease and a 35-fold increase in expression of Rb and p19/ARF mRNA, respectively. |
16424006 |
Human |
arf |
skin tumors |
Induction of Nevi and Skin Tumors in Ink4a/Arf Xpa Knockout Mice by Neonatal, Intermittent, or Chronic UVB Exposures. |
16510579 |
Mouse |
arf |
round cell liposarcoma |
Frequent alteration of p16INK4a/p14ARF and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14ARF expression both correlate with poor prognosis. |
16622896 |
Human |
arf |
supratentorial pnet |
High promoter hypermethylation frequency of p14/ARF in supratentorial PNET but not in medulloblastoma. |
16623784 |
Human |
arf |
histiocytic sarcoma |
The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. |
16697958 |
Human |
arf |
malignant pleural mesothelioma |
p53-Induced Apoptosis Occurs in the Absence of p14(ARF) in Malignant Pleural Mesothelioma. |
16867217 |
Human |
arf |
malignant pleural mesotheliomas |
Malignant pleural mesotheliomas (MPMs) are usually wild type for the p53 gene but contain homozygous deletions in the INK4A locus that encodes p14(ARF), an inhibitor of p53-MDM2 interaction. |
16867217 |
Human |
ink4 |
cervical squamous intraepithelial lesions |
BACKGROUND/AIM: It is generally assumed that similar pathways are involved in human papillomavirus (HPV) induced pathogenesis of cervical squamous intraepithelial lesions (SILs) and cancers and a subset of conjunctival intraepithelial neoplasm (CIN)-that |
16540490 |
Human |
cdkn2a |
recurrent carcinoma |
The results showed that a considerable frequency (35%, 7 of 20) of CDKN2A methylation was present in histologically negative margins, and methylation pattern analysis might be valuable for studying the cellular origin of recurrent carcinoma. |
16269133 |
Human |
cdkn2a |
acute promyelocytic leukaemia |
Serial studies of methylation of CDKN2B and CDKN2A in relapsed acute promyelocytic leukaemia treated with arsenic trioxide. |
16351640 |
Human |
cdkn2a |
pleural mesotheliomas |
Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and P16/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic Prediction. |
16540645 |
Human |
cdkn2a |
urothelial cell carcinoma (ucc) |
The CDKN2A locus is frequently inactivated in urothelial cell carcinoma (UCC), yet how this alteration contributes to bladder tumorigenesis is not known. |
16619045 |
Human |
cdkn2a |
advanced cancers |
Comparative mutational profiling for different genomic loci [1p36(CCM = cutaneous malignant melanoma], 3p26(OGGI = 8 oxoguanine DNA glycosylase), 5q23 (APC, MCC = mutated in colorectal cancer), 9p21(p16/CDKN2A = cyclin-dependent kinase 2A), 10q23(PTEN = p |
16719202 |
Human |
cdkn2a |
supratentorial primitive neuroectodermal tumor |
In addition, one supratentorial primitive neuroectodermal tumor had lost both copies of the tumor-suppressor genes CDKN2A and CDKN2B. |
16783165 |
Human |
cdkn2a |
adenomatous polyps |
We investigated the methylation status in the promoter regions of the CDKN2A/p16, hMLH1, and MGMT genes in human non-neoplastic rectal mucosa and evaluated whether these methylation markers may predict the presence of adenomatous polyps in the colon. |
16820927 |
Human |
p16ink4a |
cervical intraepithelial neoplasia grade 1 |
We evaluated the expression of HSP40, HSP60, HSP70, and HSP90 in normal tissues (N=30), in cervical intraepithelial neoplasia grade 1 (CIN1)(synonymous with productive HPV infections) (N=32), and in CIN3 (cervical precancer)(N=25) by immunohistochemistry |
16112431 |
Human |
p16ink4a |
neuroendocrine tumor |
Of all seven markers tested for, p16INK4A methylation was observed in both components of one composite carcinoma and hMLH1 was methylated in the neuroendocrine tumor component within the same tumor. |
16218931 |
Human |
p16ink4a |
rhabdoid tumor |
Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. hSNF5, the smallest member of the SWI/SNF chromatin remodeling complex, is lost in most malignant rhabd |
16288006 |
Human |
p16ink4a |
squamous cervical cancer |
It was shown that the expression of p16ink4a in the squamous cervical cancer was induced by HPV. |
16637315 |
Human |
p16ink4 |
cervical squamous intraepithelial lesion |
Increased Ki-67 proliferative index and absence of P16INK4 in CIN-HPV related pathogenic pathways different from cervical squamous intraepithelial lesion. |
16540490 |
Human |
p14 |
primary endometrial squamous cell carcinoma |
The purpose of this study was to evaluate the role of p14, p16, p53, cyclin D1, steroid hormone receptors, and human papillomaviruses (HPV) infection in the pathogenesis of primary endometrial squamous cell carcinoma. |
16844559 |
Human |
ink4a |
early lung cancer |
Our study indicates that a high frequency of hypermethylation for RARbeta2, p16(INK4A) and RASSF1A promoters is present in spiral CT-detected tumors, whereas promoter hypermethylation of this panel of genes in uninduced sputum has a limited diagnostic val |
16152615 |
Human |
ink4a |
nevi and melanomas |
Nevi and melanomas correlate to childhood and intermittent solar UV exposure, xeroderma pigmentosum patients run increased risk, and p16(Ink4a) expression is often lost in malignant progression. |
16510579 |
Human |
ink4a |
nonsmall cell lung carcinoma |
The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. |
16598757 |
Human |
p16 |
ii lung cancer |
In stage I and II lung cancer, the obvious inactivation rate of the tumor suppressor gene p16 or RB was 32.6% or 28.3%. |
11832187 |
Human |
p16 |
salivary adenoid cystic carcinoma |
p16 tumor suppressor therapy in salivary adenoid cystic carcinoma cell line SACC83. |
15953919 |
Human |
p16 |
salivary adenoid cystic carcinoma (sacc) |
OBJECTIVE: This study aimed to determine the growth inhibitory effects of transfecting the wild-type p16 gene into human salivary adenoid cystic carcinoma (SACC) cells in vitro. |
15953919 |
Human |
p16 |
salivary adenoid cystic carcinoma |
CONCLUSION: The study confirmed the reversal effect of wild-type p16 on malignant phenotype of the salivary adenoid cystic carcinoma and provides valuable data for further clinical trial of gene therapy with p16. |
15953919 |
Human |
p16 |
early lung cancer |
Our study indicates that a high frequency of hypermethylation for RARbeta2, p16(INK4A) and RASSF1A promoters is present in spiral CT-detected tumors, whereas promoter hypermethylation of this panel of genes in uninduced sputum has a limited diagnostic val |
16152615 |
Human |
p16 |
cardiac carcinomas |
Results: The C/G genotype of p16 was identified in 10.4% of esophageal carcinomas, 13.3% of cardiac carcinomas, and in 14.1% of gastric carcinomas, compared to 17.4% in the healthy control group. |
16163549 |
Human |
p16 |
early invasive cervical cancers |
Methods: Peripheral blood samples and cervical tissues, from 36 cervical tissues from high-grade squamous intraepithelial lesions (HSIL) and 31 early invasive cervical cancers (EICC), were analyzed for HPV 16/18 DNA and HPV 16/18 E7 mRNA expression, as we |
16289504 |
Human |
p16 |
nevi and melanomas |
Nevi and melanomas correlate to childhood and intermittent solar UV exposure, xeroderma pigmentosum patients run increased risk, and p16(Ink4a) expression is often lost in malignant progression. |
16510579 |
Human |
p16 |
nonsmall cell lung carcinoma |
The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. |
16598757 |
Human |
p16 |
condyloma |
Spotty p16 immunoreactivity was observed in 8.1% negative, 8.3% condyloma, 14.3% AIN I, 12.0% AIN II, and 12.5% AIN III cases. |
16819320 |
Human |
p16 |
primary endometrial squamous cell carcinoma |
The purpose of this study was to evaluate the role of p14, p16, p53, cyclin D1, steroid hormone receptors, and human papillomaviruses (HPV) infection in the pathogenesis of primary endometrial squamous cell carcinoma. |
16844559 |
Human |
p16ink4a |
malignant rhabdoid tumors (mrt) |
Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. hSNF5, the smallest member of the SWI/SNF chromatin remodeling complex, is lost in most malignant rhabd |
16288006 |
Human |
p16ink4a |
breast cancer metastases |
Expression of Retinoblastoma Protein in Breast Cancer Metastases to Sentinel Nodes: Evaluation of its Role as a Marker for the Presence of Metastases in Non-Sentinel Axillary Nodes, and Comparison to p16INK4a. |
16540733 |
Human |
p16ink4a |
nevi and melanomas |
Atypical nevi have been clinically considered to be precursors of melanoma, and recently, biochemical abnormalities have been found that are present in both nevi and melanomas, including inactivation of the p16INK4a tumor suppressor gene and mutations in |
16924053 |
Human |
mts1 |
solid tumors |
Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. |
8521382 |
Human |
cdkn2 |
solid tumors |
Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. |
8521382 |
Human |
p16 |
npc |
These findings suggest that complete inactivation of the p16 gene may play a role in the development of NPC. |
7743498 |
Human |
p16 |
npc |
In the NPC xenograft (xeno-666) and its newly derived cell line (cell-666), both showing hypermethylation of the p16 gene, no p16 gene expression was found. |
8665502 |
Human |
p16 |
pre-cancerous lesions |
In the pre-cancerous lesions, Waf1p21 and pRb were detected in cells surrounding the top of the lesioned region, p16-positive cells were scattered in the basal cell hyperplastic and dysplastic lesions and p53-positive cells existed in 2 distinct patterns: |
9311588 |
Human |
p16 |
mantle cell lymphoma |
Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. |
9377576 |
Human |
p16 |
diffuse large cell lymphomas |
All but 3 of the RB- and p16-negative cases were diffuse large cell lymphomas, for an abnormality rate of 55% in this category. |
9620022 |
Human |
p16 |
nodular melanomas |
Eighteen of 26 (69%) superficial spreading melanomas, 17 of 28 (61%) nodular melanomas, all of three lentigo maligna melanomas, and all of five melanoma metastases were found to harbor less than 10% p16-positive tumor cells. |
9694617 |
Human |
p16 |
lentigo maligna melanomas |
Eighteen of 26 (69%) superficial spreading melanomas, 17 of 28 (61%) nodular melanomas, all of three lentigo maligna melanomas, and all of five melanoma metastases were found to harbor less than 10% p16-positive tumor cells. |
9694617 |
Human |
p16 |
neuroblastoma |
We previously reported that loss of heterozygosity (LOH) on chromosome 9p21 correlates with poor prognosis of neuroblastoma and the p16 gene is not expressed in approximately two thirds of neuroblastoma cell lines. |
9872329 |
Human |
p16 |
invasive breast carcinomas |
Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas. |
9990866 |
Human |
p16ink4a |
erythroleukemia |
In mouse MEL erythroleukemia cells, p16INK4a associates preferentially with cdk6 under conditions where cdk4 and cdk6 are coexpressed at equivalent levels. |
7651726 |
Mouse |
p16ink4a |
tumor-specific antigen |
These results suggest that mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a. |
7652577 |
Human |
p16ink4a |
solid tumors |
Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. |
8521382 |
Human |
cdkn2a |
cancerous lesions |
Point mutations of p16(CDKN2A) exon 1 were found in all of the precancerous and cancerous lesions. |
17091472 |
Human |
p14arf |
stage i adenocarcinoma of the lung |
In this pathway, the immunohistochemical profile of p14ARF-negative/MDM2-positive/p53-negative is characteristic of stage I adenocarcinoma of the lung. |
11940214 |
Human |
p14arf |
renal carcinoma |
It has recently been suggested that p53 function is unusually compromised in renal carcinoma cells by a novel dominant, MDM2/p14ARF-independent mechanism. |
16061625 |
Human |
p14arf |
round cell liposarcoma |
Frequent alteration of p16INK4a/p14ARF and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14ARF expression both correlate with poor prognosis. |
16622896 |
Human |
p14arf |
common tumor |
Knowledge of the roles of proteins that are abnormally suppressed or activated due to mutation in the DNA sequences of the common tumor suppressor genes, p14ARF and p53, is critical to the understanding the pathogenesis of breast cancer. |
16919268 |
Human |
p14 |
tumor antigens |
These tools include tumor antigens or products (e.g., carbohydrate antigen [CA] 19-9), cytokines (e.g., interleukin-6), metabolic products (e.g., lactate), proteases (e.g., trypsinogen-2), regulatory peptides (e.g., pancreatic polypeptide), and (epi-)gene |
15192787 |
Human |
p14 |
colorectal tumours |
The MethyLight assay was used to provide quantitative estimates of MLH1, P16, TIMP3, P14, DAPK and APC methylation levels in 199 unselected colorectal tumours. |
16981189 |
Human |
p14 |
nervous system tumors |
Alterations in the p14(ARF) tumor suppressor are frequent in many human cancers and are associated with susceptibility to melanoma, pancreatic cancer, and nervous system tumors. |
17035234 |
Human |
p14 |
papillary carcinomas |
Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. |
17117177 |
Human |
p14 |
follicular adenomas |
Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. |
17117177 |
Human |
p14 |
oncocytic adenomas |
Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. |
17117177 |
Human |
p14 |
follicular carcinomas |
Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. |
17117177 |
Human |
p14 |
papillary carcinomas |
In all histological types, except papillary carcinomas, we observed a statistically significant relationship between p14ARF and E2F1 (r=0.64 to 1, P<0.05). |
17117177 |
Human |
mts1 |
carcinogenesis |
Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de |
15161057 |
Human |
mts1 |
invasive breast cancers |
[Flow cytometric quantitative analysis of multiple tumor suppressor gene 1 (MTS1) and cyclooxygenase-2 (COX-2) gene expressions in invasive breast cancers and their clinical significance] OBJECTIVE: The purpose of the present study was to explore the expr |
17147116 |
Human |
mts1 |
primary invasive breast cancers |
METHODS: Flow cytometry was used to analyze the expression level of MTS1 and COX-2 in cancer tissues and corresponding para-cancer tissues from 66 cases of primary invasive breast cancers. |
17147116 |
Human |
ink4a |
xeroderma pigmentosum |
Association between INK4a-ARF and p53 mutations in skin carcinomas of xeroderma pigmentosum patients. |
11078762 |
Human |
ink4a |
xeroderma pigmentosum (xp) |
We examined the frequency of INK4a-ARF, p53, and CDK4 mutations in skin carcinomas from patients with xeroderma pigmentosum (XP), a rare autosomal disease that is associated with a defect in DNA repair and that predisposes patients to skin cancer. |
11078762 |
Human |
ink4a |
hepatocarcinogenesis |
The INK4a-ARF-/p53-pathway was disrupted in 86% of HCC, either by p53 mutations or by INK4a-ARF inactivation, and may have co-operative effects in hepatocarcinogenesis. |
11704835 |
Human |
ink4a |
rms |
Here we show that simultaneous loss of Ink4a/Arf function and disruption of c-Met signaling in Ink4a/Arf(-/-) mice transgenic for hepatocyte growth factor/scatter factor (HGF/SF) induces RMS with extremely high penetrance and short latency. |
12368906 |
Mouse |
ink4a |
rms |
Our data indicate that human c-MET and INK4a/ARF, situated at the nexus of pathways regulating myogenic growth and differentiation, represent critical targets in RMS pathogenesis. |
12368906 |
Human |
ink4a |
pleomorphic adenoma of the parotid gland |
Alterations of the INK4a-ARF gene locus in pleomorphic adenoma of the parotid gland. |
12375265 |
Human |
ink4a |
angiosarcoma of the liver |
This study was done to investigate the contribution of the INK4a-ARF locus in tumorigenesis of angiosarcoma of the liver. |
12378512 |
Human |
ink4a |
angiosarcoma of the liver |
In conclusion, our data indicate that the INK4a-ARF locus is frequently inactivated in angiosarcoma of the liver and occurs independently of p53 mutations. |
12378512 |
Human |
ink4a |
xeroderma pigmentosum group c |
Germline and somatic mutations of the INK4a-ARF gene in a xeroderma pigmentosum group C patient. |
12485439 |
Human |
ink4a |
xeroderma pigmentosum |
An elevated proportion of tumors from xeroderma pigmentosum patients harbor ultraviolet-induced mutations (CC:GG > TT:AA tandem transitions) of the p53 and/or the INK4a-ARF genes. |
12485439 |
Human |
ink4a |
atypical fibroxanthoma |
Single strand conformation polymorphism and sequencing analysis of the p53 and INK4a-ARF genes were carried out in DNA from normal skin and different tumors (four actinic keratosis, two microinvasive squamous cell carcinomas, one basal cell carcinoma, and |
12485439 |
Human |
ink4a |
xeroderma pigmentosum |
After characterization of the xeroderma pigmentosum C complementation group, we found unexpectedly that this patient also carried a germline mutation of the INK4a-ARF locus affecting the p16INK4A reading frame. |
12485439 |
Human |
ink4a |
xeroderma pigmentosum |
Furthermore, this study confirms that concomitant somatic mutations of INK4a-ARF and p53 occur in some xeroderma pigmentosum associated tumors, and seem to accumulate during tumor progression rather than the initiation step. |
12485439 |
Human |
ink4a |
rms |
We used cDNA microarray analysis of RMS cell lines, derived from Ink4a/Arf-deficient mice transgenic for hepatocyte growth factor/scatter factor (HGF/SF), to identify a set of genes whose expression was significantly different between highly and poorly me |
14704789 |
Mouse |
ink4a |
skin tumors |
This study demonstrates for the first time UV-induced mutations of INK4a-ARF that occur in a small percentage in late stages skin tumors. |
15057871 |
Human |
ink4a |
carcinogenesis |
Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de |
15161057 |
Human |
ink4a |
barrett's adenocarcinoma |
INK4a-ARF alterations in Barrett's epithelium, intraepithelial neoplasia and Barrett's adenocarcinoma. |
15185075 |
Human |
ink4a |
tumor antigens |
These tools include tumor antigens or products (e.g., carbohydrate antigen [CA] 19-9), cytokines (e.g., interleukin-6), metabolic products (e.g., lactate), proteases (e.g., trypsinogen-2), regulatory peptides (e.g., pancreatic polypeptide), and (epi-)gene |
15192787 |
Human |
ink4a |
skin tumor |
In conclusion, molecular analysis using a combination of p53 and INK4a-ARF mutation analysis can identify the corresponding primary skin tumor in case of CSCC metastases in the majority of cases. |
15613867 |
Human |
ink4a |
skin tumors |
The high level of ras oncogene activation, Ink4a-Arf and p53 tumor suppressor gene modifications as well as alterations of the different partners of the mitogenic sonic hedgehog signaling pathway (patched, smoothened and sonic hedgehog), characterized in |
15748637 |
Human |
ink4a |
cancerous lesions |
The aim was to investigate in biopsies the expression of p16(INK4a) of normal uterine cervical tissue, pre-cancerous and cancerous lesions, and their relation with human papilloma virus (HPV) and HIV status. |
16376485 |
Human |
ink4a |
uterine cervical cancers |
[Study of p16(INK4A) expression and DNA ploidy in HPV-negative cervical cancers and precursors] OBJECTIVE: To investigate the clinicopathological significance of p16(INK4A) expression and DNA ploidy status in HPV-negative uterine cervical cancers and thei |
17069677 |
Human |
ink4a |
colorectal adenomas |
Here, we show that, in a series of human colorectal adenomas, those with deregulation of cyclin D1 and/or p16(Ink4a) showed little evidence of constitutive DNA damage response (DDR), contrary to cyclin E-overexpressing higher-grade cases. |
17079443 |
Human |
ink4a |
oncocytic adenomas |
Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. |
17117177 |
Human |
ink4a |
follicular carcinomas |
Overexpression of p14ARF and pl6INK4A was observed in follicular adenomas, follicular carcinomas and papillary carcinomas, while downregulation was found in oncocytic adenomas compared to nontumoral paired thyroid tissues. |
17117177 |
Human |
tp16 |
schwannomas |
METHODS: The methylation status of 16 tumor-related genes including RASSF1A, RAR-B, VHL, PTEN, HMLH1, RB1, TP16, CASP8, ER, TIMP3, MGMT, DAPK, TP73, GSTP1, TP14, and THBS1 was examined in a series of 22 vestibular schwannomas.The bisulfite modification of |
16983315 |
Human |
cdkn2 |
childhood chronic myeloid leukemia |
Here we report the absence of point mutations in the CDKN2-binding site of CDK4 in 100 cases of childhood ALL, 2 cases of childhood chronic myeloid leukemia and 9 hematologic cell lines screened by PCR-SSCP (polymerase chain reaction single stranded confo |
11426564 |
Human |
cdkn2 |
carcinogenesis |
Based on the concept that tumor suppressor genes are involved in the pathogenesis of urinary bladder carcinogenesis, we analysed the mRNA expression of the retinoblastoma (Rb) and p16 (CDKN2, INK4A, MTS1) genes as well as of the proto-oncogene cyclin D-de |
15161057 |
Human |
cdkn2 |
seminoma |
Human male germ-cell tumors of seminoma type display aberrant expression of INK4-family inhibitors of the cell cycle including CDKN2-encoded p16INK4A. |
15734211 |
Human |
cdkn2 |
squamous cell carcinoma of buccal mucosa |
[The relationship between methylation of p16 INK 4/CDKN2 gene in promoter region and progress of squamous cell carcinoma of buccal mucosa] OBJECTIVE: To determine the correlation between methylation of p16 gene in promoter region and the carcinogenesis an |
16784614 |
Human |
cdkn2 |
squamous cell carcinoma of buccal mucosa |
[Study of p16INK4/CDKN2 gene homozygous deletions and point mutation in squamous cell carcinoma of buccal mucosa] OBJECTIVE: To explore the correlation between homozygous deletions and mutation of p16 gene and the carcinogenesis and progression of squamou |
16999361 |
Human < |